New search for studies and content updated (conclusions changed)

Summary of findings {#CD001233-sec1-0001}
===================

###### Balloon (Foley or ATAD) compared to vaginal prostaglandin E2 for third trimester labour induction in women with a viable fetus

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------------------- ---------------------------------- ---------------------------------------- --------------
  **Balloon (Foley or ATAD) compared to vaginal prostaglandin E2 for third trimester labour induction in women with a viable fetus**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Patient or population:** third trimester labour induction in women with a viable fetus  **Setting:** Australia, China, Denmark, Iran, Jordan, India, Italy, Israel, Nigeria, Pakistan, Singapore, Sweden, the Netherlands, USA, UK  **Intervention:** balloon (Foley or ATAD)  **Comparison:** vaginal prostaglandin E2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**   **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)**   **Comments**
  **Risk with vaginal prostaglandin E2**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **Risk with balloon (Foley or ATAD)**                                                                                                                       
  Vaginal delivery not achieved in 24 hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study population                                RR 1.01  (0.82 to 1.26)         1685  (7 RCTs)                     ⊕⊕⊝⊝  LOW ^1\ 2^                          
  528 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           533 per 1000  (433 to 665)                                                                                                                                  
  Uterine hyperstimulation with FHR changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study population                                RR 0.35  (0.18 to 0.67)         1966  (6 RCTs)                     ⊕⊕⊕⊝  MODERATE ^1^                        
  31 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            11 per 1000  (6 to 21)                                                                                                                                      
  Caesarean section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Study population                                RR 1.00  (0.92 to 1.09)         6619  (28 RCTs)                    ⊕⊕⊕⊝  MODERATE ^1^                        
  238 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           238 per 1000  (219 to 260)                                                                                                                                  
  Serious neonatal morbidity or perinatal death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Study population                                RR 0.48  (0.25 to 0.93)         2757  (8 RCTs)                     ⊕⊕⊕⊝  MODERATE ^1^                        
  20 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            9 per 1000  (5 to 18)                                                                                                                                       
  Serious maternal morbidity or death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study population                                RR 0.20  (0.01 to 4.12)         1481  (4 RCTs)                     ⊕⊝⊝⊝  VERY LOW ^1\ 3^                     
  3 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1 per 1000  (0 to 11)                                                                                                                                       
  Apgar score \< 7 at 5 minutes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Study population                                RR 0.74  (0.49 to 1.14)         4271  (14 RCTs)                    ⊕⊕⊝⊝  LOW ^1\ 4^                          
  22 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            16 per 1000  (11 to 25)                                                                                                                                     
  Neonatal intensive care unit admission                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Study population                                RR 0.82  (0.65 to 1.04)         3647  (12 RCTs)                    ⊕⊕⊝⊝  LOW ^1\ 4^                          
  74 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            60 per 1000  (48 to 77)                                                                                                                                     
  \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).    **CI:** Confidence interval; **RR:** Risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **GRADE Working Group grades of evidence**  **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect  **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect  **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------------------- ---------------------------------- ---------------------------------------- --------------

^1^We downgraded (1) level for serious limitation in study design due to lack of blinding (although not feasible due to nature of event)

^2^We downgraded (1) level for serious inconsistency due to evidence of statistical heterogeneity (I^2^ = \>30%)

^3^We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and small number of events

^4^We downgraded (1) level for serious imprecision due to wide CI crossing the line of no effect

###### Balloon (Foley or ATAD) compared to low‐dose vaginal misoprostol for third trimester induction of labour in women with a viable fetus

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------------------- ---------------------------------- ---------------------------------------- ----------------------------------------
  **Balloon (Foley or ATAD) compared to low‐dose vaginal misoprostol for third trimester induction of labour in women with a viable fetus**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **Patient or population:** third trimester induction of labour in women with a viable fetus  **Setting:** Brazil, Egypt, India, Iran, Nigeria, the Netherlands, Sweden  **Intervention:** balloon (Foley or ATAD)  **Comparison:** low‐dose vaginal misoprostol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**   **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)**   **Comments**
  **Risk with low‐dose vaginal misoprostol**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **Risk with balloon (Foley or ATAD)**                                                                                                                       
  Vaginal delivery not achieved in 24 hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study population                                RR 1.09  (0.85 to 1.39)         340  (2 RCTs)                      ⊕⊕⊝⊝  LOW ^1\ 2^                          
  412 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           449 per 1000  (350 to 573)                                                                                                                                  
  Uterine hyperstimulation with FHR changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study population                                RR 0.39  (0.18 to 0.85)         1322  (8 RCTs)                     ⊕⊕⊕⊝  MODERATE ^1^                        
  33 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            13 per 1000  (6 to 28)                                                                                                                                      
  Caesarean section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Study population                                RR 1.28  (1.02 to 1.60)         1756  (12 RCTs)                    ⊕⊕⊝⊝  LOW ^1\ 3^                          
  243 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           311 per 1000  (247 to 388)                                                                                                                                  
  Serious neonatal morbidity or perinatal death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Study population                                RR 0.58  (0.12 to 2.66)         381  (3 RCTs)                      ⊕⊝⊝⊝  VERY LOW ^1\ 4^                     
  21 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            12 per 1000  (2 to 55)                                                                                                                                      
  Serious maternal morbidity or death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study population                                not estimable                   464  (4 RCTs)                      ⊕⊝⊝⊝  VERY LOW ^1\ 5^                    no events occurred in included studies
  0 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             0 per 1000  (0 to 0)                                                                                                                                        
  Apgar score \< 7 at 5 minutes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Study population                                RR 1.00  (0.50 to 1.97)         941  (7 RCTs)                      ⊕⊕⊝⊝  LOW ^1\ 2^                          
  30 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            30 per 1000  (15 to 59)                                                                                                                                     
  Neonatal intensive care unit admission                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Study population                                RR 1.00  (0.61 to 1.63)         1302  (9 RCTs)                     ⊕⊕⊝⊝  LOW ^1\ 2\ 6^                       
  47 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            47 per 1000  (29 to 77)                                                                                                                                     
  \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).    **CI:** Confidence interval; **RR:** Risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **GRADE Working Group grades of evidence**  **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect  **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect  **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------------------- ---------------------------------- ---------------------------------------- ----------------------------------------

^1^We downgraded (1) level for serious limitation in study design due to lack of blinding (although not feasible due to nature of event)

^2^We downgraded (1) level for serious imprecision due to wide CI crossing the line of no effect

^3^We downgraded (1) level for serious inconsistency due to evidence of statistical heterogeneity (I^2^ = \>30%)

^4^We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and small number of events

^5^ We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and no events reported in included studies

^6^ Although there was some evidence suggesting small‐study effect we did not downgrade for publication bias because individual studies did not reach statistical significance and there was low heterogeneity across all studies for this outcome. Also, no difference was found between fixed‐effect or random‐effect analyses

###### Balloon (Foley or ATAD) compared to low‐dose oral misoprostol for third trimester induction of labour in women with a viable fetus

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------------------- ---------------------------------- ---------------------------------------- --------------
  **Balloon (Foley or ATAD) compared to low‐dose oral misoprostol for third trimester induction of labour in women with a viable fetus**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Patient or population:** third trimester induction of labour in women with a viable fetus  **Setting:** Finland, India, Pakistan, Sri Lanka, the Netherlands  **Intervention:** balloon (Foley or ATAD)  **Comparison:** low‐dose oral misoprostol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**   **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)**   **Comments**
  **Risk with low‐dose oral misoprostol**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                **Risk with balloon (Foley or ATAD)**                                                                                                                       
  Vaginal delivery not achieved within 24 hours                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Study population                                RR 1.28  (1.13 to 1.46)         782  (2 RCTs)                      ⊕⊕⊕⊝  MODERATE ^1^                        
  476 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           609 per 1000  (538 to 695)                                                                                                                                  
  Uterine hyperstimulation with FHR changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Study population                                RR 0.81  (0.48 to 1.38)         2033  (2 RCTs)                     ⊕⊕⊝⊝  LOW ^1\ 2^                          
  29 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            24 per 1000  (14 to 40)                                                                                                                                     
  Caesarean section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Study population                                RR 1.17  (1.04 to 1.32)         3178  (7 RCTs)                     ⊕⊕⊕⊝  MODERATE ^1\ 3^                     
  222 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           259 per 1000  (230 to 293)                                                                                                                                  
  Serious neonatal morbidity or perinatal death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Study population                                RR 1.11  (0.60 to 2.06)         2627  (3 RCTs)                     ⊕⊕⊝⊝  LOW ^1\ 2\ 4^                       
  14 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            16 per 1000  (9 to 30)                                                                                                                                      
  Serious maternal morbidity or death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Study population                                RR 0.50  (0.05 to 5.52)         2627  (3 RCTs)                     ⊕⊝⊝⊝  VERY LOW ^1\ 5^                     
  2 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1 per 1000  (0 to 8)                                                                                                                                        
  Apgar score \< 7 after 5 minutes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study population                                RR 0.71  (0.38 to 1.32)         2693  (4 RCTs)                     ⊕⊕⊝⊝  LOW ^1\ 2\ 4^                       
  18 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            13 per 1000  (6 to 28)                                                                                                                                      
  Neonatal intensive care unit admission                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Study population                                RR 0.82  (0.58 to 1.17)         2873  (5 RCTs)                     ⊕⊕⊝⊝  LOW ^1\ 2\ 4^                       
  46 per 1000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            37 per 1000  (26 to 53)                                                                                                                                     
  \***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).    **CI:** Confidence interval; **RR:** Risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **GRADE Working Group grades of evidence**  **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect  **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect  **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------- ------------------------------- ---------------------------------- ---------------------------------------- --------------

^1^We downgraded (1) level for serious limitation in study design due to lack of blinding (although not feasible due to nature of event)

^2^We downgraded (1) level for serious imprecision due to wide CI crossing the line of no effect

^3^ Trial of [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"} did not meet the pre‐specified population as pregnancies with a non viable fetus were included. Sensitivity analyses did not alter the estimated effect size. Therefore we did not downgrade

^4^ Trial of [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"} did not meet the pre‐specified population as pregnancies with a non viable fetus were included. Sensitivity analysis did not change the direction of the effect size and numbers of events were not higher compared to other trials. Therefore we did not downgrade.

^5^ We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and small number of events

Background {#CD001233-sec1-0002}
==========

The previous version of this review formed one of a series of reviews of methods for induction of labour that followed a standardised published 'generic' protocol ([Hofmeyr 2009](#CD001233-bbs2-0323){ref-type="ref-list"}). These reviews were initially developed to help inform the recommendations of the National Institute for Health and Care Excellence (NICE) clinical practice guidelines on induction of labour ([NICE 2008](#CD001233-bbs2-0330){ref-type="ref-list"}). This review no longer strictly follows the original protocol and has been updated with the intention of being a stand‐alone review. This is an update of a review first published in 2001 ([Boulvain 2001](#CD001233-bbs2-0338){ref-type="ref-list"}), and last updated in 2012 ([Jozwiak 2012](#CD001233-bbs2-0339){ref-type="ref-list"}).

Description of the condition {#CD001233-sec2-0001}
----------------------------

Labour induction is a common obstetric procedure, which is generally carried out when the risk of continuing pregnancy outweighs the benefits. Also, induction of labour is being used more and more at the request of pregnant women to shorten the duration of pregnancy or to time the birth of the baby according to the convenience of the mother and/or healthcare workers ([WHO 2011](#CD001233-bbs2-0336){ref-type="ref-list"}). In the USA, approximately one in four women are induced and in the last decade, the induction rate in the UK has risen up to almost 30% ([NICE 2008](#CD001233-bbs2-0330){ref-type="ref-list"}; [NHS 2017](#CD001233-bbs2-0329){ref-type="ref-list"}). Although rates are generally lower in developing countries, in some settings they can be as high as those observed in developed countries ([WHO 2011](#CD001233-bbs2-0336){ref-type="ref-list"}). To maximise the success of induction of labour in women with an unfavourable cervix, various ripening methods are available.

Description of the intervention {#CD001233-sec2-0002}
-------------------------------

Mechanical methods were the first methods developed to ripen the cervix and induce labour ([Thiery 1989](#CD001233-bbs2-0333){ref-type="ref-list"}). Devices that were used in this context include various type of catheters and laminaria tents, introduced into the cervical canal or through the cervix into the extra‐amniotic space. During recent decades they were partly substituted by pharmacological methods, including various prostaglandin E2 (PGE2) preparations (vaginal gel, tablets, inserts, intracervical gel), prostaglandin E1 (PGE1; misoprostol tablets, applied either orally or vaginally) and oxytocin. Pharmacological methods however, have a variety of effects at different sites and receptors in the body that can lead to unwanted side effects when used, such as uterine hyperstimulation (excessive contractions of the uterus) and as result, fetal distress. Therefore, mechanical induction methods are gaining in popularity as it has the potential to have a better safety profile compared to pharmacological methods, however possibly at the cost of a longer duration of labour. These factors need to be considered to determine the most appropriate methods depending on the clinical situation, with impact on labour duration possibly being of secondary importance as more women have labour induced for less urgent indications.

How the intervention might work {#CD001233-sec2-0003}
-------------------------------

The goal of mechanical induction methods is to ripen the cervix, which can be achieved directly through dilatation of the canal, indirectly by increasing prostaglandin or oxytocin secretion, or both ([Keirse 1983](#CD001233-bbs2-0182){ref-type="ref-list"}). In addition to the local effect, mechanisms which involve neuro‐endocrine reflexes (the Ferguson reflex) may promote the onset of contractions, leading to labour onset ([Krammer 1995b](#CD001233-bbs2-0326){ref-type="ref-list"}).

The standard Foley urinary catheter can be used, as well as a specially developed \'Atad\' double‐balloon catheter ([Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}) or Cook balloon. The catheter is introduced through the cervical canal to reach the extra‐amniotic space. The balloon is then inflated to keep the catheter in place. Traction is applied to the catheter in some cases. Another method involving catheters consists of infusing saline solution or prostaglandins through a catheter inserted, via the cervical canal, in the extra‐amniotic space (EASI).

Laminaria tents, made from sterile sea‐weed or synthetic hydrophilic materials (e.g. Lamicel), are introduced into the cervical canal. These devices increase in diameter because of their hydrophilic properties. This achieves a gradual stretching of the cervix.

Digital stripping or sweeping of the membranes is evaluated in a different review ([Boulvain 2005](#CD001233-bbs2-0316){ref-type="ref-list"}).

Why it is important to do this review {#CD001233-sec2-0004}
-------------------------------------

Mechanical methods were never completely abandoned, but were substituted by pharmacological methods in recent decades. However, as induction rates rise and indications are often less urgent, the safety aspects of induction methods become more important, although this could be at the expense of effectiveness. Apart for being widely available and low in cost, potential advantages of mechanical methods over pharmacological ones may include a reduction in side effects, such as uterine hyperstimulation, thereby having the potential to improve neonatal outcomes.

Objectives {#CD001233-sec1-0003}
==========

To determine the effectiveness and safety of mechanical methods for third trimester (\> 24 weeks\' gestation) induction of labour in comparison with prostaglandin E2 (PGE2) (vaginal and intracervical), low‐dose misoprostol (oral and vaginal), amniotomy or oxytocin.

Methods {#CD001233-sec1-0004}
=======

Criteria for considering studies for this review {#CD001233-sec2-0005}
------------------------------------------------

### Types of studies {#CD001233-sec3-0001}

Clinical trials, comparing mechanical methods for cervical ripening or labour induction with other induction methods. Quasi‐randomised controlled trials and trials only reported as abstract were eligible for inclusion. Cluster‐randomised trials are unlikely to be conducted in this area, however, if identified by a future search, they will be handled with appropriate methods.

### Types of participants {#CD001233-sec3-0002}

Pregnant women due for third trimester induction of labour, carrying a viable fetus.

Predefined subgroup comparisons were: previous caesarean section or not, nulliparity or multiparity. Only those outcomes with data appear in the analyses tables.

### Types of interventions {#CD001233-sec3-0003}

Different types of intervention have been considered as mechanical methods: (1) the introduction of a catheter (Foley single balloon, Atad/Cook double balloon or other type), through the cervix into the extra‐amniotic space, either with or without traction; (2) introduction of laminaria tents, or their synthetic equivalent (Dilapan), into the cervical canal; (3) use of a catheter to inject fluids, usually saline water, in the extra‐amniotic space (EASI).

Mechanical methods were compared with other induction methods (i.e. vaginal PGE2, intracervical PGE2, intravenous oxytocin, amniotomy, vaginal and oral misoprostol). For this update, the comparison with placebo/no treatment was left out. When the protocol for reviews of induction methods was designed, it was relevant to know if cervical ripening before actual induction of labour (rupturing the membranes, and if needed, administer of oxytocin) was beneficial. Since we already know the advantages of cervical ripening in case of an unfavourable cervix, no future trials will be done to study the effect of cervical ripening with a mechanical method versus no ripening. Also, in the case of pharmacological methods, it is possible to perform a placebo‐controlled study, but with mechanical methods of labour, this is not possible. Studies which do make this comparison between mechanical induction and no treatment, explore other objectives rather than the ones relevant for his review (induction of labour versus expectant management to improve birth outcome). Therefore, the choice was made to depart from the original research protocol and leave out this pre‐specified comparison. For this update, we also chose only to include low‐dose misoprostol (defined as ≤ 50 mcg every ≥ 4 hours) as evidence suggests low‐dose misoprostol is superior to high‐dose misoprostol regarding safety outcomes and being equally effective ([Alfirevic 2014](#CD001233-bbs2-0314){ref-type="ref-list"}; [Hofmeyr 2010](#CD001233-bbs2-0324){ref-type="ref-list"}).

In addition, other comparisons were made: (1) a single balloon compared to a double balloon; (2) laminaria tent compared to other hygroscopic dilatators; (3) addition of prostaglandins or oxytocin to mechanical methods compared with prostaglandins or oxytocin alone. These comparisons were not pre‐specified in the generic protocol of induction of labour reviews ([Hofmeyr 2009](#CD001233-bbs2-0323){ref-type="ref-list"}).

### Types of outcome measures {#CD001233-sec3-0004}

We included all clinically relevant outcomes for trials of methods of cervical ripening/labour induction as had been pre‐specified by two authors of the generic protocol for labour induction reviews (Justus Hofmeyr and Zarko Alfirevic). We added six more outcomes to the list of the original protocol. Differences were settled by discussion.

#### Primary outcomes {#CD001233-sec4-0001}

Five primary outcomes were chosen as being most representative of the clinically important measures of effectiveness and complications. Subgroup comparisons were limited to the primary outcomes:

vaginal delivery not achieved within 24 hours (from start cervical ripening);uterine hyperstimulation with fetal heart rate (FHR) changes;caesarean section;serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood);serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia).

Perinatal and maternal morbidity and mortality are composite outcomes. This is not an ideal solution because some components are clearly less severe than others. It is possible for one intervention to cause more deaths but less severe morbidity. However, in the context of labour induction in mainly term pregnancies, this is unlikely. All these events are rare, and a modest change in their incidence will be easier to detect if composite outcomes are presented. The incidence of individual components were explored as secondary outcomes (see below).

Secondary outcomes relate to measures of effectiveness, complications and satisfaction.

##### Measures of effectiveness: {#CD001233-sec5-0001}

cervix unfavourable/unchanged after 12 to 24 hours;oxytocin augmentation.

##### Complications: {#CD001233-sec5-0002}

uterine hyperstimulation without FHR changes;uterine rupture;epidural analgesia;instrumental vaginal delivery;meconium‐stained liquor;Apgar score less than seven at five minutes;neonatal intensive care unit (NICU) admission;neonatal encephalopathy;perinatal death;disability in childhood;maternal side effects (all);maternal nausea;maternal vomiting;maternal diarrhoea;other maternal side effects;postpartum haemorrhage (as defined by the trial authors);serious maternal complications (e.g. intensive care unit admission, septicaemia but excluding uterine rupture);maternal death.

##### Measures of satisfaction: {#CD001233-sec5-0003}

woman not satisfied;caregiver not satisfied.

The terminology of uterine hyperstimulation is problematic ([Curtis 1987](#CD001233-bbs2-0320){ref-type="ref-list"}). In the review, we use the term \'uterine hyperstimulation without FHR changes\' to include uterine tachysystole (more than five contractions per 10 minutes for at least 20 minutes) and uterine hypersystole/hypertonus (a contraction lasting at least two minutes) and \'uterine hyperstimulation with FHR changes\' to denote uterine hyperstimulation syndrome (tachysystole or hypersystole with FHR changes such as persistent decelerations, tachycardia or decreased short‐term variability).

Search methods for identification of studies {#CD001233-sec2-0006}
--------------------------------------------

The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth.

### Electronic searches {#CD001233-sec3-0005}

For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register by contacting their Information Specialist (9 January 2018). We updated this search on 19 March 2019 and added the results to [Studies awaiting classification](#CD001233-bbs1-0003){ref-type="ref-list"} for consideration in the next update.

The Register is a database containing over 25,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth's Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this [link](link).

Briefly, Cochrane Pregnancy and Childbirth's Trials Register is maintained by their Information Specialist and contains trials identified from:

monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);weekly searches of MEDLINE (Ovid);weekly searches of Embase (Ovid);monthly searches of CINAHL (EBSCO);handsearches of 30 journals and the proceedings of major conferences;weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.

Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics) and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (Included, Excluded, Awaiting Classification or Ongoing).

In addition, we searched [ClinicalTrials.gov](ClinicalTrials.gov) and the WHO International Clinical Trials Registry Platform ([ICTRP](ICTRP)) for unpublished, planned and ongoing trial reports (19 March 2019) using the search methods detailed in [Appendix 1](#CD001233-sec2-0016){ref-type="app"}.

### Searching other resources {#CD001233-sec3-0006}

We searched the reference lists of retrieved studies.

We did not apply any language or date restrictions.

Data collection and analysis {#CD001233-sec2-0007}
----------------------------

For methods used in the previous version of this review, *see*[Jozwiak 2012](#CD001233-bbs2-0339){ref-type="ref-list"}.

For this update, the following methods were used for assessing the 247 reports that were identified as a result of the updated search. The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth.

### Selection of studies {#CD001233-sec3-0007}

Two review authors (Marieke de Vaan and Mieke ten Eikelder) independently assessed all potential studies identified as a result of the search strategy for inclusion. Any disagreement was resolved through discussion, or if required, by involving a third review author (Marta Jozwiak).

### Data extraction and management {#CD001233-sec3-0008}

We designed a form to extract data. For eligible studies, two groups of two review authors (Marieke de Vaan, Marta Jozwiak, Ben Willem Mol and Kirsten Palmer) extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third review author. Data were entered into Review Manager software ([RevMan 2014](#CD001233-bbs2-0331){ref-type="ref-list"}) and checked by a second review author for accuracy.

When information regarding any of the above was unclear, we contacted authors of the original reports to provide further details.

### Assessment of risk of bias in included studies {#CD001233-sec3-0009}

Two review authors (Marieke de Vaan and Mieke ten Eikelder) independently assessed risk of bias for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#CD001233-bbs2-0322){ref-type="ref-list"}). Any disagreement was resolved by discussion or by involving a third assessor (Marta Jozwiak).

#### (1) Random sequence generation (checking for possible selection bias) {#CD001233-sec4-0002}

We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.

We assessed the method as:

low risk of bias (any truly random process, e.g. random number table; computer random number generator);high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number);unclear risk of bias.

#### (2) Allocation concealment (checking for possible selection bias) {#CD001233-sec4-0003}

We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.

We assessed the methods as:

low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth);unclear risk of bias.

#### (3.1) Blinding of participants and personnel (checking for possible performance bias) {#CD001233-sec4-0004}

We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.

We assessed the methods as:

low, high or unclear risk of bias for participants;low, high or unclear risk of bias for personnel.

#### (3.2) Blinding of outcome assessment (checking for possible detection bias) {#CD001233-sec4-0005}

We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.

We assessed methods used to blind outcome assessment as:

low, high or unclear risk of bias.

#### (4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) {#CD001233-sec4-0006}

We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re‐include missing data in the analyses which we undertook.

We assessed methods as:

low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation);unclear risk of bias.

#### (5) Selective reporting (checking for reporting bias) {#CD001233-sec4-0007}

We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.

We assessed the methods as:

low risk of bias (where it is clear that all of the study's pre‐specified outcomes and all expected outcomes of interest to the review have been reported);high risk of bias (where not all the study's pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);unclear risk of bias.

#### (6) Other bias (checking for bias due to problems not covered by (1) to (5) above) {#CD001233-sec4-0008}

We described for each included study any important concerns we had about other possible sources of bias.

#### Assessment of the quality of the evidence using the GRADE approach {#CD001233-sec4-0009}

For this update, the quality of the evidence was assessed for the comparisons relating to the most frequently used methods of cervical ripening (i.e. vaginal prostaglandin E2 (PGE2), vaginal misoprostol, and oral misoprostol) using the GRADE approach as outlined in the [GRADE handbook](GRADE handbook) in order to assess the quality of the body of evidence relating to the following outcomes.

Vaginal delivery not achieved within 24 hoursUterine hyperstimulation with FHR changesCaesarean sectionSerious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood)Serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia)Neonatal intensive care unit admissionApgar score less than seven at five minutes

For the main comparisons we used [GRADEpro](GRADEpro) Guideline Development Tool to import data from Review Manager 5.3 ([RevMan 2014](#CD001233-bbs2-0331){ref-type="ref-list"}) in order to create 'Summary of findings' tables. A summary of the intervention effect and a measure of quality for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from \'high quality\' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias.

### Measures of treatment effect {#CD001233-sec3-0010}

#### Dichotomous data {#CD001233-sec4-0010}

For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals.

#### Continuous data {#CD001233-sec4-0011}

No continuous data were analysed in this update. If outcomes using continuous data are included in future versions of this review, we will use the mean difference if outcomes are measured in the same way between trials. We will use the standardised mean difference to combine trials that measure the same outcome but use different methods.

### Unit of analysis issues {#CD001233-sec3-0011}

#### Cluster‐randomised trials {#CD001233-sec4-0012}

Cluster‐randomised trials are eligible for inclusion in the analyses along with individually‐randomised trials. None have currently been identified. If in the future such trials are identified, we will adjust their standard errors using the methods described in the Handbook ([Higgins 2011](#CD001233-bbs2-0322){ref-type="ref-list"}) using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely.

We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.

#### Cross‐over trials {#CD001233-sec4-0013}

Cross‐over trials were not eligible for inclusion.

#### Other unit of analysis issues {#CD001233-sec4-0014}

Trials in pregnancy and childbirth may include outcomes for multiple pregnancies, but the trials identified to date have included singleton pregnancies only. Trials with multiple pregnancy will be included, but the outcomes relating to the babies will have to take account of clustering of events, as outlined in the Pregnancy and Childbirth Group Methodological Guidelines and the *Handbook* ([Higgins 2011](Higgins 2011)).

Some trials are multi‐arm studies, where this occurs only the intervention arms relevant to this review were included and this is noted in the [Characteristics of included studies](#CD001233-sec2-0019){ref-type="sec"} table.

### Dealing with missing data {#CD001233-sec3-0012}

For included studies, levels of attrition were noted. In future updates, if more eligible studies are included, we will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.

For all outcomes, analyses were carried out, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.

### Assessment of heterogeneity {#CD001233-sec3-0013}

We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either a Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. In the case of substantial heterogeneity (above 30%), if possible, we explored it by subgroup analyses.

### Assessment of reporting biases {#CD001233-sec3-0014}

When there were 10 or more studies in the meta‐analysis, we investigated reporting biases (such as publication bias) using funnel plots. We assessed funnel plot asymmetry visually. If asymmetry was suggested by a visual assessment, we performed exploratory analyses to investigate it.

### Data synthesis {#CD001233-sec3-0015}

We carried out statistical analysis using the Review Manager software ([RevMan 2014](#CD001233-bbs2-0331){ref-type="ref-list"}). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials' populations and methods were judged sufficiently similar.

If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was treated as the average range of possible treatment effects and the clinical implications of treatment effects differing between trials is discussed. If the average treatment effect was not clinically meaningful, we did not combine trials. When random‐effects analyses were used, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².

### Subgroup analysis and investigation of heterogeneity {#CD001233-sec3-0016}

We did not carry out formal subgroup analysis to investigate heterogeneity, but carried out additional analyses of subgroups of trials based on the following.

Previous caesarean section or notNulliparity or multiparity

The following outcomes were used in the subgroups.

Vaginal delivery not achieved within 24 hoursUterine hyperstimulation with FHR changesCaesarean sectionSerious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood)Serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia)

### Sensitivity analysis {#CD001233-sec3-0017}

We carried out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates, or both, with poor quality studies being excluded from the analyses in order to assess whether this made any difference to the overall result.

Results {#CD001233-sec1-0005}
=======

Description of studies {#CD001233-sec2-0008}
----------------------

### Results of the search {#CD001233-sec3-0018}

See: [Figure 1](#CD001233-fig-0001){ref-type="fig"}.

![Study flow diagram.](nCD001233-AFig-FIG01){#CD001233-fig-0001}

For this update, we identified 418 trial reports to assess in the search of 9 January 2018. One study ([Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}) was retrieved through other sources. When exploring the included trial registration of this study, we found out that an abstract of this study was published.

We also reassessed the 17 reports awaiting classification and the four ongoing studies in the previous version of the review ([Jozwiak 2012](#CD001233-bbs2-0339){ref-type="ref-list"}). One hundred and seventy‐one reports were screened out because they did not meet the scope for this review or were not randomised controlled trials. We then assessed trial reports which related to 166 new trials (247 reports). We included 60 new trials (120 reports), added two trial reports to already included studies and excluded 74 trials (102 reports). Two trials from the January 2018 search are awaiting classification ([Agboghoroma 2015](#CD001233-bbs2-0253){ref-type="ref-list"}; [Mallah 2011](#CD001233-bbs2-0269){ref-type="ref-list"}), and 21 are ongoing ([Argilagos 2016](#CD001233-bbs2-0291){ref-type="ref-list"}; [Beckmann 2013](#CD001233-bbs2-0292){ref-type="ref-list"}; [Bekele 2017](#CD001233-bbs2-0293){ref-type="ref-list"}; [Berndl 2016](#CD001233-bbs2-0294){ref-type="ref-list"}; [Bhide 2017](#CD001233-bbs2-0295){ref-type="ref-list"}; [Eser 2016](#CD001233-bbs2-0296){ref-type="ref-list"}; [Goli 2017](#CD001233-bbs2-0297){ref-type="ref-list"}; [Goonewardene 2016](#CD001233-bbs2-0298){ref-type="ref-list"}; [Gupta 2016](#CD001233-bbs2-0299){ref-type="ref-list"}; [Hassanzadeh 2017](#CD001233-bbs2-0300){ref-type="ref-list"}; [Igwe 2017](#CD001233-bbs2-0301){ref-type="ref-list"}; [Lacarin 2017](#CD001233-bbs2-0302){ref-type="ref-list"}; [Lauterbach 2017](#CD001233-bbs2-0303){ref-type="ref-list"}; [Levy 2016](#CD001233-bbs2-0304){ref-type="ref-list"}; [Osoti 2016](#CD001233-bbs2-0305){ref-type="ref-list"}; [Park 2012](#CD001233-bbs2-0306){ref-type="ref-list"}; [Perrotin 2016](#CD001233-bbs2-0307){ref-type="ref-list"}; [Tagore 2015](#CD001233-bbs2-0308){ref-type="ref-list"}; [Viteri 2015](#CD001233-bbs2-0309){ref-type="ref-list"}; [Wise 2016](#CD001233-bbs2-0310){ref-type="ref-list"}; [Yildirim 2017](#CD001233-bbs2-0311){ref-type="ref-list"}).

Of the 71 previous included studies, we excluded 18 trials because they were no longer within the scope of this review. Four studies were excluded because they compared a mechanical method with a placebo or no cervical ripening ([De Oliveira 2003](#CD001233-bbs2-0140){ref-type="ref-list"}; [Gilson 1996](#CD001233-bbs2-0158){ref-type="ref-list"}; [Gower 1982](#CD001233-bbs2-0160){ref-type="ref-list"}; [Lackritz 1979](#CD001233-bbs2-0183){ref-type="ref-list"}), 11 studies because of the use of high‐dose misoprostol ([Adeniji 2005b](#CD001233-bbs2-0116){ref-type="ref-list"}; [Barrilleaux 2002a](#CD001233-bbs2-0126){ref-type="ref-list"}; [Buccellato 2000](#CD001233-bbs2-0129){ref-type="ref-list"}; [Chung 2003](#CD001233-bbs2-0133){ref-type="ref-list"}; [Greybush 2001](#CD001233-bbs2-0161){ref-type="ref-list"}; [Hill 2009](#CD001233-bbs2-0167){ref-type="ref-list"}; [Kashanian 2006](#CD001233-bbs2-0178){ref-type="ref-list"}; [Owolabi 2005](#CD001233-bbs2-0215){ref-type="ref-list"}; [Rust 2001](#CD001233-bbs2-0223){ref-type="ref-list"}; [Sciscione 2001](#CD001233-bbs2-0231){ref-type="ref-list"}; [Vengalil 1998](#CD001233-bbs2-0241){ref-type="ref-list"}), two studies compared extra‐amniotic space infusion (EASI) versus induction with a balloon or laminaria ([El‐Torkey 1995](#CD001233-bbs2-0146){ref-type="ref-list"}; [Lin 1995](#CD001233-bbs2-0190){ref-type="ref-list"}), and one study compared a balloon versus prostaglandin F2alpha ([Mawire 1999](#CD001233-bbs2-0201){ref-type="ref-list"}).

In the updated search of 19 March 2019, we identified an additional 38 trial reports which were added to [Studies awaiting classification](#CD001233-bbs1-0003){ref-type="ref-list"} for consideration in the next update. The references have been assessed but not incorporated into the review. Only seven of these trials are likely to contribute data for this review and are mainly small trials ([Khatib 2019](#CD001233-bbs2-0266){ref-type="ref-list"}; [Lim 2018](#CD001233-bbs2-0268){ref-type="ref-list"}; [Osoti 2018](#CD001233-bbs2-0284){ref-type="ref-list"}; [Souizi 2018](#CD001233-bbs2-0287){ref-type="ref-list"}; [ten Eikelder 2017](#CD001233-bbs2-0288){ref-type="ref-list"}; [Tulek 2018](#CD001233-bbs2-0289){ref-type="ref-list"}; [Viteri 2019](#CD001233-bbs2-0290){ref-type="ref-list"}). We imputed the data for these trials and this resulted in no changes in terms of the direction or strength of the evidence. We will incorporate these studies fully at the next update.

### Included studies {#CD001233-sec3-0019}

Altogether, this review now comprises 113 included studies, 105 of which contributed data. The studies that contributed data involved 22,373 women (see [Characteristics of included studies](#CD001233-sec2-0019){ref-type="sec"}). Trials with more than two arms may be included in more than one comparison. No cluster‐randomised trials were identified by the search.

Eight studies did not contribute any data to this review because the outcomes of interest were not reported, or reported in a format that could not be included in this review ([Biron‐Shental 2004](#CD001233-bbs2-0011){ref-type="ref-list"}; [Deo 2013](#CD001233-bbs2-0023){ref-type="ref-list"}; [Hughes 2002](#CD001233-bbs2-0043){ref-type="ref-list"}; [Jalilian 2011](#CD001233-bbs2-0046){ref-type="ref-list"}; [Peedicayil 1998](#CD001233-bbs2-0078){ref-type="ref-list"}; [Qamar 2012](#CD001233-bbs2-0083){ref-type="ref-list"}; [Thiery 1981](#CD001233-bbs2-0106){ref-type="ref-list"}; [Zahoor 2014](#CD001233-bbs2-0113){ref-type="ref-list"}). These studies are therefore not included in the descriptions of study details and \'Risk of bias\' assessment below.

#### Design {#CD001233-sec4-0015}

All included studies were randomised controlled trials although the randomisation method was not always well described and in three studies the allocation process was not truly random ([Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}; [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}). All studies involved two trial arms except for [Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}, [Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}, [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}, [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}, [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}, [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}, [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}, [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}, [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}, [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}, [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}, [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}, [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}, [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}, [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}, [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"} and [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}, which had three arms. [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}, [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"} and [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"} had four arms, and [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"} had five arms. Not all comparisons in these studies were relevant for this review and therefore one or more arms in the studies of [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}, [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}, [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"} and [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"} were excluded.

#### Setting {#CD001233-sec4-0016}

Nine studies were multicentre studies ([Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}), the remaining studies were single‐centre studies.

All studies took place in a hospital setting, except for [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}, in which the period of cervical ripening took place in an outpatient setting.

The included studies were conducted in the following countries: Australia ([Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}), Brazil ([Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}; [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}, Canada ([Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}), Czech Republic ([Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}), China ([Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}; [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}; [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}), Denmark ([Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}), Egypt ([Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}), Finland ([Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}), France ([Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"};), India ([Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}; [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}; [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), Iran ([Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}; [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}; [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}; [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}) Italy ([Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}; [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}), Israel ([Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}; [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}; [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}), Jordan ([Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}; [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}), the Netherlands ([Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}), Nigeria ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}), Norway ([Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}), Pakistan ([Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}; [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}; [Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}; [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}), Russia ([Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}), Rwanda ([Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}), South Africa ([Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}; [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"}), Singapore ([Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}), Sri Lanka ([Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}), Sweden ([Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}; [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}), Tunis ([Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}), Turkey ([Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}), the UK ([Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}), the USA ([Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"}; [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}; [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}; [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}; [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}; [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}; [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}; [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}; [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"}; [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}; [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}; [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"}; [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}; [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}).

#### Dates {#CD001233-sec4-0017}

The study of [Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"} and [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"} took place between 1980 and 1989; the studies of [Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}, [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}, [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}, [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}, [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}, [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}, [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}, [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}, [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}, [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}, [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}, [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}, [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"} and [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"} between 1990 and 1999; the studies of [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}, [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"} and [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"} between 1998 and 2001; the studies of [Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}, [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}, [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}, [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}, [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}, [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}, [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}, [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}, [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}, [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}, [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}, [Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}, [Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}, [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}, [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}, [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}, [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}, [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}, [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}, [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}, [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"} and [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"} between 2000 and 2009; the studies of [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"} and [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"} between 2008 and 2011; and the studies of [Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}, [Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}, [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}, [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}, [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}, [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}, [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}, [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}, [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}, [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}, [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}, [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}, [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}, [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}, [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}, [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}, [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}, [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}, [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}, [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}, [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}, [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}, [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}, [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}, [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}, [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}, [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}, [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"} and [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"} between 2010 and the present day.

For the remaining studies, no study period was reported ([Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}; [Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}; [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}; [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}; [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}; [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}; [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}; [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"}; [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}; [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}; [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}).

#### Participants {#CD001233-sec4-0018}

Most studies included both nulliparous and multiparous women. Nine studies included only nulliparous women ([Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}; [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}; [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}) and two studies included only multiparous women ([Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}).

Thirteen studies included women with a specific indication for labour induction or specific patient groups, i.e. women with a hypertensive disease ([Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}), women with a body mass index (BMI) greater than 30 ([Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}), post‐date pregnancies ([Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}; [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}), oligohydramnios ([Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}) or pre labour rupture of membranes (PROM; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}). Most authors specified that only women with intact membranes were included, except for [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}, in which this was not an exclusion criteria. [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}, [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"} and [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"} reported nothing on membrane status, so it was not clear if women with ruptured membranes could be included.

Most studies excluded women with a past history of caesarean section, although four studies only included women with a past history of caesarean section ([Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}). Three studies did not exclude women with a past history of caesarean section, but did not specify the outcomes for this subgroup of women separately ([Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}; [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}). [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}, [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}, [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}, [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}, [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}, [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}, [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}, [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}, and [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"} reported nothing on previous caesarean section in their inclusion and exclusion criteria.

The majority of studies included women with a gestational age beyond 37 weeks, except for [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"} and [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"} who reported a minimal gestational age of 36 weeks, [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}, [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}, [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}, [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}, [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}[Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}, [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"} and [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"} of 34 weeks, [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"} of 33 weeks, [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"} of 32 weeks, [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}, [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"} and [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"} of 28 weeks, [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"} of 26 weeks, [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"} of 24 weeks and [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"} of 20 weeks, although in this last study, no women with a gestational age below 28 weeks were included.

Twenty‐four studies were not clear on their inclusion and exclusion criteria: [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}, [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"} and [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"} reported no inclusion or exclusion criteria. [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}, [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"} and [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"} only reported that women with intact membranes were included. [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"} only reported that women with a previous caesarean section were excluded. [Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}, [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}, [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}, [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}, [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}, [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"} reported that only women with an indication for labour induction with an unfavourable cervix were included. [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"} reported nothing on membrane status or previous caesarean section. [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}, [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}, [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}, [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}, [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}, [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"} and [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"} reported nothing on fetal presentation, membrane status or previous caesarean section. [Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"} and [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"} reported nothing on gestational age, fetal presentation, membrane status or previous caesarean section.

#### Interventions and comparisons {#CD001233-sec4-0019}

The protocol of administration in the intervention and in the control groups varied between studies. Different mechanical devices were evaluated (i.e. balloon catheter, laminaria tents, and extra‐amniotic infusion). Prostaglandins (intracervical or intravaginal PGE2, and oral or vaginal misoprostol) were used with different protocols of administration. We regrouped these protocols as follows: (1) balloon catheter versus other interventions; (2) laminaria tent versus other interventions: (3) extra‐amniotic infusion versus other interventions; (4) any mechanical method combined with other (non‐mechanical) intervention versus other interventions. For this last group of comparisons, we considered both PGE2 (intracervical or intravaginal PGE2) and misoprostol (oral or vaginal misoprostol) as a single intervention. The information on comparisons made in each trial, used device and balloon size is summarised below.

Studies evaluating laminaria or Dilapan were considered together, irrespective of the number of devices inserted. Similarly, evaluations of a Foley catheter (regardless of sizes and amount of liquid used to inflate the balloon and traction applied on the catheter) and a specially designed double‐balloon catheter (ATAD or Cook catheter), we considered as similar interventions. However, when a catheter was used to perform extra‐amniotic saline infusion (EASI), we considered these studies separately. Despite having regrouped similar interventions, this review still includes a large number of comparisons.

Most of the studies included in the review examined a balloon and compared it with either vaginal PGE2 or with vaginal or oral misoprostol. A smaller number of studies examined a balloon versus either intracervical PGE2 or oxytocin. Since the last update, no more studies have been published about induction of labour with a Laminaria tent or with EASI. None of the included studies examined the combination of a mechanical method with amniotomy.

The following comparisons were made in this review.

##### 1. Balloon comparisons {#CD001233-sec5-0004}

**Balloon (Foley or ATAD) versus vaginal prostaglandin E2**

*PGE2 tablets*: [Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"} (50 cc); [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"} (double balloon); [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"} (80 cc); [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"} (50 cc to 60 cc); [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"} (double balloon); [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"} (30 cc); [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"} (40 cc); [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"} (30 cc and double balloon); [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"} (double balloon).

*PGE2 gel*: [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"} (40 cc); [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"} (30 cc); [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"} (balloon size unknown); [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"} (30 cc); [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"} (30 cc); [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"} (30 cc); [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"} (30 cc); [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"} (30 cc); [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"} (40 cc).

*PGE2 vaginal insert:*[Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"} (50 cc; for this comparison the two groups of Foley catheter (12 hours and 24 hours) were combined); [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"} (double balloon); [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"} (30 cc); [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"} (30 cc); [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"} (30 cc); [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"} (30 cc); [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"} (balloon size unknown); [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"} (40 cc to 50cc); [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"} (double balloon); [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"} (double balloon); [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"} (80 cc); [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"} (double balloon); [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"} (double balloon).

**Balloon (Foley or ATAD) versus intracervical prostaglandin E2**

*PGE2 intracervical gel***:**[Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"} (50 cc); gel: [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"} (40 cc); [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"} (30 cc); [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"} (balloon size unknown); [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"} (40 cc); [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"} (30 cc); [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}: (balloon size unknown); [Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"} (30 cc); [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"} (30 cc); [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"} (30 cc); [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"} (30 cc); [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"} (double balloon).

**Balloon (Foley or ATAD) versus low‐dose vaginal misoprostol**

*Misoprostol tablets*: [Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"} (30 cc); [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"} (30 cc); [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"} (30 cc); [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"} (30 cc); [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"} (30 cc); [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"} (balloon size unknown); [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"} (50 cc); [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"} (30 cc); [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"} (30 cc); [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"} (50 cc); [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"} (30 cc); [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"} (50 cc).

**Balloon (Foley or ATAD) versus low‐dose oral misoprostol**

*Misoprostol tablets:*[Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"} (balloon size unknown); [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"} (50 cc to 60 cc); [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"} (30 cc); [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"} (40 cc to 50 cc); [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"} (30 cc); [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"} (60 cc);[ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"} (30 cc). *misoprostol solution:*[Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"} (50 cc).

**Balloon (Foley or ATAD) versus oxytocin**

[Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"} (60 cc); [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"} (double balloon); [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"} (30 cc); [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"} (50 cc); [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"} (70 to 80 cc); [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; (30 cc); [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"} (30 cc); [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"} (30 cc); [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"} (50 cc).

**Balloon (Foley or ATAD) versus amniotomy**

[Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"} (70 cc to 80 cc).

**Single balloon (Foley versus double balloon (ATAD)**

[Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"} (50 cc); [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"} (size unknown); [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"} (30 cc); [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"} (30 cc); [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"} (60 cc); [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"} (balloon size unknown).

No studies were found for the comparison of a balloon versus oxytocin with amniotomy.

**2. Laminaria comparisons**

**Laminaria tent versus vaginal prostaglandin E2**

*PGE2 tablets:*[Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"} (Lamicel); [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"} (Dilapan); [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; (laminaria).

*PGE2 gel:*[Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"} (Lamicel); [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"} (Dilapan); [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"} (Dilapan).

**Laminaria tent versus intracervical prostaglandin E2**

*PGE2 intracervical gel:*[Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"} (Dilapan); [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"} (Dilapan); [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}; (Dilapan); [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"} (Dilapan).

***Laminaria tent versus oxytocin***

[Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"} (70 to 80 cc); [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"} (Lamicel).

**Laminaria tent versus amniotomy**

[Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"} (70 to 80 cc).

**Laminaria tent versus other hygroscopic dilator**

[Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"} (Dilapan versus laminaria tent).

No studies were found for the comparison of laminaria tent versus oxytocin with amniotomy or laminaria tent versus vaginal or oral misoprostol.

**3. EASI comparisons**

The only studies which were found compared EASI with PGE2.

**EASI versus vaginal prostaglandin E2**

*Vaginal insert:*[Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}.

**EASI versus intracervical prostaglandin E2**

*Intracervical gel:*[Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}.

**4. Any mechanical combined with prostaglandin E2 comparisons**

**Any mechanical method combined with prostaglandin E2 versus prostaglandin E2 alone**

*PGE2 intracervical gel:*[Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"} (50 cc); [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"} (50 cc); [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"} (Lamicel); [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"} (50 cc).

*PGE2 vaginal gel:*[Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"} (40 cc); [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"} (Dilapan); [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; (Lamicel); [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"} (Laminaria)

**Any mechanical method combined with prostaglandin E2 versus low‐dose misoprostol alone**

*Vaginal misoprostol:*[Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}.

**Any mechanical method combined with prostaglandin E2 versus oxytocin alone**

[Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"} (Lamicel).

No studies were found which compared a mechanical method combined with PGE2 with amniotomy or oxytocin with amniotomy

**5. Any mechanical combined with low‐dose misoprostol comparisons**

**Any mechanical method combined with low‐dose misoprostol versus prostaglandin E2 alone**

*Oral misoprostol:*[Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}.

**Any mechanical method combined with low‐dose misoprostol versus low‐dose misoprostol alone**

*Vaginal misoprostol:*[Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"} (30 cc); [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"} (60 cc); [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"} (60 cc); [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"} (balloon size and dosage of misoprostol unknown); [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"} (30 cc).

*Oral misoprostol:*[Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"} (30 cc); [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"} (50 cc).

No studies were found which compared a mechanical method combined with low‐dose misoprostol with amniotomy, oxytocin or oxytocin with amniotomy.

**6. Any mechanical method combined with oxytocin comparisons**

**Any mechanical method combined with oxytocin versus prostaglandin E2 alone**

*PGE2 intracervical gel:*[Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"} (laminaria + oxytocin and EASI + oxytocin); [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"} (Lamicel); [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"} (EASI).

**Any mechanical method combined with oxytocin versus low‐dose misoprostol alone**

*Vaginal misoprostol:*[Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"} (30 cc); [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"} (balloon size unknown); [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"} (30 cc); [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"} (balloon size and dosage of misoprostol unknown); [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}.

**Any mechanical method combined with oxytocin versus oxytocin alone**

[El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"} (30 cc); [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"} (Lamicel); [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"} (30 cc); [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"} (balloon size unknown); [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"} (double balloon).

No studies were found which compared a mechanical method combined with oxytocin to amniotomy or oxytocin with amniotomy.

#### Outcomes {#CD001233-sec4-0020}

The study authors frequently reported on continuous outcome measures such as change in the cervical status or time to onset of labour, but also mean Apgar score after five minutes and mean pH in the umbilical artery. As these were not pre‐specified in our protocol, we have not included these results in the review. In several studies, the only pre‐specified result available was the number of women delivered by caesarean section. Maternal or neonatal death were infrequently pre‐specified by the authors and therefore not specifically reported. Therefore, these outcomes could not be included in this review.

Maternal satisfaction was reported in seven studies ([Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}; [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}). Of these seven studies, only three studies contributed data for the meta‐analysis ([Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}). The other four studies reported on maternal satisfaction with continuous data. Because of the importance of this outcome, we decided to report these results in narrative form.

#### Source of trial funding {#CD001233-sec4-0021}

Only 14 trials provided details for their funding sources: [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"} received financial support from CAPES. [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"} reported that UpJohn Pharmaceuticals provided funds to purchase study drugs. [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"} received a grand from the Finnish medical society Duodecim and Helsinky university central hospital. [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"} reported the randomisation procedure was funded by Snedkermester Sophus Jacobsen & Astrid Jacobsens fond and the Danish Toyota Foundation. [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"} received a small internal grant to assist with the conduct and statistical analyses for the entire study. [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"} received funding from the Department for International Development, Medical Research Council, and Wellcome Trust Joint Global Health Trials Scheme. The study of [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"} was supported by a grant from the Women and Infants Research Foundation and Adeza Biomedical Corporation contributed support for the fetal fibronectin test kits. [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"} and [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"} stated they were supported by the Vicksburg hospital medical foundation. [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"} received funding from the Emek medical centre. [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"} reported that the double balloons were provided by Cook medical. [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"} received funding from Fonds Nuts Ohra. [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"} received financial support of The People's Liberation Army. [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"} received a grant from the Nature Science Foundation of China.

Thirteen studies reported they received no funding ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}). All other studies did not provide information on received funding.

#### Declarations of interest {#CD001233-sec4-0022}

Thirty‐five studies declared no conflict of interest ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}; [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}; [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}; [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}; [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"};[Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}; [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}).

Two studies reported they had conflicts of interest. [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"} stated that the first author has a patent licensing arrangement for Atad ripening device and thus has the potential gain from its sales. [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"} reported that one of the authors was a scientific adviser to Azanta, a Danish pharmaceutical company.

The remaining studies did not report whether any conflicts of interest were present.

### Excluded studies {#CD001233-sec3-0020}

In total, 138 studies were excluded (see [Characteristics of excluded studies](#CD001233-sec2-0020){ref-type="sec"}), 74 studies (102 reports) in this update. In this update, most of the excluded trials (54 studies) made comparisons not within the scope of this review ([Ahmad 2015](#CD001233-bbs2-0119){ref-type="ref-list"}; [Arsenijevic 2012](#CD001233-bbs2-0121){ref-type="ref-list"}; [Arshad 2016](#CD001233-bbs2-0122){ref-type="ref-list"}; [Caughey 2007](#CD001233-bbs2-0131){ref-type="ref-list"}; [Connolly 2016](#CD001233-bbs2-0134){ref-type="ref-list"}; [Connolly 2017](#CD001233-bbs2-0135){ref-type="ref-list"}; [Demirel 2015](#CD001233-bbs2-0139){ref-type="ref-list"}; [Edwards 2017](#CD001233-bbs2-0143){ref-type="ref-list"}; [El‐Khayat 2016](#CD001233-bbs2-0144){ref-type="ref-list"}; [El Sharkwy 2017](#CD001233-bbs2-0145){ref-type="ref-list"}; [Forgie 2016](#CD001233-bbs2-0150){ref-type="ref-list"}; [Forooshani 2011](#CD001233-bbs2-0151){ref-type="ref-list"}; [Fruhman 2017](#CD001233-bbs2-0152){ref-type="ref-list"}; [Gadel 2015](#CD001233-bbs2-0153){ref-type="ref-list"}; [Ghanaei 2009](#CD001233-bbs2-0155){ref-type="ref-list"}; [Ghanaie 2013](#CD001233-bbs2-0156){ref-type="ref-list"}; [Gibson 2013](#CD001233-bbs2-0157){ref-type="ref-list"}; [Gu 2015](#CD001233-bbs2-0162){ref-type="ref-list"}; [Haghighi 2015](#CD001233-bbs2-0164){ref-type="ref-list"}; [Hallak 2008](#CD001233-bbs2-0165){ref-type="ref-list"}; [He 2000](#CD001233-bbs2-0166){ref-type="ref-list"}; [Hill 2013](#CD001233-bbs2-0168){ref-type="ref-list"}; [Hussein 2012](#CD001233-bbs2-0169){ref-type="ref-list"}; [Ifnan 2006](#CD001233-bbs2-0170){ref-type="ref-list"}; [Jonsson 2011](#CD001233-bbs2-0174){ref-type="ref-list"}; [Kehl 2012](#CD001233-bbs2-0180){ref-type="ref-list"}; [Kehl 2015](#CD001233-bbs2-0181){ref-type="ref-list"}; [Lam 2006](#CD001233-bbs2-0184){ref-type="ref-list"}; [Leong 2017](#CD001233-bbs2-0186){ref-type="ref-list"}; [Levine 2016](#CD001233-bbs2-0187){ref-type="ref-list"}; [Lutgendorf 2012](#CD001233-bbs2-0193){ref-type="ref-list"}; [Manish 2016](#CD001233-bbs2-0197){ref-type="ref-list"}; [Mattingly 2015](#CD001233-bbs2-0200){ref-type="ref-list"}; [McGee 2016](#CD001233-bbs2-0202){ref-type="ref-list"}; [Mei‐Dan 2012a](#CD001233-bbs2-0205){ref-type="ref-list"}; [Mei‐Dan 2014](#CD001233-bbs2-0206){ref-type="ref-list"}; [Movahed 2016](#CD001233-bbs2-0210){ref-type="ref-list"}; [Mullin 2014](#CD001233-bbs2-0211){ref-type="ref-list"}; [Neethurani 2013](#CD001233-bbs2-0214){ref-type="ref-list"}; [Rameez 2007](#CD001233-bbs2-0220){ref-type="ref-list"}; [Rezk 2014](#CD001233-bbs2-0222){ref-type="ref-list"}; [Saad 2016](#CD001233-bbs2-0224){ref-type="ref-list"}; [Salmeen 2012](#CD001233-bbs2-0226){ref-type="ref-list"}; [Sandberg 2017](#CD001233-bbs2-0228){ref-type="ref-list"}; [Schoen 2017](#CD001233-bbs2-0229){ref-type="ref-list"}; [Sharma 2015a](#CD001233-bbs2-0232){ref-type="ref-list"}; [Sharma 2017](#CD001233-bbs2-0233){ref-type="ref-list"}; [Siddiqui 2013](#CD001233-bbs2-0235){ref-type="ref-list"}; [Torbenson 2015](#CD001233-bbs2-0239){ref-type="ref-list"};[Walfisch 2015](#CD001233-bbs2-0243){ref-type="ref-list"}; [Wickramasinghe 2014](#CD001233-bbs2-0245){ref-type="ref-list"}; [Wilkinson 2015](#CD001233-bbs2-0246){ref-type="ref-list"}; [Yaddehige 2015](#CD001233-bbs2-0247){ref-type="ref-list"}; [Zakaria 2017](#CD001233-bbs2-0249){ref-type="ref-list"}). Four studies were not randomised trials ([Du 2015](#CD001233-bbs2-0142){ref-type="ref-list"}; [Miller 2015](#CD001233-bbs2-0207){ref-type="ref-list"}; [Naseem 2007](#CD001233-bbs2-0212){ref-type="ref-list"}; [Nasir 2012](#CD001233-bbs2-0213){ref-type="ref-list"}) and one study did a cross‐over after 24 hours ([Ugwu 2013](#CD001233-bbs2-0240){ref-type="ref-list"}). Thirteen trial registration were excluded because they exceeded the participated end date by more than two years and it was presumed the trial was terminated before enrolment ([Anabosy 2014](#CD001233-bbs2-0120){ref-type="ref-list"}; [Baacke 2006](#CD001233-bbs2-0125){ref-type="ref-list"}; [Behrashi 2013](#CD001233-bbs2-0127){ref-type="ref-list"}; [Cullimore 2009](#CD001233-bbs2-0137){ref-type="ref-list"}; [Dias 2008](#CD001233-bbs2-0141){ref-type="ref-list"}[EUCTR 2012](#CD001233-bbs2-0148){ref-type="ref-list"}; [Kamilya 2011](#CD001233-bbs2-0175){ref-type="ref-list"}; [Mei‐Dan 2012](#CD001233-bbs2-0204){ref-type="ref-list"}; [Park 2011](#CD001233-bbs2-0216){ref-type="ref-list"}[Pathiraja 2014](#CD001233-bbs2-0217){ref-type="ref-list"}; [Reif 2012](#CD001233-bbs2-0221){ref-type="ref-list"}; [Yazdani 2011](#CD001233-bbs2-0248){ref-type="ref-list"}; [Zhang 2014](#CD001233-bbs2-0250){ref-type="ref-list"}). For more information, see [Characteristics of excluded studies](#CD001233-sec2-0020){ref-type="sec"}.

Risk of bias in included studies {#CD001233-sec2-0009}
--------------------------------

The quality assessments are graphically summarised in [Figure 2](#CD001233-fig-0002){ref-type="fig"} and [Figure 3](#CD001233-fig-0003){ref-type="fig"}.

![\'Risk of bias\' graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.](nCD001233-AFig-FIG02){#CD001233-fig-0002}

![\'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.](nCD001233-AFig-FIG03){#CD001233-fig-0003}

This review update includes nine comparisons with more than 10 studies, of which we constructed funnel plots ([Figure 4](#CD001233-fig-0004){ref-type="fig"}; [Figure 5](#CD001233-fig-0005){ref-type="fig"}; [Figure 6](#CD001233-fig-0006){ref-type="fig"}; [Figure 7](#CD001233-fig-0007){ref-type="fig"}; [Figure 8](#CD001233-fig-0008){ref-type="fig"}; [Figure 9](#CD001233-fig-0009){ref-type="fig"}; [Figure 10](#CD001233-fig-0010){ref-type="fig"}; [Figure 11](#CD001233-fig-0011){ref-type="fig"}; [Figure 12](#CD001233-fig-0012){ref-type="fig"}). Visual inspection of one funnel plot ([Figure 5](#CD001233-fig-0005){ref-type="fig"}) was somewhat asymmetrical suggesting some form of publication bias for this outcome (oxytocin augmentation) for the comparison of a balloon versus vaginal PGE2. Visual assessment of the other funnel plots did not show asymmetry, suggesting there is no publication bias for these comparisons.

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.3 Caesarean section.](nCD001233-AFig-FIG04){#CD001233-fig-0004}

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.6 Oxytocin augmentation.](nCD001233-AFig-FIG05){#CD001233-fig-0005}

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.7 Uterine hyperstimulation without fetal heart rate changes.](nCD001233-AFig-FIG06){#CD001233-fig-0006}

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.10 Instrumental vaginal delivery.](nCD001233-AFig-FIG07){#CD001233-fig-0007}

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.12 Apgar score \< 7 at 5 minutes.](nCD001233-AFig-FIG08){#CD001233-fig-0008}

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.13 Neonatal intensive care unit admission.](nCD001233-AFig-FIG09){#CD001233-fig-0009}

![Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.21 Fetal distress.](nCD001233-AFig-FIG10){#CD001233-fig-0010}

![Funnel plot of comparison: 4 Balloon (Foley or ATAD) versus intracervical Prostaglandin E2: all women, outcome: 4.3 Caesarean section.](nCD001233-AFig-FIG11){#CD001233-fig-0011}

![Funnel plot of comparison: 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, outcome: 7.3 Caesarean section.](nCD001233-AFig-FIG12){#CD001233-fig-0012}

### Allocation {#CD001233-sec3-0021}

#### Sequence generation {#CD001233-sec4-0023}

We judged 62 trials to be at low risk of selection bias, reporting some form of adequate random sequencing such as a computer‐generated sequence or a list of random numbers ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}; [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}; [Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}; [Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}; [Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"}; [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}; [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}; [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}; [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}; [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}; [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}; [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}; [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}; [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}; [Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}; [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}; [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"}; [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}; [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}; [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}; [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}; [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}; [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"}; [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}; [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}; [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}; [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}; [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}; [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}).

Three trials were classified as high risk because they were quasi‐randomised trials. [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"} randomised by last digit of the chart number, [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"} randomised by odd or even admission date and [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"} randomised by week of admission.

We judged the remaining 40 trials to be at unclear risk of selection bias, as they did not report on how a random sequence was generated ([Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}; [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}; [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}; [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}; [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}; [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}; [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}; [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}; [Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}; [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}; [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}; [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}; [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}; [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}; [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"};[Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}; [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}).

#### Allocation concealment {#CD001233-sec4-0024}

Fifty‐five studies reported a method of allocation concealment likely to have a low risk of bias, either by central randomisation or sequentially numbered, sealed, opaque envelopes ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}; [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"}; [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}; [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}; [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}; [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}; [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}; [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}; [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}; [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}; [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}; [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"}; [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}; [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}; [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}; [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}; [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}; [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}; [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}; [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}; [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}; [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}; [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}; [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}; [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}).

Five studies were judged to be high risk. In the quasi‐randomised trials of [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}, [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"} and [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"} no measures were taken to conceal the allocation; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"} stated that the allocation was not concealed and [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"} allocated women by odd or even randomisation number.

The remaining 45 studies did not report a method for concealing allocation and were judged as being at unclear risk of bias ([Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}; [Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}; [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}; [Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}; [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}; [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}; [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}; [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}; [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}; [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}; [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}; [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}; [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}; [Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}; [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}; [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}; [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}; [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}; [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}).

### Blinding {#CD001233-sec3-0022}

#### Performance bias {#CD001233-sec4-0025}

Given the nature of the intervention (mechanical methods for induction of labour) and comparison (pharmacological methods for induction of labour), it was not possible for women or clinicians to be blinded to the treatment group in any of the trials. For the more objective outcomes such as perinatal death, the lack of blinding is unlikely to be a major source of bias. Therefore, risk of performance bias was judged as unclear in all studies, but was a reason to downgrade the quality of evidence from high to moderate.

#### Detection bias {#CD001233-sec4-0026}

It would have been possible for outcome assessment to have been undertaken by someone blinded to allocation groups. However, only four trials reported blinded outcome assessment (rated as low risk of bias). [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"} blinded only for the outcome of hyperstimulation. In the studies of [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"} and [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}, data were collected by research midwives who were blinded to the intervention. [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"} and [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"} both stated they performed a double blind‐trial but provided too little information to assess how this was done. The remaining 101 trials did not detail whether outcome assessment was blinded, and thus we judged risk of detection bias to be unclear. Measurement of outcomes such as perinatal death are unlikely to be biased by lack of blinding.

### Incomplete outcome data {#CD001233-sec3-0023}

We considered 38 studies to be at low risk of attrition bias with data analyses according to intention‐ to‐treat and minimal/no loss to follow‐up or exclusion of women ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}; [Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}; [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}; [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}; [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}; [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}; [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}; [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}; [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}; [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"}; [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}; [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}; [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}; [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}; [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}; [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}; [Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}).

Forty‐three studies were judged to be at unclear risk of attrition bias, mainly because it was not clear if intention‐to‐treat analyses was used ([Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}; [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}; [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}; [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}; [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}; [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}; [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}; [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"}; [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}; [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}), or there was too little information to judge attrition bias ([Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}; [Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}; [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}; [Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}; [Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}; [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}).

Twenty‐four studies were classified as high risk for attrition bias. In the studies of [Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}, [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"} and [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}, women were excluded because of failed placement of the balloon. [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"} also excluded nine patients because of failed placement of the Foley catheter, but replaced them with women who did receive a Foley catheter. [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"} analysed data as treated and also four cases went missing without a given explanation. [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}, [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}, [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}, [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}, [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}, [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}, [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"} and [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"} excluded cases because of protocol violation and [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"} reported they analysed intention‐to‐treat, but eventually excluded women because of protocol violation or if they delivered within six hours after induction had started. [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"} also excluded women if they went into spontaneous labour after the intervention. [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"} excluded women if they delivered after 48 hours of induction had started. [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"} excluded women if they had an unfavourable cervix after 12 hours of induction. [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"} excluded women after failed induction. The studies of [Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}, [Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"}, [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}, [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"}, [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}, [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"} were judged to be of high risk for attrition bias because cases were missing without a given explanation.

### Selective reporting {#CD001233-sec3-0024}

Seventy‐two studies were judged to be at low risk of reporting bias as all pre‐specified outcomes were reported ([Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}; [Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}; [Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}; [Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}; [Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}; [Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}; [Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}; [Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"}; [Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}; [Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}; [Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}; [Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}; [Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}; [Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}; [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}; [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}; [El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}; [Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}; [Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}; [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}; [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}; [Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}; [Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}; [Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}; [Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}; [Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}; [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}; [Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}; [Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}; [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}; [Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}; [Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}; [Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}; [Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}; [Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}; [Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}; [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}; [Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}; [Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}; [Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"};[Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}; [Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"}; [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}; [Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}; [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}; [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}; [Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}; [Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}; [Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}; [Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}; [Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}; [St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}; [Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}; [Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}; [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"};[Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}; [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}). It is important to note that not all studies had a trial protocol available and therefore it was not possible to check if there were other pre‐specified outcomes not reported in the method section of the article.

Twenty‐eight studies were judged to be of unclear risk of reporting bias. In 10 studies no outcomes were pre‐specified in the methods section ([Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}; [Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}; [Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}; [Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}; [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}; [Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"} and in 18 studies there was too little information to judge reporting bias ([Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}; [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}; [Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}; [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}; [Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}; [Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}; [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}; [Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}).

The studies of [Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}, [Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}, [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}, [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"} and [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"} were judged as high risk as not all pre‐specified outcomes were reported in the results section.

### Other potential sources of bias {#CD001233-sec3-0025}

For 24 studies it was not clear if there was another source of bias and these were therefore judged as unclear. For one study ([Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}), only a manuscript with no tables was available. Two trials ([Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}; [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}) were not published, but the results of the primary outcome and adverse events were reported in the trial registration. [Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"} stopped recruiting women for one arm of the study without an explanation. [Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"} calculated a sample size of 140 women but included 200 women without explanation. [Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"} included patients who did not meet inclusion criteria. Eighteen studies were only published as abstracts, or there was too little information provided and so it was not possible to judge the risk of bias ([Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}; [Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}; [Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}; [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}; [Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}; [Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}; [Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}; [Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}; [Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}; [Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}; [Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}; [Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}; [Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}; [Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}; [Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}).

The studies of [Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}, [Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}, and [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"} were judged as high risk for other potential sources of bias as they were terminated early before the required sample size was recruited.

Effects of interventions {#CD001233-sec2-0010}
------------------------

See: [Table 1](#CD001233-tbl-0001){ref-type="table"}; [Table 2](#CD001233-tbl-0002){ref-type="table"}; [Table 3](#CD001233-tbl-0003){ref-type="table"}

### Balloon (single or double) versus vaginal prostaglandin E2 (28 trials involving 6619 women) {#CD001233-sec3-0026}

#### Primary outcomes {#CD001233-sec4-0027}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0005}

There may be little or no difference in vaginal deliveries not achieved within 24 hours between induction of labour with a balloon catheter and vaginal PGE2 (average risk ratio (RR) 1.01, 95% confidence interval (CI) 0.82 to 1.26; 7 studies; 1685 women; low‐quality evidence; [Analysis 1.1](#CD001233-fig-00101){ref-type="fig"}), although there was substantial heterogeneity for this outcome (Tau² = 0.06; Chi² = 29.06, df = 6 (P =\< 0.0001); I² = 79%).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of concealment or attrition bias ([Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}), did not change the effect observed, despite the result becoming less precise (average RR 1.10, 95% CI 0.86 to 1.41; 1351 women; 5 studies; I² = 82%).

The same result was seen on a subgroup comparison for primiparous women (RR 1.01, 95% CI 0.83 to 1.23; 330 women; 1 study; [Analysis 2.1](#CD001233-fig-00201){ref-type="fig"}). While for multiparous women, a balloon catheter may increase the risk of a vaginal delivery not being achieved within 24 hours (RR 4.38, 95% CI 1.74 to 10.98; 147 women; 1 study; [Analysis 3.1](#CD001233-fig-00301){ref-type="fig"}).

##### Uterine hyperstimulation with fetal heart rate (FHR) changes {#CD001233-sec5-0006}

A balloon catheter probably reduces the risk of uterine hyperstimulation with FHR changes when compared to vaginal PGE2 (RR 0.35, 95% CI 0.18 to 0.67; 6 studies; 1966 women; moderate‐quality evidence; [Analysis 1.2](#CD001233-fig-00102){ref-type="fig"}), the absolute effect being 21 less per 1000 deliveries.

The same result was seen on a subgroup comparison for primiparous women (RR 0.05, 95% CI 0.00 to 0.85; 330 women; 1 study; [Analysis 2.2](#CD001233-fig-00202){ref-type="fig"}). For multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0007}

There probably is little or no difference in caesarean sections between both induction methods (RR 1.00, 95% CI 0.92 to 1.09; 28 studies; 6619 women; moderate‐quality evidence; [Analysis 1.3](#CD001233-fig-00103){ref-type="fig"}). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 4](#CD001233-fig-0004){ref-type="fig"}).

It is uncertain whether there is a difference in caesarean sections between both induction methods on subgroups for both primiparous women (average RR 0.89, 95% CI 0.59 to 1.33; 828 women; 5 studies; [Analysis 2.3](#CD001233-fig-00203){ref-type="fig"}) and multiparous women (RR 1.31, 95% CI 0.65 to 2.63; 180 women; 2 studies; [Analysis 3.2](#CD001233-fig-00302){ref-type="fig"}) as the results of these outcomes were imprecise. Furthermore, for the primiparous group, there was also substantial heterogeneity (Tau² = 0.11; Chi² = 10.01, df = 4 (P = 0.04); I² = 60%).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0008}

A balloon catheter probably reduces the risk of serious neonatal morbidity or perinatal death when compared to vaginal PGE2 (RR 0.48, 95% CI 0.25 to 0.93; 8 studies; 2757 women; moderate‐quality evidence; [Analysis 1.4](#CD001233-fig-00104){ref-type="fig"}). However, numbers are low (12/1483 versus 25/1274, respectively) and almost all of these numbers were cases of birth asphyxia. Only two perinatal deaths were reported, both in the PGE2 group ([Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}). No heterogeneity was seen for this outcome.

For primiparous women, it is uncertain whether there is a difference in effect as the result for this outcome was imprecise (RR 0.17, 95% CI 0.01 to 4.24; 330 women; 1 study; [Analysis 2.4](#CD001233-fig-00204){ref-type="fig"}). For multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0009}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (RR 0.20, 95% CI 0.01 to 4.12; 4 studies; 1481 women; very low‐quality evidence; [Analysis 1.5](#CD001233-fig-00105){ref-type="fig"}). Of all the 28 studies included for this comparison, only four studies reported on this composite outcome. No events were reported in the balloon group. One author ([Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}) reported two events in the PGE2 group, both events being uterine rupture.

Only one study (60 women) reported on this outcome in primiparous women, in which no events were seen ([Analysis 2.5](#CD001233-fig-00205){ref-type="fig"}). For multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0028}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0010}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0011}

Induction of labour with a balloon catheter may increase the risk of oxytocin augmentation when compared to vaginal PGE2 (average RR 1.54, 95% CI 1.35 to 1.76; 4828 women; 16 studies; [Analysis 1.6](#CD001233-fig-00106){ref-type="fig"}), although there was substantial heterogeneity for this outcome (Tau² = 0.05; Chi² = 141.47, df = 15 (P = \< 0.0001); I² = 89%). Visual inspection of the funnel plot was somewhat asymmetrical, suggesting some form of publication bias ([Figure 5](#CD001233-fig-0005){ref-type="fig"}).

A sensitivity analysis, after eliminating the five trials assessed as having a potentially higher risk of allocation or attrition bias ([Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}), did not alter the result, nor did it lower heterogeneity (average RR 1.37, 95% CI 1.21 to 1.54; 4005 women; 11 studies; I² = 87%).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0012}

A balloon catheter may reduce the risk of uterine hyperstimulation without FHR changes when compared to vaginal PGE2 (average RR 0.27, 95% CI 0.11 to 0.66; 2444 women; 15 studies; [Analysis 1.7](#CD001233-fig-00107){ref-type="fig"}), although there was moderate heterogeneity for this outcome (Tau² = 1.13; Chi² = 22.28, df = 12 (P = 0.03); I² = 46%). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 6](#CD001233-fig-0006){ref-type="fig"}).

A sensitivity analysis, after eliminating the seven trials assessed as having a potentially higher risk of allocation or attrition bias ([Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}; [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}; [Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}; [Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}; [Zahoor 2014](#CD001233-bbs2-0113){ref-type="ref-list"}), made this result less precise and therefore raises uncertainty as to whether there is a difference in uterine hyperstimulation without FHR changes (average RR 0.26, 95% CI 0.06 to 1.05; 1694 women; 8 studies; I² = 62%).

##### Uterine rupture {#CD001233-sec5-0013}

It is uncertain whether there is a difference in uterine rupture between both induction methods (RR 0.20, 95% CI 0.01 to 4.12; 1045 women; 2 studies; [Analysis 1.8](#CD001233-fig-00108){ref-type="fig"}). Only two cases of uterine rupture were reported, both in the PGE2 group in the study of [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}. Uterine rupture was defined by the authors as a separation of the uterine wall, and in one case this was caused by inserting an intrauterine pressure catheter.

##### Epidural analgesia {#CD001233-sec5-0014}

A balloon catheter may slightly increase the use of epidural analgesia during labour when compared to vaginal PGE2 (average RR 1.14, 95% CI 1.00 to 1.29; 2828 women; 8 studies; [Analysis 1.9](#CD001233-fig-00109){ref-type="fig"}). However, there was substantial heterogeneity for this outcome (Tau² = 0.02; Chi² = 32.09, df = 7 (P = \< 0.0001); I² = 78%).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of allocation or attrition bias ([Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}; [Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}), did not alter the result, nor did it lower heterogeneity (average RR 1.11, 95% CI 0.97 to 1.28; 2537 women; 6 studies; I² = 80%).

##### Instrumental vaginal delivery {#CD001233-sec5-0015}

There probably is little or no difference in instrumental vaginal deliveries between both induction methods (RR 0.93, 95% CI 0.79 to 1.09; 4514 women; 16 studies; [Analysis 1.10](#CD001233-fig-00110){ref-type="fig"}). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 7](#CD001233-fig-0007){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0016}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.89, 95% CI 0.67 to 1.19; 964 women; 4 studies; [Analysis 1.11](#CD001233-fig-00111){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0017}

It is uncertain whether there is a difference in Apgar score less than seven at five minutes between both induction methods (RR 0.74, 95% CI 0.49 to 1.14; 4271 women; 14 studies; low‐quality evidence; [Analysis 1.12](#CD001233-fig-00112){ref-type="fig"}). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 8](#CD001233-fig-0008){ref-type="fig"}).

##### Neonatal intensive care unit (NICU) admission {#CD001233-sec5-0018}

A balloon catheter may reduce the risk of a NICU admission when compared to vaginal PGE2 (RR 0.82, 95% CI 0.65 to 1.04; 3647 women; 12 studies; low‐quality evidence; [Analysis 1.13](#CD001233-fig-00113){ref-type="fig"}), the absolute effect being 15 fewer NICU admission per 1000 deliveries. Although it should be noted that there is a wide range of treatment effects that are compatible with the data, from a very small increase in risk to very large decrease. Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 9](#CD001233-fig-0009){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0019}

Not reported.

##### Perinatal death {#CD001233-sec5-0020}

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 0.21, 95% CI 0.01 to 4.27; 1036 women; 5 studies; [Analysis 1.14](#CD001233-fig-00114){ref-type="fig"}). Only two cases of perinatal death were reported by [Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}, both being cases of neonatal death and born to women randomised to vaginal PGE2. The authors describe that in both cases the neonates died as a result of complications related to a congenital diaphragmatic hernia and were unrelated to the induction method.

##### Disability in childhood {#CD001233-sec5-0021}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0022}

Not reported.

##### Maternal nausea {#CD001233-sec5-0023}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0024}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0025}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0026}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0027}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.82, 95% CI 0.63 to 1.06; 2215 women; 8 studies; [Analysis 1.15](#CD001233-fig-00115){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0028}

Not reported.

##### Maternal death {#CD001233-sec5-0029}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0030}

A balloon catheter may reduce the amount of women not being satisfied with the induction method when compared to prostaglandin E2 (RR 0.61, 95% CI 0.39 to 0.97; 93 women; 1 study; [Analysis 1.16](#CD001233-fig-00116){ref-type="fig"}), the absolute effect being 224 fewer women not satisfied per 1000 deliveries. This outcome was reported by [Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"} by asking the women if they would choose the randomised induction method again. Patient satisfaction was also reported by [Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}, but could not be included in the meta‐analysis. In this study women were asked to score their satisfaction with the induction process on a five‐point Likert scale. No difference in satisfaction was seen between both induction methods (3.41 (± 1.3) versus 3.33 (± 1.2), respectively; P *=* 0.860).

##### Caregiver not satisfied {#CD001233-sec5-0031}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0029}

##### Maternal fever during labour {#CD001233-sec5-0032}

It is uncertain whether there is a difference in maternal fever during labour between both methods (RR 0.87, 95% CI 0.65 to 1.17; 2362 women; 7 studies; [Analysis 1.17](#CD001233-fig-00117){ref-type="fig"}).

##### Antibiotics during labour {#CD001233-sec5-0033}

It is uncertain whether there is a difference in antibiotics during labour between both methods (RR 1.43, 95% CI 0.89 to 2.29; 330 women; 1 study; [Analysis 1.18](#CD001233-fig-00118){ref-type="fig"}).

##### Chorioamnionitis {#CD001233-sec5-0034}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 0.69, 95% CI 0.32 to 1.49; 376 women; 1 study; [Analysis 1.19](#CD001233-fig-00119){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0035}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 0.49, 95% CI 0.19 to 1.27; 706 women; 2 studies; [Analysis 1.20](#CD001233-fig-00120){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0036}

A balloon catheter probably reduces the risk of fetal distress for which a caesarean section is indicated when compared to vaginal PGE2 (RR 0.71, 95% CI 0.60 to 0.83; 4753 women; 20 studies; [Analysis 1.21](#CD001233-fig-00121){ref-type="fig"}). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 10](#CD001233-fig-0010){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0037}

A balloon catheter probably reduces the risk of an umbilical artery pH less than 7.10 directly postpartum when compared to vaginal PGE2 (RR 0.65, 95% CI 0.44 to 0.94; 2675 women, 8 studies; [Analysis 1.22](#CD001233-fig-00122){ref-type="fig"}). However, numbers occurred infrequently in both groups (35 per 1000 versus 56 per 1000, respectively).

### Balloon (single or double) versus cervical prostaglandin E2 (10 trials involving 1428 women) {#CD001233-sec3-0027}

#### Primary outcomes {#CD001233-sec4-0030}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0038}

It is uncertain whether there is a difference in vaginal deliveries achieved within 24 hours between induction of labour with a balloon catheter and cervical PGE2 (average RR 1.01, 95% CI 0.35 to 2.91; 200 women; 2 studies; [Analysis 4.1](#CD001233-fig-00401){ref-type="fig"}). There also was substantial heterogeneity for this outcome (Tau² = 0.53; Chi² = 10.35, df = 1 (P = 0.001); I² = 90%). Even though data were pooled, both studies may be incompatible as no overlap of CIs is present. No sensitivity analysis was conducted as no potential high‐risk studies were included for this outcome.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0039}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.37, 95% CI 0.02 to 8.90; 447 women; 4 studies; [Analysis 4.2](#CD001233-fig-00402){ref-type="fig"}).

Only one small study (53 women) reported this outcome for the subgroups of primiparous and multiparous women. No events were reported in primiparous women ([Analysis 5.1](#CD001233-fig-00501){ref-type="fig"}). For multiparous women, it is uncertain whether there is a difference for this outcome between both induction methods (RR 0.30, 95% CI 0.01 to 7.02; 53 women; 1 study; [Analysis 6.1](#CD001233-fig-00601){ref-type="fig"}).

##### Caesarean section {#CD001233-sec5-0040}

There probably is little or no difference in caesarean sections between both induction methods (RR 0.97, 95% CI 0.81 to 1.15; 1309 women; 9 studies; [Analysis 4.3](#CD001233-fig-00403){ref-type="fig"}). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 11](#CD001233-fig-0011){ref-type="fig"}).

It is uncertain whether there is a difference in caesarean sections between both induction methods on subgroup comparisons for both primiparous women (RR 1.30, 95% CI 0.86 to 1.95; 245 women; 3 studies; [Analysis 5.2](#CD001233-fig-00502){ref-type="fig"}) and multiparous women (average RR 0.66, 95% CI 0.16 to 2.78; 136 women; 3 studies; [Analysis 6.2](#CD001233-fig-00602){ref-type="fig"}) as the results for both comparisons were imprecise. For the multiparous group, there also was substantial heterogeneity (Tau² = 0.90; Chi² = 4.78, df = 2 (P = 0.09); I² = 58%).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0041}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.78, 95% CI 0.29 to 2.05; 500 women; 2 studies; [Analysis 4.4](#CD001233-fig-00404){ref-type="fig"}). Of the 10 studies included for this comparison, two studies ([Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}; [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}) reported on this composite outcome. All reported events in these studies were cases of perinatal death.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0042}

Not reported.

#### Secondary outcomes {#CD001233-sec4-0031}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0043}

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (RR 0.96, 95% CI 0.70 to 1.34; 219 women; 2 studies; [Analysis 4.5](#CD001233-fig-00405){ref-type="fig"}).

##### Oxytocin augmentation {#CD001233-sec5-0044}

There may be little or no difference in oxytocin augmentation between both induction methods (RR 1.08, 95% CI 0.93 to 1.26; 400 women; 1 study; [Analysis 4.6](#CD001233-fig-00406){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0045}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (average RR 0.99, 95% CI 0.09 to 10.38; 654 women; 5 studies; [Analysis 4.7](#CD001233-fig-00407){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 2.92; Chi² = 6.33, df = 2 (P = 0.04); I² = 68%).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of allocation or attrition bias ([Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}; [Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}) did not alter the result, nor did it lower heterogeneity (average RR 0.56, 95% CI 0.01 to 39.31; 430 women; 3 studies; I² = 76%).

##### Uterine rupture {#CD001233-sec5-0046}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0047}

There may be little or no difference in epidural analgesia during labour between both induction methods (RR 0.91, 95% CI 0.81 to 1.02; 149 women; 1 study; [Analysis 4.8](#CD001233-fig-00408){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0048}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.18, 95% CI 0.68 to 2.05; 337 women; 3 studies; [Analysis 4.9](#CD001233-fig-00409){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0049}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 1.17, 95% CI 0.42 to 3.26; 118 women; 1 study; [Analysis 4.10](#CD001233-fig-00410){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0050}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes (RR 0.79, 95% CI 0.41 to 1.53; 475 women; 2 studies; [Analysis 4.11](#CD001233-fig-00411){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0051}

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.88, 95% CI 0.60 to 1.31; 400 women; 1 study; [Analysis 4.12](#CD001233-fig-00412){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0052}

Not reported.

##### Perinatal death {#CD001233-sec5-0053}

It is uncertain whether there is difference in perinatal death between both induction methods (RR 0.78, 95% CI 0.29 to 2.05; 500 women; 2 studies. [Analysis 4.13](#CD001233-fig-00413){ref-type="fig"}). Noteworthy, there was a relatively high number of neonatal deaths reported in the study of [Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"} for the balloon group (6/200), as well as in the cervical PGE2 group (8/200), for which no explanation was given by the authors.

##### Disability in childhood {#CD001233-sec5-0054}

Not reported.

##### Maternal side effects {#CD001233-sec5-0055}

It is uncertain whether there is a difference in maternal side effects (RR 0.15, 95% CI 0.02 to 1.24; 211 women; 2 studies; [Analysis 4.14](#CD001233-fig-00414){ref-type="fig"}). The nature of the side effects was not specified in both included studies.

##### Maternal nausea {#CD001233-sec5-0056}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0057}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0058}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0059}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0060}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.20, 95% CI 0.01 to 4.06; 100 women; 1 study; [Analysis 4.15](#CD001233-fig-00415){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0061}

Not reported.

##### Maternal death {#CD001233-sec5-0062}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0063}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0064}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0032}

##### Maternal fever during labour {#CD001233-sec5-0065}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0066}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0067}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.00, 95% CI 0.21 to 4.75; 118 women; 1 study; [Analysis 4.16](#CD001233-fig-00416){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0068}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.00, 95% CI 0.06 to 15.61; 118 women; 1 study; [Analysis 4.17](#CD001233-fig-00417){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0069}

A balloon catheter probably reduces the risk of fetal distress for which a caesarean section is indicated when compared to cervical PGE2 (RR 0.61, 95% CI 0.42 to 0.89; 1023 women; 6 studies; [Analysis 4.18](#CD001233-fig-00418){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0070}

Not reported.

### Balloon (single or double) versus low‐dose vaginal misoprostol (13 trials involving 1818 women) {#CD001233-sec3-0028}

#### Primary outcomes {#CD001233-sec4-0033}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0071}

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between induction of labour with a balloon catheter and vaginal misoprostol (RR 1.09, 95% CI 0.85 to 1.39; 340 women; 2 studies; low‐quality evidence; [Analysis 7.1](#CD001233-fig-00701){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0072}

A balloon catheter probably reduces the risk of uterine hyperstimulation with FHR changes when compared to vaginal misoprostol (RR 0.39, 95% CI 0.18 to 0.85; 1322 women; moderate‐quality evidence; 8 studies; [Analysis 7.2](#CD001233-fig-00702){ref-type="fig"}), the absolute effect being 22 fewer cases per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0073}

A balloon catheter may increase the risk of a caesarean section when compared to vaginal misoprostol (average RR 1.28, 95% CI 1.02 to 1.60; 1756 women; 12 studies; low‐quality evidence; [Analysis 7.3](#CD001233-fig-00703){ref-type="fig"}), the absolute effect being 53 more caesarean sections per 1000 deliveries. However, there was moderate heterogeneity for this outcome (Tau² = 0.06; Chi² = 19.86, df = 11 (P = 0.05); I² = 45%).

A sensitivity analysis, after eliminating the three trials assessed as having a potentially higher risk of allocation or attrition bias ([Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}; [Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), did not alter the result, nor did it lower heterogeneity (average RR 1.34, 95% CI 1.05 to 1.71; 1492 women; 10 studies; I² = 48%). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias ([Figure 12](#CD001233-fig-0012){ref-type="fig"}).

For the subgroup of primiparous women, it is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.82, 95% CI 0.59 to 1.13; 255 women; 1 study; [Analysis 8.1](#CD001233-fig-00801){ref-type="fig"}). For multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0074}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.58, 95% CI 0.12 to 2.66; 381 women; 3 studies; very low‐quality evidence; [Analysis 7.4](#CD001233-fig-00704){ref-type="fig"}). All of the cases included for this composite outcome were cases of perinatal asphyxia (2/187 versus 4/194, respectively).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0075}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (very low‐quality evidence; [Analysis 7.5](#CD001233-fig-00705){ref-type="fig"}). Of the 13 studies included for this comparison, four studies (464 women) reported on this composite outcome. No events of maternal morbidity or death occurred in one of these studies.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0034}

##### Cervix unfavourable/unchanged after 12 hours {#CD001233-sec5-0076}

It is uncertain whether there is a difference in an unfavourable cervix after 12 hours between both induction methods (average RR 2.66, 95% CI 0.60 to 11.89; 200 women; 2 studies; [Analysis 7.6](#CD001233-fig-00706){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Tau² = 0.63; Chi² = 1.56, df = 1 (P = 0.21); I² = 36%). No studies reported on a time period of 24 hours.

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias ([Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), did not change the result, but did narrow the CI (RR 1.82, 95% CI 0.94 to 3.51; 1 study).

##### Oxytocin augmentation {#CD001233-sec5-0077}

A balloon catheter probably increases the risk of oxytocin augmentation when compared to vaginal misoprostol (average RR 1.62, 95% CI 1.38 to 1.90; 911 women; 9 studies; [Analysis 7.7](#CD001233-fig-00707){ref-type="fig"}), although there was substantial heterogeneity for this outcome (Tau² = 0.03; Chi² = 21.93, df = 8 (P = 0.005); I² = 64%).

In the sensitivity analysis, after eliminating two trial assessed as having a potentially higher risk of allocation or attrition bias ([Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"} and [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), heterogeneity was lost without altering the effect observed (average RR 1.50, 95% CI 1.36 to 1.64; 751 women, 7 studies; I² = 0%).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0078}

A balloon catheter probably reduces the risk of uterine hyperstimulation without FHR changes when compared to vaginal misoprostol (RR 0.25, 95% CI 0.14 to 0.44; 1139 women; 9 studies; [Analysis 7.8](#CD001233-fig-00708){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0079}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 7.9](#CD001233-fig-00709){ref-type="fig"}). Of the 13 studies included for this comparison, only three studies (364 women) reported on this outcome. No events of uterine rupture occurred in one of these studies.

##### Epidural analgesia {#CD001233-sec5-0080}

A balloon catheter probably slightly increases the use of epidural analgesia during labour when compared to vaginal misoprostol (RR 1.22, 95% CI 1.06 to 1.41; 517 women; 2 studies; [Analysis 7.10](#CD001233-fig-00710){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0081}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.72, 95% CI 0.50 to 1.05; 721 women; 4 studies; [Analysis 7.11](#CD001233-fig-00711){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0082}

A balloon catheter probably reduces the risk of meconium‐stained liquor when compared to vaginal misoprostol (RR 0.64, 95% CI 0.48 to 0.87; 1268 women; 7 studies; [Analysis 7.12](#CD001233-fig-00712){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0083}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 1.00, 95% CI 0.50 to 1.97; 941 women; 7 studies; low‐quality evidence; [Analysis 7.13](#CD001233-fig-00713){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0084}

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.00, 95% CI 0.61 to 1.63; 1302 women; 9 studies; low‐quality evidence; [Analysis 7.14](#CD001233-fig-00714){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0085}

Not reported.

##### Perinatal death {#CD001233-sec5-0086}

It is uncertain whether there is difference in perinatal death between both induction methods ([Analysis 7.15](#CD001233-fig-00715){ref-type="fig"}). Of the 13 studies included for this comparison, only one study (121 women) pre‐specified this outcome. No cases of perinatal death were reported in this study.

##### Disability in childhood {#CD001233-sec5-0087}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0088}

Not reported.

##### Maternal nausea {#CD001233-sec5-0089}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0090}

It is uncertain whether there is difference in maternal vomiting between both induction methods ([Analysis 7.16](#CD001233-fig-00716){ref-type="fig"}). Of all the 13 studies included for this comparison, only one study (60 women) pre‐specified this outcome. No cases of maternal vomiting were reported in this study.

##### Maternal diarrhoea {#CD001233-sec5-0091}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0092}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0093}

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 1.14, 95% CI 0.24 to 5.44; 120 women; 1 study; ([Analysis 7.17](#CD001233-fig-00717){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0094}

Not reported.

##### Maternal death {#CD001233-sec5-0095}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0096}

One study ([Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}) reported on patient satisfaction, but could not be included in the meta‐analysis. In this study, satisfaction was assessed by a visual analogue score ranging from zero to five (0 = very poor; 5 = very good), in which no difference between both induction methods was seen (100 women; 4.5 \[4‐5\] versus 4.45 \[3‐5\], respectively; P = 0.488).

##### Caregiver not satisfied {#CD001233-sec5-0097}

Not reported.

#### Not pre‐specified outcomes {#CD001233-sec4-0035}

##### Maternal fever during labour {#CD001233-sec5-0098}

It is uncertain whether there is a difference in maternal fever during labour between both methods (average RR 1.84, 95% CI 0.22 to 15.62; 617 women; 3 studies; [Analysis 7.18](#CD001233-fig-00718){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 1.86; Chi² = 3.95, df = 1 (P = 0.05); I² = 75%). No sensitivity analysis was performed as no potential high‐risk studies were included for this outcome.

##### Antibiotics during labour {#CD001233-sec5-0099}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0100}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.24, 95% CI 0.31 to 4.88; 200 women; 2 studies; [Analysis 7.19](#CD001233-fig-00719){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0101}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 2.95, 95% CI 0.12 to 71.72; 240 women; 1 study; [Analysis 7.20](#CD001233-fig-00720){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0102}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated (RR 0.84, 95% CI 0.67 to 1.05; 1127 women; 7 studies; [Analysis 7.21](#CD001233-fig-00721){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0103}

It is uncertain whether there is a difference in umbilical artery pH less than 7.10 directly postpartum between both induction methods (RR 1.14, 95% CI 0.35 to 3.74; 120 women; 1 study; [Analysis 7.22](#CD001233-fig-00722){ref-type="fig"}).

### Balloon (single or double) versus low‐dose oral misoprostol (seven trials involving 3178 women) {#CD001233-sec3-0029}

#### Primary outcomes {#CD001233-sec4-0036}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0104}

A balloon catheter probably increases the risk of a vaginal delivery not achieved within 24 hours when compared to oral misoprostol (RR 1.28, 95% CI 1.13 to 1.46; 782 women, 2 studies. moderate‐quality evidence, [Analysis 9.1](#CD001233-fig-00901){ref-type="fig"}), the absolute effect being 133 more per 1000 deliveries.

The same results were seen on parity subgroup comparisons for primiparous women (RR 1.19, 95% CI 1.04 to 1.37; 573 women; 2 studies; [Analysis 10.1](#CD001233-fig-01001){ref-type="fig"}) and multiparous women (RR 1.55, 95% CI 1.17 to 2.06; 209 women; 2 studies; [Analysis 11.1](#CD001233-fig-01101){ref-type="fig"}).

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0105}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.81, 95% CI 0.48 to 1.38; 2033 women; 2 studies; low‐quality evidence; [Analysis 9.2](#CD001233-fig-00902){ref-type="fig"}).

The same results were seen on parity subgroup comparisons for primiparous women (RR 0.81, 95% CI 0.45 to 1.46; 1206 women; 1 study; [Analysis 10.2](#CD001233-fig-01002){ref-type="fig"} and multiparous women (RR 1.45, 95% CI 0.24 to 8.61; 639 women; 1 study; [Analysis 11.2](#CD001233-fig-01102){ref-type="fig"}).

##### Caesarean section {#CD001233-sec5-0106}

A balloon catheter probably slightly increases the risk of a caesarean section when compared to oral misoprostol (RR 1.17, 95% CI 1.04 to 1.32; 3178 women; 7 studies; moderate‐quality evidence; [Analysis 9.3](#CD001233-fig-00903){ref-type="fig"}), the absolute effect being 37 more caesarean sections per 1000 deliveries.

The same result was seen on the subgroup of primiparous women (RR 1.21, 95% CI 1.06 to 1.38; 1778 women; 3 studies; [Analysis 10.3](#CD001233-fig-01003){ref-type="fig"}). For multiparous women, it is uncertain whether there is a difference in caesarean sections between both methods (RR 1.22, 95% CI 0.79 to 1.87; 848 women; 3 studies; [Analysis 11.3](#CD001233-fig-01103){ref-type="fig"}).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0107}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 1.11, 95% CI 0.60 to 2.06; 2627 women; 3 studies; low‐quality evidence; [Analysis 9.4](#CD001233-fig-00904){ref-type="fig"}).

The same results were seen on parity subgroup comparisons for primiparous women (RR 4.49, 95% CI 0.77 to 26.14; 1296 women; 2 studies; [Analysis 10.4](#CD001233-fig-01004){ref-type="fig"}) and multiparous women (RR 0.98, 95% CI 0.14 to 6.86; 729 women; 2 studies; [Analysis 11.4](#CD001233-fig-01104){ref-type="fig"}).

##### Serious maternal morbidity or death {#CD001233-sec5-0108}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (RR 0.50, 95% CI 0.05 to 5.52; 2627 women; 3 studies; very low‐quality evidence; [Analysis 9.5](#CD001233-fig-00905){ref-type="fig"}).

The same results were seen on parity subgroup comparisons for primiparous women (RR 0.51, 95% CI 0.05 to 5.63; 1296 women; 2 studies; [Analysis 10.5](#CD001233-fig-01005){ref-type="fig"}) and multiparous women ([Analysis 11.5](#CD001233-fig-01105){ref-type="fig"}). In the latter group, no events of maternal morbidity or death were reported (2 studies; 729 women).

#### Secondary outcomes {#CD001233-sec4-0037}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0109}

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (average RR 0.98, 95% CI 0.61 to 1.56; 994 women; 4 studies; [Analysis 9.6](#CD001233-fig-00906){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Tau² = 0.06; Chi² = 2.96, df = 2 (P = 0.23); I² = 33%).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of allocation or attrition bias ([Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), did not change the result, although heterogeneity was lost (RR 1.31, 95% CI 0.81 to 2.15; 782 women; 2 studies; I² = 0%).

##### Oxytocin augmentation {#CD001233-sec5-0110}

A balloon catheter may increase the risk of oxytocin augmentation when compared to oral misoprostol (average RR 1.28, 95% CI 1.09 to 1.49; 2847 women; 5 studies; [Analysis 9.7](#CD001233-fig-00907){ref-type="fig"}) although there was substantial heterogeneity for this outcome (Tau² = 0.03; Chi² = 31.32, df = 4 (P \< 0.000001); I² = 87%).

A sensitivity analysis, after eliminating the three trials assessed as having a potentially higher risk of allocation or attrition bias ([Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}; [Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}; [Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), did not change this result, nor did it lower heterogeneity (average RR 1.35, 95% CI 1.02 to 1.79; 2447 women; 2 studies; I² = 95%).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0111}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (average RR 0.50, 95% CI 0.12 to 2.07; 2838 women; 5 studies; [Analysis 9.8](#CD001233-fig-00908){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 1.26; Chi² = 8.12, df = 4 (P = 0.09); I² = 51%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}), did not change the effect observed, nor did it lower heterogeneity (average RR 0.49, 95% CI 0.09 to 2.64; 2778 women; 4 studies; I² = 60%).

##### Uterine rupture {#CD001233-sec5-0112}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 9.9](#CD001233-fig-00909){ref-type="fig"}). Of the seven studies included for this comparison, three studies (2627 women) pre‐specified this outcome. No events of uterine rupture occurred in any of these studies.

##### Epidural analgesia {#CD001233-sec5-0113}

A balloon catheter may slightly increase the risk for epidural analgesia when compared to oral misoprostol (average RR 1.08, 95% CI 0.96 to 1.22; 2635 women; 3 studies; [Analysis 9.10](#CD001233-fig-00910){ref-type="fig"}). However, the result is still too imprecise to make a valid judgement on this outcome. Also, there was substantial heterogeneity for this outcome (Chi² = 4.73, df = 2 (P = 0.09); I² = 58%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}), did not change this result, but did lower heterogeneity for this outcome (RR 1.13, 95% CI 1.03 to 1.24; 2447; 2 studies; I² = 5%).

##### Instrumental vaginal delivery {#CD001233-sec5-0114}

A balloon catheter probably reduces the risk of an instrumental vaginal delivery when compared to oral misoprostol (RR 0.71, 95% CI 0.55 to 0.92; 2627 women; 3 studies; [Analysis 9.11](#CD001233-fig-00911){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0115}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (average RR 0.77, 95% CI 0.44 to 1.35; 2627 women; 3 studies; [Analysis 9.12](#CD001233-fig-00912){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Tau² = 0.11; Chi² = 3.09, df = 2 (P = 0.21); I² = 35%). No sensitivity analysis was conducted as no potential high‐risk studies were included for this outcome.

##### Apgar score less than seven at five minutes {#CD001233-sec5-0116}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.71, 95% CI 0.38 to 1.32; 2693 women; 4 studies; low‐quality evidence; [Analysis 9.13](#CD001233-fig-00913){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0117}

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 0.82, 95% CI 0.58 to 1.17; 2873 women; 5 studies; low‐quality evidence; [Analysis 9.14](#CD001233-fig-00914){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0118}

It is uncertain whether there is a difference in neonatal encephalopathy between both induction methods (RR 0.81, 95% CI 0.32 to 2.03; 600 women; 1 study; [Analysis 9.15](#CD001233-fig-00915){ref-type="fig"}).

##### Perinatal death {#CD001233-sec5-0119}

It is uncertain whether there is difference in perinatal death between both induction methods (RR 1.28, 95% CI 0.49 to 3.30; 2627 women; 3 studies; [Analysis 9.16](#CD001233-fig-00916){ref-type="fig"}) as the result was imprecise and events occurred infrequently (9/1310 versus 7/1317, respectively). In the balloon group, two cases of perinatal death were related to asphyxia, compared to one case in the misoprostol group.

##### Disability in childhood {#CD001233-sec5-0120}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0121}

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 0.61, 95% CI 0.33 to 1.13; 662 women; 2 studies; [Analysis 9.17](#CD001233-fig-00917){ref-type="fig"}).

##### Maternal nausea {#CD001233-sec5-0122}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0123}

It is uncertain whether there is a difference in maternal vomiting between both induction methods (RR 0.73, 95% CI 0.37 to 1.46; 662 women; 2 studies; [Analysis 9.18](#CD001233-fig-00918){ref-type="fig"}).

##### Maternal diarrhoea {#CD001233-sec5-0124}

It is uncertain whether there is a difference in maternal diarrhoea between both induction methods (RR 0.29, 95% CI 0.06 to 1.37; 602 women; 1 study; [Analysis 9.19](#CD001233-fig-00919){ref-type="fig"}).

##### Other maternal side effects {#CD001233-sec5-0125}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0126}

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 1.03, 95% CI 0.79 to 1.34; 2966 women; 5 studies; [Analysis 9.20](#CD001233-fig-00920){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0127}

Not reported.

##### Maternal death {#CD001233-sec5-0128}

It is uncertain whether there is a difference in maternal death between both induction methods ([Analysis 9.21](#CD001233-fig-00921){ref-type="fig"}). Of the 13 studies included for this comparison, three studies (2627 women) pre‐specified this outcome. No events of maternal death occurred in one of these studies.

##### Woman not satisfied {#CD001233-sec5-0129}

A balloon catheter may increase the risk of women not being satisfied when compared to oral misoprostol (RR 1.70, 95% CI 1.15 to 2.50; 602 women; 1 study; [Analysis 9.22](#CD001233-fig-00922){ref-type="fig"}), the absolute effect being 80 more women not satisfied per 1000 deliveries. In the one study included for this outcome, women were asked if they would choose the same induction method again in a future induction of labour.

##### Caregiver not satisfied {#CD001233-sec5-0130}

Not reported.

#### Not pre‐specified outcomes {#CD001233-sec4-0038}

##### Maternal fever during labour {#CD001233-sec5-0131}

There probably is little or no difference in maternal fever during labour between both induction methods (RR 0.98, 95% CI 0.78 to 1.24; 2033 women; 2 studies; [Analysis 9.23](#CD001233-fig-00923){ref-type="fig"}).

##### Antibiotics during labour {#CD001233-sec5-0132}

It is uncertain whether there is a difference in antibiotics during labour between both induction methods (RR 1.22, 95% CI 0.75 to 2.00; 2033 women; 2 studies; [Analysis 9.24](#CD001233-fig-00924){ref-type="fig"}).

##### Chorioamnionitis {#CD001233-sec5-0133}

Not reported.

##### Endometritis {#CD001233-sec5-0134}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 0.56, 95% CI 0.05 to 6.03; 188 women; 1 study; [Analysis 9.25](#CD001233-fig-00925){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0135}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.82, 95% CI 0.61 to 1.09; 2966 women; 5 studies; [Analysis 9.26](#CD001233-fig-00926){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0136}

It is uncertain whether there is a difference in umbilical artery pH less than 7.10 directly postpartum between both induction methods (RR 0.77, 95% CI 0.53 to 1.12; 1535 women; 2 studies; [Analysis 9.27](#CD001233-fig-00927){ref-type="fig"}).

### Balloon (single or double) versus oxytocin (eight trials involving 781 women) {#CD001233-sec3-0030}

#### Primary outcomes {#CD001233-sec4-0039}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0137}

Not reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0138}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between induction of labour with a balloon and oxytocin (RR 0.20, 95% CI 0.01 to 4.11; 200 women; 1 study; [Analysis 12.1](#CD001233-fig-01201){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0139}

A balloon catheter probably reduces the risk of a caesarean section when compared to oxytocin (RR 0.68, 95% CI 0.56 to 0.83; 781 women; 8 studies; [Analysis 12.2](#CD001233-fig-01202){ref-type="fig"}), the absolute effect being 126 fewer caesarean sections per 1000 deliveries.

For women with a previous caesarean section, a balloon catheter may slightly reduce the risk of a caesarean section when compared to oxytocin (RR 0.80, 95% CI 0.64 to 1.00; 364 women; 3 studies; [Analysis 13.1](#CD001233-fig-01301){ref-type="fig"}). However, the result is still too imprecise to make a valid judgement on this outcome.

For primiparous women, it is uncertain whether there is a difference in effect as the result of this outcome was imprecise (RR 0.43, 95% CI 0.12 to 1.50; 60 women; 1 study; [Analysis 14.1](#CD001233-fig-01401){ref-type="fig"}). For multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0140}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods ([Analysis 12.3](#CD001233-fig-01203){ref-type="fig"}). Of the eight studies included for this comparison, one study (100 women) reported on this composite outcome. No events of neonatal morbidity or perinatal death occurred in this study.

The same result was seen on a subgroup of women with a previous caesarean section. One study (100 women) reported on this outcome, in which no events of serious neonatal morbidity of perinatal death occurred ([Analysis 13.2](#CD001233-fig-01302){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0141}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 12.4](#CD001233-fig-01204){ref-type="fig"}). Of the eight studies included for this comparison, two studies (160 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in these studies.

The same result was seen on a subgroup of women with a previous caesarean section. One study (100 women) reported on this outcome, in which no events of serious maternal morbidity of death occurred ([Analysis 13.3](#CD001233-fig-01303){ref-type="fig"}).

On parity subgroup comparisons, one study (60 women) reported on this outcome in primiparous women, in which no events were seen ([Analysis 14.2](#CD001233-fig-01402){ref-type="fig"}). For multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0040}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0142}

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (RR 0.56, 95% CI 0.20 to 1.54; 100 women; 1 study; [Analysis 12.5](#CD001233-fig-01205){ref-type="fig"}).

##### Oxytocin augmentation {#CD001233-sec5-0143}

Not a relevant outcome because all women in the comparison group received oxytocin.

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0144}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 1.00, 95% CI 0.23 to 4.29; 192 women; 3 studies; [Analysis 12.6](#CD001233-fig-01206){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0145}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 12.7](#CD001233-fig-01207){ref-type="fig"}). Of the eight studies included for this comparison, one study (100 women) pre‐specified this outcome. No events of uterine rupture occurred in this study.

##### Epidural analgesia {#CD001233-sec5-0146}

Not reported.

##### Instrumental vaginal delivery {#CD001233-sec5-0147}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.19, 95% CI 0.55 to 2.57; 220 women; 3 studies; [Analysis 12.8](#CD001233-fig-01208){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0148}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.53, 95% CI 0.23 to 1.21; 272 women; 2 studies; [Analysis 12.9](#CD001233-fig-01209){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0149}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.71, 95% CI 0.14 to 3.53; 300 women; 2 studies; [Analysis 12.10](#CD001233-fig-01210){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0150}

It is uncertain whether there is difference in NICU admissions between both induction methods (RR 0.80, 95% CI 0.32 to 1.98; 372 women; 3 studies; [Analysis 12.11](#CD001233-fig-01211){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0151}

Not reported.

##### Perinatal death {#CD001233-sec5-0152}

It is uncertain whether there is a difference in perinatal death between both induction methods ([Analysis 12.12](#CD001233-fig-01212){ref-type="fig"}). Of the eight studies included for this comparison, one study (100 women) pre‐specified this outcome. No cases of perinatal death occurred in this study.

##### Disability in childhood {#CD001233-sec5-0153}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0154}

Not reported.

##### Maternal nausea {#CD001233-sec5-0155}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0156}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0157}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0158}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0159}

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 1.26, 95% CI 0.51 to 3.11; 396 women; 4 studies; [Analysis 12.13](#CD001233-fig-01213){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0160}

Not reported.

##### Maternal death {#CD001233-sec5-0161}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0162}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0163}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0041}

##### Maternal fever during labour {#CD001233-sec5-0164}

It is uncertain whether there is difference in maternal fever during labour between both induction methods (RR 0.20, 95% CI 0.01 to 4.00; 60 women; 1 study; [Analysis 12.14](#CD001233-fig-01214){ref-type="fig"}).

##### Antibiotics during labour {#CD001233-sec5-0165}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0166}

Not reported.

##### Endometritis {#CD001233-sec5-0167}

Not reported.

##### Fetal distress {#CD001233-sec5-0168}

A balloon catheter probably reduces the risk of fetal distress for which a caesarean section is indicated when compared to oxytocin (RR 0.43, 95% CI 0.19 to 0.98; 332 women; 3 studies; [Analysis 12.15](#CD001233-fig-01215){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0169}

Not reported.

### Balloon (single or double) versus amniotomy (one trial involving 20 women) {#CD001233-sec3-0031}

The only outcome of interest reported for this comparison was caesarean section. Other outcomes were not reported.

#### Caesarean section {#CD001233-sec4-0042}

It is uncertain whether there is difference in caesarean sections between induction of labour with a balloon and amniotomy (RR 0.25, 95% CI 0.03 to 1.86; 20 women; 1 study; [Analysis 15.1](#CD001233-fig-01501){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

### Singe balloon (Foley) versus double balloon (ATAD/Cook) (five trials involving 826 women) {#CD001233-sec3-0032}

#### Primary outcomes {#CD001233-sec4-0043}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0170}

There may be little or no difference in vaginal deliveries not achieved within 24 hours between induction of labour with a single balloon and a double balloon (average RR 0.97, 95% CI 0.75 to 1.25; 608 women; 3 studies; [Analysis 16.1](#CD001233-fig-01601){ref-type="fig"}), although there was substantial heterogeneity for this outcome (Chi² = 5.64, df = 2 (P = 0.06); I² = 65%). No sensitivity analysis was performed as no high‐risk studies were included for this outcome.

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between both induction methods on subgroups for both primiparous women (RR 1.14, 95% CI 0.95 to 1.38; 50 women; 1 study; [Analysis 17.1](#CD001233-fig-01701){ref-type="fig"}) and multiparous women (RR 1.24, 95% CI 0.80 to 1.93; 48 women; 1 study; [Analysis 18.1](#CD001233-fig-01801){ref-type="fig"}) as the results for these outcomes were imprecise.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0171}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes ([Analysis 16.2](#CD001233-fig-01602){ref-type="fig"}), as events seem to occur infrequently after the use of both induction methods. Of the five studies included for this comparison, one study (217 women) reported on this outcome. No events of uterine hyperstimulation with FHR occurred in this study.

##### Caesarean section {#CD001233-sec5-0172}

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.97, 95% CI 0.71 to 1.33; 862 women; 5 studies; [Analysis 16.3](#CD001233-fig-01603){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Chi² = 6.99, df = 4 (P = 0.14); I² = 43%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of concealment or attrition bias ([Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}), did not change the effect observed, nor did it lower heterogeneity (average RR 0.92, 95% CI 0.65 to 1.32; 788 women; 5 studies; I² = 50%).

The same result was seen on parity subgroup comparisons for primiparous women (average RR 1.30, 95% CI 0.76 to 2.22; 374 women; 4 studies; [Analysis 17.2](#CD001233-fig-01702){ref-type="fig"}) and multiparous women (RR 0.74, 95% CI 0.30 to 1.84; 186 women; 2 studies; [Analysis 18.2](#CD001233-fig-01802){ref-type="fig"}). Furthermore, for the primiparous group, there was also substantial heterogeneity (Tau² = 0.18; Chi² = 7.96, df = 3 (P = 0.05); I² = 62%).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0173}

Not reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0174}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 16.4](#CD001233-fig-01604){ref-type="fig"}). Of the five studies included for this comparison, one study (217 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in this study.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0044}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0175}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0176}

There probably is little or no difference in oxytocin augmentation between both induction methods (RR 0.94, 95% CI 0.82 to 1.08; 278 women; 2 studies; [Analysis 16.5](#CD001233-fig-01605){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0177}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes ([Analysis 16.6](#CD001233-fig-01606){ref-type="fig"}), although events seem to occur infrequently after the use of both induction methods. Of the five studies included for this comparison, one study (217 women) reported on this outcome. No events of uterine hyperstimulation without FHR occurred in this study.

##### Uterine rupture {#CD001233-sec5-0178}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 16.7](#CD001233-fig-01607){ref-type="fig"}). Of the five studies included for this comparison, one study (217 women) reported on this outcome. No events of uterine rupture occurred in this study.

##### Epidural analgesia {#CD001233-sec5-0179}

There probably is little or no difference in epidural analgesia between both induction methods (RR 0.93, 95% CI 0.83 to 1.03; 608 women; 3 studies; [Analysis 16.8](#CD001233-fig-01608){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0180}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.86, 95% CI 0.61 to 1.20; 690 women; 3 studies; [Analysis 16.9](#CD001233-fig-01609){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0181}

A single balloon may reduce the risk of meconium‐stained liquor when compared to a double balloon (RR 0.40, 95% CI 0.15 to 1.04; 98 women; 1 study; [Analysis 16.10](#CD001233-fig-01610){ref-type="fig"}). However, the result is still too imprecise to make a valid judgement on this outcome.

##### Apgar score less than seven at five minutes {#CD001233-sec5-0182}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.84, 95% CI 0.25 to 2.79; 608 women; 3 studies; [Analysis 16.11](#CD001233-fig-01611){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0183}

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.67, 95% CI 0.71 to 3.93; 391 women; 2 studies; [Analysis 16.12](#CD001233-fig-01612){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0184}

Not reported.

##### Perinatal death {#CD001233-sec5-0185}

Not reported.

##### Disability in childhood {#CD001233-sec5-0186}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0187}

Not reported.

##### Maternal nausea {#CD001233-sec5-0188}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0189}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0190}

Not reported.

##### Other maternal side effects: pain after insertion {#CD001233-sec5-0191}

It is uncertain whether there is a difference in pain after insertion of the catheter between both induction methods (RR 0.67, 95% CI 0.20 to 2.17; 74 women; 1 study; [Analysis 16.13](#CD001233-fig-01613){ref-type="fig"}).

##### Postpartum haemorrhage {#CD001233-sec5-0192}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.83, 95% CI 0.27 to 2.52; 291 women; 2 studies; [Analysis 16.14](#CD001233-fig-01614){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0193}

Not reported.

##### Maternal death {#CD001233-sec5-0194}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0195}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0196}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0045}

##### Maternal fever during labour {#CD001233-sec5-0197}

It is uncertain whether there is a difference in maternal fever during labour between both induction methods (average RR 0.61, 95% CI 0.16 to 2.34; 584 women; 3 studies; [Analysis 16.15](#CD001233-fig-01615){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Chi² = 2.85, df = 1 (P = 0.09); I² = 65%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}), did not alter the result, nor did it lower heterogeneity (average RR 0.61, 95% CI 0.16 to 2.34; 510 women; 2 studies; I² = 65%).

##### Antibiotics during labour {#CD001233-sec5-0198}

It is uncertain whether there is a difference in antibiotics during labour between both induction methods (RR 0.97, 95% CI 0.61 to 1.56; 217 women; 1 study; [Analysis 16.16](#CD001233-fig-01616){ref-type="fig"}).

##### Chorioamnionitis {#CD001233-sec5-0199}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.56, 95% CI 0.47 to 5.20; 98 women;1 study; [Analysis 16.17](#CD001233-fig-01617){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0200}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.95, 95% CI 0.18 to 21.14; 217 women; 1 study; [Analysis 16.18](#CD001233-fig-01618){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0201}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated (RR 0.98, 95% CI 0.70 to 1.36; 682 women; 4 studies; [Analysis 16.19](#CD001233-fig-01619){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0202}

It is uncertain whether there is a difference in umbilical artery pH less than 7.10 directly postpartum between both induction methods (RR 0.42, 95% CI 0.11 to 1.57; 217 women; 1 study; [Analysis 16.20](#CD001233-fig-01620){ref-type="fig"}).

### Laminaria tent versus vaginal prostaglandin E2 (five trials involving 263 women) {#CD001233-sec3-0033}

#### Primary outcomes {#CD001233-sec4-0046}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0203}

Not reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0204}

A laminaria tent probably reduces the risk of uterine hyperstimulation with FHR changes when compared to vaginal prostaglandin E2 (RR 0.11, 95% CI 0.02 to 0.60; 188 women; 3 studies; [Analysis 19.1](#CD001233-fig-01901){ref-type="fig"}), the absolute effect being 118 fewer per 1000 deliveries.

For primiparous women, it is uncertain whether there is a difference in effect as the result of this outcome was imprecise (RR 0.33, 95% CI 0.01 to 7.95; 80 women; 1 study; [Analysis 20.1](#CD001233-fig-02001){ref-type="fig"}). For multiparous women, this outcome was not reported.

##### Caesarean section {#CD001233-sec5-0205}

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.91, 95% CI 0.56 to 1.48; 263 women; 5 studies; [Analysis 19.2](#CD001233-fig-01902){ref-type="fig"}).

The same result was seen on parity subgroup comparisons for primiparous women (average RR 1.07, 95% CI 0.24 to 4.89; 90 women; 2 studies; [Analysis 20.2](#CD001233-fig-02002){ref-type="fig"}) and multiparous women (RR 0.50, 95% CI 0.06 to 3.91; 10 women; 1 study; [Analysis 21.1](#CD001233-fig-02101){ref-type="fig"}). Furthermore, for the primiparous group, there was also substantial heterogeneity (Chi² = 2.25, df = 1 (P = 0.13); I² = 56%).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0206}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods ([Analysis 19.3](#CD001233-fig-01903){ref-type="fig"}). Of the five studies included for this comparison, one study (80 women) reported on this composite outcome. No events of neonatal morbidity or perinatal death occurred in this study.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0207}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 19.4](#CD001233-fig-01904){ref-type="fig"}). Of the five studies included for this comparison, one study (28 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in this study.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0047}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0208}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0209}

Not reported.

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0210}

A laminaria tent may reduce the risk of uterine hyperstimulation without FHR changes when compared to vaginal PGE2 (RR 0.22, 95% CI 0.09 to 0.49; 180 women; 3 studies; [Analysis 19.5](#CD001233-fig-01905){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0211}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0212}

It is uncertain whether there is a difference in epidural analgesia between both induction methods (RR 0.91, 95% CI 0.74 to 1.13; 80 women; 1 study; [Analysis 19.6](#CD001233-fig-01906){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0213}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.71, 95% CI 0.43 to 1.17; 80 women; 1 study; [Analysis 19.7](#CD001233-fig-01907){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0214}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.14, 95% CI 0.01 to 2.68; 80 women; 1 study; [Analysis 19.8](#CD001233-fig-01908){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0215}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods ([Analysis 19.9](#CD001233-fig-01909){ref-type="fig"}). Of the five studies included for this comparison, two studies (160 women) reported on this outcome. No events of Apgar scores less than seven at five minutes occurred in these studies.

##### Neonatal intensive care unit admission {#CD001233-sec5-0216}

Not reported.

##### Neonatal encephalopathy {#CD001233-sec5-0217}

Not reported.

##### Perinatal death {#CD001233-sec5-0218}

It is uncertain whether there is a difference in perinatal death between both induction methods ([Analysis 19.10](#CD001233-fig-01910){ref-type="fig"}). Of the five studies included for this comparison, one study (80 women) reported on this outcome. No events of perinatal deaths occurred in this study.

##### Disability in childhood {#CD001233-sec5-0219}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0220}

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 0.29, 95% CI 0.01 to 6.60; 28 women; 1 study; [Analysis 19.11](#CD001233-fig-01911){ref-type="fig"}).

##### Maternal nausea {#CD001233-sec5-0221}

It is uncertain whether there is a difference in maternal nausea between both induction methods (RR 0.29, 95% CI 0.01 to 6.60; 28 women; 1 study; [Analysis 19.12](#CD001233-fig-01912){ref-type="fig"}).

##### Maternal vomiting {#CD001233-sec5-0222}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0223}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0224}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0225}

Not reported.

##### Serious maternal complications {#CD001233-sec5-0226}

Not reported.

##### Maternal death {#CD001233-sec5-0227}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0228}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0229}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0048}

##### Maternal fever during labour {#CD001233-sec5-0230}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0231}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0232}

Not reported.

##### Endometritis {#CD001233-sec5-0233}

Not reported.

##### Fetal distress {#CD001233-sec5-0234}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.62, 95% CI 0.34 to 1.15; 188 women; 3 studies; [Analysis 19.13](#CD001233-fig-01913){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0235}

Not reported.

### Laminaria tent versus cervical prostaglandin E2 (five trials involving 920 women) {#CD001233-sec3-0034}

#### Primary outcomes {#CD001233-sec4-0049}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0236}

Not reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0237}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between induction of labour with a laminaria tent and cervical PGE2 (RR 0.17, 95% CI 0.02 to 1.42; 350 women; 2 studies; [Analysis 22.1](#CD001233-fig-02201){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0238}

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 1.16, 95% CI 0.93 to 1.45; 920 women; 5 studies; [Analysis 22.2](#CD001233-fig-02202){ref-type="fig"}).

The same results were seen on parity subgroup comparisons for primiparous women (RR 1.15, 95% CI 0.62 to 2.13; 116 women; 1 study; [Analysis 23.1](#CD001233-fig-02301){ref-type="fig"}) and multiparous women (RR 1.28, 95% CI 0.45 to 3.65; 69 women; 1 study; [Analysis 24.1](#CD001233-fig-02401){ref-type="fig"}).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0239}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 3.16, 95% CI 0.13 to 76.70; 185 women; 1 study; [Analysis 22.3](#CD001233-fig-02203){ref-type="fig"}). One event, a case of perinatal death, was reported in the laminaria group. No events occurred in the cervical PGE2 group.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0240}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (RR 0.35, 95% CI 0.01 to 8.52; 185 women; 1 study; [Analysis 22.4](#CD001233-fig-02204){ref-type="fig"}). No events occurred in the laminaria group. One event, a uterine rupture, was reported in the cervical PGE2 group.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0050}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0241}

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (average RR 0.46, 95% CI 0.11 to 1.96; 218 women; 2 studies; [Analysis 22.5](#CD001233-fig-02205){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.62; Chi² = 1.98, df = 1 (P = 0.16); I² = 50%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}), did not alter the result (RR 0.16, 95% CI 0.02 to 1.24; 53 women; 1 study; I² = 0%).

##### Oxytocin augmentation {#CD001233-sec5-0242}

A laminaria tent probably increases the risk of oxytocin augmentation when compared to cervical PGE2 (RR 1.41, 95% CI 1.21 to 1.64; 185 women; 1 study; [Analysis 22.6](#CD001233-fig-02206){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0243}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.17, 95% CI 0.02 to 1.36; 601 women; 2 studies; [Analysis 22.7](#CD001233-fig-02207){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0244}

It is uncertain whether there is a difference in uterine rupture between both induction methods (RR 0.35, 95% CI 0.01 to 8.52; 185 women; 1 study; [Analysis 22.8](#CD001233-fig-02208){ref-type="fig"}). One study reported on this outcome in which one uterine rupture occurred in the PGE2 group. No uterine ruptures were seen in the laminaria group.

##### Epidural analgesia {#CD001233-sec5-0245}

Not reported.

##### Instrumental vaginal delivery {#CD001233-sec5-0246}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.05, 95% CI 0.65 to 1.69; 424 women; 3 studies; [Analysis 22.9](#CD001233-fig-02209){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0247}

Not reported.

##### Apgar score less than seven at five minutes {#CD001233-sec5-0248}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 5.28, 95% CI 0.63 to 44.30; 185 women; 1 study; [Analysis 22.10](#CD001233-fig-02210){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0249}

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.58, 95% CI 0.58 to 4.33; 259 women; 2 studies; [Analysis 22.11](#CD001233-fig-02211){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0250}

Not reported.

##### Perinatal death {#CD001233-sec5-0251}

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 3.16, 95% CI 0.13 to 76.70; 185 women; 1 study; [Analysis 22.12](#CD001233-fig-02212){ref-type="fig"}). One study reported on this outcome, in which one perinatal death occurred in the laminaria group. No perinatal death were seen in the cervical PGE2 group.

##### Disability in childhood {#CD001233-sec5-0252}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0253}

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 0.20, 95% CI 0.01 to 4.15; 165 women; 1 study; [Analysis 22.13](#CD001233-fig-02213){ref-type="fig"}). The one study included for this outcome reported on gastro‐intestinal symptoms without specifying what the symptoms were.

##### Maternal nausea {#CD001233-sec5-0254}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0255}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0256}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0257}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0258}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 1.14, 95% CI 0.46 to 2.81; 239 women; 2 studies; [Analysis 22.14](#CD001233-fig-02214){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0259}

Not reported.

##### Maternal death {#CD001233-sec5-0260}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0261}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0262}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0051}

##### Maternal fever during labour {#CD001233-sec5-0263}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0264}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0265}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 3.17, 95% CI 0.35 to 29.06; 74 women; 1 study; [Analysis 22.15](#CD001233-fig-02215){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0266}

It is uncertain whether there is a difference in endometritis between both induction methods (average RR 0.30, 95% CI 0.08 to 1.09; 490 women; 2 studies; [Analysis 22.16](#CD001233-fig-02216){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.54; Chi² = 2.54, df = 1 (P = 0.11); I² = 61%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}), did not alter the result (RR 0.63, 95% CI 0.16 to 2.46; 74 women; 1 study; I² = 0%).

##### Fetal distress {#CD001233-sec5-0267}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.44, 95% CI 0.07 to 2.90; 128 women; 2 studies; [Analysis 22.17](#CD001233-fig-02217){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0268}

Not reported.

### Laminaria tent versus oxytocin (two trials involving 73 women) {#CD001233-sec3-0035}

The only outcomes of interest reported for this comparison were caesarean section and fetal distress. Other outcomes were not reported.

#### Caesarean section {#CD001233-sec4-0052}

It is uncertain whether there is a difference in caesarean sections between induction of labour with a laminaria tent and oxytocin (RR 0.83, 95% CI 0.36 to 1.89; 73 women; 2 studies; [Analysis 25.1](#CD001233-fig-02501){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Fetal distress {#CD001233-sec4-0053}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 2.69, 95% CI 0.11 to 63.18; 53 women; 1 study; [Analysis 25.2](#CD001233-fig-02502){ref-type="fig"}).

### Laminaria tent versus amniotomy (one trial involving 20 women) {#CD001233-sec3-0036}

The only outcome of interest reported for this comparison was caesarean section. Other outcomes were not reported.

#### Caesarean section {#CD001233-sec4-0054}

It is uncertain whether there is a difference in caesarean sections between induction of labour with a laminaria tent compared to amniotomy (RR 0.75, 95% CI 0.22 to 2.52; 20 women; 1 study; [Analysis 26.1](#CD001233-fig-02601){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

### Laminaria tent versus other hygroscopic dilators (one trial involving 41 women) {#CD001233-sec3-0037}

The only outcome of interest reported for this comparison was caesarean section. Other outcomes were not reported.

#### Caesarean section {#CD001233-sec4-0055}

It is uncertain whether there is a difference in caesarean sections between induction of labour with a laminaria tent and other hygroscopic dilators (RR 1.70, 95% CI 0.44 to 6.66; 41 women; 1 study; [Analysis 27.1](#CD001233-fig-02701){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

### Extra amniotic saline infusion (EASI) versus vaginal prostaglandin E2 (two trials involving 221 women) {#CD001233-sec3-0038}

#### Primary outcomes {#CD001233-sec4-0056}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0269}

EASI probably increases the risk of a vaginal delivery not achieved within 24 hours when compared to vaginal PGE2 (RR 1.74, 95% CI 1.21 to 2.49; 109 women; 1 study; [Analysis 28.1](#CD001233-fig-02801){ref-type="fig"}).

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0270}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.23, 95% CI 0.03 to 2.07; 221 women; 2 studies; [Analysis 28.2](#CD001233-fig-02802){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0271}

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 1.35, 95% CI 0.94 to 1.96; 221 women; 2 studies; [Analysis 28.3](#CD001233-fig-02803){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Chi² = 5.24, df = 1 (P = 0.02); I² = 81%). No sensitivity analysis could be done as both included studies were assessed as having a potentially higher risk of allocation or attrition bias.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0272}

Not reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0273}

Not reported.

#### Secondary outcomes {#CD001233-sec4-0057}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0274}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0275}

EASI may increase the risk of oxytocin augmentation when compared to vaginal PGE2 (RR 12.71, 95% CI 3.20 to 50.57; 109 women; 1 study; [Analysis 28.4](#CD001233-fig-02804){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0276}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.23, 95% CI 0.03 to 2.07; 221 women; 2 studies; [Analysis 28.5](#CD001233-fig-02805){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0277}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0278}

There may be little or no difference in epidural analgesia between both induction methods (RR 1.00, 95% CI 0.97 to 1.04; 112 women; 1 study; [Analysis 28.6](#CD001233-fig-02806){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0279}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.58, 95% CI 0.30 to 1.14; 109 women; 1 study; [Analysis 28.7](#CD001233-fig-02807){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0280}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 3.00, 95% CI 0.12 to 72.10; 112 women; 1 study; [Analysis 28.8](#CD001233-fig-02808){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0281}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 4.25, 95% CI 0.21 to 86.51; 109 women; 1 study; [Analysis 28.9](#CD001233-fig-02809){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0282}

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.50, 95% CI 0.45 to 5.03; 112 women; 1 study; [Analysis 28.10](#CD001233-fig-02810){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0283}

Not reported.

##### Perinatal death {#CD001233-sec5-0284}

Not reported.

##### Disability in childhood {#CD001233-sec5-0285}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0286}

Not reported.

##### Maternal nausea {#CD001233-sec5-0287}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0288}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0289}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0290}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0291}

Not reported.

##### Serious maternal complications {#CD001233-sec5-0292}

Not reported.

##### Maternal death {#CD001233-sec5-0293}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0294}

It is uncertain whether there is a difference in women not being satisfied between both induction methods (RR 0.56, 95% CI 0.10 to 3.25; 109 women; 1 study; [Analysis 28.11](#CD001233-fig-02811){ref-type="fig"}). For this outcome, women in the included study were asked to comment on the induction method, for which they could choose between recommendable, satisfactory and unsatisfactory.

##### Caregiver not satisfied {#CD001233-sec5-0295}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0058}

##### Maternal fever during labour {#CD001233-sec5-0296}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0297}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0298}

Not reported.

##### Endometritis {#CD001233-sec5-0299}

Not reported.

##### Fetal distress {#CD001233-sec5-0300}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 1.20, 95% CI 0.39 to 3.71; 112 women; 1 study; [Analysis 28.12](#CD001233-fig-02812){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0301}

Not reported.

### Extra amniotic saline infusion versus cervical prostaglandin E2 (two trials involving 155 women) {#CD001233-sec3-0039}

#### Primary outcomes {#CD001233-sec4-0059}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0302}

Not reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0303}

Not reported.

##### Caesarean section {#CD001233-sec5-0304}

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.73, 95% CI 0.10 to 5.12; 155 women; 2 studies; [Analysis 29.1](#CD001233-fig-02901){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 1.60; Chi² = 5.11, df = 1 (P = 0.02); I² = 80%). As the results for both included studies show no overlap of CI, this makes the pooled result for this outcome less meaningful. No sensitivity analysis was performed as no potential high‐risk studies were included for this outcome.

The same result was seen on a subgroup comparison for primiparous women (RR 0.25, 95% CI 0.06 to 1.09; 70 women; 1 study; [Analysis 30.1](#CD001233-fig-03001){ref-type="fig"}). For multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0305}

Not reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0306}

Not reported.

#### Secondary outcomes {#CD001233-sec4-0060}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0307}

EASI may reduce the risk of an unfavourable cervix after 24 hours when compared to cervical PGE2 (RR 0.06, 95% CI 0.00 to 0.97; 85 women; 1 study; [Analysis 29.2](#CD001233-fig-02902){ref-type="fig"}).

##### Oxytocin augmentation {#CD001233-sec5-0308}

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (RR 1.10, 95% CI 0.54 to 2.25; 70 women; 1 study; [Analysis 29.3](#CD001233-fig-02903){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0309}

Not reported.

##### Uterine rupture {#CD001233-sec5-0310}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0311}

Not reported.

##### Instrumental vaginal delivery {#CD001233-sec5-0312}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.33, 95% CI 0.04 to 3.01; 85 women; 1 study; [Analysis 29.4](#CD001233-fig-02904){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0313}

Not reported.

##### Apgar score less than seven at five minutes {#CD001233-sec5-0314}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods ([Analysis 29.5](#CD001233-fig-02905){ref-type="fig"}). One study (85 women) pre‐specified this outcome in which no Apgar scores less than seven after five minutes were reported.

##### Neonatal intensive care unit admission {#CD001233-sec5-0315}

Not reported.

##### Neonatal encephalopathy {#CD001233-sec5-0316}

Not reported.

##### Perinatal death {#CD001233-sec5-0317}

Not reported.

##### Disability in childhood {#CD001233-sec5-0318}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0319}

Not reported.

##### Maternal nausea {#CD001233-sec5-0320}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0321}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0322}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0323}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0324}

Not reported.

##### Serious maternal complications {#CD001233-sec5-0325}

Not reported.

##### Maternal death {#CD001233-sec5-0326}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0327}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0328}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0061}

##### Maternal fever during labour {#CD001233-sec5-0329}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0330}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0331}

Not reported.

##### Endometritis {#CD001233-sec5-0332}

It is uncertain whether there is a difference in endometritis between both induction methods ([Analysis 29.6](#CD001233-fig-02906){ref-type="fig"}). One study (85 women) pre‐specified this outcome in which no cases of endometritis were reported.

##### Fetal distress {#CD001233-sec5-0333}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.29, 95% CI 0.06 to 1.28; 70 women; 1 study; [Analysis 29.7](#CD001233-fig-02907){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0334}

Not reported.

### Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone (eight trials involving 639 women) {#CD001233-sec3-0040}

#### Primary outcomes {#CD001233-sec4-0062}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0335}

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between induction of labour with a mechanical method combined with PGE2 and PGE2 alone (RR 0.84, 95% CI 0.53 to 1.33; 39 women; 1 study; [Analysis 31.1](#CD001233-fig-03101){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0336}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.26, 95% CI 0.01 to 5.12; 122 women; 2 studies; [Analysis 31.2](#CD001233-fig-03102){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0337}

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.96, 95% CI 0.66 to 1.40; 517 women; 7 studies; [Analysis 31.3](#CD001233-fig-03103){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Tau² = 0.11; Chi² = 11.16, df = 6 (P = 0.08); I² = 46%).

A sensitivity analysis, after eliminating three trials assessed as having a potentially higher risk of allocation or attrition bias ([Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}; [Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}), did not alter the result nor did it lower heterogeneity (average RR 1.02, 95% CI 0.56 to 1.84; 364 women; 4 studies; I² = 70%).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0338}

Not reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0339}

Not reported.

#### Secondary outcomes {#CD001233-sec4-0063}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0340}

A mechanical method combined with PGE2 may reduce the risk of an unfavourable cervix after 24 hours when compared to PGE2 alone (RR 0.52, 95% CI 0.31 to 0.85; 122 women; 1 study; [Analysis 31.4](#CD001233-fig-03104){ref-type="fig"}).

##### Oxytocin augmentation {#CD001233-sec5-0341}

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (RR 0.95, 95% CI 0.64 to 1.41; 44 women; 1 study; [Analysis 31.5](#CD001233-fig-03105){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0342}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods ([Analysis 31.6](#CD001233-fig-03106){ref-type="fig"}). Of the eight studies included for this comparison, three studies (239 women) pre‐specified this outcome. No events of uterine hyperstimulation without FHR changes occurred in these studies.

##### Uterine rupture {#CD001233-sec5-0343}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0344}

There may be little or no difference in epidural analgesia during labour between both induction methods (RR 0.98, 95% CI 0.77 to 1.24; 39 women; 1 study; [Analysis 31.7](#CD001233-fig-03107){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0345}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.56, 95% CI 0.22 to 1.45; 78 women; 2 studies; [Analysis 31.8](#CD001233-fig-03108){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0346}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.97, 95% CI 0.33 to 2.83; 120 women; 1 study; [Analysis 31.9](#CD001233-fig-03109){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0347}

Not reported.

##### Neonatal intensive care unit admission {#CD001233-sec5-0348}

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.26, 95% CI 0.01 to 5.12; 44 women; 1 study; [Analysis 31.10](#CD001233-fig-03110){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0349}

Not reported.

##### Perinatal death {#CD001233-sec5-0350}

Not reported.

##### Disability in childhood {#CD001233-sec5-0351}

Not reported.

##### Maternal side effects {#CD001233-sec5-0352}

Not reported.

##### Maternal nausea {#CD001233-sec5-0353}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0354}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0355}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0356}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0357}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods ([Analysis 31.11](#CD001233-fig-03111){ref-type="fig"}). Of the eight studies included for this comparison, one study (39 women) pre‐specified this outcome. No events of postpartum haemorrhage occurred in this study.

##### Serious maternal complications {#CD001233-sec5-0358}

Not reported.

##### Maternal death {#CD001233-sec5-0359}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0360}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0361}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0064}

##### Maternal fever during labour {#CD001233-sec5-0362}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0363}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0364}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.56, 95% CI 0.45 to 5.45; 122 women; 2 studies; [Analysis 31.12](#CD001233-fig-03112){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0365}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.07, 95% CI 0.41 to 2.78; 237 women; 3 studies; [Analysis 31.13](#CD001233-fig-03113){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0366}

It is uncertain whether there is a difference fetal distress for which a caesarean section is indicated between both induction methods (RR 2.28, 95% CI 0.54 to 9.69; 140 women; 2 studies; [Analysis 31.14](#CD001233-fig-03114){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0367}

Not reported.

### Any mechanical method and prostaglandin E2 versus low‐dose misoprostol alone (one trial involving 127 women) {#CD001233-sec3-0041}

#### Primary outcomes {#CD001233-sec4-0065}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0368}

A mechanical method combined with PGE2 probably reduces the risk of a vaginal delivery not achieved within 24 hours when compared to misoprostol (RR 0.32, 95% CI 0.12 to 0.82; 127 women; 1 study; [Analysis 32.1](#CD001233-fig-03201){ref-type="fig"}). the absolute effect being 165 less per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0369}

Not reported.

##### Caesarean section {#CD001233-sec5-0370}

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 1.09, 95% CI 0.58 to 2.04; 127 women; 1 study; [Analysis 32.2](#CD001233-fig-03202){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0371}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.19, 95% CI 0.01 to 3.90; 127 women; 1 study; [Analysis 32.3](#CD001233-fig-03203){ref-type="fig"}). Two events occurred in the misoprostol group, both being cases of perinatal death.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0372}

Not reported.

#### Secondary outcomes {#CD001233-sec4-0066}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0373}

A mechanical method combined with PGE2 probably reduces the risk of an unfavourable cervix after 24 hours when compared to misoprostol (RR 0.41, 95% CI 0.25 to 0.67; 127 women; 1 study; [Analysis 32.4](#CD001233-fig-03204){ref-type="fig"}).

##### Oxytocin augmentation {#CD001233-sec5-0374}

A mechanical method combined with PGE2 probably slightly increases the risk of oxytocin augmentation when compared to misoprostol (RR 1.21, 95% CI 1.01 to 1.46; 127; 1 study; [Analysis 32.5](#CD001233-fig-03205){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0375}

A mechanical method combined with PGE2 probably increases the risk of uterine hyperstimulation without FHR changes when compared to misoprostol (RR 4.05, 95% CI 1.44 to 11.38; 127; 1 study; [Analysis 32.6](#CD001233-fig-03206){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0376}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0377}

Not reported.

##### Instrumental vaginal delivery {#CD001233-sec5-0378}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.26, 95% CI 0.77 to 2.04; 127 women; 1 study; [Analysis 32.7](#CD001233-fig-03207){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0379}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.56, 95% CI 0.23 to 1.32; 127 women; 1 study; [Analysis 32.8](#CD001233-fig-03208){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0380}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 1.91, 95% CI 0.18 to 20.51; 127 women; 1 study; [Analysis 32.9](#CD001233-fig-03209){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0381}

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.64, 95% CI 0.31 to 1.31; 127 women; 1 study; [Analysis 32.10](#CD001233-fig-03210){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0382}

Not reported.

##### Perinatal death {#CD001233-sec5-0383}

It is uncertain whether there is a difference in perinatal death between both methods (RR 0.19, 95% CI 0.01 to 3.90; 127 women; 1 study; [Analysis 32.11](#CD001233-fig-03211){ref-type="fig"}). Two cases of neonatal death were reported by [Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}, both were born to women randomised to misoprostol. The authors describe that in both cases the neonates died as a result of complications of congenital malformations and were unrelated to the induction method.

##### Disability in childhood {#CD001233-sec5-0384}

Not reported.

##### Maternal side effects {#CD001233-sec5-0385}

Not reported.

##### Maternal nausea {#CD001233-sec5-0386}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0387}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0388}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0389}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0390}

Not reported.

##### Serious maternal complications {#CD001233-sec5-0391}

Not reported.

##### Maternal death {#CD001233-sec5-0392}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0393}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0394}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0067}

##### Maternal fever during labour {#CD001233-sec5-0395}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0396}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0397}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.91, 95% CI 0.18 to 20.51; 127 women; 1 study; [Analysis 32.12](#CD001233-fig-03212){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0398}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.91, 95% CI 0.36 to 10.05; 127 women; 1 study; [Analysis 32.13](#CD001233-fig-03213){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0399}

Not reported.

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0400}

Not reported.

### Any mechanical method and prostaglandin E2 versus oxytocin alone (one trial involving 44 women) {#CD001233-sec3-0042}

The only outcomes of interest reported for this comparison were caesarean section, instrumental vaginal delivery and endometritis. Other outcomes were not reported.

#### Caesarean section {#CD001233-sec4-0068}

It is uncertain whether there is a difference in caesarean sections between induction of labour with a mechanical method combined with PGE2 versus oxytocin (RR 0.30, 95% CI 0.04 to 2.47; 44 women; 1 study; [Analysis 33.1](#CD001233-fig-03301){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Instrumental vaginal delivery {#CD001233-sec4-0069}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.60, 95% CI 0.12 to 2.94; 44 women; 1 study; [Analysis 33.2](#CD001233-fig-03302){ref-type="fig"}).

#### Endometritis {#CD001233-sec4-0070}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 3.57, 95% CI 0.15 to 83.14; 44 women; 1 study; [Analysis 33.3](#CD001233-fig-03303){ref-type="fig"}).

### Any mechanical method and low‐dose misoprostol versus prostaglandin E2 alone (one trial involving 350 women) {#CD001233-sec3-0043}

#### Primary outcomes {#CD001233-sec4-0071}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0401}

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between induction of labour with a mechanical method combined with misoprostol and prostaglandin E2 (RR 1.14, 95% CI 0.89 to 1.46; 350 women; 1 study; [Analysis 34.1](#CD001233-fig-03401){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0402}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.75, 95% CI 0.27 to 2.13; 327 women; 1 study; [Analysis 34.2](#CD001233-fig-03402){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0403}

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.85, 95% CI 0.57 to 1.25; 350 women; 1 study; [Analysis 34.3](#CD001233-fig-03403){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0404}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 2.04, 95% CI 0.19 to 22.24; 345 women; 1 study; [Analysis 34.4](#CD001233-fig-03404){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0405}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 34.5](#CD001233-fig-03405){ref-type="fig"}). No events of maternal morbidity or death occurred in the one included study (350 women).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0072}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0406}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0407}

A mechanical method combined with misoprostol probably reduces the risk of oxytocin augmentation when compared to PGE2 (RR 0.54, 95% CI 0.34 to 0.86; 350 women; 1 study; [Analysis 34.6](#CD001233-fig-03406){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0408}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.54, 95% CI 0.22 to 1.32; 327 women; 1 study; [Analysis 34.7](#CD001233-fig-03407){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0409}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 34.8](#CD001233-fig-03408){ref-type="fig"}). No events of uterine rupture occurred in the one included study (350 women).

##### Epidural analgesia {#CD001233-sec5-0410}

Not reported.

##### Instrumental vaginal delivery {#CD001233-sec5-0411}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.01, 95% CI 0.26 to 3.98; 350 women; 1 study; [Analysis 34.9](#CD001233-fig-03409){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0412}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 1.15, 95% CI 0.60 to 2.23; 339 women; 1 study; [Analysis 34.10](#CD001233-fig-03410){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0413}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.68, 95% CI 0.25 to 1.88; 346 women; 1 study; [Analysis 34.11](#CD001233-fig-03411){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0414}

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.68, 95% CI 0.12 to 4.03; 346 women; 1 study; [Analysis 34.12](#CD001233-fig-03412){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0415}

Not reported.

##### Perinatal death {#CD001233-sec5-0416}

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 1.02, 95% CI 0.06 to 16.14; 345 women; 1 study; [Analysis 34.13](#CD001233-fig-03413){ref-type="fig"}). Two cases of perinatal death were reported by [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}, one in each group. No further information was given on timing or cause of the demise.

##### Disability in childhood {#CD001233-sec5-0417}

Not reported.

##### Maternal side effects {#CD001233-sec5-0418}

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 1.16, 95% CI 0.95 to 1.43; 314 women; 1 study; [Analysis 34.14](#CD001233-fig-03414){ref-type="fig"}).

##### Maternal nausea {#CD001233-sec5-0419}

A mechanical method combined with misoprostol may increase the risk of maternal nausea when compared to PGE2 (RR 1.65, 95% CI 0.98 to 2.79; 300 women; 1 study; [Analysis 34.15](#CD001233-fig-03415){ref-type="fig"}). However, the result is still too imprecise to make a valid judgement on this outcome.

##### Maternal vomiting {#CD001233-sec5-0420}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0421}

A mechanical method combined with misoprostol probably increases the risk of maternal diarrhoea when compared to PGE2 (RR 3.72, 95% CI 1.53 to 9.00; 313 women; 1 study; [Analysis 34.16](#CD001233-fig-03416){ref-type="fig"}).

##### Other maternal side effects {#CD001233-sec5-0422}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0423}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.98, 95% CI 0.67 to 1.41; 348 women; 1 study; [Analysis 34.17](#CD001233-fig-03417){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0424}

It is uncertain whether there is a difference in serious maternal complications between both induction methods ([Analysis 34.18](#CD001233-fig-03418){ref-type="fig"}). One study (350 women) was included for this outcome in which no cases of septicaemia or intensive care unit admission were reported.

##### Maternal death {#CD001233-sec5-0425}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0426}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0427}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0073}

##### Maternal fever during labour {#CD001233-sec5-0428}

It is uncertain whether there is a difference in maternal fever during labour between both induction methods (RR 1.53, 95% CI 0.26 to 9.02; 347 women; 1 study; [Analysis 34.19](#CD001233-fig-03419){ref-type="fig"}).

##### Antibiotics during labour {#CD001233-sec5-0429}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0430}

Not reported.

##### Endometritis {#CD001233-sec5-0431}

Not reported.

##### Fetal distress {#CD001233-sec5-0432}

Not reported.

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0433}

Not reported.

### Any mechanical method and low dose misoprostol versus misoprostol alone (seven trials involving 1422 women) {#CD001233-sec3-0044}

#### Primary outcomes {#CD001233-sec4-0074}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0434}

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between any mechanical method combined with misoprostol and misoprostol alone (average RR 0.70, 95% CI 0.25 to 1.95; 668 women; 2 studies; [Analysis 35.1](#CD001233-fig-03501){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.51; Chi² = 14.00, df = 1 (P = 0.0002); I² = 93%).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias ([Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}), did not alter the result (average RR 1.14, 95% CI 0.89 to 1.46; 350 women; 1 study).

The same results were seen on a subgroup comparison for primiparous women (RR 0.83, 95% CI 0.23 to 2.96; 53 women; 1 study; [Analysis 36.1](#CD001233-fig-03601){ref-type="fig"}). For multiparous women, a mechanical method combined with misoprostol may reduce the risk of a vaginal delivery not achieved within 24 hours (RR 0.37, 95% CI 0.21 to 0.63; 265 women; 1 study; [Analysis 37.1](#CD001233-fig-03701){ref-type="fig"}).

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0435}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (average RR 0.54, 95% CI 0.20 to 1.45; 707 women; 4 studies; [Analysis 35.2](#CD001233-fig-03502){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.57; Chi² = 7.40, df = 2 (P = 0.02); I² = 73%). No sensitivity analysis was performed as no potential high‐risk studies were included for this outcome.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0436}

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.87, 95% CI 0.66 to 1.15; 1422 women; 7 studies; [Analysis 35.3](#CD001233-fig-03503){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.07; Chi² = 13.33, df = 6 (P = 0.04); I² = 55%).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias ([Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}), showed there probably is little or no difference in caesarean sections between both induction methods (RR 0.96, 95% CI 0.79 to 1.17; 1104 women; 6 studies; I² = 5%).

The same results were seen on a subgroup comparison for primiparous women (RR 0.62, 95% CI 0.15 to 2.51; 53 women; 1 study; [Analysis 36.2](#CD001233-fig-03602){ref-type="fig"}). For multiparous women, a mechanical method combined with misoprostol may reduce the risk a caesarean section (RR 0.35, 95% CI 0.18 to 0.68; 265 women; 1 study; [Analysis 37.2](#CD001233-fig-03702){ref-type="fig"}).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0437}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 1.25, 95% CI 0.34 to 4.55; 487 women; 2 studies; [Analysis 35.4](#CD001233-fig-03504){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0438}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 35.5](#CD001233-fig-03505){ref-type="fig"}). Of the seven studies included for this comparison, two studies (490 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in these studies.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0075}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0439}

A mechanical method combined with misoprostol probably reduces the risk of an unfavourable cervix after 24 hours when compared to misoprostol alone (RR 0.27, 95% CI 0.08 to 0.94; 140 women; 1 study; [Analysis 35.6](#CD001233-fig-03506){ref-type="fig"}).

##### Oxytocin augmentation {#CD001233-sec5-0440}

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (average RR 0.94, 95% CI 0.70 to 1.25; 1051 women; 5 studies; [Analysis 35.7](#CD001233-fig-03507){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.07; Chi² = 16.91, df = 4 (P = 0.002); I² = 76%).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias ([Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}), did not alter the result nor did it lower heterogeneity (average RR 0.98, 95% CI 0.66 to 1.48; 733 women; 4 studies; I² = 82%).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0441}

A mechanical method combined with misoprostol probably reduces the risk of uterine hyperstimulation without FHR changes when compared to misoprostol alone (RR 0.53, 95% CI 0.32 to 0.90; 982 women; 4 studies; [Analysis 35.8](#CD001233-fig-03508){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0442}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 35.9](#CD001233-fig-03509){ref-type="fig"}). Of the seven studies included for this comparison, two studies (490 women) reported on this outcome. No events of uterine rupture occurred in one of these studies.

##### Epidural analgesia {#CD001233-sec5-0443}

There may be little or no difference in epidural analgesia between both induction methods (average RR 1.00, 95% CI 0.91 to 1.10; 443 women; 3 studies; [Analysis 35.10](#CD001233-fig-03510){ref-type="fig"}), although there was moderate heterogeneity for this outcome (Tau² = 0.00; Chi² = 3.52, df = 2 (P = 0.17); 43%).

No sensitivity analysis was performed as no potential high‐risk studies were included for this outcome.

##### Instrumental vaginal delivery {#CD001233-sec5-0444}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.93, 95% CI 0.58 to 1.51; 676 women; 3 studies; [Analysis 35.11](#CD001233-fig-03511){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0445}

A mechanical method combined with misoprostol may reduce the risk of meconium‐stained liquor when compared to misoprostol alone (average RR 0.61, 95% CI 0.35 to 1.04; 1243 women; 6 studies; [Analysis 35.12](#CD001233-fig-03512){ref-type="fig"}). However, the result is still too imprecise to make a valid judgement on this outcome. Also, there was substantial heterogeneity for this outcome (Tau² = 0.24; Chi² = 11.55, df = 5 (P = 0.04); I² = 57%).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias ([Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}), did not alter the result nor did it lower heterogeneity (average RR 0.55, 95% CI 0.26 to 1.14; 925 women; 5 studies; I² = 64%).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0446}

It is uncertain whether there is a difference in Apgar score less than seven at five minutes between both induction methods (average RR 0.71, 95% CI 0.37 to 1.36; 802 women; 3 studies; [Analysis 35.13](#CD001233-fig-03513){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.11; Chi² = 2.89, df = 2 (P = 0.24); I² = 31%).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias ([Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}), did not alter the result, although heterogeneity was lost (RR 1.10, 95% CI 0.50 to 2.44; 484 women; 2 studies; I² = 0%).

##### Neonatal intensive care unit admission {#CD001233-sec5-0447}

A mechanical method combined with misoprostol may reduce the risk of NICU admission when compared to misoprostol alone (RR 0.57, 95% CI 0.36 to 0.91; 1246 women; 6 studies; [Analysis 35.14](#CD001233-fig-03514){ref-type="fig"}), the absolute effect being 30 fewer NICU admissions per 1000 deliveries.

##### Neonatal encephalopathy {#CD001233-sec5-0448}

Not reported.

##### Perinatal death {#CD001233-sec5-0449}

It is uncertain whether there is difference in perinatal death between both induction methods (RR 3.09, 95% CI 0.13 to 75.26; 347 women; 1 study; [Analysis 35.15](#CD001233-fig-03515){ref-type="fig"}). One case of perinatal death was reported by [Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}, which occurred in the combined method group. No further information was given on timing or cause of the demise.

##### Disability in childhood {#CD001233-sec5-0450}

Not reported.

##### Maternal side effects (all) {#CD001233-sec5-0451}

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 1.06, 95% CI 0.87 to 1.30; 300 women; 1 study; [Analysis 35.16](#CD001233-fig-03516){ref-type="fig"}).

##### Maternal nausea {#CD001233-sec5-0452}

It is uncertain whether there is a difference in maternal nausea between both induction methods (RR 1.37, 95% CI 0.84 to 2.23; 300 women; study; [Analysis 35.17](#CD001233-fig-03517){ref-type="fig"}).

##### Maternal vomiting {#CD001233-sec5-0453}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0454}

A mechanical method combined with misoprostol probably increases the risk of maternal diarrhoea when compared to misoprostol alone (RR 3.38, 95% CI 1.40 to 8.17; 298 women; 1 study; [Analysis 35.18](#CD001233-fig-03518){ref-type="fig"}).

##### Other maternal side effects {#CD001233-sec5-0455}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0456}

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 0.93, 95% CI 0.65 to 1.33; 466 women; 2 studies; [Analysis 35.19](#CD001233-fig-03519){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0457}

It is uncertain whether there is a difference in serious maternal complications between both induction methods ([Analysis 35.20](#CD001233-fig-03520){ref-type="fig"}). One study (350 women) was included for this outcome in which no cases of septicaemia or intensive care unit admissions were seen.

##### Maternal death {#CD001233-sec5-0458}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0459}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0460}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0076}

##### Maternal fever during labour {#CD001233-sec5-0461}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0462}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0463}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 0.63, 95% CI 0.28 to 1.38; 443 women; 3 studies; [Analysis 35.21](#CD001233-fig-03521){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0464}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 0.41, 95% CI 0.08 to 2.08; 435 women; 2 studies; [Analysis 35.22](#CD001233-fig-03522){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0465}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.78, 95% CI 0.53 to 1.14; 784 women; 4 studies; [Analysis 35.23](#CD001233-fig-03523){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0466}

Not reported.

### Any mechanical method and oxytocin versus prostaglandin E2 alone (four trials involving 713 women) {#CD001233-sec3-0045}

#### Primary outcomes {#CD001233-sec4-0077}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0467}

Not reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0468}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between a mechanical method combined with oxytocin and PGE2 (RR 1.48, 95% CI 0.55 to 3.95; 151 women; 1 study; [Analysis 38.1](#CD001233-fig-03801){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0469}

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.93, 95% CI 0.72 to 1.20; 713 women; 4 studies; [Analysis 38.2](#CD001233-fig-03802){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0470}

Not reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0471}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 38.3](#CD001233-fig-03803){ref-type="fig"}). One study (200 women) was included for this composite outcome in which no events of maternal morbidity or death occurred.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0078}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0472}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0473}

A mechanical method combined with oxytocin probably increases the risk of oxytocin augmentation when compared to PGE2 (RR 2.48, 95% CI 1.95 to 3.15; 200 women; 1 study; [Analysis 38.4](#CD001233-fig-03804){ref-type="fig"}).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0474}

A mechanical method combined with oxytocin probably increases the risk of uterine hyperstimulation without FHR changes when compared to PGE2 (RR 2.19, 95% CI 1.39 to 3.46; 151 women; 1 study; [Analysis 38.5](#CD001233-fig-03805){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0475}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0476}

Not reported.

##### Instrumental vaginal delivery {#CD001233-sec5-0477}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.35, 95% CI 0.08 to 1.58; 41 women; 1 study; [Analysis 38.6](#CD001233-fig-03806){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0478}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 1.13, 95% CI 0.43 to 2.95; 151 women; 1 study; [Analysis 38.7](#CD001233-fig-03807){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0479}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 2.96, 95% CI 0.12 to 71.55; 151 women; 1 study; [Analysis 38.8](#CD001233-fig-03808){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0480}

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.85, 95% CI 0.30 to 2.40; 151 women; 1 study; [Analysis 38.9](#CD001233-fig-03809){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0481}

Not reported.

##### Perinatal death {#CD001233-sec5-0482}

Not reported.

##### Disability in childhood {#CD001233-sec5-0483}

Not reported.

##### Maternal side effects {#CD001233-sec5-0484}

Not reported.

##### Maternal nausea {#CD001233-sec5-0485}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0486}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0487}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0488}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0489}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.14, 95% CI 0.01 to 2.68; 151 women; 1 study; [Analysis 38.10](#CD001233-fig-03810){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0490}

Not reported.

##### Maternal death {#CD001233-sec5-0491}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0492}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0493}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0079}

##### Maternal fever during labour {#CD001233-sec5-0494}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0495}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0496}

Not reported.

##### Endometritis {#CD001233-sec5-0497}

It is uncertain whether there is a difference in endometritis between both induction methods ([Analysis 38.11](#CD001233-fig-03811){ref-type="fig"}). One study (41 women) reported on this outcome. No events of endometritis occurred in this study.

##### Fetal distress {#CD001233-sec5-0498}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (average RR 0.97, 95% CI 0.61 to 1.56; 498 women; 3 studies; [Analysis 38.12](#CD001233-fig-03812){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Tau² = 0.06; Chi² = 2.93, df = 2 (P = 0.23); I² = 32%).

No sensitivity analysis was performed as no potential high‐risk studies were included for this outcome.

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0499}

Not reported.

### Any mechanical method and oxytocin versus misoprostol alone (six trials involving 1779 women) {#CD001233-sec3-0046}

#### Primary outcomes {#CD001233-sec4-0080}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0500}

A mechanical method combined with oxytocin probably reduces the risk of a vaginal delivery not being achieved within 24 hours when compared to misoprostol (RR 0.48, 95% CI 0.37 to 0.63; 362 women; 2 studies; [Analysis 39.1](#CD001233-fig-03901){ref-type="fig"}), the absolute effect being 285 fewer per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0501}

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.43, 95% CI 0.17 to 1.11; 1463 women; 3 studies; [Analysis 39.2](#CD001233-fig-03902){ref-type="fig"}).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Caesarean section {#CD001233-sec5-0502}

There probably is little or difference in caesarean sections between both induction methods (RR 0.95, 95% CI 0.80 to 1.12; 1779 women; 5 studies; [Analysis 39.3](#CD001233-fig-03903){ref-type="fig"}).

For the subgroup of primiparous women, no outcomes were reported. For multiparous women, it is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.45, 95% CI 0.19 to 1.11; 136 women; 1 study; [Analysis 40.1](#CD001233-fig-04001){ref-type="fig"}).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0503}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.82, 95% CI 0.18 to 3.65;1263 women; 2 studies; [Analysis 39.4](#CD001233-fig-03904){ref-type="fig"}). All the events included for this composite outcome were cases of neonatal death.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0504}

Not reported.

#### Secondary outcomes {#CD001233-sec4-0081}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0505}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0506}

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (average RR 3.89, 95% CI 0.70 to 21.72; 336 women; 2 studies; [Analysis 39.5](#CD001233-fig-03905){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 1.46; Chi² = 18.47, df = 1 (P \< 0.0001); I² = 95%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}), changed the result in favour of misoprostol as it showed a mechanical method combined with oxytocin may increase the risk of oxytocin augmentation (RR 1.91, 95% CI 1.59 to 2.31; 200 women; 1 study).

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0507}

A mechanical method combined with oxytocin probably reduces the risk of uterine hyperstimulation without FHR changes when compared to misoprostol (RR 0.52, 95% CI 0.30 to 0.92; 498 women; 3 studies; [Analysis 39.6](#CD001233-fig-03906){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0508}

Not reported.

##### Epidural analgesia {#CD001233-sec5-0509}

It is uncertain whether there is a difference in epidural analgesia between both induction methods (RR 1.07, 95% CI 0.90 to 1.27; 162 women; 1 study; [Analysis 39.7](#CD001233-fig-03907){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0510}

Not reported.

##### Meconium‐stained liquor {#CD001233-sec5-0511}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.72, 95% CI 0.43 to 1.19; 362 women; 2 studies; [Analysis 39.8](#CD001233-fig-03908){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0512}

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.95, 95% CI 0.20 to 4.58; 162 women; 1 study; [Analysis 39.9](#CD001233-fig-03909){ref-type="fig"}).

##### Neonatal intensive care unit admission {#CD001233-sec5-0513}

A mechanical method combined with oxytocin probably reduces the risk of a NICU admission when compared to misoprostol (RR 0.66, 95% CI 0.49 to 0.90; 1599 women; 4 studies; [Analysis 39.10](#CD001233-fig-03910){ref-type="fig"}), the absolute effect being 37 fewer NICU admissions per 1000 deliveries.

##### Neonatal encephalopathy {#CD001233-sec5-0514}

Not reported.

##### Perinatal death {#CD001233-sec5-0515}

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 0.82, 95% CI 0.18 to 3.65; 1263 women; 2 studies; [Analysis 39.11](#CD001233-fig-03911){ref-type="fig"}). Perinatal death occurred in one of the included studies ([Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}). All were cases of neonatal death. No further information was given on cause of the demise.

##### Disability in childhood {#CD001233-sec5-0516}

Not reported.

##### Maternal side effects {#CD001233-sec5-0517}

Not reported.

##### Maternal nausea {#CD001233-sec5-0518}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0519}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0520}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0521}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0522}

Not reported.

##### Serious maternal complications {#CD001233-sec5-0523}

Not reported.

##### Maternal death {#CD001233-sec5-0524}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0525}

A mechanical method combined with oxytocin may increase the risk of women not being satisfied when compared to misoprostol (RR 1.68, 95% CI 1.47 to 1.93; 866 women; 1 study; [Analysis 39.12](#CD001233-fig-03912){ref-type="fig"}), the absolute effect being 260 more women not satisfied per 1000 deliveries. For this outcome, women in the study of [Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"} were asked if they would choose the same method again if induction of labour was needed in a future pregnancy.

##### Caregiver not satisfied {#CD001233-sec5-0526}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0082}

##### Maternal fever during labour {#CD001233-sec5-0527}

A mechanical method combined with oxytocin may reduce the risk of maternal fever during labour when compared to misoprostol (RR 0.13, 95% CI 0.04 to 0.50; 298 women; 2 studies; [Analysis 39.13](#CD001233-fig-03913){ref-type="fig"}).

##### Antibiotics during labour {#CD001233-sec5-0528}

Not reported.

##### Chorioamnionitis {#CD001233-sec5-0529}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 0.65, 95% CI 0.32 to 1.31; 200 women; 1 study; [Analysis 39.14](#CD001233-fig-03914){ref-type="fig"}).

##### Endometritis {#CD001233-sec5-0530}

Not reported.

##### Fetal distress {#CD001233-sec5-0531}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.55, 95% CI 0.25 to 1.21; 362 women; 2 studies; [Analysis 39.15](#CD001233-fig-03915){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0532}

Not reported.

### Any mechanical method and oxytocin versus oxytocin alone (six trials involving 718 women) {#CD001233-sec3-0047}

#### Primary outcomes {#CD001233-sec4-0083}

##### Vaginal delivery not achieved within 24 hours {#CD001233-sec5-0533}

It is uncertain whether there is a difference in a vaginal delivery not being achieved within 24 hours between induction of labour with a mechanical method combined with oxytocin and oxytocin alone (average RR 0.71, 95% CI 0.21 to 2.40; 321 women; 2 studies; [Analysis 41.1](#CD001233-fig-04101){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.72; Chi² = 19.17, df = 1 (P,0.0001); I² = 95%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}), changed the result in favour of a mechanical method combined with oxytocin as it showed it may reduce the risk of vaginal delivery not being achieved within 24 hours (RR 0.39, 95% CI 0.27 to 0.55; 120 women; 1 study), the absolute effect being 550 fewer per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Uterine hyperstimulation with FHR changes {#CD001233-sec5-0534}

Not reported.

##### Caesarean section {#CD001233-sec5-0535}

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.68, 95% CI 0.39 to 1.20; 718 women; 6 studies; [Analysis 41.2](#CD001233-fig-04102){ref-type="fig"}). Also, there was substantial heterogeneity for this outcome (Tau² = 0.32; Chi² = 17.15, df = 5 (P = 0.004); I² = 71%).

A sensitivity analysis, after eliminating the three trials assessed as having a potentially higher risk of allocation or attrition bias ([Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}; [Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}; [Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}), did not alter the result nor did it lower heterogeneity (average RR 0.57, 95% CI 0.21 to 1.52; 319 women; 3 studies; I² = 82%).

##### Serious neonatal morbidity or perinatal death {#CD001233-sec5-0536}

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.71, 95% CI 0.12 to 4.13; 321 women; 2 studies; [Analysis 41.3](#CD001233-fig-04103){ref-type="fig"}). All the events included for this composite outcome were cases of asphyxia.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

##### Serious maternal morbidity or death {#CD001233-sec5-0537}

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods ([Analysis 41.4](#CD001233-fig-04104){ref-type="fig"}). Of the six included studies for this comparison, two studies (321 women) reported on this composite outcome. No events of maternal morbidity or death occurred in these studies.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

#### Secondary outcomes {#CD001233-sec4-0084}

##### Cervix unfavourable/unchanged after 24 hours {#CD001233-sec5-0538}

Not reported.

##### Oxytocin augmentation {#CD001233-sec5-0539}

Not reported.

##### Uterine hyperstimulation without FHR changes {#CD001233-sec5-0540}

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.85, 95% CI 0.34 to 2.09; 199 women; 2 studies; [Analysis 41.5](#CD001233-fig-04105){ref-type="fig"}).

##### Uterine rupture {#CD001233-sec5-0541}

It is uncertain whether there is a difference in uterine rupture between both induction methods ([Analysis 41.6](#CD001233-fig-04106){ref-type="fig"}). Of the six included studies for this comparison, one study (120 women) reported on this outcome. No events of uterine rupture occurred in this study.

##### Epidural analgesia {#CD001233-sec5-0542}

There probably is little or no difference in epidural analgesia between both induction methods (RR 1.03, 95% CI 0.98 to 1.09; 127 women; 1 study; [Analysis 41.7](#CD001233-fig-04107){ref-type="fig"}).

##### Instrumental vaginal delivery {#CD001233-sec5-0543}

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.99, 95% CI 0.48 to 2.02; 293 women; 3 studies; [Analysis 41.8](#CD001233-fig-04108){ref-type="fig"}).

##### Meconium‐stained liquor {#CD001233-sec5-0544}

It is uncertain whether there is a difference in meconium‐stained liquor between both induction methods (RR 0.72, 95% CI 0.32 to 1.63; 319 women; 3 studies; [Analysis 41.9](#CD001233-fig-04109){ref-type="fig"}).

##### Apgar score less than seven at five minutes {#CD001233-sec5-0545}

Not reported.

##### Neonatal intensive care unit admission {#CD001233-sec5-0546}

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 0.98, 95% CI 0.61 to 1.58; 400 women; 3 studies; [Analysis 41.10](#CD001233-fig-04110){ref-type="fig"}).

##### Neonatal encephalopathy {#CD001233-sec5-0547}

Not reported.

##### Perinatal death {#CD001233-sec5-0548}

Not reported.

##### Disability in childhood {#CD001233-sec5-0549}

Not reported.

##### Maternal side effects {#CD001233-sec5-0550}

Not reported.

##### Maternal nausea {#CD001233-sec5-0551}

Not reported.

##### Maternal vomiting {#CD001233-sec5-0552}

Not reported.

##### Maternal diarrhoea {#CD001233-sec5-0553}

Not reported.

##### Other maternal side effects {#CD001233-sec5-0554}

Not reported.

##### Postpartum haemorrhage {#CD001233-sec5-0555}

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 1.18, 95% CI 0.44 to 3.18; 319 women; 3 studies; [Analysis 41.11](#CD001233-fig-04111){ref-type="fig"}).

##### Serious maternal complications {#CD001233-sec5-0556}

It is uncertain whether there is a difference in serious maternal complications between both induction methods ([Analysis 41.12](#CD001233-fig-04112){ref-type="fig"}). Of the six included studies for this comparison, one study (201 women) reported on maternal sepsis. No events occurred in this study.

##### Maternal death {#CD001233-sec5-0557}

Not reported.

##### Woman not satisfied {#CD001233-sec5-0558}

Not reported.

##### Caregiver not satisfied {#CD001233-sec5-0559}

Not reported.

#### Other outcomes (not pre‐specified) {#CD001233-sec4-0085}

##### Maternal fever during labour {#CD001233-sec5-0560}

Not reported.

##### Antibiotics during labour {#CD001233-sec5-0561}

It is uncertain whether there is a difference in antibiotics during labour between both induction methods (RR 2.32, 95% CI 0.82 to 6.55; 201 women; 1 study; [Analysis 41.13](#CD001233-fig-04113){ref-type="fig"}).

##### Chorioamnionitis {#CD001233-sec5-0562}

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (average RR 4.34, 95% CI 0.55 to 34.01; 328 women; 2 studies; [Analysis 41.14](#CD001233-fig-04114){ref-type="fig"}). Also, there was moderate heterogeneity for this outcome (Tau² = 1.19; Chi² = 1.92, df = 1 (P = 0.17); I² = 48%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias ([Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}), did not alter the result (RR 2.16, 95% CI 0.57 to 8.28; 127 women; 1 study).

##### Endometritis {#CD001233-sec5-0563}

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.08, 95% CI 0.16 to 7.45; 374 women; 3 studies; [Analysis 41.15](#CD001233-fig-04115){ref-type="fig"}).

##### Fetal distress {#CD001233-sec5-0564}

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 1.37, 95% CI 0.68 to 2.77; 400 women; 3 studies; [Analysis 41.16](#CD001233-fig-04116){ref-type="fig"}).

##### Umbilical artery pH \< 7.10 {#CD001233-sec5-0565}

Not reported.

Discussion {#CD001233-sec1-0006}
==========

We set out to explore the effectiveness of mechanical methods for labour induction and their adverse effects for women and their babies in comparison to different pharmacological methods. We included a total of 113 studies, with 105 studies contributing data involving 22,373 women. This updated review now consists of 21 different comparisons (and 20 subgroup comparisons), where in most of the comparisons a mechanical method (balloon, laminaria or extra‐amniotic space infusion (EASI)) was compared with prostaglandin E2 (PGE2), misoprostol or oxytocin. We explored the combination of a mechanical method combined with a pharmacological method, as well as a single versus a double balloon.

Summary of main results {#CD001233-sec2-0011}
-----------------------

### Balloon {#CD001233-sec3-0048}

#### Balloon versus PGE2 {#CD001233-sec4-0086}

A balloon catheter is probably as effective for inducing labour as vaginal PGE2, as there was little or no difference in a vaginal delivery not achieved within 24 hours (low‐quality evidence) and caesarean sections (moderate‐quality evidence) between both induction methods. However, oxytocin augmentation is probably more often required when labour is induced with a balloon catheter. As for perinatal outcomes, a balloon catheter appears to have a more favourable safety profile compared to vaginal PGE2, as it probably reduces the risk of uterine hyperstimulation with and without fetal heart rate (FHR) changes (moderate‐quality evidence), fetal distress for which a caesarean section is required and an umbilical artery pH less than 7.10. Also, a balloon catheter may slightly reduce the risk of a neonatal intensive care unit (NICU) admission (low‐quality evidence), although conventional statistical significance was not reached as the result was still too imprecise to make a valid judgement. Of note, a balloon catheter probably reduces the risk of serious neonatal morbidity or perinatal death (moderate‐risk evidence). However, this outcome should be interpreted with caution as only a few studies (eight out of 28 studies), reported on this composite outcome and therefore a bias for this result could exist. Most of the serious perinatal adverse events in this composite outcome were cases of perinatal asphyxia. Regarding our other main outcomes for this comparison, it was unclear if there is a difference in five‐minute Apgar score less than seven (low‐quality evidence) or serious maternal morbidity or death (very low‐quality evidence).

There was no evidence of a difference in outcomes between induction of labour with a balloon compared to cervical PGE2, although the risk of fetal distress for which a caesarean section is indicated is probably reduced when a balloon is used.

#### Balloon versus misoprostol {#CD001233-sec4-0087}

A balloon catheter may be less effective for induction of labour when compared to low‐dose oral misoprostol, as a balloon probably increases the risk of a vaginal delivery not achieved within 24 hours (moderate‐quality evidence), oxytocin augmentation and probably slightly increases the risk of a caesarean section (moderate‐quality evidence). Regarding safety outcomes for the neonate, which are hyperstimulation with (low‐quality evidence) and without FHR changes, serious neonatal morbidity or perinatal death (low‐quality evidence), NICU admission (low‐quality evidence), five‐minute Apgar score less than seven (low‐quality evidence), fetal distress and umbilical artery pH less than 7.10, it is unclear if there is a difference between both methods as results were too imprecise to make a valid judgement. This was also the case for the composite outcome serious maternal morbidity or death (very low‐quality evidence).

When compared to low‐dose vaginal misoprostol, a balloon catheter may increase the risk of a caesarean section and oxytocin augmentation (low‐quality evidence). However, there was substantial heterogeneity for both outcomes. For the outcome caesarean section, heterogeneity was not reduced after sensitivity analysis. The risk of hyperstimulation, with and without FHR changes, is probably reduced when a balloon catheter is used, as well as the risk of meconium‐stained liquor (moderate‐quality evidence). Regarding our other main outcomes for this comparison, it was unclear if there was a difference between serious neonatal morbidity or perinatal death (very low‐quality evidence), serious maternal morbidity or death (very low‐quality evidence), NICU admission (low‐quality evidence) and five‐minute Apgar score less than seven (low‐quality evidence) as these results were too imprecise to make a valid judgement.

Epidural analgesia is probably used slightly more after induction of labour with a balloon compared to low‐dose oral misoprostol, as well as vaginal misoprostol.

#### Balloon versus oxytocin {#CD001233-sec4-0088}

In women with an unfavourable cervix, cervical ripening with a balloon seems to be more effective than induction with oxytocin as it probably reduces the risk of caesarean section and the risk of fetal distress for which a caesarean section is indicated. For women with a previous caesarean section, a balloon catheter may slightly reduce the risk of a caesarean section when compared to oxytocin. However, the result is too imprecise to make a valid judgement on this outcome.

#### Single balloon versus double balloon {#CD001233-sec4-0089}

There is no evidence of benefit of a double balloon over a single balloon. There is little or no difference in vaginal deliveries not achieved within 24 hours and in oxytocin augmentation. No clear difference in caesarean section rate was seen between these induction methods. However, the result was still too imprecise to make a valid judgement. Hyperstimulation seems to occur infrequently with either balloons, as no events of uterine hyperstimulation with or without FHR changes were reported in the one study (217 women) which reported on these outcomes.

#### Laminaria tent {#CD001233-sec4-0090}

There was no evidence of a difference in outcomes between a laminaria tent compared to vaginal PGE2. However, results were too imprecise to make a valid judgement. Compared to cervical PGE2, a laminaria tent probably reduces the risk uterine hyperstimulation both with and without FHR changes.

#### EASI {#CD001233-sec4-0091}

Only a few small studies compared EASI with other methods. When compared to vaginal PGE2, EASI may increase the risk of a vaginal delivery not achieved within 24 hours and oxytocin augmentation.

#### Mechanical method combined with a pharmacological method {#CD001233-sec4-0092}

There was no evidence of clear benefit for a mechanical method combined with PGE2 compared to PGE2 alone or to oxytocin. When compared to low‐dose misoprostol, a mechanical method combined with PGE2 may reduce the risk of a vaginal delivery not achieved within 24 hours. However, only one study (127 women) reported on this comparison. When a mechanical method is combined with misoprostol or with oxytocin, it may reduce the risk of a NICU admission when compared to misoprostol alone. However, regarding other perinatal outcomes for both comparisons, there was no evidence for a difference in serious neonatal morbidity or perinatal death, Apgar scores less than seven at five minutes or fetal distress.

#### Infection {#CD001233-sec4-0093}

Risk of infection may theoretically be associated with the insertion of foreign material in the cervix. Most studies did not report on this outcome, resulting in limited data, reported as various outcomes (maternal fever during labour, antibiotic use during labour, chorioamnionitis and endometritis). According to the limited data available, there is no evidence of an increased risk of infectious morbidity with mechanical methods. These data should however be cautiously interpreted as results were imprecise.

#### Women\'s view {#CD001233-sec4-0094}

Data on patient satisfaction or patient preferences are sparse and not all data could be included in the meta‐analyses. When a balloon catheter was compared to vaginal PGE2, more women who were randomised to a balloon would choose the allocated induction method again in a subsequent pregnancy, as compared to women who were randomised to PGE2. However, when a balloon catheter was compared to oral misoprostol, more women would choose misoprostol in a subsequent pregnancy. For both outcomes, only one study was included.

Overall completeness and applicability of evidence {#CD001233-sec2-0012}
--------------------------------------------------

This review was previously one of a series of Cochrane Reviews examining various methods for induction of labour and now serves as a stand‐alone review. Other reviews have examined pharmacological and non‐pharmacological methods including vaginal prostaglandins ([Thomas 2014](#CD001233-bbs2-0334){ref-type="ref-list"}); intracervical prostaglandins ([Boulvain 2008](#CD001233-bbs2-0317){ref-type="ref-list"}); intravenous oxytocin ([Alferivic 2009](#CD001233-bbs2-0313){ref-type="ref-list"}); amniotomy ([Bricker 2000](#CD001233-bbs2-0318){ref-type="ref-list"}); intravenous oxytocin with amniotomy ([Howarth 2001](#CD001233-bbs2-0325){ref-type="ref-list"}); vaginal misoprostol ([Hofmeyr 2010](#CD001233-bbs2-0324){ref-type="ref-list"}); oral misoprostol ([Alfirevic 2014](#CD001233-bbs2-0314){ref-type="ref-list"}), and other methods.

Despite including 113 studies and including data from 105 studies, there were relatively few clear results. Only for the comparison of a balloon versus vaginal prostaglandin E2, including 28 studies involving 6619 women, were there enough data to make a valid judgement on effectiveness and adverse events between these methods.

Most of the outcomes of interest were poorly reported in the included studies, especially serious maternal or perinatal morbidity or death. Also, for some outcomes such as duration from start of induction to vaginal delivery, Apgar score or umbilical cord pH, only continuous data were reported and therefore were not included in this review. Outcomes should therefore be interpreted with caution. Caesarean section on the other hand, was reported in almost every study. Therefore, caesarean section may be the most reliable outcome by which to assess the effectiveness of mechanical methods for cervical ripening and induction of labour.

The external validity of our results can be questioned as the policy of labour induction varies across the different settings in which trials took place. There was a difference seen in maximum ripening time (e.g. the maximum time cervical ripening was awaited, ranging from six hours to 96 hours) and for when induction of labour was declared as failed. As it may take longer to achieve successful cervical ripening when a balloon is used, this could influence the outcome measures of effectiveness used, such as caesarean section. Also, the caesarean rate differs according to the setting in which trials took place, ranging from 9% ([Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}) to 70% ([Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}).

Studies ranged in date of publication from 1982 to 2018. While we did not consider the potential influence of date on our results, it is possible that changes in management of labour can mean that for some comparisons, in which relatively older studies were included, may not be generalisable to the current clinical context.

Quality of the evidence {#CD001233-sec2-0013}
-----------------------

Risk of bias varied throughout the included trials (see [Figure 2](#CD001233-fig-0002){ref-type="fig"} and [Figure 3](#CD001233-fig-0003){ref-type="fig"}). A great proportion of the trial methods were not well reported and were assessed to be at unclear risk of bias in many domains. Three trials were assessed as using inadequate random sequence generation, and in five trials no measures were taken to conceal allocation. In almost all studies, no blinding was done due to the nature of the intervention. However, blinding of the research personnel would have been possible, but was only described in four studies. Two studies reported to have performed a double‐blind study, but did not describe how this was achieved. We rated many trials at unclear risk of attrition bias, mainly because it was not clear if intention‐to‐treat was performed. Although we did attempt to assess reporting bias, lack of trial protocols for most of the older studies, meant this assessment relied on information available in the published trial report.

The outcomes were assessed using the GRADE approach. We determined the evidence to be moderate‐quality, low‐quality or very low‐quality. All evidence was downgraded for lack of blinding. Other reasons for downgrading were predominately for imprecision (uncertain effect estimates, small sample sizes and low event rates) and inconsistencies (heterogeneity). For our three main comparisons (balloon versus vaginal PGE2; balloon versus vaginal misoprostol; balloon versus oral misoprostol), a \'Summary of findings\' table was produced ([Table 1](#CD001233-tbl-0001){ref-type="table"}; [Table 2](#CD001233-tbl-0002){ref-type="table"}; [Table 3](#CD001233-tbl-0003){ref-type="table"}).

Although no publication bias was detected for our main outcomes, there is still a possibility of publication bias. Most comparisons had less than 10 studies included and therefore, a funnel plot could not be produced. Also, for 11 trial registrations the anticipated end date was overdue by two years and it was not clear if the trials had started, were ongoing or finished recruiting ([Baacke 2006](#CD001233-bbs2-0125){ref-type="ref-list"}; [Behrashi 2013](#CD001233-bbs2-0127){ref-type="ref-list"}; [Cullimore 2009](#CD001233-bbs2-0137){ref-type="ref-list"}; [Dias 2008](#CD001233-bbs2-0141){ref-type="ref-list"}; [EUCTR 2012](#CD001233-bbs2-0148){ref-type="ref-list"}; [Kamilya 2011](#CD001233-bbs2-0175){ref-type="ref-list"}; [Park 2011](#CD001233-bbs2-0216){ref-type="ref-list"}; [Pathiraja 2014](#CD001233-bbs2-0217){ref-type="ref-list"}; [Reif 2012](#CD001233-bbs2-0221){ref-type="ref-list"}; [Yazdani 2011](#CD001233-bbs2-0248){ref-type="ref-list"}; [Zhang 2014](#CD001233-bbs2-0250){ref-type="ref-list"}). Therefore, a potential risk exists as results from these studies were not published.

We acknowledge that with so many comparisons within the review, there is also a risk of statistical type 1 error, meaning a false‐positive result. The results where there are very few studies included, moderate or substantial heterogeneity, or those where the meta‐analysis result is of borderline statistical significance must therefore be treated with caution.

Potential biases in the review process {#CD001233-sec2-0014}
--------------------------------------

We are aware that the possibility of introducing bias was present at every stage of the reviewing process. We attempted to minimise bias in a number of ways; two review authors assessed studies for eligibility, assessed risk of bias and carried out data extraction. Each review author worked independently. We resolved discrepancies through discussion, or if required we consulted a third review author. Nevertheless, the process of assessing risk of bias, for example, is not an exact science and includes many personal judgements. Four review authors, Mieke ten Eikelder, Marta Jozwiak , Kitty Bloemenkamp and Ben Willem Mol are also trial authors for the following included studies: [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}. Data extraction and risk of bias assessments were conducted by other review authors for these studies (Marieke de Vaan; Kirsten Palmer).

Agreements and disagreements with other studies or reviews {#CD001233-sec2-0015}
----------------------------------------------------------

This review is one the most extensive reviews on mechanical methods of labour induction as most reviews on this subject only contain one or two of the comparisons included in this review. We found eight recent systematic reviews covering one or more of our main comparisons, being balloon versus vaginal PGE2, balloon versus vaginal misoprostol or balloon versus oral misoprostol.

Our review was in line with other systematic reviews on induction of labour with a balloon versus vaginal PGE2. [Liu 2018](#CD001233-bbs2-0327){ref-type="ref-list"} compared a double balloon with a vaginal PGE2 insert and they found no difference in vaginal deliveries achieved within 24 hours or caesarean section rate. They also found a reduction in uterine hyperstimulation and umbilical artery pH \< 7.10 when a balloon was used. All of the five studies included in the review of [Liu 2018](#CD001233-bbs2-0327){ref-type="ref-list"}, were also included in our review. [Du 2017](#CD001233-bbs2-0321){ref-type="ref-list"} compared a double balloon with PGE2 (vaginal as well as cervical) and produced the same results as described in our review and the review of [Liu 2018](#CD001233-bbs2-0327){ref-type="ref-list"}. However, they found no difference in fetal distress for which a caesarean section was indicated. All eight studies were also included in this review. [Zhu 2018](#CD001233-bbs2-0337){ref-type="ref-list"} compared a Foley catheter with a vaginal PGE2 and included eight studies of which one ([Ghanaie 2013](#CD001233-bbs2-0156){ref-type="ref-list"}) was excluded in our review because oxytocin was administered concurrent to both induction methods. Just as the other reviews, [Zhu 2018](#CD001233-bbs2-0337){ref-type="ref-list"} found no difference in caesarean section rate. They also looked at the induction to delivery interval on a continuous level and found no difference between both induction methods. [Wang 2016](#CD001233-bbs2-0335){ref-type="ref-list"} however, found a longer induction to delivery interval when a Foley catheter was used in comparison to PGE2 vaginal insert. The authors did not compare vaginal delivery rates within 24 hours.

[Chen 2016](#CD001233-bbs2-0319){ref-type="ref-list"} performed a network meta‐analysis in which direct and indirect comparisons between different induction agents, including Foley catheter, vaginal PGE2, vaginal misoprostol and oral misoprostol were made. Studies with high‐dose misoprostol were included in the review of [Chen 2016](#CD001233-bbs2-0319){ref-type="ref-list"} as opposed to our review and only indirect comparisons could be made between a Foley catheter and oral misoprostol in the review of [Chen 2016](#CD001233-bbs2-0319){ref-type="ref-list"}. The outcomes of interest were vaginal delivery not achieved within 24 hours, uterine hyperstimulation with FHR changes and caesarean section. Not all results were in line with our results. In the network meta‐analysis, a Foley catheter increased the risk of vaginal delivery not achieved within 24 hours compared to vaginal misoprostol, where in our review the outcome was uncertain. When compared to oral misoprostol, no clear difference in vaginal deliveries within 24 hours was seen by [Chen 2016](#CD001233-bbs2-0319){ref-type="ref-list"} compared to an increased risk in our review. In our review no clear difference was seen in uterine hyperstimulation with FHR changes, but in the network analysis of [Chen 2016](#CD001233-bbs2-0319){ref-type="ref-list"}, a reduced risk was seen when a Foley catheter was used compared to oral misoprostol. For the outcome of caesarean section, the network meta‐analyses of [Chen 2016](#CD001233-bbs2-0319){ref-type="ref-list"} showed the same results as our review. They found that a Foley catheter may slightly increase the risk of a caesarean section when compared to vaginal or oral misoprostol, with moderate heterogeneity for the comparison with vaginal misoprostol.

[Alfirevic 2016](#CD001233-bbs2-0315){ref-type="ref-list"} performed a extensive systematic review on induction of labour. The authors included 34 active treatment types/regimens including different dose regimens and routes of administration, and performed a network meta‐analysis in which all different treatments were ranked in relation to each other, including direct as well as indirect comparisons. Ranking was done on absolute risks for all pre specified outcomes. Mechanical induction with a balloon was divided in a single or double balloon. [Alfirevic 2016](#CD001233-bbs2-0315){ref-type="ref-list"} used other cut‐off points in dividing oral and vaginal tablets in dose regimens. In our review low dose was defined as ≤ 50 mcg every ≥ four hours, opposed to the cut‐of point of ≥ 50 mcg in the review of [Alfirevic 2016](#CD001233-bbs2-0315){ref-type="ref-list"}. Vaginal PGE2 was divided into tablets, gel, slow‐release and normal‐release inserts. For the outcome of a vaginal delivery not achieved within 24 hours, low‐dose vaginal misoprostol scored better, as well as all different regimens of vaginal PGE2 compared to induction with a balloon (single as well as double). For the outcome caesarean section, a single balloon and vaginal PGE2 gel had a similar mean ranking in the mid regions. Noteworthy is that low‐dose titrated oral misoprostol had one of the lowest mean rankings, as compared to oral misoprostol \< 50 mcg, which was ranked relatively high. The same high ranking for this outcome was seen for a double balloon. In line with our review, all mechanical methods had a low ranking regarding uterine hyperstimulation with FHR changes. [Alfirevic 2016](#CD001233-bbs2-0315){ref-type="ref-list"} also looked at neonatal and maternal mortality and severe morbidity, but for these composite outcomes no network meta‐analysis was possible as events were rare and poorly reported in studies. For the outcomes of NICU‐admission as well as five‐minute Apgar score less than seven, there was considerable uncertainty on the probability of the mean ranking as the 95% confidence intervals (CIs) for these rankings were relatively broad.

[Ten Eikelder 2016](#CD001233-bbs2-0332){ref-type="ref-list"} looked at safety outcomes between induction of labour with a Foley catheter and misoprostol (any route, any dose) and found less uterine hyperstimulation with FHR changes and less fetal distress for which a caesarean section was indicated when a Foley was used. They found that a Foley catheter may slightly increase the caesarean section rate, although conventional statistical significance was not reached and there was moderate heterogeneity for this outcome. Studies with high‐dose misoprostol were not excluded in the review of [Ten Eikelder 2016](#CD001233-bbs2-0332){ref-type="ref-list"}. In subgroup analyses for 25 mcg and 50 mcg vaginal misoprostol, no evidence for a difference in safety outcomes were found.

In our review, there was no evidence for a difference in outcomes related to infection between mechanical induction and other methods for induction of labour. However, the results of outcomes covering infection were still too imprecise to make a valid judgement. [McMaster 2015](#CD001233-bbs2-0328){ref-type="ref-list"} addressed this question by comparing induction of labour with a balloon versus locally‐applied prostaglandin and included 26 trials. Their results were in line with our results and found no evidence for a difference in chorioamnionitis, endometritis and neonatal infection. When infection outcomes were pooled, little or no difference was seen, suggesting a Foley catheter does not increase the risk of infection compared to locally‐applied prostaglandin.

Authors\' conclusions {#CD001233-sec1-0007}
=====================

Implications for practiceMechanical induction with a balloon is probably as effective as induction of labour with vaginal PGE2 with little or no difference in vaginal deliveries not achieved within 24 hours and caesarean section rate between the two methods. However, a balloon seems to have a more favourable safety profile compared to vaginal PGE2, as it probably reduces the risk of uterine hyperstimulation with and without fetal heart rate (FHR) changes, fetal distress for which a caesarean section is indicated and serious neonatal morbidity or perinatal death.A balloon catheter may be less effective for induction of labour when compared to low‐dose oral misoprostol as a balloon probably increases the risk of a vaginal delivery not achieved within 24 hours and probably slightly increases the risk of a caesarean section. It is unclear if there is a difference in hyperstimulation with FHR changes. When compared to low‐dose vaginal misoprostol, a balloon catheter may increase the risk of a caesarean section but probably reduces the risk of hyperstimulation, with and without FHR change as well as the risk of meconium‐stained liquor.Cervical ripening with a balloon seems to be more effective than induction with oxytocin as it probably reduces the risk of caesarean section and the risk of fetal distress. For women with a previous caesarean section, a balloon catheter may slightly reduce the risk of a caesarean section when compared to oxytocin.There is no evidence of a benefit of a double balloon over a single balloon. For the comparisons of a laminaria tent or extra‐amniotic space infusion (EASI) with other induction methods, results were mostly too imprecise to make a valid judgement.There was no evidence of clear benefit for a mechanical method combined with PGE2 to PGE2 alone or to oxytocin. When a mechanical method is combined with misoprostol or with oxytocin, it may reduce the risk of neonatal intensive care unit (NICU) admissions when compared to misoprostol alone. However, regarding other perinatal outcomes for both comparisons, there was no evidence for a difference in serious neonatal morbidity or perinatal death, Apgar scores less than seven at five minutes or fetal distress.The advantages of mechanical methods are their wide availability and the low cost of the devices, especially Foley catheters. Storage and preservation of mechanical devices is less problematic than PGE2, which should be kept refrigerated. However, special attention should be paid to contraindications (e.g. low‐lying placenta) when inserting these devices.

Implications for researchThere seems to be sufficient data to make a valid judgement on the safety and effectiveness of balloon in comparison to vaginal PGE2. More research on this comparison does not seem warranted as moderate‐quality evidence suggests a balloon is equally effective, but has a better safety profile. GRADE assessment for important outcomes for this comparison can never be assessed as \'high quality\' because blinding is not possible and this is the reason the evidence being downgraded from high‐quality evidence to moderate‐quality evidence for key outcomes. Future research could focus on comparing a balloon with low‐dose misoprostol or a combination of mechanical methods with low‐dose misoprostol. More studies evaluating mechanical methods for induction of labour in women with a history of prior caesarean section could be of benefit.To facilitate future meta‐analyses of labour induction, we recommend the standardisation of outcomes through core outcome sets. This would minimise the reporting challenges experienced in this review, where many included studies reported outcomes in a highly varied manner, resulting in many being excluded from analyses. Also, while there were many large randomised trials included in this review, only a few reported on rare but serious adverse events or included women\'s views regarding induction methods. As safety aspects and maternal satisfaction become more and more important with rising induction rates, large multicentre studies focusing on safety aspects for the neonate and maternal satisfaction, could help clinicians make a more carefully balanced choice when arranging an induction of labour.

What\'s new {#CD001233-sec1-0013}
===========

**DateEventDescription**9 January 2018New citation required and conclusions have changedIn this updated review, there is now evidence that mechanical induction of labour with a balloon probably is as effective as vaginal prostaglandin E2 (PGE2), but safer for the neonate. A balloon catheter may be slightly less effective as oral misoprostol, but It remains unclear if there is a difference in safety outcomes for the neonate. When compared to low‐dose vaginal misoprostol, a balloon catheter may be less effective, but probably has a better safety profile.9 January 2018New search has been performedSearch updated. We included 60 new studies and excluded 74 new studies. Eighteen studies (previous included) are now excluded as they are no longer eligible. Also, 21 ongoing studies were identified ([Ongoing studies](#CD001233-bbs1-0004){ref-type="ref-list"}) and two studies are awaiting further classification ([Agboghoroma 2015](#CD001233-bbs2-0253){ref-type="ref-list"}; [Mallah 2011](#CD001233-bbs2-0269){ref-type="ref-list"}).\
We updated the search on 19 March 2019 and added a further 38 trial reports to [Studies awaiting classification](#CD001233-bbs1-0003){ref-type="ref-list"} for the next update. The references have been assessed but not incorporated into the review. Only seven of these trials are likely to contribute data for this review and are mainly small trials ([Khatib 2019](#CD001233-bbs2-0266){ref-type="ref-list"}; [Lim 2018](#CD001233-bbs2-0268){ref-type="ref-list"}; [Osoti 2018](#CD001233-bbs2-0284){ref-type="ref-list"}; [Souizi 2018](#CD001233-bbs2-0287){ref-type="ref-list"}; [ten Eikelder 2017](#CD001233-bbs2-0288){ref-type="ref-list"}; [Tulek 2018](#CD001233-bbs2-0289){ref-type="ref-list"}; [Viteri 2019](#CD001233-bbs2-0290){ref-type="ref-list"}). We imputed the data for these trials and there is no change in results (not in direction or strength of the evidence). We will incorporate these trials fully at the next update.\
For this review, studies with high‐dose misoprostol were excluded. Balloons, laminaria tents and extra‐amniotic space infusion (EASI) were compared separately with other pharmacological methods and new comparisons were included. Comparisons with no intervention or placebo were excluded.

History {#CD001233-sec1-0014}
=======

Protocol first published: Issue 2, 2000  Review first published: Issue 4, 2001

**DateEventDescription**30 September 2011New citation required and conclusions have changedNew trials were added and the review was edited accordingly: the conclusion on primary outcome delivery before 24 hours has changed, partly due to change in statistical method (random‐effects model, due to substantial heterogeneity). Also, some conclusions on secondary outcome measures have changed.\
We updated the search on 16 January 2012 and added the results to [Studies awaiting classification](#CD001233-bbs1-0003){ref-type="ref-list"} for consideration in the next update.30 April 2011New search has been performedSearch updated. We have included 27 new studies and excluded 28 new studies. One trial (previously included) has now been reclassified as excluded ([Abramovici 1999](#CD001233-bbs2-0114){ref-type="ref-list"}). Four new ongoing studies have also been identified (Hallak 2008a; Jozwiak 2009a; Lin 2006a; Manyonda 2007a).18 September 2008AmendedConverted to new review format.

This review was originally conducted by Prof MJNC Keirse. We would like to thank Cornelia Lohse and Catalin Stan for their work on the [Boulvain 2001](#CD001233-bbs2-0338){ref-type="ref-list"} version of this review; and Benjamin Lamy, Pernille Lau and Aidan Tan for the translation of articles.

As part of the pre‐publication editorial process, this review has been commented on by two peers (an editor and referee who is external to the editorial team), a member of Cochrane Pregnancy and Childbirth\'s international panel of consumers and the Group\'s Statistical Adviser. The authors are grateful to the following peer reviewer for her time and comments: Elaine Finucane, National University of Ireland Galway, Galway, Ireland.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIIHR, NHS or the Department of Health.
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###### Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women

  Outcome or subgroup title                                                                            No. of studies   No. of participants   Statistical method                 Effect size
  ---------------------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-00101){ref-type="fig"}                   7                1685                  Risk Ratio (M‐H, Random, 95% CI)   1.01 \[0.82, 1.26\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-00102){ref-type="fig"}                   6                1966                  Risk Ratio (M‐H, Fixed, 95% CI)    0.35 \[0.18, 0.67\]
  [3 Caesarean section](#CD001233-fig-00103){ref-type="fig"}                                           28               6619                  Risk Ratio (M‐H, Fixed, 95% CI)    1.00 \[0.92, 1.09\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-00104){ref-type="fig"}                  8                2757                  Risk Ratio (M‐H, Fixed, 95% CI)    0.48 \[0.25, 0.93\]
  [5 Serious maternal morbidity or death](#CD001233-fig-00105){ref-type="fig"}                         4                1481                  Risk Ratio (M‐H, Fixed, 95% CI)    0.20 \[0.01, 4.12\]
  [6 Oxytocin augmentation](#CD001233-fig-00106){ref-type="fig"}                                       16               4828                  Risk Ratio (M‐H, Random, 95% CI)   1.54 \[1.35, 1.76\]
  [7 Uterine hyperstimulation without fetal heart rate changes](#CD001233-fig-00107){ref-type="fig"}   15               2444                  Risk Ratio (M‐H, Random, 95% CI)   0.27 \[0.11, 0.66\]
  [8 Uterine rupture](#CD001233-fig-00108){ref-type="fig"}                                             2                1045                  Risk Ratio (M‐H, Fixed, 95% CI)    0.20 \[0.01, 4.12\]
  [9 Epidural analgesia](#CD001233-fig-00109){ref-type="fig"}                                          8                2828                  Risk Ratio (M‐H, Random, 95% CI)   1.14 \[1.00, 1.29\]
  [10 Instrumental vaginal delivery](#CD001233-fig-00110){ref-type="fig"}                              16               4514                  Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.79, 1.09\]
  [11 Meconium‐stained liquor](#CD001233-fig-00111){ref-type="fig"}                                    4                964                   Risk Ratio (M‐H, Fixed, 95% CI)    0.89 \[0.67, 1.19\]
  [12 Apgar score \< 7 at 5 minutes](#CD001233-fig-00112){ref-type="fig"}                              14               4271                  Risk Ratio (M‐H, Fixed, 95% CI)    0.74 \[0.49, 1.14\]
  [13 Neonatal intensive care unit admission](#CD001233-fig-00113){ref-type="fig"}                     12               3647                  Risk Ratio (M‐H, Fixed, 95% CI)    0.82 \[0.65, 1.04\]
  [14 Perinatal death](#CD001233-fig-00114){ref-type="fig"}                                            5                1036                  Risk Ratio (M‐H, Fixed, 95% CI)    0.21 \[0.01, 4.27\]
  [15 Postpartum haemorrhage](#CD001233-fig-00115){ref-type="fig"}                                     8                2215                  Risk Ratio (M‐H, Fixed, 95% CI)    0.82 \[0.63, 1.06\]
  [16 Women not satisfied](#CD001233-fig-00116){ref-type="fig"}                                        1                93                    Risk Ratio (M‐H, Fixed, 95% CI)    0.61 \[0.39, 0.97\]
  [17 Maternal fever during labour](#CD001233-fig-00117){ref-type="fig"}                               7                2362                  Risk Ratio (M‐H, Fixed, 95% CI)    0.87 \[0.65, 1.17\]
  [18 Antibiotics during labour](#CD001233-fig-00118){ref-type="fig"}                                  1                330                   Risk Ratio (M‐H, Fixed, 95% CI)    1.43 \[0.89, 2.29\]
  [19 Chorioamnionitis](#CD001233-fig-00119){ref-type="fig"}                                           1                376                   Risk Ratio (M‐H, Fixed, 95% CI)    0.69 \[0.32, 1.49\]
  [20 Endometritis](#CD001233-fig-00120){ref-type="fig"}                                               2                706                   Risk Ratio (M‐H, Fixed, 95% CI)    0.49 \[0.19, 1.27\]
  [21 Fetal distress](#CD001233-fig-00121){ref-type="fig"}                                             20               4753                  Risk Ratio (M‐H, Fixed, 95% CI)    0.71 \[0.60, 0.83\]
  [22 Umbilical artery pH \< 7.10](#CD001233-fig-00122){ref-type="fig"}                                8                2675                  Odds Ratio (M‐H, Fixed, 95% CI)    0.65 \[0.44, 0.94\]

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-001-01){#CD001233-fig-00101}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-001-02){#CD001233-fig-00102}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section.](nCD001233-CMP-001-03){#CD001233-fig-00103}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-001-04){#CD001233-fig-00104}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-001-05){#CD001233-fig-00105}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.](nCD001233-CMP-001-06){#CD001233-fig-00106}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without fetal heart rate changes.](nCD001233-CMP-001-07){#CD001233-fig-00107}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture.](nCD001233-CMP-001-08){#CD001233-fig-00108}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia.](nCD001233-CMP-001-09){#CD001233-fig-00109}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental vaginal delivery.](nCD001233-CMP-001-10){#CD001233-fig-00110}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 11 Meconium‐stained liquor.](nCD001233-CMP-001-11){#CD001233-fig-00111}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 12 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-001-12){#CD001233-fig-00112}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 13 Neonatal intensive care unit admission.](nCD001233-CMP-001-13){#CD001233-fig-00113}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 14 Perinatal death.](nCD001233-CMP-001-14){#CD001233-fig-00114}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 15 Postpartum haemorrhage.](nCD001233-CMP-001-15){#CD001233-fig-00115}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 16 Women not satisfied.](nCD001233-CMP-001-16){#CD001233-fig-00116}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 17 Maternal fever during labour.](nCD001233-CMP-001-17){#CD001233-fig-00117}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 18 Antibiotics during labour.](nCD001233-CMP-001-18){#CD001233-fig-00118}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 19 Chorioamnionitis.](nCD001233-CMP-001-19){#CD001233-fig-00119}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 20 Endometritis.](nCD001233-CMP-001-20){#CD001233-fig-00120}

![Analysis\
Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 21 Fetal distress.](nCD001233-CMP-001-21){#CD001233-fig-00121}
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Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 22 Umbilical artery pH \< 7.10.](nCD001233-CMP-001-22){#CD001233-fig-00122}

###### Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae

  Outcome or subgroup title                                                             No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-00201){ref-type="fig"}    1                330                   Risk Ratio (M‐H, Fixed, 95% CI)    1.01 \[0.83, 1.23\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-00202){ref-type="fig"}    1                330                   Risk Ratio (M‐H, Fixed, 95% CI)    0.05 \[0.00, 0.85\]
  [3 Caesarean section](#CD001233-fig-00203){ref-type="fig"}                            5                828                   Risk Ratio (M‐H, Random, 95% CI)   0.89 \[0.59, 1.33\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-00204){ref-type="fig"}   1                330                   Risk Ratio (M‐H, Fixed, 95% CI)    0.17 \[0.01, 4.24\]
  [5 Serious maternal morbidity or death](#CD001233-fig-00205){ref-type="fig"}          1                60                    Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]

![Analysis\
Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-002-01){#CD001233-fig-00201}

![Analysis\
Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-002-02){#CD001233-fig-00202}

![Analysis\
Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 3 Caesarean section.](nCD001233-CMP-002-03){#CD001233-fig-00203}

![Analysis\
Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-002-04){#CD001233-fig-00204}

![Analysis\
Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-002-05){#CD001233-fig-00205}

###### Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-00301){ref-type="fig"}   1                147                   Risk Ratio (M‐H, Fixed, 95% CI)   4.38 \[1.74, 10.98\]
  [2 Caesarean section](#CD001233-fig-00302){ref-type="fig"}                           2                180                   Risk Ratio (M‐H, Fixed, 95% CI)   1.31 \[0.65, 2.63\]

![Analysis\
Comparison 3 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-003-01){#CD001233-fig-00301}

![Analysis\
Comparison 3 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae, Outcome 2 Caesarean section.](nCD001233-CMP-003-02){#CD001233-fig-00302}

###### Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-00401){ref-type="fig"}      2                200                   Risk Ratio (M‐H, Random, 95% CI)   1.01 \[0.35, 2.91\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-00402){ref-type="fig"}      4                447                   Risk Ratio (M‐H, Fixed, 95% CI)    0.37 \[0.02, 8.90\]
  [3 Caesarean section](#CD001233-fig-00403){ref-type="fig"}                              9                1309                  Risk Ratio (M‐H, Fixed, 95% CI)    0.97 \[0.81, 1.15\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-00404){ref-type="fig"}     2                500                   Risk Ratio (M‐H, Fixed, 95% CI)    0.78 \[0.29, 2.05\]
  [5 Cervix unfavourable/unchanged after 24 hours](#CD001233-fig-00405){ref-type="fig"}   2                219                   Risk Ratio (M‐H, Fixed, 95% CI)    0.96 \[0.70, 1.34\]
  [6 Oxytocin augmentation](#CD001233-fig-00406){ref-type="fig"}                          1                400                   Risk Ratio (M‐H, Fixed, 95% CI)    1.08 \[0.93, 1.26\]
  [7 Uterine hyperstimulation without FHR changes](#CD001233-fig-00407){ref-type="fig"}   5                654                   Risk Ratio (M‐H, Random, 95% CI)   0.99 \[0.09, 10.38\]
  [8 Epidural analgesia](#CD001233-fig-00408){ref-type="fig"}                             1                149                   Risk Ratio (M‐H, Fixed, 95% CI)    0.91 \[0.81, 1.02\]
  [9 Instrumental vaginal delivery](#CD001233-fig-00409){ref-type="fig"}                  3                337                   Risk Ratio (M‐H, Fixed, 95% CI)    1.18 \[0.68, 2.05\]
  [10 Meconium‐stained liquor](#CD001233-fig-00410){ref-type="fig"}                       1                118                   Risk Ratio (M‐H, Fixed, 95% CI)    1.17 \[0.42, 3.26\]
  [11 Apgar score \< 7 at 5 minutes](#CD001233-fig-00411){ref-type="fig"}                 2                475                   Risk Ratio (M‐H, Fixed, 95% CI)    0.79 \[0.41, 1.53\]
  [12 Neonatal intensive care unit admission](#CD001233-fig-00412){ref-type="fig"}        1                400                   Risk Ratio (M‐H, Fixed, 95% CI)    0.88 \[0.60, 1.31\]
  [13 Perinatal death](#CD001233-fig-00413){ref-type="fig"}                               2                500                   Risk Ratio (M‐H, Fixed, 95% CI)    0.78 \[0.29, 2.05\]
  [14 Maternal side effects](#CD001233-fig-00414){ref-type="fig"}                         2                211                   Risk Ratio (M‐H, Fixed, 95% CI)    0.15 \[0.02, 1.24\]
  [15 Postpartum haemorrhage](#CD001233-fig-00415){ref-type="fig"}                        1                100                   Risk Ratio (M‐H, Fixed, 95% CI)    0.2 \[0.01, 4.06\]
  [16 Chorioamnionitis](#CD001233-fig-00416){ref-type="fig"}                              1                118                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.21, 4.75\]
  [17 Endometritis](#CD001233-fig-00417){ref-type="fig"}                                  1                118                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.06, 15.61\]
  [18 Fetal distress](#CD001233-fig-00418){ref-type="fig"}                                6                1023                  Risk Ratio (M‐H, Fixed, 95% CI)    0.61 \[0.42, 0.89\]
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Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-004-01){#CD001233-fig-00401}
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Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-004-02){#CD001233-fig-00402}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 3 Caesarean section.](nCD001233-CMP-004-03){#CD001233-fig-00403}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-004-04){#CD001233-fig-00404}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 5 Cervix unfavourable/unchanged after 24 hours.](nCD001233-CMP-004-05){#CD001233-fig-00405}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.](nCD001233-CMP-004-06){#CD001233-fig-00406}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-004-07){#CD001233-fig-00407}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 8 Epidural analgesia.](nCD001233-CMP-004-08){#CD001233-fig-00408}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 9 Instrumental vaginal delivery.](nCD001233-CMP-004-09){#CD001233-fig-00409}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 10 Meconium‐stained liquor.](nCD001233-CMP-004-10){#CD001233-fig-00410}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 11 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-004-11){#CD001233-fig-00411}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 12 Neonatal intensive care unit admission.](nCD001233-CMP-004-12){#CD001233-fig-00412}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 13 Perinatal death.](nCD001233-CMP-004-13){#CD001233-fig-00413}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 14 Maternal side effects.](nCD001233-CMP-004-14){#CD001233-fig-00414}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 15 Postpartum haemorrhage.](nCD001233-CMP-004-15){#CD001233-fig-00415}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 16 Chorioamnionitis.](nCD001233-CMP-004-16){#CD001233-fig-00416}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 17 Endometritis.](nCD001233-CMP-004-17){#CD001233-fig-00417}

![Analysis\
Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 18 Fetal distress.](nCD001233-CMP-004-18){#CD001233-fig-00418}

###### Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-00501){ref-type="fig"}   1                53                    Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [2 Caesarean section](#CD001233-fig-00502){ref-type="fig"}                           3                245                   Risk Ratio (M‐H, Fixed, 95% CI)   1.30 \[0.86, 1.95\]

![Analysis\
Comparison 5 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae, Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-005-01){#CD001233-fig-00501}

![Analysis\
Comparison 5 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae, Outcome 2 Caesarean section.](nCD001233-CMP-005-02){#CD001233-fig-00502}

###### Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-00601){ref-type="fig"}   1                53                    Risk Ratio (M‐H, Fixed, 95% CI)    0.30 \[0.01, 7.02\]
  [2 Caesarean section](#CD001233-fig-00602){ref-type="fig"}                           3                136                   Risk Ratio (M‐H, Random, 95% CI)   0.66 \[0.16, 2.78\]

![Analysis\
Comparison 6 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae, Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-006-01){#CD001233-fig-00601}

![Analysis\
Comparison 6 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae, Outcome 2 Caesarean section.](nCD001233-CMP-006-02){#CD001233-fig-00602}

###### Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-00701){ref-type="fig"}      2                340                   Risk Ratio (M‐H, Fixed, 95% CI)    1.09 \[0.85, 1.39\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-00702){ref-type="fig"}      8                1322                  Risk Ratio (M‐H, Fixed, 95% CI)    0.39 \[0.18, 0.85\]
  [3 Caesarean section](#CD001233-fig-00703){ref-type="fig"}                              12               1756                  Risk Ratio (M‐H, Random, 95% CI)   1.28 \[1.02, 1.60\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-00704){ref-type="fig"}     3                381                   Risk Ratio (M‐H, Fixed, 95% CI)    0.58 \[0.12, 2.66\]
  [5 Serious maternal morbidity or death](#CD001233-fig-00705){ref-type="fig"}            4                464                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [6 Cervix unfavourable/unchanged after 12 hours](#CD001233-fig-00706){ref-type="fig"}   2                200                   Risk Ratio (M‐H, Random, 95% CI)   2.66 \[0.60, 11.89\]
  [7 Oxytocin augmentation](#CD001233-fig-00707){ref-type="fig"}                          9                911                   Risk Ratio (M‐H, Random, 95% CI)   1.62 \[1.38, 1.90\]
  [8 Uterine hyperstimulation without FHR changes](#CD001233-fig-00708){ref-type="fig"}   9                1139                  Risk Ratio (M‐H, Fixed, 95% CI)    0.25 \[0.14, 0.44\]
  [9 Uterine rupture](#CD001233-fig-00709){ref-type="fig"}                                3                364                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [10 Epidural analgesia](#CD001233-fig-00710){ref-type="fig"}                            2                517                   Risk Ratio (M‐H, Fixed, 95% CI)    1.22 \[1.06, 1.41\]
  [11 Instrumental vaginal delivery](#CD001233-fig-00711){ref-type="fig"}                 4                721                   Risk Ratio (M‐H, Fixed, 95% CI)    0.72 \[0.50, 1.05\]
  [12 Meconium‐stained liquor](#CD001233-fig-00712){ref-type="fig"}                       7                1268                  Risk Ratio (M‐H, Fixed, 95% CI)    0.64 \[0.48, 0.87\]
  [13 Apgar score \< 7 at 5 minutes](#CD001233-fig-00713){ref-type="fig"}                 7                941                   Risk Ratio (M‐H, Fixed, 95% CI)    1.00 \[0.50, 1.97\]
  [14 Neonatal intensive care unit admission](#CD001233-fig-00714){ref-type="fig"}        9                1302                  Risk Ratio (M‐H, Fixed, 95% CI)    1.00 \[0.61, 1.63\]
  [15 Perinatal death](#CD001233-fig-00715){ref-type="fig"}                               1                121                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [16 Maternal vomiting](#CD001233-fig-00716){ref-type="fig"}                             1                60                    Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [17 Postpartum haemorrhage](#CD001233-fig-00717){ref-type="fig"}                        1                120                   Risk Ratio (M‐H, Fixed, 95% CI)    1.14 \[0.24, 5.44\]
  [18 Maternal fever during labour](#CD001233-fig-00718){ref-type="fig"}                  3                617                   Risk Ratio (M‐H, Random, 95% CI)   1.84 \[0.22, 15.62\]
  [19 Chorioamnionitis](#CD001233-fig-00719){ref-type="fig"}                              2                200                   Risk Ratio (M‐H, Fixed, 95% CI)    1.24 \[0.31, 4.88\]
  [20 Endometritis](#CD001233-fig-00720){ref-type="fig"}                                  1                240                   Risk Ratio (M‐H, Fixed, 95% CI)    2.95 \[0.12, 71.72\]
  [21 Fetal distress](#CD001233-fig-00721){ref-type="fig"}                                7                1127                  Risk Ratio (M‐H, Fixed, 95% CI)    0.84 \[0.67, 1.05\]
  [22 Umbilical artery pH \<7.10](#CD001233-fig-00722){ref-type="fig"}                    1                120                   Risk Ratio (M‐H, Fixed, 95% CI)    1.14 \[0.35, 3.74\]

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-007-01){#CD001233-fig-00701}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-007-02){#CD001233-fig-00702}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 3 Caesarean section.](nCD001233-CMP-007-03){#CD001233-fig-00703}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-007-04){#CD001233-fig-00704}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-007-05){#CD001233-fig-00705}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 6 Cervix unfavourable/unchanged after 12 hours.](nCD001233-CMP-007-06){#CD001233-fig-00706}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 7 Oxytocin augmentation.](nCD001233-CMP-007-07){#CD001233-fig-00707}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 8 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-007-08){#CD001233-fig-00708}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 9 Uterine rupture.](nCD001233-CMP-007-09){#CD001233-fig-00709}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 10 Epidural analgesia.](nCD001233-CMP-007-10){#CD001233-fig-00710}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 11 Instrumental vaginal delivery.](nCD001233-CMP-007-11){#CD001233-fig-00711}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 12 Meconium‐stained liquor.](nCD001233-CMP-007-12){#CD001233-fig-00712}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 13 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-007-13){#CD001233-fig-00713}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 14 Neonatal intensive care unit admission.](nCD001233-CMP-007-14){#CD001233-fig-00714}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 15 Perinatal death.](nCD001233-CMP-007-15){#CD001233-fig-00715}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 16 Maternal vomiting.](nCD001233-CMP-007-16){#CD001233-fig-00716}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 17 Postpartum haemorrhage.](nCD001233-CMP-007-17){#CD001233-fig-00717}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 18 Maternal fever during labour.](nCD001233-CMP-007-18){#CD001233-fig-00718}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 19 Chorioamnionitis.](nCD001233-CMP-007-19){#CD001233-fig-00719}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 20 Endometritis.](nCD001233-CMP-007-20){#CD001233-fig-00720}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 21 Fetal distress.](nCD001233-CMP-007-21){#CD001233-fig-00721}

![Analysis\
Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 22 Umbilical artery pH \<7.10.](nCD001233-CMP-007-22){#CD001233-fig-00722}

###### Balloon (Foley or ATAD versus low dose vaginal misoprostol: all primiparae

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-00801){ref-type="fig"}   1                255                   Risk Ratio (M‐H, Fixed, 95% CI)   0.82 \[0.59, 1.13\]

![Analysis\
Comparison 8 Balloon (Foley or ATAD versus low dose vaginal misoprostol: all primiparae, Outcome 1 Caesarean section.](nCD001233-CMP-008-01){#CD001233-fig-00801}

###### Balloon (Foley or ATAD) versus low dose oral misoprostol: all women

  Outcome or subgroup title                                                                No. of studies   No. of participants   Statistical method                 Effect size
  ---------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Vaginal delivery not achieved within 24 hours](#CD001233-fig-00901){ref-type="fig"}   2                782                   Risk Ratio (M‐H, Fixed, 95% CI)    1.28 \[1.13, 1.46\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-00902){ref-type="fig"}       2                2033                  Risk Ratio (M‐H, Fixed, 95% CI)    0.81 \[0.48, 1.38\]
  [3 Caesarean section](#CD001233-fig-00903){ref-type="fig"}                               7                3178                  Risk Ratio (M‐H, Fixed, 95% CI)    1.17 \[1.04, 1.32\]
  [4 Serious perinatal morbidity/perinatal death](#CD001233-fig-00904){ref-type="fig"}     3                2627                  Risk Ratio (M‐H, Fixed, 95% CI)    1.11 \[0.60, 2.06\]
  [5 Serious maternal morbidity or death](#CD001233-fig-00905){ref-type="fig"}             3                2627                  Risk Ratio (M‐H, Fixed, 95% CI)    0.50 \[0.05, 5.52\]
  [6 Cervix unfavourable after 24 hours](#CD001233-fig-00906){ref-type="fig"}              4                994                   Risk Ratio (M‐H, Random, 95% CI)   0.98 \[0.61, 1.56\]
  [7 Oxytocin augmentation](#CD001233-fig-00907){ref-type="fig"}                           5                2847                  Risk Ratio (M‐H, Random, 95% CI)   1.28 \[1.09, 1.49\]
  [8 Uterine hyperstimulation without FHR changes](#CD001233-fig-00908){ref-type="fig"}    5                2838                  Risk Ratio (M‐H, Random, 95% CI)   0.50 \[0.12, 2.07\]
  [9 Uterine rupture](#CD001233-fig-00909){ref-type="fig"}                                 3                2627                  Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [10 Epidural](#CD001233-fig-00910){ref-type="fig"}                                       3                2635                  Risk Ratio (M‐H, Random, 95% CI)   1.08 \[0.96, 1.22\]
  [11 Instrumental vaginal delivery](#CD001233-fig-00911){ref-type="fig"}                  3                2627                  Risk Ratio (M‐H, Fixed, 95% CI)    0.71 \[0.55, 0.92\]
  [12 Meconium‐stained liquor](#CD001233-fig-00912){ref-type="fig"}                        3                2627                  Risk Ratio (M‐H, Random, 95% CI)   0.77 \[0.44, 1.35\]
  [13 Apgar score \< 7 after 5 minutes](#CD001233-fig-00913){ref-type="fig"}               4                2693                  Risk Ratio (M‐H, Fixed, 95% CI)    0.71 \[0.38, 1.32\]
  [14 Neonatal intensive care unit admission](#CD001233-fig-00914){ref-type="fig"}         5                2873                  Risk Ratio (M‐H, Fixed, 95% CI)    0.82 \[0.58, 1.17\]
  [15 Neonatal encephalopathy](#CD001233-fig-00915){ref-type="fig"}                        1                600                   Risk Ratio (M‐H, Fixed, 95% CI)    0.81 \[0.32, 2.03\]
  [16 Perinatal death](#CD001233-fig-00916){ref-type="fig"}                                3                2627                  Risk Ratio (M‐H, Fixed, 95% CI)    1.28 \[0.49, 3.30\]
  [17 Maternal side effects (all)](#CD001233-fig-00917){ref-type="fig"}                    2                662                   Risk Ratio (M‐H, Fixed, 95% CI)    0.61 \[0.33, 1.13\]
  [18 Maternal vomiting](#CD001233-fig-00918){ref-type="fig"}                              2                662                   Risk Ratio (M‐H, Fixed, 95% CI)    0.73 \[0.37, 1.46\]
  [19 Maternal diarrhoea](#CD001233-fig-00919){ref-type="fig"}                             1                602                   Risk Ratio (M‐H, Fixed, 95% CI)    0.29 \[0.06, 1.37\]
  [20 Postpartum haemorrhage](#CD001233-fig-00920){ref-type="fig"}                         5                2966                  Risk Ratio (M‐H, Fixed, 95% CI)    1.03 \[0.79, 1.34\]
  [21 Maternal death](#CD001233-fig-00921){ref-type="fig"}                                 3                2627                  Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [22 Women not satisfied](#CD001233-fig-00922){ref-type="fig"}                            1                602                   Risk Ratio (M‐H, Fixed, 95% CI)    1.70 \[1.15, 2.50\]
  [23 Maternal fever during labour](#CD001233-fig-00923){ref-type="fig"}                   2                2033                  Risk Ratio (M‐H, Fixed, 95% CI)    0.98 \[0.78, 1.24\]
  [24 Antibiotics during labour](#CD001233-fig-00924){ref-type="fig"}                      2                2033                  Risk Ratio (M‐H, Fixed, 95% CI)    1.22 \[0.75, 2.00\]
  [25 Endometritis](#CD001233-fig-00925){ref-type="fig"}                                   1                188                   Risk Ratio (M‐H, Fixed, 95% CI)    0.56 \[0.05, 6.03\]
  [26 Fetal distress](#CD001233-fig-00926){ref-type="fig"}                                 5                2966                  Risk Ratio (M‐H, Fixed, 95% CI)    0.82 \[0.61, 1.09\]
  [27 Umbilical artery pH \< 7.10](#CD001233-fig-00927){ref-type="fig"}                    2                1535                  Risk Ratio (M‐H, Fixed, 95% CI)    0.77 \[0.53, 1.12\]

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 1 Vaginal delivery not achieved within 24 hours.](nCD001233-CMP-009-01){#CD001233-fig-00901}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-009-02){#CD001233-fig-00902}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 3 Caesarean section.](nCD001233-CMP-009-03){#CD001233-fig-00903}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 4 Serious perinatal morbidity/perinatal death.](nCD001233-CMP-009-04){#CD001233-fig-00904}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-009-05){#CD001233-fig-00905}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 6 Cervix unfavourable after 24 hours.](nCD001233-CMP-009-06){#CD001233-fig-00906}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 7 Oxytocin augmentation.](nCD001233-CMP-009-07){#CD001233-fig-00907}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 8 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-009-08){#CD001233-fig-00908}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 9 Uterine rupture.](nCD001233-CMP-009-09){#CD001233-fig-00909}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 10 Epidural.](nCD001233-CMP-009-10){#CD001233-fig-00910}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 11 Instrumental vaginal delivery.](nCD001233-CMP-009-11){#CD001233-fig-00911}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 12 Meconium‐stained liquor.](nCD001233-CMP-009-12){#CD001233-fig-00912}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 13 Apgar score \< 7 after 5 minutes.](nCD001233-CMP-009-13){#CD001233-fig-00913}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 14 Neonatal intensive care unit admission.](nCD001233-CMP-009-14){#CD001233-fig-00914}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 15 Neonatal encephalopathy.](nCD001233-CMP-009-15){#CD001233-fig-00915}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 16 Perinatal death.](nCD001233-CMP-009-16){#CD001233-fig-00916}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 17 Maternal side effects (all).](nCD001233-CMP-009-17){#CD001233-fig-00917}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 18 Maternal vomiting.](nCD001233-CMP-009-18){#CD001233-fig-00918}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 19 Maternal diarrhoea.](nCD001233-CMP-009-19){#CD001233-fig-00919}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 20 Postpartum haemorrhage.](nCD001233-CMP-009-20){#CD001233-fig-00920}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 21 Maternal death.](nCD001233-CMP-009-21){#CD001233-fig-00921}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 22 Women not satisfied.](nCD001233-CMP-009-22){#CD001233-fig-00922}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 23 Maternal fever during labour.](nCD001233-CMP-009-23){#CD001233-fig-00923}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 24 Antibiotics during labour.](nCD001233-CMP-009-24){#CD001233-fig-00924}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 25 Endometritis.](nCD001233-CMP-009-25){#CD001233-fig-00925}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 26 Fetal distress.](nCD001233-CMP-009-26){#CD001233-fig-00926}

![Analysis\
Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 27 Umbilical artery pH \< 7.10.](nCD001233-CMP-009-27){#CD001233-fig-00927}

###### Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae

  Outcome or subgroup title                                                             No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-01001){ref-type="fig"}    2                573                   Risk Ratio (M‐H, Fixed, 95% CI)   1.19 \[1.04, 1.37\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-01002){ref-type="fig"}    1                1206                  Risk Ratio (M‐H, Fixed, 95% CI)   0.81 \[0.45, 1.46\]
  [3 Caesarean section](#CD001233-fig-01003){ref-type="fig"}                            3                1778                  Risk Ratio (M‐H, Fixed, 95% CI)   1.21 \[1.06, 1.38\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-01004){ref-type="fig"}   2                1296                  Risk Ratio (M‐H, Fixed, 95% CI)   4.49 \[0.77, 26.14\]
  [5 Serious maternal morbidity or death](#CD001233-fig-01005){ref-type="fig"}          2                1296                  Risk Ratio (M‐H, Fixed, 95% CI)   0.51 \[0.05, 5.63\]

![Analysis\
Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-010-01){#CD001233-fig-01001}

![Analysis\
Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-010-02){#CD001233-fig-01002}

![Analysis\
Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 3 Caesarean section.](nCD001233-CMP-010-03){#CD001233-fig-01003}

![Analysis\
Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-010-04){#CD001233-fig-01004}

![Analysis\
Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-010-05){#CD001233-fig-01005}

###### Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae

  Outcome or subgroup title                                                             No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-01101){ref-type="fig"}    2                209                   Risk Ratio (M‐H, Fixed, 95% CI)   1.55 \[1.17, 2.06\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-01102){ref-type="fig"}    1                639                   Risk Ratio (M‐H, Fixed, 95% CI)   1.45 \[0.24, 8.61\]
  [3 Caesarean section](#CD001233-fig-01103){ref-type="fig"}                            3                848                   Risk Ratio (M‐H, Fixed, 95% CI)   1.22 \[0.79, 1.87\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-01104){ref-type="fig"}   2                729                   Risk Ratio (M‐H, Fixed, 95% CI)   0.98 \[0.14, 6.86\]
  [5 Serious maternal morbidity or death](#CD001233-fig-01105){ref-type="fig"}          2                729                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-011-01){#CD001233-fig-01101}

![Analysis\
Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-011-02){#CD001233-fig-01102}

![Analysis\
Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean section.](nCD001233-CMP-011-03){#CD001233-fig-01103}

![Analysis\
Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-011-04){#CD001233-fig-01104}

![Analysis\
Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-011-05){#CD001233-fig-01105}

###### Balloon (Foley or ATAD) versus oxytocin: all women

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-01201){ref-type="fig"}      1                200                   Risk Ratio (M‐H, Fixed, 95% CI)   0.2 \[0.01, 4.11\]
  [2 Caesarean section](#CD001233-fig-01202){ref-type="fig"}                              8                781                   Risk Ratio (M‐H, Fixed, 95% CI)   0.68 \[0.56, 0.83\]
  [3 Serious neonatal morbidity/perinatal death](#CD001233-fig-01203){ref-type="fig"}     1                100                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [4 Serious maternal morbidity or death](#CD001233-fig-01204){ref-type="fig"}            2                160                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [5 Cervix unfavourable after 24 hours](#CD001233-fig-01205){ref-type="fig"}             1                100                   Risk Ratio (M‐H, Fixed, 95% CI)   0.56 \[0.20, 1.54\]
  [6 Uterine hyperstimulation without FHR changes](#CD001233-fig-01206){ref-type="fig"}   3                192                   Risk Ratio (M‐H, Fixed, 95% CI)   1.0 \[0.23, 4.29\]
  [7 Uterine rupture](#CD001233-fig-01207){ref-type="fig"}                                1                100                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [8 Instrumental vaginal delivery](#CD001233-fig-01208){ref-type="fig"}                  3                220                   Risk Ratio (M‐H, Fixed, 95% CI)   1.19 \[0.55, 2.57\]
  [9 Meconium‐stained liquor](#CD001233-fig-01209){ref-type="fig"}                        2                272                   Risk Ratio (M‐H, Fixed, 95% CI)   0.53 \[0.23, 1.21\]
  [10 Apgar score \< 7 at 5 minutes](#CD001233-fig-01210){ref-type="fig"}                 2                300                   Risk Ratio (M‐H, Fixed, 95% CI)   0.71 \[0.14, 3.53\]
  [11 Neonatal intensive care unit admission](#CD001233-fig-01211){ref-type="fig"}        3                372                   Risk Ratio (M‐H, Fixed, 95% CI)   0.8 \[0.32, 1.98\]
  [12 Perinatal death](#CD001233-fig-01212){ref-type="fig"}                               1                100                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [13 Hemorrhagia postpartum](#CD001233-fig-01213){ref-type="fig"}                        4                396                   Risk Ratio (M‐H, Fixed, 95% CI)   1.26 \[0.51, 3.11\]
  [14 Maternal fever during labour](#CD001233-fig-01214){ref-type="fig"}                  1                60                    Risk Ratio (M‐H, Fixed, 95% CI)   0.2 \[0.01, 4.00\]
  [15 Fetal distress](#CD001233-fig-01215){ref-type="fig"}                                3                332                   Risk Ratio (M‐H, Fixed, 95% CI)   0.43 \[0.19, 0.98\]

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-012-01){#CD001233-fig-01201}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section.](nCD001233-CMP-012-02){#CD001233-fig-01202}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-012-03){#CD001233-fig-01203}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or death.](nCD001233-CMP-012-04){#CD001233-fig-01204}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 hours.](nCD001233-CMP-012-05){#CD001233-fig-01205}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-012-06){#CD001233-fig-01206}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture.](nCD001233-CMP-012-07){#CD001233-fig-01207}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery.](nCD001233-CMP-012-08){#CD001233-fig-01208}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium‐stained liquor.](nCD001233-CMP-012-09){#CD001233-fig-01209}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-012-10){#CD001233-fig-01210}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit admission.](nCD001233-CMP-012-11){#CD001233-fig-01211}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death.](nCD001233-CMP-012-12){#CD001233-fig-01212}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia postpartum.](nCD001233-CMP-012-13){#CD001233-fig-01213}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour.](nCD001233-CMP-012-14){#CD001233-fig-01214}

![Analysis\
Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress.](nCD001233-CMP-012-15){#CD001233-fig-01215}

###### Balloon (Foley or ATAD) versus oxytocin: previous caesarean section

  Outcome or subgroup title                                                             No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-01301){ref-type="fig"}                            3                364                   Risk Ratio (M‐H, Fixed, 95% CI)    0.80 \[0.64, 1.00\]
  [2 Serious neonatal morbidity/perinatal death](#CD001233-fig-01302){ref-type="fig"}   1                100                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [3 Serious maternal morbidity or death](#CD001233-fig-01303){ref-type="fig"}          1                100                   Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean section.](nCD001233-CMP-013-01){#CD001233-fig-01301}

![Analysis\
Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-013-02){#CD001233-fig-01302}

![Analysis\
Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal morbidity or death.](nCD001233-CMP-013-03){#CD001233-fig-01303}

###### Balloon (Foley or ATAD) versus oxytocin: all primiparae

  Outcome or subgroup title                                                      No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-01401){ref-type="fig"}                     1                60                    Risk Ratio (M‐H, Fixed, 95% CI)   0.43 \[0.12, 1.50\]
  [2 Serious maternal morbidity or death](#CD001233-fig-01402){ref-type="fig"}   1                60                    Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section.](nCD001233-CMP-014-01){#CD001233-fig-01401}

![Analysis\
Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death.](nCD001233-CMP-014-02){#CD001233-fig-01402}

###### Balloon (foley or ATAD) versus amniotomy: all women

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-01501){ref-type="fig"}   1                20                    Risk Ratio (M‐H, Fixed, 95% CI)   0.25 \[0.03, 1.86\]

![Analysis\
Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section.](nCD001233-CMP-015-01){#CD001233-fig-01501}

###### Single balloon (Foley) versus double balloon (ATAD/Cook): all women

  Outcome or subgroup title                                                                     No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-01601){ref-type="fig"}            3                608                   Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.75, 1.25\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-01602){ref-type="fig"}            1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [3 Caesarean section](#CD001233-fig-01603){ref-type="fig"}                                    5                862                   Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.71, 1.33\]
  [4 Serious maternal morbidity or death](#CD001233-fig-01604){ref-type="fig"}                  1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [5 Oxytcocin augmentation](#CD001233-fig-01605){ref-type="fig"}                               2                278                   Risk Ratio (M‐H, Fixed, 95% CI)    0.94 \[0.82, 1.08\]
  [6 Uterine hyperstimulation without FHR changes](#CD001233-fig-01606){ref-type="fig"}         1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [7 Uterine rupture](#CD001233-fig-01607){ref-type="fig"}                                      1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [8 Epidural analgesia](#CD001233-fig-01608){ref-type="fig"}                                   3                608                   Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.83, 1.03\]
  [9 Instrumental vaginal delivery](#CD001233-fig-01609){ref-type="fig"}                        3                690                   Risk Ratio (M‐H, Fixed, 95% CI)    0.86 \[0.61, 1.20\]
  [10 Meconium‐stained liquor](#CD001233-fig-01610){ref-type="fig"}                             1                98                    Risk Ratio (M‐H, Fixed, 95% CI)    0.40 \[0.15, 1.04\]
  [11 Apgar score \< 7 at 5 minutes](#CD001233-fig-01611){ref-type="fig"}                       3                608                   Risk Ratio (M‐H, Fixed, 95% CI)    0.84 \[0.25, 2.79\]
  [12 Neonatal intensive care unit admission](#CD001233-fig-01612){ref-type="fig"}              2                391                   Risk Ratio (M‐H, Fixed, 95% CI)    1.67 \[0.71, 3.93\]
  [13 Other maternal side‐effects: pain after insertion](#CD001233-fig-01613){ref-type="fig"}   1                74                    Risk Ratio (M‐H, Fixed, 95% CI)    0.67 \[0.20, 2.17\]
  [14 Postpartum haemorrhage](#CD001233-fig-01614){ref-type="fig"}                              2                291                   Risk Ratio (M‐H, Fixed, 95% CI)    0.83 \[0.27, 2.52\]
  [15 Maternal fever during labour](#CD001233-fig-01615){ref-type="fig"}                        3                584                   Risk Ratio (M‐H, Random, 95% CI)   0.61 \[0.16, 2.34\]
  [16 Antibiotics during labour](#CD001233-fig-01616){ref-type="fig"}                           1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    0.97 \[0.61, 1.56\]
  [17 Chorioamnionitis](#CD001233-fig-01617){ref-type="fig"}                                    1                98                    Risk Ratio (M‐H, Fixed, 95% CI)    1.56 \[0.47, 5.20\]
  [18 Endometritis](#CD001233-fig-01618){ref-type="fig"}                                        1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    1.95 \[0.18, 21.14\]
  [19 Fetal distress](#CD001233-fig-01619){ref-type="fig"}                                      4                682                   Risk Ratio (M‐H, Fixed, 95% CI)    0.98 \[0.70, 1.36\]
  [20 Umbilical artery pH \< 7.10](#CD001233-fig-01620){ref-type="fig"}                         1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    0.42 \[0.11, 1.57\]

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-016-01){#CD001233-fig-01601}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-016-02){#CD001233-fig-01602}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean section.](nCD001233-CMP-016-03){#CD001233-fig-01603}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 4 Serious maternal morbidity or death.](nCD001233-CMP-016-04){#CD001233-fig-01604}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 5 Oxytcocin augmentation.](nCD001233-CMP-016-05){#CD001233-fig-01605}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 6 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-016-06){#CD001233-fig-01606}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 7 Uterine rupture.](nCD001233-CMP-016-07){#CD001233-fig-01607}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 8 Epidural analgesia.](nCD001233-CMP-016-08){#CD001233-fig-01608}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 9 Instrumental vaginal delivery.](nCD001233-CMP-016-09){#CD001233-fig-01609}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium‐stained liquor.](nCD001233-CMP-016-10){#CD001233-fig-01610}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-016-11){#CD001233-fig-01611}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal intensive care unit admission.](nCD001233-CMP-016-12){#CD001233-fig-01612}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other maternal side‐effects: pain after insertion.](nCD001233-CMP-016-13){#CD001233-fig-01613}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum haemorrhage.](nCD001233-CMP-016-14){#CD001233-fig-01614}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal fever during labour.](nCD001233-CMP-016-15){#CD001233-fig-01615}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics during labour.](nCD001233-CMP-016-16){#CD001233-fig-01616}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 Chorioamnionitis.](nCD001233-CMP-016-17){#CD001233-fig-01617}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 Endometritis.](nCD001233-CMP-016-18){#CD001233-fig-01618}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress.](nCD001233-CMP-016-19){#CD001233-fig-01619}

![Analysis\
Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH \< 7.10.](nCD001233-CMP-016-20){#CD001233-fig-01620}

###### Single balloon (Foley) versus double balloon (ATAD): all primiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-01701){ref-type="fig"}   1                50                    Risk Ratio (M‐H, Fixed, 95% CI)    1.14 \[0.95, 1.38\]
  [2 Caesarean section](#CD001233-fig-01702){ref-type="fig"}                           4                374                   Risk Ratio (M‐H, Random, 95% CI)   1.30 \[0.76, 2.22\]

![Analysis\
Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-017-01){#CD001233-fig-01701}

![Analysis\
Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section.](nCD001233-CMP-017-02){#CD001233-fig-01702}

###### Single balloon (Foley) versus double balloon (ATAD): all multiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-01801){ref-type="fig"}   1                48                    Risk Ratio (M‐H, Fixed, 95% CI)   1.24 \[0.80, 1.93\]
  [2 Caesarean section](#CD001233-fig-01802){ref-type="fig"}                           2                186                   Risk Ratio (M‐H, Fixed, 95% CI)   0.74 \[0.30, 1.84\]

![Analysis\
Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-018-01){#CD001233-fig-01801}

![Analysis\
Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section.](nCD001233-CMP-018-02){#CD001233-fig-01802}

###### Laminaria tent versus vaginal prostaglandin E2: all women

  Outcome or subgroup title                                                                            No. of studies   No. of participants   Statistical method                Effect size
  ---------------------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-01901){ref-type="fig"}                   3                188                   Risk Ratio (M‐H, Fixed, 95% CI)   0.11 \[0.02, 0.60\]
  [2 Caesarean section](#CD001233-fig-01902){ref-type="fig"}                                           5                263                   Risk Ratio (M‐H, Fixed, 95% CI)   0.91 \[0.56, 1.48\]
  [3 Serious perinatal morbidity/perinatal death](#CD001233-fig-01903){ref-type="fig"}                 1                80                    Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [4 Serious maternal morbidity or death](#CD001233-fig-01904){ref-type="fig"}                         1                28                    Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [5 Uterine hyperstimulation without fetal heart rate changes](#CD001233-fig-01905){ref-type="fig"}   3                180                   Risk Ratio (M‐H, Fixed, 95% CI)   0.22 \[0.09, 0.49\]
  [6 Epidural analgesia](#CD001233-fig-01906){ref-type="fig"}                                          1                80                    Risk Ratio (M‐H, Fixed, 95% CI)   0.91 \[0.74, 1.13\]
  [7 Instrumental vaginal delivery](#CD001233-fig-01907){ref-type="fig"}                               1                80                    Risk Ratio (M‐H, Fixed, 95% CI)   0.71 \[0.43, 1.17\]
  [8 Meconium‐stained liquor](#CD001233-fig-01908){ref-type="fig"}                                     1                80                    Risk Ratio (M‐H, Fixed, 95% CI)   0.14 \[0.01, 2.68\]
  [9 Apgar score \< 7 at 5 minutes](#CD001233-fig-01909){ref-type="fig"}                               2                160                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [10 Perinatal death](#CD001233-fig-01910){ref-type="fig"}                                            1                80                    Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [11 Maternal side effects: all](#CD001233-fig-01911){ref-type="fig"}                                 1                28                    Risk Ratio (M‐H, Fixed, 95% CI)   0.29 \[0.01, 6.60\]
  [12 Maternal nausea](#CD001233-fig-01912){ref-type="fig"}                                            1                28                    Risk Ratio (M‐H, Fixed, 95% CI)   0.29 \[0.01, 6.60\]
  [13 Fetal distress](#CD001233-fig-01913){ref-type="fig"}                                             3                188                   Risk Ratio (M‐H, Fixed, 95% CI)   0.62 \[0.34, 1.15\]

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-019-01){#CD001233-fig-01901}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section.](nCD001233-CMP-019-02){#CD001233-fig-01902}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death.](nCD001233-CMP-019-03){#CD001233-fig-01903}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death.](nCD001233-CMP-019-04){#CD001233-fig-01904}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes.](nCD001233-CMP-019-05){#CD001233-fig-01905}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia.](nCD001233-CMP-019-06){#CD001233-fig-01906}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery.](nCD001233-CMP-019-07){#CD001233-fig-01907}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium‐stained liquor.](nCD001233-CMP-019-08){#CD001233-fig-01908}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 9 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-019-09){#CD001233-fig-01909}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 10 Perinatal death.](nCD001233-CMP-019-10){#CD001233-fig-01910}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 11 Maternal side effects: all.](nCD001233-CMP-019-11){#CD001233-fig-01911}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 12 Maternal nausea.](nCD001233-CMP-019-12){#CD001233-fig-01912}

![Analysis\
Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 13 Fetal distress.](nCD001233-CMP-019-13){#CD001233-fig-01913}

###### Laminaria tent versus vaginal prostaglandin E2: all primiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-02001){ref-type="fig"}   1                80                    Risk Ratio (M‐H, Fixed, 95% CI)    0.33 \[0.01, 7.95\]
  [2 Caesarean section](#CD001233-fig-02002){ref-type="fig"}                           2                90                    Risk Ratio (M‐H, Random, 95% CI)   1.07 \[0.24, 4.89\]

![Analysis\
Comparison 20 Laminaria tent versus vaginal prostaglandin E2: all primiparae, Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-020-01){#CD001233-fig-02001}

![Analysis\
Comparison 20 Laminaria tent versus vaginal prostaglandin E2: all primiparae, Outcome 2 Caesarean section.](nCD001233-CMP-020-02){#CD001233-fig-02002}

###### Laminaria tent versus vaginal prostaglandin E2: all multiparae

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- --------------------
  [1 Caesarean section](#CD001233-fig-02101){ref-type="fig"}   1                10                    Risk Ratio (M‐H, Fixed, 95% CI)   0.5 \[0.06, 3.91\]

![Analysis\
Comparison 21 Laminaria tent versus vaginal prostaglandin E2: all multiparae, Outcome 1 Caesarean section.](nCD001233-CMP-021-01){#CD001233-fig-02101}

###### Laminaria tent versus intracervical prostaglandin E2: all women

  Outcome or subgroup title                                                                  No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ----------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-02201){ref-type="fig"}         2                350                   Risk Ratio (M‐H, Fixed, 95% CI)    0.17 \[0.02, 1.42\]
  [2 Caesarean section](#CD001233-fig-02202){ref-type="fig"}                                 5                920                   Risk Ratio (M‐H, Fixed, 95% CI)    1.16 \[0.93, 1.45\]
  [3 Serious neonatal morbidity/perinatal death](#CD001233-fig-02203){ref-type="fig"}        1                185                   Risk Ratio (M‐H, Fixed, 95% CI)    3.16 \[0.13, 76.70\]
  [4 Serious maternal morbidity or death](#CD001233-fig-02204){ref-type="fig"}               1                185                   Risk Ratio (M‐H, Fixed, 95% CI)    0.35 \[0.01, 8.52\]
  [5 Cervix unfavourable/unchanged after 12‐24 hours](#CD001233-fig-02205){ref-type="fig"}   2                218                   Risk Ratio (M‐H, Random, 95% CI)   0.46 \[0.11, 1.96\]
  [6 Oxytocin augmentation](#CD001233-fig-02206){ref-type="fig"}                             1                185                   Risk Ratio (M‐H, Fixed, 95% CI)    1.41 \[1.21, 1.64\]
  [7 Uterine hyperstimulation without FHR changes](#CD001233-fig-02207){ref-type="fig"}      2                601                   Risk Ratio (M‐H, Fixed, 95% CI)    0.17 \[0.02, 1.36\]
  [8 Uterine rupture](#CD001233-fig-02208){ref-type="fig"}                                   1                185                   Risk Ratio (M‐H, Fixed, 95% CI)    0.35 \[0.01, 8.52\]
  [9 Instrumental vaginal delivery](#CD001233-fig-02209){ref-type="fig"}                     3                424                   Risk Ratio (M‐H, Fixed, 95% CI)    1.05 \[0.65, 1.69\]
  [10 Apgar score \< 7 at 5 minutes](#CD001233-fig-02210){ref-type="fig"}                    1                185                   Risk Ratio (M‐H, Fixed, 95% CI)    5.28 \[0.63, 44.30\]
  [11 Neonatal intensive care unit admission](#CD001233-fig-02211){ref-type="fig"}           2                259                   Risk Ratio (M‐H, Fixed, 95% CI)    1.58 \[0.58, 4.33\]
  [12 Perinatal death](#CD001233-fig-02212){ref-type="fig"}                                  1                185                   Risk Ratio (M‐H, Fixed, 95% CI)    3.16 \[0.13, 76.70\]
  [13 Maternal side effects](#CD001233-fig-02213){ref-type="fig"}                            1                165                   Risk Ratio (M‐H, Fixed, 95% CI)    0.20 \[0.01, 4.15\]
  [14 Postpartum haemorrhage](#CD001233-fig-02214){ref-type="fig"}                           2                239                   Risk Ratio (M‐H, Fixed, 95% CI)    1.14 \[0.46, 2.81\]
  [15 Chorioamnionitis](#CD001233-fig-02215){ref-type="fig"}                                 1                74                    Risk Ratio (M‐H, Fixed, 95% CI)    3.17 \[0.35, 29.06\]
  [16 Endometritis](#CD001233-fig-02216){ref-type="fig"}                                     2                490                   Risk Ratio (M‐H, Random, 95% CI)   0.30 \[0.08, 1.09\]
  [17 Fetal distress](#CD001233-fig-02217){ref-type="fig"}                                   2                128                   Risk Ratio (M‐H, Fixed, 95% CI)    0.44 \[0.07, 2.90\]

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-022-01){#CD001233-fig-02201}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 2 Caesarean section.](nCD001233-CMP-022-02){#CD001233-fig-02202}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 3 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-022-03){#CD001233-fig-02203}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death.](nCD001233-CMP-022-04){#CD001233-fig-02204}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 5 Cervix unfavourable/unchanged after 12‐24 hours.](nCD001233-CMP-022-05){#CD001233-fig-02205}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.](nCD001233-CMP-022-06){#CD001233-fig-02206}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-022-07){#CD001233-fig-02207}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 8 Uterine rupture.](nCD001233-CMP-022-08){#CD001233-fig-02208}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 9 Instrumental vaginal delivery.](nCD001233-CMP-022-09){#CD001233-fig-02209}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 10 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-022-10){#CD001233-fig-02210}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 11 Neonatal intensive care unit admission.](nCD001233-CMP-022-11){#CD001233-fig-02211}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 12 Perinatal death.](nCD001233-CMP-022-12){#CD001233-fig-02212}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 13 Maternal side effects.](nCD001233-CMP-022-13){#CD001233-fig-02213}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 14 Postpartum haemorrhage.](nCD001233-CMP-022-14){#CD001233-fig-02214}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 15 Chorioamnionitis.](nCD001233-CMP-022-15){#CD001233-fig-02215}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 16 Endometritis.](nCD001233-CMP-022-16){#CD001233-fig-02216}

![Analysis\
Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 17 Fetal distress.](nCD001233-CMP-022-17){#CD001233-fig-02217}

###### Laminaria tent versus intracervical prostaglandin E2: all primiparae

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-02301){ref-type="fig"}   1                116                   Risk Ratio (M‐H, Fixed, 95% CI)   1.15 \[0.62, 2.13\]

![Analysis\
Comparison 23 Laminaria tent versus intracervical prostaglandin E2: all primiparae, Outcome 1 Caesarean section.](nCD001233-CMP-023-01){#CD001233-fig-02301}

###### Laminaria tent versus intracervical: prostaglandin E2 all multiparae

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-02401){ref-type="fig"}   1                69                    Risk Ratio (M‐H, Fixed, 95% CI)   1.28 \[0.45, 3.65\]

![Analysis\
Comparison 24 Laminaria tent versus intracervical: prostaglandin E2 all multiparae, Outcome 1 Caesarean section.](nCD001233-CMP-024-01){#CD001233-fig-02401}

###### Laminaria tent versus oxytocin: all women

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ----------------------
  [1 Caesarean section](#CD001233-fig-02501){ref-type="fig"}   2                73                    Risk Ratio (M‐H, Fixed, 95% CI)   0.83 \[0.36, 1.89\]
  [2 Fetal distress](#CD001233-fig-02502){ref-type="fig"}      1                53                    Risk Ratio (M‐H, Fixed, 95% CI)   2.69 \[0.11, 63.18\]

![Analysis\
Comparison 25 Laminaria tent versus oxytocin: all women, Outcome 1 Caesarean section.](nCD001233-CMP-025-01){#CD001233-fig-02501}

![Analysis\
Comparison 25 Laminaria tent versus oxytocin: all women, Outcome 2 Fetal distress.](nCD001233-CMP-025-02){#CD001233-fig-02502}

###### Laminaria tent versus amniotomy: all women

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-02601){ref-type="fig"}   1                20                    Risk Ratio (M‐H, Fixed, 95% CI)   0.75 \[0.22, 2.52\]

![Analysis\
Comparison 26 Laminaria tent versus amniotomy: all women, Outcome 1 Caesarean section.](nCD001233-CMP-026-01){#CD001233-fig-02601}

###### Laminaria tent versus other hygroscopic dilator: all women

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-02701){ref-type="fig"}   1                41                    Risk Ratio (M‐H, Fixed, 95% CI)   1.70 \[0.44, 6.66\]

![Analysis\
Comparison 27 Laminaria tent versus other hygroscopic dilator: all women, Outcome 1 Caesarean section.](nCD001233-CMP-027-01){#CD001233-fig-02701}

###### EASI versus vaginal prostaglandin E2: all women

  Outcome or subgroup title                                                                            No. of studies   No. of participants   Statistical method                Effect size
  ---------------------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- -----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-02801){ref-type="fig"}                   1                109                   Risk Ratio (M‐H, Fixed, 95% CI)   1.74 \[1.21, 2.49\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-02802){ref-type="fig"}                   2                221                   Risk Ratio (M‐H, Fixed, 95% CI)   0.23 \[0.03, 2.07\]
  [3 Caesarean section](#CD001233-fig-02803){ref-type="fig"}                                           2                221                   Risk Ratio (M‐H, Fixed, 95% CI)   1.35 \[0.94, 1.96\]
  [4 Oxytocin augmentation](#CD001233-fig-02804){ref-type="fig"}                                       1                109                   Risk Ratio (M‐H, Fixed, 95% CI)   12.71 \[3.20, 50.57\]
  [5 Uterine hyperstimulation without fetal heart rate changes](#CD001233-fig-02805){ref-type="fig"}   2                221                   Risk Ratio (M‐H, Fixed, 95% CI)   0.23 \[0.03, 2.07\]
  [6 Epidural analgesia](#CD001233-fig-02806){ref-type="fig"}                                          1                112                   Risk Ratio (M‐H, Fixed, 95% CI)   1.0 \[0.97, 1.04\]
  [7 Instrumental vaginal delivery](#CD001233-fig-02807){ref-type="fig"}                               1                109                   Risk Ratio (M‐H, Fixed, 95% CI)   0.58 \[0.30, 1.14\]
  [8 Meconium‐stained liquor](#CD001233-fig-02808){ref-type="fig"}                                     1                112                   Risk Ratio (M‐H, Fixed, 95% CI)   3.0 \[0.12, 72.10\]
  [9 Apgar score \< 7 at 5 minutes](#CD001233-fig-02809){ref-type="fig"}                               1                109                   Risk Ratio (M‐H, Fixed, 95% CI)   4.25 \[0.21, 86.51\]
  [10 Neonatal intensive care unit admission](#CD001233-fig-02810){ref-type="fig"}                     1                112                   Risk Ratio (M‐H, Fixed, 95% CI)   1.5 \[0.45, 5.03\]
  [11 Woman not satisfied](#CD001233-fig-02811){ref-type="fig"}                                        1                109                   Risk Ratio (M‐H, Fixed, 95% CI)   0.56 \[0.10, 3.25\]
  [12 Fetal distress](#CD001233-fig-02812){ref-type="fig"}                                             1                112                   Risk Ratio (M‐H, Fixed, 95% CI)   1.2 \[0.39, 3.71\]

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-028-01){#CD001233-fig-02801}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-028-02){#CD001233-fig-02802}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section.](nCD001233-CMP-028-03){#CD001233-fig-02803}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 4 Oxytocin augmentation.](nCD001233-CMP-028-04){#CD001233-fig-02804}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes.](nCD001233-CMP-028-05){#CD001233-fig-02805}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia.](nCD001233-CMP-028-06){#CD001233-fig-02806}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery.](nCD001233-CMP-028-07){#CD001233-fig-02807}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 8 Meconium‐stained liquor.](nCD001233-CMP-028-08){#CD001233-fig-02808}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 9 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-028-09){#CD001233-fig-02809}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 10 Neonatal intensive care unit admission.](nCD001233-CMP-028-10){#CD001233-fig-02810}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 11 Woman not satisfied.](nCD001233-CMP-028-11){#CD001233-fig-02811}

![Analysis\
Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 12 Fetal distress.](nCD001233-CMP-028-12){#CD001233-fig-02812}

###### EASI versus intracervical prostaglandin E2: all women

  Outcome or subgroup title                                                                  No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-02901){ref-type="fig"}                                 2                155                   Risk Ratio (M‐H, Random, 95% CI)   0.73 \[0.10, 5.12\]
  [2 Cervix unfavourable/unchanged after 12‐24 hours](#CD001233-fig-02902){ref-type="fig"}   1                85                    Risk Ratio (M‐H, Fixed, 95% CI)    0.06 \[0.00, 0.97\]
  [3 Oxytocin augmentation](#CD001233-fig-02903){ref-type="fig"}                             1                70                    Risk Ratio (M‐H, Fixed, 95% CI)    1.1 \[0.54, 2.25\]
  [4 Instrumental vaginal delivery](#CD001233-fig-02904){ref-type="fig"}                     1                85                    Risk Ratio (M‐H, Fixed, 95% CI)    0.33 \[0.04, 3.01\]
  [5 Apgar score \< 7 at 5 minutes](#CD001233-fig-02905){ref-type="fig"}                     1                85                    Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [6 Endometritis](#CD001233-fig-02906){ref-type="fig"}                                      1                85                    Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [7 Fetal distress](#CD001233-fig-02907){ref-type="fig"}                                    1                70                    Risk Ratio (M‐H, Fixed, 95% CI)    0.29 \[0.06, 1.28\]

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 1 Caesarean section.](nCD001233-CMP-029-01){#CD001233-fig-02901}

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 2 Cervix unfavourable/unchanged after 12‐24 hours.](nCD001233-CMP-029-02){#CD001233-fig-02902}

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 3 Oxytocin augmentation.](nCD001233-CMP-029-03){#CD001233-fig-02903}

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 4 Instrumental vaginal delivery.](nCD001233-CMP-029-04){#CD001233-fig-02904}

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 5 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-029-05){#CD001233-fig-02905}

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 6 Endometritis.](nCD001233-CMP-029-06){#CD001233-fig-02906}

![Analysis\
Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 7 Fetal distress.](nCD001233-CMP-029-07){#CD001233-fig-02907}

###### EASI versus intracervical prostaglandin E2: all primiparae

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-03001){ref-type="fig"}   1                70                    Risk Ratio (M‐H, Fixed, 95% CI)   0.25 \[0.06, 1.09\]

![Analysis\
Comparison 30 EASI versus intracervical prostaglandin E2: all primiparae, Outcome 1 Caesarean section.](nCD001233-CMP-030-01){#CD001233-fig-03001}

###### Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03101){ref-type="fig"}      1                39                    Risk Ratio (M‐H, Fixed, 95% CI)    0.84 \[0.53, 1.33\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-03102){ref-type="fig"}      2                122                   Risk Ratio (M‐H, Fixed, 95% CI)    0.26 \[0.01, 5.12\]
  [3 Caesarean section](#CD001233-fig-03103){ref-type="fig"}                              7                517                   Risk Ratio (M‐H, Random, 95% CI)   0.96 \[0.66, 1.40\]
  [4 Cervix unfavourable/unchanged after 24 hours](#CD001233-fig-03104){ref-type="fig"}   1                122                   Risk Ratio (M‐H, Fixed, 95% CI)    0.52 \[0.31, 0.85\]
  [5 Oxytocin augmentation](#CD001233-fig-03105){ref-type="fig"}                          1                44                    Risk Ratio (M‐H, Fixed, 95% CI)    0.95 \[0.64, 1.41\]
  [6 Uterine hyperstimulation without FHR changes](#CD001233-fig-03106){ref-type="fig"}   3                239                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [7 Epidural analgesia](#CD001233-fig-03107){ref-type="fig"}                             1                39                    Risk Ratio (M‐H, Fixed, 95% CI)    0.98 \[0.77, 1.24\]
  [8 Instrumental vaginal delivery](#CD001233-fig-03108){ref-type="fig"}                  2                78                    Risk Ratio (M‐H, Fixed, 95% CI)    0.56 \[0.22, 1.45\]
  [9 Meconium‐stained liquor](#CD001233-fig-03109){ref-type="fig"}                        1                120                   Risk Ratio (M‐H, Fixed, 95% CI)    0.97 \[0.33, 2.83\]
  [10 Neonatal intensive care unit admission](#CD001233-fig-03110){ref-type="fig"}        1                44                    Risk Ratio (M‐H, Fixed, 95% CI)    0.26 \[0.01, 5.12\]
  [11 Postpartum haemorrhage](#CD001233-fig-03111){ref-type="fig"}                        1                39                    Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [12 Chorioamnionitis](#CD001233-fig-03112){ref-type="fig"}                              2                122                   Risk Ratio (M‐H, Fixed, 95% CI)    1.56 \[0.45, 5.45\]
  [13 Endometritis](#CD001233-fig-03113){ref-type="fig"}                                  3                237                   Risk Ratio (M‐H, Fixed, 95% CI)    1.07 \[0.41, 2.78\]
  [14 Fetal distress](#CD001233-fig-03114){ref-type="fig"}                                2                140                   Risk Ratio (M‐H, Fixed, 95% CI)    2.28 \[0.54, 9.69\]

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-031-01){#CD001233-fig-03101}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-031-02){#CD001233-fig-03102}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 3 Caesarean section.](nCD001233-CMP-031-03){#CD001233-fig-03103}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 4 Cervix unfavourable/unchanged after 24 hours.](nCD001233-CMP-031-04){#CD001233-fig-03104}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 5 Oxytocin augmentation.](nCD001233-CMP-031-05){#CD001233-fig-03105}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 6 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-031-06){#CD001233-fig-03106}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 7 Epidural analgesia.](nCD001233-CMP-031-07){#CD001233-fig-03107}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 8 Instrumental vaginal delivery.](nCD001233-CMP-031-08){#CD001233-fig-03108}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 9 Meconium‐stained liquor.](nCD001233-CMP-031-09){#CD001233-fig-03109}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 10 Neonatal intensive care unit admission.](nCD001233-CMP-031-10){#CD001233-fig-03110}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 11 Postpartum haemorrhage.](nCD001233-CMP-031-11){#CD001233-fig-03111}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 12 Chorioamnionitis.](nCD001233-CMP-031-12){#CD001233-fig-03112}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 13 Endometritis.](nCD001233-CMP-031-13){#CD001233-fig-03113}

![Analysis\
Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 14 Fetal distress.](nCD001233-CMP-031-14){#CD001233-fig-03114}

###### Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women

  Outcome or subgroup title                                                                  No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03201){ref-type="fig"}         1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   0.32 \[0.12, 0.82\]
  [2 Caesarean section](#CD001233-fig-03202){ref-type="fig"}                                 1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   1.09 \[0.58, 2.04\]
  [3 Serious neonatal morbidity/perinatal death](#CD001233-fig-03203){ref-type="fig"}        1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   0.19 \[0.01, 3.90\]
  [4 Cervix unfavourable/unchanged after 12‐24 hours](#CD001233-fig-03204){ref-type="fig"}   1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   0.41 \[0.25, 0.67\]
  [5 Oxytocin augmentation](#CD001233-fig-03205){ref-type="fig"}                             1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   1.21 \[1.01, 1.46\]
  [6 Uterine hyperstimulation without FHR changes](#CD001233-fig-03206){ref-type="fig"}      1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   4.05 \[1.44, 11.38\]
  [7 Instrumental vaginal delivery](#CD001233-fig-03207){ref-type="fig"}                     1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   1.26 \[0.77, 2.04\]
  [8 Meconium‐stained liquor](#CD001233-fig-03208){ref-type="fig"}                           1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   0.56 \[0.23, 1.32\]
  [9 Apgar score \< 7 at 5 minutes](#CD001233-fig-03209){ref-type="fig"}                     1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   1.91 \[0.18, 20.51\]
  [10 Neonatal intensive care unit admission](#CD001233-fig-03210){ref-type="fig"}           1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   0.64 \[0.31, 1.31\]
  [11 Perinatal death](#CD001233-fig-03211){ref-type="fig"}                                  1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   0.19 \[0.01, 3.90\]
  [12 Chorioamnionitis](#CD001233-fig-03212){ref-type="fig"}                                 1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   1.91 \[0.18, 20.51\]
  [13 Endometritis](#CD001233-fig-03213){ref-type="fig"}                                     1                127                   Risk Ratio (M‐H, Fixed, 95% CI)   1.91 \[0.36, 10.05\]

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-032-01){#CD001233-fig-03201}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 2 Caesarean section.](nCD001233-CMP-032-02){#CD001233-fig-03202}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 3 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-032-03){#CD001233-fig-03203}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 4 Cervix unfavourable/unchanged after 12‐24 hours.](nCD001233-CMP-032-04){#CD001233-fig-03204}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 5 Oxytocin augmentation.](nCD001233-CMP-032-05){#CD001233-fig-03205}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 6 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-032-06){#CD001233-fig-03206}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 7 Instrumental vaginal delivery.](nCD001233-CMP-032-07){#CD001233-fig-03207}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 8 Meconium‐stained liquor.](nCD001233-CMP-032-08){#CD001233-fig-03208}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 9 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-032-09){#CD001233-fig-03209}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 10 Neonatal intensive care unit admission.](nCD001233-CMP-032-10){#CD001233-fig-03210}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 11 Perinatal death.](nCD001233-CMP-032-11){#CD001233-fig-03211}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 12 Chorioamnionitis.](nCD001233-CMP-032-12){#CD001233-fig-03212}

![Analysis\
Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 13 Endometritis.](nCD001233-CMP-032-13){#CD001233-fig-03213}

###### Any mechanical method and prostaglandin E2 versus oxytocin alone: all women

  Outcome or subgroup title                                                No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ----------------------
  [1 Caesarean section](#CD001233-fig-03301){ref-type="fig"}               1                44                    Risk Ratio (M‐H, Fixed, 95% CI)   0.3 \[0.04, 2.47\]
  [2 Instrumental vaginal delivery](#CD001233-fig-03302){ref-type="fig"}   1                44                    Risk Ratio (M‐H, Fixed, 95% CI)   0.6 \[0.12, 2.94\]
  [3 Endometritis](#CD001233-fig-03303){ref-type="fig"}                    1                44                    Risk Ratio (M‐H, Fixed, 95% CI)   3.57 \[0.15, 83.14\]

![Analysis\
Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 1 Caesarean section.](nCD001233-CMP-033-01){#CD001233-fig-03301}

![Analysis\
Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 2 Instrumental vaginal delivery.](nCD001233-CMP-033-02){#CD001233-fig-03302}

![Analysis\
Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 3 Endometritis.](nCD001233-CMP-033-03){#CD001233-fig-03303}

###### Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women

  Outcome or subgroup title                                                                            No. of studies   No. of participants   Statistical method                Effect size
  ---------------------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03401){ref-type="fig"}                   1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   1.14 \[0.89, 1.46\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-03402){ref-type="fig"}                   1                327                   Risk Ratio (M‐H, Fixed, 95% CI)   0.75 \[0.27, 2.13\]
  [3 Caesarean section](#CD001233-fig-03403){ref-type="fig"}                                           1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   0.85 \[0.57, 1.25\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-03404){ref-type="fig"}                  1                345                   Risk Ratio (M‐H, Fixed, 95% CI)   2.04 \[0.19, 22.24\]
  [5 Serious maternal morbidity or death](#CD001233-fig-03405){ref-type="fig"}                         1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [6 Oxytocin augmentation](#CD001233-fig-03406){ref-type="fig"}                                       1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   0.54 \[0.34, 0.86\]
  [7 Uterine hyperstimulation without fetal heart rate changes](#CD001233-fig-03407){ref-type="fig"}   1                327                   Risk Ratio (M‐H, Fixed, 95% CI)   0.54 \[0.22, 1.32\]
  [8 Uterine rupture](#CD001233-fig-03408){ref-type="fig"}                                             1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [9 Instrumental vaginal delivery](#CD001233-fig-03409){ref-type="fig"}                               1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   1.01 \[0.26, 3.98\]
  [10 Meconium‐stained liquor](#CD001233-fig-03410){ref-type="fig"}                                    1                339                   Risk Ratio (M‐H, Fixed, 95% CI)   1.15 \[0.60, 2.23\]
  [11 Apgar score \< 7 at 5 minutes](#CD001233-fig-03411){ref-type="fig"}                              1                346                   Risk Ratio (M‐H, Fixed, 95% CI)   0.68 \[0.25, 1.88\]
  [12 Neonatal intensive care unit admission](#CD001233-fig-03412){ref-type="fig"}                     1                346                   Risk Ratio (M‐H, Fixed, 95% CI)   0.68 \[0.12, 4.03\]
  [13 Perinatal death](#CD001233-fig-03413){ref-type="fig"}                                            1                345                   Risk Ratio (M‐H, Fixed, 95% CI)   1.02 \[0.06, 16.14\]
  [14 Maternal side effects](#CD001233-fig-03414){ref-type="fig"}                                      1                314                   Risk Ratio (M‐H, Fixed, 95% CI)   1.16 \[0.95, 1.43\]
  [15 Maternal nausea](#CD001233-fig-03415){ref-type="fig"}                                            1                300                   Risk Ratio (M‐H, Fixed, 95% CI)   1.65 \[0.98, 2.79\]
  [16 Maternal diarrhoea](#CD001233-fig-03416){ref-type="fig"}                                         1                313                   Risk Ratio (M‐H, Fixed, 95% CI)   3.72 \[1.53, 9.00\]
  [17 Postpartum haemorrhage](#CD001233-fig-03417){ref-type="fig"}                                     1                348                   Risk Ratio (M‐H, Fixed, 95% CI)   0.98 \[0.67, 1.41\]
  [18 Serious maternal complications](#CD001233-fig-03418){ref-type="fig"}                             1                350                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  [19 Maternal fever during labour](#CD001233-fig-03419){ref-type="fig"}                               1                347                   Risk Ratio (M‐H, Fixed, 95% CI)   1.53 \[0.26, 9.02\]

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-034-01){#CD001233-fig-03401}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-034-02){#CD001233-fig-03402}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 3 Caesarean section.](nCD001233-CMP-034-03){#CD001233-fig-03403}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-034-04){#CD001233-fig-03404}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-034-05){#CD001233-fig-03405}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 6 Oxytocin augmentation.](nCD001233-CMP-034-06){#CD001233-fig-03406}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 7 Uterine hyperstimulation without fetal heart rate changes.](nCD001233-CMP-034-07){#CD001233-fig-03407}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 8 Uterine rupture.](nCD001233-CMP-034-08){#CD001233-fig-03408}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 9 Instrumental vaginal delivery.](nCD001233-CMP-034-09){#CD001233-fig-03409}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 10 Meconium‐stained liquor.](nCD001233-CMP-034-10){#CD001233-fig-03410}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 11 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-034-11){#CD001233-fig-03411}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 12 Neonatal intensive care unit admission.](nCD001233-CMP-034-12){#CD001233-fig-03412}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 13 Perinatal death.](nCD001233-CMP-034-13){#CD001233-fig-03413}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 14 Maternal side effects.](nCD001233-CMP-034-14){#CD001233-fig-03414}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 15 Maternal nausea.](nCD001233-CMP-034-15){#CD001233-fig-03415}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 16 Maternal diarrhoea.](nCD001233-CMP-034-16){#CD001233-fig-03416}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 17 Postpartum haemorrhage.](nCD001233-CMP-034-17){#CD001233-fig-03417}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 18 Serious maternal complications.](nCD001233-CMP-034-18){#CD001233-fig-03418}

![Analysis\
Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 19 Maternal fever during labour.](nCD001233-CMP-034-19){#CD001233-fig-03419}

###### Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03501){ref-type="fig"}      2                668                   Risk Ratio (M‐H, Random, 95% CI)   0.70 \[0.25, 1.95\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-03502){ref-type="fig"}      4                707                   Risk Ratio (M‐H, Random, 95% CI)   0.54 \[0.20, 1.45\]
  [3 Caesarean section](#CD001233-fig-03503){ref-type="fig"}                              7                1422                  Risk Ratio (M‐H, Random, 95% CI)   0.87 \[0.66, 1.15\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-03504){ref-type="fig"}     2                487                   Risk Ratio (M‐H, Fixed, 95% CI)    1.25 \[0.34, 4.55\]
  [5 Serious maternal morbidity or death](#CD001233-fig-03505){ref-type="fig"}            2                490                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [6 Cervix unfavourable/unchanged after 12 hours](#CD001233-fig-03506){ref-type="fig"}   1                140                   Risk Ratio (M‐H, Fixed, 95% CI)    0.27 \[0.08, 0.94\]
  [7 Oxytocin augmentation](#CD001233-fig-03507){ref-type="fig"}                          5                1051                  Risk Ratio (M‐H, Random, 95% CI)   0.94 \[0.70, 1.25\]
  [8 Uterine hyperstimulation without FHR changes](#CD001233-fig-03508){ref-type="fig"}   4                982                   Risk Ratio (M‐H, Fixed, 95% CI)    0.53 \[0.32, 0.90\]
  [9 Uterine rupture](#CD001233-fig-03509){ref-type="fig"}                                2                490                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [10 Epidural analgesia](#CD001233-fig-03510){ref-type="fig"}                            3                443                   Risk Ratio (M‐H, Random, 95% CI)   1.00 \[0.91, 1.10\]
  [11 Instrumental vaginal delivery](#CD001233-fig-03511){ref-type="fig"}                 3                676                   Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.58, 1.51\]
  [12 Meconium‐stained liquor](#CD001233-fig-03512){ref-type="fig"}                       6                1243                  Risk Ratio (M‐H, Random, 95% CI)   0.61 \[0.35, 1.04\]
  [13 Apgar score \< 7 at 5 minutes](#CD001233-fig-03513){ref-type="fig"}                 3                802                   Risk Ratio (M‐H, Random, 95% CI)   0.71 \[0.37, 1.36\]
  [14 Neonatal intensive care unit admission](#CD001233-fig-03514){ref-type="fig"}        6                1246                  Risk Ratio (M‐H, Fixed, 95% CI)    0.57 \[0.36, 0.91\]
  [15 Perinatal death](#CD001233-fig-03515){ref-type="fig"}                               1                347                   Risk Ratio (M‐H, Fixed, 95% CI)    3.09 \[0.13, 75.26\]
  [16 Maternal side effects](#CD001233-fig-03516){ref-type="fig"}                         1                300                   Risk Ratio (M‐H, Fixed, 95% CI)    1.06 \[0.87, 1.30\]
  [17 Maternal nausea](#CD001233-fig-03517){ref-type="fig"}                               1                300                   Risk Ratio (M‐H, Fixed, 95% CI)    1.37 \[0.84, 2.23\]
  [18 Maternal diarrhoea](#CD001233-fig-03518){ref-type="fig"}                            1                298                   Risk Ratio (M‐H, Fixed, 95% CI)    3.38 \[1.40, 8.17\]
  [19 Postpartum haemorrhage](#CD001233-fig-03519){ref-type="fig"}                        2                466                   Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.65, 1.33\]
  [20 Serious maternal complications](#CD001233-fig-03520){ref-type="fig"}                1                350                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [21 Chorioamnionitis](#CD001233-fig-03521){ref-type="fig"}                              3                443                   Risk Ratio (M‐H, Fixed, 95% CI)    0.63 \[0.28, 1.38\]
  [22 Endometrits](#CD001233-fig-03522){ref-type="fig"}                                   2                435                   Risk Ratio (M‐H, Fixed, 95% CI)    0.41 \[0.08, 2.08\]
  [23 Fetal distress](#CD001233-fig-03523){ref-type="fig"}                                4                784                   Risk Ratio (M‐H, Fixed, 95% CI)    0.78 \[0.53, 1.14\]

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-035-01){#CD001233-fig-03501}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-035-02){#CD001233-fig-03502}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 3 Caesarean section.](nCD001233-CMP-035-03){#CD001233-fig-03503}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-035-04){#CD001233-fig-03504}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 5 Serious maternal morbidity or death.](nCD001233-CMP-035-05){#CD001233-fig-03505}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Cervix unfavourable/unchanged after 12 hours.](nCD001233-CMP-035-06){#CD001233-fig-03506}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Oxytocin augmentation.](nCD001233-CMP-035-07){#CD001233-fig-03507}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 8 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-035-08){#CD001233-fig-03508}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine rupture.](nCD001233-CMP-035-09){#CD001233-fig-03509}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia.](nCD001233-CMP-035-10){#CD001233-fig-03510}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Instrumental vaginal delivery.](nCD001233-CMP-035-11){#CD001233-fig-03511}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium‐stained liquor.](nCD001233-CMP-035-12){#CD001233-fig-03512}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 13 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-035-13){#CD001233-fig-03513}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission.](nCD001233-CMP-035-14){#CD001233-fig-03514}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death.](nCD001233-CMP-035-15){#CD001233-fig-03515}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects.](nCD001233-CMP-035-16){#CD001233-fig-03516}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea.](nCD001233-CMP-035-17){#CD001233-fig-03517}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea.](nCD001233-CMP-035-18){#CD001233-fig-03518}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage.](nCD001233-CMP-035-19){#CD001233-fig-03519}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications.](nCD001233-CMP-035-20){#CD001233-fig-03520}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis.](nCD001233-CMP-035-21){#CD001233-fig-03521}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits.](nCD001233-CMP-035-22){#CD001233-fig-03522}

![Analysis\
Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress.](nCD001233-CMP-035-23){#CD001233-fig-03523}

###### Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03601){ref-type="fig"}   1                53                    Risk Ratio (M‐H, Fixed, 95% CI)   0.83 \[0.23, 2.96\]
  [2 Caesarean section](#CD001233-fig-03602){ref-type="fig"}                           1                53                    Risk Ratio (M‐H, Fixed, 95% CI)   0.62 \[0.15, 2.51\]

![Analysis\
Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-036-01){#CD001233-fig-03601}

![Analysis\
Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 2 Caesarean section.](nCD001233-CMP-036-02){#CD001233-fig-03602}

###### Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae

  Outcome or subgroup title                                                            No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03701){ref-type="fig"}   1                265                   Risk Ratio (M‐H, Fixed, 95% CI)   0.37 \[0.21, 0.63\]
  [2 Caesarean section](#CD001233-fig-03702){ref-type="fig"}                           1                265                   Risk Ratio (M‐H, Fixed, 95% CI)   0.35 \[0.18, 0.68\]

![Analysis\
Comparison 37 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-037-01){#CD001233-fig-03701}

![Analysis\
Comparison 37 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae, Outcome 2 Caesarean section.](nCD001233-CMP-037-02){#CD001233-fig-03702}

###### Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified)

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Uterine hyperstimulation with FHR changes](#CD001233-fig-03801){ref-type="fig"}      1                151                   Risk Ratio (M‐H, Fixed, 95% CI)    1.48 \[0.55, 3.95\]
  [2 Caesarean section](#CD001233-fig-03802){ref-type="fig"}                              4                713                   Risk Ratio (M‐H, Fixed, 95% CI)    0.93 \[0.72, 1.20\]
  [3 Serious maternal morbidity or death](#CD001233-fig-03803){ref-type="fig"}            1                200                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [4 Oxytocin augmentation](#CD001233-fig-03804){ref-type="fig"}                          1                200                   Risk Ratio (M‐H, Fixed, 95% CI)    2.48 \[1.95, 3.15\]
  [5 Uterine hyperstimulation without FHR changes](#CD001233-fig-03805){ref-type="fig"}   1                151                   Risk Ratio (M‐H, Fixed, 95% CI)    2.19 \[1.39, 3.46\]
  [6 Instrumental vaginal delivery](#CD001233-fig-03806){ref-type="fig"}                  1                41                    Risk Ratio (M‐H, Fixed, 95% CI)    0.35 \[0.08, 1.58\]
  [7 Meconium‐stained liquor](#CD001233-fig-03807){ref-type="fig"}                        1                151                   Risk Ratio (M‐H, Fixed, 95% CI)    1.13 \[0.43, 2.95\]
  [8 Apgar score \< 7 at 5 minutes](#CD001233-fig-03808){ref-type="fig"}                  1                151                   Risk Ratio (M‐H, Fixed, 95% CI)    2.96 \[0.12, 71.55\]
  [9 Neonatal intensive care unit admission](#CD001233-fig-03809){ref-type="fig"}         1                151                   Risk Ratio (M‐H, Fixed, 95% CI)    0.85 \[0.30, 2.40\]
  [10 Postpartum haemorrhage](#CD001233-fig-03810){ref-type="fig"}                        1                151                   Risk Ratio (M‐H, Fixed, 95% CI)    0.14 \[0.01, 2.68\]
  [11 Endometritis](#CD001233-fig-03811){ref-type="fig"}                                  1                41                    Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [12 Fetal distress](#CD001233-fig-03812){ref-type="fig"}                                3                498                   Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.61, 1.56\]

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 1 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-038-01){#CD001233-fig-03801}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 2 Caesarean section.](nCD001233-CMP-038-02){#CD001233-fig-03802}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 3 Serious maternal morbidity or death.](nCD001233-CMP-038-03){#CD001233-fig-03803}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 4 Oxytocin augmentation.](nCD001233-CMP-038-04){#CD001233-fig-03804}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 5 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-038-05){#CD001233-fig-03805}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 6 Instrumental vaginal delivery.](nCD001233-CMP-038-06){#CD001233-fig-03806}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 7 Meconium‐stained liquor.](nCD001233-CMP-038-07){#CD001233-fig-03807}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 8 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-038-08){#CD001233-fig-03808}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 9 Neonatal intensive care unit admission.](nCD001233-CMP-038-09){#CD001233-fig-03809}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 10 Postpartum haemorrhage.](nCD001233-CMP-038-10){#CD001233-fig-03810}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 11 Endometritis.](nCD001233-CMP-038-11){#CD001233-fig-03811}

![Analysis\
Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre‐specified), Outcome 12 Fetal distress.](nCD001233-CMP-038-12){#CD001233-fig-03812}

###### Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified)

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-03901){ref-type="fig"}      2                362                   Risk Ratio (M‐H, Fixed, 95% CI)    0.48 \[0.37, 0.63\]
  [2 Uterine hyperstimulation with FHR changes](#CD001233-fig-03902){ref-type="fig"}      3                1463                  Risk Ratio (M‐H, Fixed, 95% CI)    0.43 \[0.17, 1.11\]
  [3 Caesarean section](#CD001233-fig-03903){ref-type="fig"}                              5                1779                  Risk Ratio (M‐H, Fixed, 95% CI)    0.95 \[0.80, 1.12\]
  [4 Serious neonatal morbidity/perinatal death](#CD001233-fig-03904){ref-type="fig"}     2                1263                  Risk Ratio (M‐H, Fixed, 95% CI)    0.82 \[0.18, 3.65\]
  [5 Oxytocin augmentation](#CD001233-fig-03905){ref-type="fig"}                          2                336                   Risk Ratio (M‐H, Random, 95% CI)   3.89 \[0.70, 21.72\]
  [6 Uterine hyperstimulation without FHR changes](#CD001233-fig-03906){ref-type="fig"}   3                498                   Risk Ratio (M‐H, Fixed, 95% CI)    0.52 \[0.30, 0.92\]
  [7 Epidural analgesia](#CD001233-fig-03907){ref-type="fig"}                             1                162                   Risk Ratio (M‐H, Fixed, 95% CI)    1.07 \[0.90, 1.27\]
  [8 Meconium‐stained liquor](#CD001233-fig-03908){ref-type="fig"}                        2                362                   Risk Ratio (M‐H, Fixed, 95% CI)    0.72 \[0.43, 1.19\]
  [9 Apgar score \< 7 at 5 minutes](#CD001233-fig-03909){ref-type="fig"}                  1                162                   Risk Ratio (M‐H, Fixed, 95% CI)    0.95 \[0.20, 4.58\]
  [10 Neonatal intensive care unit admission](#CD001233-fig-03910){ref-type="fig"}        4                1599                  Risk Ratio (M‐H, Fixed, 95% CI)    0.66 \[0.49, 0.90\]
  [11 Perinatal death](#CD001233-fig-03911){ref-type="fig"}                               2                1263                  Risk Ratio (M‐H, Fixed, 95% CI)    0.82 \[0.18, 3.65\]
  [12 Women not satisfied](#CD001233-fig-03912){ref-type="fig"}                           1                866                   Risk Ratio (M‐H, Fixed, 95% CI)    1.68 \[1.47, 1.93\]
  [13 Maternal fever](#CD001233-fig-03913){ref-type="fig"}                                2                298                   Risk Ratio (M‐H, Fixed, 95% CI)    0.13 \[0.04, 0.50\]
  [14 Chorioamnionitis](#CD001233-fig-03914){ref-type="fig"}                              1                200                   Risk Ratio (M‐H, Fixed, 95% CI)    0.65 \[0.32, 1.31\]
  [15 Fetal distress](#CD001233-fig-03915){ref-type="fig"}                                2                362                   Risk Ratio (M‐H, Fixed, 95% CI)    0.55 \[0.25, 1.21\]

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-039-01){#CD001233-fig-03901}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 2 Uterine hyperstimulation with FHR changes.](nCD001233-CMP-039-02){#CD001233-fig-03902}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 3 Caesarean section.](nCD001233-CMP-039-03){#CD001233-fig-03903}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 4 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-039-04){#CD001233-fig-03904}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 5 Oxytocin augmentation.](nCD001233-CMP-039-05){#CD001233-fig-03905}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 6 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-039-06){#CD001233-fig-03906}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 7 Epidural analgesia.](nCD001233-CMP-039-07){#CD001233-fig-03907}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 8 Meconium‐stained liquor.](nCD001233-CMP-039-08){#CD001233-fig-03908}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 9 Apgar score \< 7 at 5 minutes.](nCD001233-CMP-039-09){#CD001233-fig-03909}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 10 Neonatal intensive care unit admission.](nCD001233-CMP-039-10){#CD001233-fig-03910}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 11 Perinatal death.](nCD001233-CMP-039-11){#CD001233-fig-03911}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 12 Women not satisfied.](nCD001233-CMP-039-12){#CD001233-fig-03912}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 13 Maternal fever.](nCD001233-CMP-039-13){#CD001233-fig-03913}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 14 Chorioamnionitis.](nCD001233-CMP-039-14){#CD001233-fig-03914}

![Analysis\
Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre‐specified), Outcome 15 Fetal distress.](nCD001233-CMP-039-15){#CD001233-fig-03915}

###### Any mechanical method and oxytocin versus low dose misoprostol alone: all multiparae

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Caesarean section](#CD001233-fig-04001){ref-type="fig"}   1                136                   Risk Ratio (M‐H, Fixed, 95% CI)   0.45 \[0.19, 1.11\]

![Analysis\
Comparison 40 Any mechanical method and oxytocin versus low dose misoprostol alone: all multiparae, Outcome 1 Caesarean section.](nCD001233-CMP-040-01){#CD001233-fig-04001}

###### Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified)

  Outcome or subgroup title                                                               No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Vaginal delivery not achieved in 24 hours](#CD001233-fig-04101){ref-type="fig"}      2                321                   Risk Ratio (M‐H, Random, 95% CI)   0.71 \[0.21, 2.40\]
  [2 Caesarean section](#CD001233-fig-04102){ref-type="fig"}                              6                718                   Risk Ratio (M‐H, Random, 95% CI)   0.68 \[0.39, 1.20\]
  [3 Serious neonatal morbidity/perinatal death](#CD001233-fig-04103){ref-type="fig"}     2                321                   Risk Ratio (M‐H, Fixed, 95% CI)    0.71 \[0.12, 4.13\]
  [4 Serious maternal morbidity or death](#CD001233-fig-04104){ref-type="fig"}            2                321                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [5 Uterine hyperstimulation without FHR changes](#CD001233-fig-04105){ref-type="fig"}   2                199                   Risk Ratio (M‐H, Fixed, 95% CI)    0.85 \[0.34, 2.09\]
  [6 Uterine rupture](#CD001233-fig-04106){ref-type="fig"}                                1                120                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [7 Epidural analgesia](#CD001233-fig-04107){ref-type="fig"}                             1                127                   Risk Ratio (M‐H, Fixed, 95% CI)    1.03 \[0.98, 1.09\]
  [8 Instrumental vaginal delivery](#CD001233-fig-04108){ref-type="fig"}                  3                293                   Risk Ratio (M‐H, Fixed, 95% CI)    0.99 \[0.48, 2.02\]
  [9 Meconium‐stained liquor](#CD001233-fig-04109){ref-type="fig"}                        3                319                   Risk Ratio (M‐H, Fixed, 95% CI)    0.72 \[0.32, 1.63\]
  [10 Neonatal intensive care unit admission](#CD001233-fig-04110){ref-type="fig"}        3                400                   Risk Ratio (M‐H, Fixed, 95% CI)    0.98 \[0.61, 1.58\]
  [11 Postpartum haemorrhage](#CD001233-fig-04111){ref-type="fig"}                        3                319                   Risk Ratio (M‐H, Fixed, 95% CI)    1.18 \[0.44, 3.18\]
  [12 Serious maternal complications](#CD001233-fig-04112){ref-type="fig"}                1                201                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  [13 Antibiotics during labour](#CD001233-fig-04113){ref-type="fig"}                     1                201                   Risk Ratio (M‐H, Fixed, 95% CI)    2.32 \[0.82, 6.55\]
  [14 Chorionamnionitis](#CD001233-fig-04114){ref-type="fig"}                             2                328                   Risk Ratio (M‐H, Random, 95% CI)   4.34 \[0.55, 34.01\]
  [15 Endometritis](#CD001233-fig-04115){ref-type="fig"}                                  3                374                   Risk Ratio (M‐H, Fixed, 95% CI)    1.08 \[0.16, 7.45\]
  [16 Fetal distress](#CD001233-fig-04116){ref-type="fig"}                                3                400                   Risk Ratio (M‐H, Fixed, 95% CI)    1.37 \[0.68, 2.77\]

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 1 Vaginal delivery not achieved in 24 hours.](nCD001233-CMP-041-01){#CD001233-fig-04101}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 2 Caesarean section.](nCD001233-CMP-041-02){#CD001233-fig-04102}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 3 Serious neonatal morbidity/perinatal death.](nCD001233-CMP-041-03){#CD001233-fig-04103}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 4 Serious maternal morbidity or death.](nCD001233-CMP-041-04){#CD001233-fig-04104}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 5 Uterine hyperstimulation without FHR changes.](nCD001233-CMP-041-05){#CD001233-fig-04105}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 6 Uterine rupture.](nCD001233-CMP-041-06){#CD001233-fig-04106}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 7 Epidural analgesia.](nCD001233-CMP-041-07){#CD001233-fig-04107}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 8 Instrumental vaginal delivery.](nCD001233-CMP-041-08){#CD001233-fig-04108}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 9 Meconium‐stained liquor.](nCD001233-CMP-041-09){#CD001233-fig-04109}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 10 Neonatal intensive care unit admission.](nCD001233-CMP-041-10){#CD001233-fig-04110}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 11 Postpartum haemorrhage.](nCD001233-CMP-041-11){#CD001233-fig-04111}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 12 Serious maternal complications.](nCD001233-CMP-041-12){#CD001233-fig-04112}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 13 Antibiotics during labour.](nCD001233-CMP-041-13){#CD001233-fig-04113}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 14 Chorionamnionitis.](nCD001233-CMP-041-14){#CD001233-fig-04114}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 15 Endometritis.](nCD001233-CMP-041-15){#CD001233-fig-04115}

![Analysis\
Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre‐specified), Outcome 16 Fetal distress.](nCD001233-CMP-041-16){#CD001233-fig-04116}

Characteristics of included studies \[ordered by study ID\] {#CD001233-sec2-0019}
===========================================================

[Aduloju 2016](#CD001233-bbs2-0001){ref-type="ref-list"}MethodsRCTParticipantsInclusion: life singleton pregnancy, cephalic presentation, intact membranes, \> 37 weeks, indication for IOL, reactive non stress test. unfavourable cervix (BS \< 6)\
Exclusion: IFD, no prenatal care in study centre, contraindication for vaginal deliveryInterventionsA: Foley catheter: 16F, 30 mL (n = 70), max 12 hours, if necessary another Foley for 12 hours (n = 70)\
B: Foley catheter (16F, 30 cc) + vaginal misoprostol 25 ug every 6 hours(n = 70), max dose 100 ug (4 gifts) (n = 70)\
C: Vaginal misoprostol alone 25 ug every 6 hours (n = 70) max dose 100 ug (4 gifts) (n = 70)\
Max induction time all groups: 24 hoursOutcomesVaginal delivery rate, time interval to achieve favourable cervix, induction delivery interval, oxytocin use, AS at 1 and 5 minutes, asphyxia, NICU admission, uterine tachysystole, uterine hypertonus, hyperstimulation, uterine rupture, FHR abnormalitiesNotesSetting: Ekiti State University Teaching tertiary healthcare institution; referral centre for primary and secondary healthcare facilities, 2400 deliveries annually, Nigeria\
Study period: 1 September, 2014 and 31 August, 2015.\
Funding: no grant or fund was received\
Declaration of interest: no conflict of interest***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlocked randomisation using random table computer‐generated numbersAllocation concealment (selection bias)Low riskSealed opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentionedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not mentioned, but is probably the case looking at Figure 1. no missing data or cases.Selective reporting (reporting bias)Low riskAll pre‐specified outcome measures were reported,Other biasLow riskNo other bias detected[Ahmed 2016](#CD001233-bbs2-0002){ref-type="ref-list"}MethodsRCTParticipantsInclusion: postdate pregnancy (\> 40 weeks) singleton gestation, intact membranes, cephalic fetal BS ≤ 4\
Exclusion: previous caesarean deliveries, EFW \> 4000 g, non‐reassuring fetal conditions, ruptured membranes, placenta previa, malpresentationInterventionsFoley catheter (n = 39), 18 F, filled with 50 mL\
Cook balloon (n = 39), filled with 80/80 mL\
Max of 12 hours of primingOutcomesCervical ripening and BS after 12 hours, VAS for catheter insertion, catheter insertion (easy, moderate or difficult), VAS for patient satisfaction after birth, insertion expulsion time, insertion amniotomy time, insertion delivery time and mode of delivery. Abnormal fetal presentation, cord prolapse, bleeding related to catheter insertion that required removal of the catheter and ASNotesSetting: Gynaecology, Suez Canal University  Hospital, Egypt\
Study period: March 2013 to April 2014\
Funding: not mentioned\
Declaration of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskShuffling 78 envelopes, 1:1Allocation concealment (selection bias)Low riskSealed envelopes, opaque?Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot describedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not mentioned, 2 women excluded because of failed placement. no missing data mentionedSelective reporting (reporting bias)High riskPre‐specified outcomes bleeding after insertion, cord prolapse and abnormal fetal presentation not described in resultsOther biasLow riskNo other bias detected[Al‐Ibraheemi 2018](#CD001233-bbs2-0003){ref-type="ref-list"}MethodsRCTParticipantsInclusion: \> 37 weeks, singleton fetus, cephalic, BS ≤ 6\
Exclusion: rupture of membranes, regular uterine contractions (3 or more contractions per 10 minutes), prior uterine surgery, multiple gestations, malpresentation, contraindication to PGs, non‐reassuring FHR tracing, vaginal bleeding, fetal demise, anomalous fetus, or any contraindication to vaginal deliveryInterventionsFoley catheter + misoprostol: (n = 100) 30 mL balloon, filled with 60 mL, gentle traction, max 24 hours and misoprostol vaginal 4‐hourly with a max of 6 doses,\
Misoprostol (n = 100) 25 ug vaginally, 4‐hourly with a max of 6 dosesOutcomesTime from placement of the first misoprostol dose to delivery, time to active phase (6 cm or greater), time from active phase to delivery, caesarean delivery rate, uterine tachysystole, estimated blood loss, chorioamnionitis, cord blood pH, 5‐minute AS, NICU admission.NotesSetting: from the Department of Obstetrics and Gynecology, Mount Sinai West Hospital, New York\
Study period: September 2015 to July 2016\
Funding: not described\
Declaration of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequenceAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT analysis, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Al‐Taani 2004](#CD001233-bbs2-0005){ref-type="ref-list"}MethodsRandomised trial, random number table, blinding unclear.ParticipantsGrand multiparous women, BS 5 or less, singleton term pregnancy, intact membranes, cephalic presentation, good fetal condition.\
Exclusion: previous CS, contraindications for vaginal birth, suspected cephalopelvic disproportion, unexplained antenatal haemorrhage.InterventionsFoley catheter 50 mL (72).\
(PGE2) tablet 3 mg (75), 6‐hourly.OutcomesRoute of delivery, change in BS, intrapartum complications, need for augmentation.NotesSetting: Queen Alia military hospital, Amman, Jordan\
Dates of study:September 2001 ‐ August 2003\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Unclear riskNo information provided.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot describedIncomplete outcome data (attrition bias)   All outcomesLow riskITT nor reported, bu seems reasonable as the numbers in both groups are equal to randomised numbers. missing outcome data mentioned.Selective reporting (reporting bias)Low riskAll primary and secondary outcomes are reported as pre‐specified.Other biasLow riskNo other bias detected[Allouche 1993](#CD001233-bbs2-0004){ref-type="ref-list"}MethodsRCT. No details were given on the method for concealment of the allocation.ParticipantsBS \< 6, vertex, singleton, no previous CS.InterventionsPGE2 (Prepidil 0.5 mg) intracervical (59 women);  Foley 50 mL (60 women);  PGE2 (Prepidil 0.5 mg) and Foley 50 mL extra‐amniotic (63 women).OutcomesUterine hyperstimulation, discomfort during the procedure, maternal and neonatal infection.NotesSetting: not reported\
Dates of study:between April and December 1992\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly stated women were randomly allocatedAllocation concealment (selection bias)Unclear riskUnclearBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, no missing data or cases reportedSelective reporting (reporting bias)Unclear riskNo outcomes pre‐specifiedOther biasLow riskNo other bias detected[Amorosa 2017](#CD001233-bbs2-0006){ref-type="ref-list"}MethodsRCTParticipantsInclusion: PROM, age ≥ 18 years, viable fetus, cephalic, singleton, GA \> 34 weeks, \< 3 cm dilation\
Exclusion: multifetal gestation, a known anomalous fetus, malpresentation, latex allergy, unexplained vaginal bleeding or contraindication to vaginal delivery (such as a placenta previa), antibiotics, previous uterine surgery, spontaneous labourInterventionsFoley catheter (n = 61) 16F, 30 mL balloon filled with 60 mL saline, traction applied (no max time described), oxytocin started after 1 hour\
Oxytocin alone directly (n = 68)\
Oxytocin in both groups, started 2 mU/minute, max 30 mU/minuteOutcomesThe primary outcome measure was time from start of induction to delivery. Secondary outcomes included mode of delivery, tachysystole, chorioamnionitis, postpartum haemorrhage, neonatal AS, and admission to the NICU.NotesSetting: Mount Sinai Hospital, New York, USA\
Study period: August 2014 to September 2016\
Funding: not reported\
Declaration of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numbersAllocation concealment (selection bias)Low riskSequential numbered sealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskModified ITT, (1 woman excluded who afterwards did not met the inclusion criteria), no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcome measures were reported in resultsOther biasLow riskNo other bias detected[Atad 1996](#CD001233-bbs2-0007){ref-type="ref-list"}MethodsRCT. Computer‐generated sequence. No details were given on the method for concealment of the allocation.ParticipantsSingleton vertex term pregnancies with intact membranes, BS \< 5 without previous CS.InterventionsAtad ripening device (35 women);  PGE2 intravaginal tablets 3 mg (30 women); oxytocin (30 women).OutcomesNeed for another method, CS, change in BS.NotesAlso reported as abstract ([Abramovici 1994](#CD001233-bbs2-0312){ref-type="ref-list"}).\
Setting: Israel\
Study period: not reported\
Funding: not reported\
Declarations of interest: J Atad has a patent licensing arrangement for Atad ripening device and thus has the potential gain from its sales***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer random‐generated allocation listAllocation concealment (selection bias)Unclear riskUnclearBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskNo ITT reported, but seems reasonable as numbers in tables are equal to randomised numbers, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Bagratee 1990](#CD001233-bbs2-0008){ref-type="ref-list"}MethodsRCT. Random number tables, stratified for parity. No details were given on the method for concealment of the allocation.ParticipantsWomen with unfavourable cervix (BS \< 7).InterventionsLamicel (40 women);  (PGE2) (2 mg tablet) (40 women).  After 6 hours, oxytocin was started in both groups.OutcomesCS, hyperstimulation, fetal distress, perinatal death.NotesNo outcome reported in subgroups.\
setting: king Edward VIII hospital, Durban, South Africa\
Study period: for 6 months, no exact dates reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number tablesAllocation concealment (selection bias)Unclear riskUnclear, not reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskNo ITT mentioned, in table 4 cases missing, not clear why.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Barda 2018](#CD001233-bbs2-0009){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: GA ≥ 37 weeks, parity 1 to 3, singleton pregnancy with a vertex presentation, BS less than 5) and intact membranes.\
Exclusion criteria: previous CS, lack of prenatal care, contraindication for vaginal deliveryInterventionsFoley catheter (n = 150): 22 F, 80 mL balloon (max 18 hours)\
Dinoproston (n = 150): 3 mg tablets (every 8 hours, max 2 gifts)OutcomesStart induction to active labour (4 cm dilatation and 80% effacement), labour within 24 hours, CS rate, excessive haemorrhage, chorioamnionitis, non‐reassuring FHR, fetal pH, NICU admission, early neonatal sepsisNotesSetting: Edith Wolfson Medical Centre, Holon, Israel\
Study period: June 2015 ‐ July 2016\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandom assigned; not described how this was done. In trial registration =\> parallel assignment.Allocation concealment (selection bias)Unclear riskRandom assigned; not described how this was done. In trial registration =\> parallel assignment.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT, no tables available, so incomplete data can not be judged, no missing data describedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasUnclear riskFull text is an accepted manuscript without tables, therefore risk of bias cannot properly be determined[Benzineb 1996](#CD001233-bbs2-0010){ref-type="ref-list"}MethodsRCT. Blocks of 10 women. No other details were given on the method for randomisation and on concealment of the allocation.ParticipantsSingleton vertex term pregnancies with intact membranes, BS \< 6.InterventionsFoley catheter inflated with 40 mL of water (50 women); PGE2 intracervical gel 0.5 mg every 24 hours. (n = 50?)OutcomesVaginal delivery not achieved within 24 hours, CS, perinatal deaths, cervix unchanged after 24 hours, postpartum haemorrhage.NotesSetting: Charles Nicolle Hospital, Tunis\
Dates of study: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were random allocated in blocks of 10Allocation concealment (selection bias)Unclear riskUnclear. not reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, no missing data or cases reportedSelective reporting (reporting bias)Unclear riskOutcomes not pre‐specifiedOther biasLow riskNo other bias detected[Biron‐Shental 2004](#CD001233-bbs2-0011){ref-type="ref-list"}MethodsRandomised trial.ParticipantsTerm, singleton pregnancy BS 4 or less, medical indication for labour induction.InterventionsPGE 2 gel 2 mg (27).\
Double balloon catheter (26)\
combined (24)OutcomesChange in BS, need for oxytocin augmentation.NotesOutcomes of interest not reported.\
Setting: Israel\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot describedIncomplete outcome data (attrition bias)   All outcomesUnclear riskBrief communication, for the reported data no missing. Incomplete outcome data not further mentioned in this report.Selective reporting (reporting bias)Unclear riskOur outcomes of interest are not reported here, main outcome is change in BS.Other biasUnclear riskHard to say, very short report, our outcomes of interest not mentioned, not clear how sample size was calculated.[Blumenthal 1990](#CD001233-bbs2-0012){ref-type="ref-list"}MethodsRCT. Randomisation by drawing a blank envelope from a stack of 50 identical envelopes containing the group allocation.ParticipantsVertex, intact membranes, BS \< 5, no previous CS.InterventionsDilapan (polyacrilonitrile hydrogel) inserted in the cervix, up to 6 sticks (23 women); Laminaria inserted in the cervix, as many as possible (18 women).OutcomesCS.NotesResults for a 3rd group of women with favourable cervix treated with oxytocin are presented. These women are not be included in the analysis, as they were not randomly allocated to the intervention.\
Setting: Michael Reese hospital, Chicago, USA\
Study period:January 1987 to January 1988\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskShuffling envelopesAllocation concealment (selection bias)Low riskWomen choose from stack of all blank, identical envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not reported. no explanation what happened to the rest of the randomised womenSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Browne 2011](#CD001233-bbs2-0013){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: single, live fetus, cephalic, presentation,reassuring fetal health assessment, GA between 26 and 42 weeks, Maternal age 18 and above, BS less than 5\
Exclusion criteria: multiple gestation (twins, triplets, quadruplets), fetal demise\
Fetal malpresentation, EFW less than 500 g or more than 4000 g, placenta previa, non‐reassuring fetal health assessment\
Maternal asthma, Latex allergy, spontaneous labour, other contraindication to vaginal deliveryInterventionsBalloon: (n = 34): 40 mL, under traction, max 6 hours.\
PGE2 vaginal (36): prepidil gel in fornix posterior, no oxytocin in 6 hours after gel is applied\
balloon and PGE2 (31): 40 mL, under traction. prepidil gel inserted through catheter.OutcomesCSNotesGrey literature: not published. primary outcomes reported in trial registration\
Setting: USA\
Study period: July 2010 ‐ February 2013\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomisation envelopes prepared by statisticians at the University of South Carolina Arnold School of Public Health. The investigator was given the next sequentially‐numbered study envelope by the patient\'s nurse.Allocation concealment (selection bias)Low riskSealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not reported. case missing for relevant outcome (CS)Selective reporting (reporting bias)High riskOnly primary outcome en adverse events reportedOther biasUnclear riskStudy not published, not clear why.[Carbone 2013](#CD001233-bbs2-0014){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singleton, viable gestation (≥ 24 weeks), cephalic, intact membranes, BS \< 7\
Exclusion: malpresentation, multifetal gestation, spontaneous labour, contraindication to PGs, fetal growth restriction, anomalous fetus, fetal demise, previous CS, or other uterine surgery.InterventionsFoley + misoprostol (n = 56): 25 mcg vaginal misoprostol every 4 hours AND Foley catheter filled with 60 mL saline; taped to the inner thigh under gentle traction.\
misoprostol alone (n = 61): 25 mcg vaginal misoprostol every 4 hours\
Not mentioned for how long misoprostol and/or Foley was given in total.OutcomesInduction to delivery time, mode of delivery, tachysystole, postpartum haemorrhage (\> 500 cc), chorioamnionitis, neonatal AS and NICU admission.NotesSetting: USA\
Study period: January 2011 to April 2012\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequenceAllocation concealment (selection bias)Low riskOpaque envelopes, not stated if these were sequential numberedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Casey 1995](#CD001233-bbs2-0015){ref-type="ref-list"}MethodsRCT. No details were given on the method for concealment of the allocation.ParticipantsSingleton term pregnancies, BS \< 6.InterventionsPGE2 intracervical gel and intracervical Foley catheter inflated with 50 cc (78 women);  PGE2 intracervical gel (68 women).OutcomesCS.NotesAbstract only.\
Setting: USA\
Study period: not reported, 11‐month period\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported it was a RCTAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskToo little information to judgeSelective reporting (reporting bias)Unclear riskToo little information to judgeOther biasUnclear riskAbstract only[Chavakula 2015](#CD001233-bbs2-0016){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singleton, cephalic, fetal growth restriction, ≥ 34 weeks.\
Exclusion: previous caesarean deliveries, uterine surgery, a multiple pregnancy, ruptured membranes, a BS \> 6, severe fetal growth restriction, abnormal FHR prior to induction, pre‐partum haemorrhage.Interventions1. Foley catheter (n = 54) 16F, 30 mL, catheter was removed after 12 hours.\
2. Vaginal misoprostol (n = 46) every 6 hours, 25 mcg, max 3 dosesOutcomesHyperstimulation with FHR changes, BS at AROM, duration of induction to delivery, vaginal delivery within 12 hours and 24 hours, CS, oxytocin, chorioamnionitis, antibiotics, NICU admission, AS \< 7 at 5 minutes, patients and caregiver satisfaction (VAS score)NotesSetting: tertiary care teaching hospital in South India with approximately 13,000 deliveries per year.\
Study period:December 2011 to June 2012.\
Funding: not stated\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence, block randomisationAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias)   All outcomesLow riskITT analysis, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Chua 1997](#CD001233-bbs2-0017){ref-type="ref-list"}MethodsRCT. Random number table, no details on the method of concealment of the allocation.ParticipantsSingleton vertex presentation, unfavourable cervix (BS \< 6).  185 women recruited (90 in Dilapan group, 95 in PGE2 group).InterventionsDilapan group: 4 dilators.  PGE2 Gel (Prepidil): 0.5 mg.  In both groups, ripening was followed by rupture of membranes and oxytocin after 12 hours.OutcomesNeed for oxytocin, CS, instrumental delivery, uterine rupture, uterine hyperstimulation, admission to NICU, perinatal death.NotesSetting: National University hospital, Singapore\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number tableAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not mentioned but seems reasonable as numbers in tables are equal to randomised numbers, no reporting of missing cases or outcomesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Cromi 2011](#CD001233-bbs2-0018){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singleton gestation, vertex presentation, BS ≤ 6, intact membranes, GA ≥ 34 weeks, reassuring FHR tracing\
Exclusion: Women with antepartum bleeding, intrauterine fetal death, previous uterine scars, known allergy to latex, placenta previa, contraindication to vaginal deliveryInterventions24‐hour Foley (n = 133): 18F, 50cc, 24 hours\
12‐hour Foley (n = 132): 18F, 50cc, 12 hours\
PGE2 vaginal insert 10 mg (n = 132): vaginal fornix, 24 hoursOutcomesvaginal delivery within 24 hours, improvement in BS after ripening, caesarean delivery, ripening‐to‐delivery interval, oxytocin administration, epidural request, neonatal outcomes.NotesSetting:Obstetrics Department of University of Insubria, Varese, Italy.\
Study period: July 2008 to June 2010\
Funding: none reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated block randomisationAllocation concealment (selection bias)Unclear riskAllocation not reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing data or cases.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Cromi 2012](#CD001233-bbs2-0019){ref-type="ref-list"}MethodsRCTParticipants210 patients.  Inclusion: singleton gestation, vertex presentation, BS *≤* 6, intact membranes, GA \> 34 weeks, and reassuring fetal heart tracing on admission.  Exclusion:antepartum bleeding, intrauterine fetal death, prior uterine scars, positive vaginal or rectal group B streptococcus screening cultures, placenta previa, other contraindication to vaginal delivery.InterventionsDouble‐balloon catheter (n = 105): inflated with 50 mL in either balloon. The double‐balloon device was left in place for approximately 12 hours.  Dinoprostone vaginal insert 10‐mg controlled‐release (n = 105): in the vaginal fornix, max 24 hoursOutcomesVaginal delivery within 24 hours, improvement in the BS after ripening, caesarean delivery rates, ripening‐to‐delivery interval, oxytocin administration, epidural request, NICU admission, AS \< 7 at 5 minutes, umbilical artery pH \< 7.00.NotesSetting: University of In‐subria, Varese, Italy\
Study period: October 2010 to October 2011\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomisation schemeAllocation concealment (selection bias)Low riskConcealment by keeping random allocation sequence in a file cabinet with access restricted to research staff?Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskNot an ITT analysis, women excluded after failed placement balloon or need for PGE2 gel after suppository expulsion.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultOther biasLow riskNo other bias detected[Culver 2004](#CD001233-bbs2-0020){ref-type="ref-list"}MethodsRCT, computer‐generated block randomisation 4 and 6, consecutively numbered envelopes.ParticipantsNulliparous women GA 28 or more weeks, BS \< 6, intact membranes, singleton, cephalic presentation,\
Exclusion: previous uterine surgery, non‐reassuring FHR, latex allergy, contraindication to vaginal birth.InterventionsFoley 30 cc + concurrent oxytocin (83 patients analysed).\
Misoprostol 25 mcg intravaginally 4‐hourly, oxytocin augmentation after ripening. (79 patients analysed.)OutcomesPrimary: CS\
Secondary: tachysystole, hyperstimulation, abnormal FHR tracing, intrapartum and postpartum fever, use of antibiotics, estimated blood loss, blood transfusions, AS, neonatal resuscitation, admission to ICU, meconium aspiration, sepsis, death.NotesPower analysis showed 266 patients were to be included, 173 were randomised. Study was stopped because principle investigator moved to other hospital. 11 patients were excluded from analysis, either received other treatment, or incomplete data.\
Setting: North Caroline Women\'s hospital and WakeMed hospital, North Carolina, USA\
Study period: June 1999 to April 2001\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence.Allocation concealment (selection bias)Low riskConsecutively numbered envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot describedIncomplete outcome data (attrition bias)   All outcomesLow risk9 patients had incomplete records (4 and 5 in both groups), they were excluded.\
2 patients (1 in every group) who did not receive the treatment were excluded, but otherwise ITT.Selective reporting (reporting bias)Low riskAll pre‐specified outcome measures are reported.Other biasHigh riskRecruitment goal was not reached, because PI moved to another institution.[Dalui 2005](#CD001233-bbs2-0021){ref-type="ref-list"}MethodsRandomised prospective study, randomisation method unclear.ParticipantsSingleton live fetus in cephalic presentation, 33‐42 weeks GA, intact membranes, BS \< 4\
Exclusion: APH, scarred uterus, low‐located placenta, cervicovaginal infection, history of cardiac disease, glaucoma, convulsive disorder, asthma, jaundice.InterventionsFoley catheter 30 mL 12 hours, followed by oxytocin (n = 50).\
PGE2 gel 0.5 mg endocervically oxytocin augmentation after 12 hours (n = 50).OutcomesBischop score after 12 hours, percentage of subjects entering spontaneous labour, insertion‐expulsion interval Foley, induction‐delivery interval, amount of oxytocin used, mode of delivery, side effects.NotesNo power calculation, BS lower than most studies, no notes on method of randomisation\
Setting: Nehru Hospital, PGIMER, Chandigarh, India\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\'Randomised\' method not described.Allocation concealment (selection bias)Unclear risk\'Randomised\' method not described.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot describedIncomplete outcome data (attrition bias)   All outcomesLow riskAlthough ITT not mentioned, it seems ITT was used. no missing cases or dataSelective reporting (reporting bias)Low riskAll pre=specified data are reported, except for expulsion interval of Foley catheter (this is not an outcome of interest for this review).Other biasLow riskNo other bias detected[Deo 2012](#CD001233-bbs2-0022){ref-type="ref-list"}MethodsRCTParticipantsInclusion: full‐term singleton gestation, cephalic presentation, indication for IOL. BS \< 6.  Exclusion: rupture of membranes, antepartum bleeding, placenta praevia, previous induction or pre‐induction agent during the pregnancy.InterventionsFoley catheter (n = 50): 16 F with 30 mL balloon, traction applied. no max hours described.  Misoprostol vaginal (n = 54): 25 ug post fornix, every 4 hours max 8 doses.\
Dinoprostone vaginal gel (n = 52), 2 mg, once every 6 hours, max of 3 dosesOutcomesChange in BS, total time for induction, delivery route, uterine tachysystole (defined as 6 contractions in 10 minutes, in 2 consecutive 10 minutes periods), uterine hypertonus (contraction lasting longer than 3 minutes), subject comfort as women were asked to evaluate their discomfort on a visual scale from 0 to 10.NotesSetting: CSM Medical University (India).\
Study period: not reported, 1 year duration\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random allocation numbersAllocation concealment (selection bias)Low riskConsecutive, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskAs treated analysis (2 or 4 exclusions? (158 cases analysed, but total of included patients makes 156)\
Primary outcome: unclear how many women in Foley were analysed, in comparison groups 4 cases missing without explanationSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Deo 2013](#CD001233-bbs2-0023){ref-type="ref-list"}MethodsRCTParticipantsInclusion: full‐term singleton gestation, cephalic presentation, indication for IOL. BS \< 6.  Exclusion: rupture of membranes, antepartum bleeding, placenta praevia, previous induction or pre‐induction agent during the pregnancy.InterventionsFoley catheter (n = 100): 16 F with 30 mL balloon, traction applied. no max hours described.\
dinoprostone vagina gel (n = 104), 2 mg, once every 6 hours, max of 3 dosesOutcomespost induction BS at 6 and 13 hours,NotesAbstract only, no outcomes of interested reported\
Setting: KGMU Lucknow India\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly described women were randomly allocated, no more information availableAllocation concealment (selection bias)Unclear riskOnly described women were randomly allocated, no more information availableBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, too little information to judgeSelective reporting (reporting bias)Unclear riskInsufficient information to judgeOther biasUnclear riskAbstract only, too little information to judge risk of bias[Deshmukh 2011](#CD001233-bbs2-0024){ref-type="ref-list"}MethodsRCTParticipantsInclusion: primigravida \> 37 weeks of gestation, singleton pregnancy, cephalic presentation BS ≤ 3, Intact membranes  Exclusion: multiple pregnancy, malpresentation, absent membranes, APH, medical disease, e.g. heart disease, renal diseaseInterventionsIntracervical Foley (n = 200): if BS \< 7 after 6 hours, PGE2 was given\
PGE2 gel vaginal (n = 200), dose repeated after 6 hours\
Failure of induction was declared if patient failed to go in active phase of labour within 24 hours of inductionOutcomesImprovement of BS, induction‐delivery interval, mode of delivery and feto‐maternal outcomesNotesSetting: India\
Study period:July 2005 to January 2008\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were randomly assignedAllocation concealment (selection bias)Unclear riskAllocation concealment not reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT. no missing cases or data. no women excludedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Dionne 2011](#CD001233-bbs2-0025){ref-type="ref-list"}MethodsRCT, stratified for parityParticipantsInclusion: indication for induction, BS \< 6InterventionsFoley catheter with oxytocin (n = 93)\
Foley catheter with intravaginal misoprostol (n = 84)\
Intravaginal misoprostol (n = 87)OutcomesDelivery within 24 hours, CS rate, maternal or fetal complicationsNotesAbstract only, no information about dosage misoprostol\
Setting: UK\
Study period: October 2001 to October 2004\
Funding: no information\
Declaration of interest: no information***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomisation not describedAllocation concealment (selection bias)Unclear riskNo informationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNo informationIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, too little information to judgeSelective reporting (reporting bias)Unclear riskPre‐specified outcome CS reported, too little information to judgeOther biasUnclear riskAbstract only, too little information to judge risk of bias[Edwards 2014c](#CD001233-bbs2-0026){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: GA \> 36 weeks, live singleton fetus in cephalic presentation, unfavourable cervix (less than 3 cm dilated; if 2 cm dilated, less than 80% effaced).\
Exclusion criteria: \< 18 years, no informed consent in English, \> 1 contraction/5 minutes, ruptured membranes, a prior caesarean delivery or any other prior uterine incision, a temperature of 38°C or higher, lethal fetal anomalies, placenta previa, other contraindication to vaginal delivery, suspected placental abruption or undiagnosed bleeding, a category II or III FHR pattern, HIV infection or any other immune dysfunction, an allergy to latex or dinoprostone, previous attempt of cervical ripening.InterventionsFoley catheter (n = 185): 16F, 30 mL, minimal tension, removed after 12 hours\
Dinoprostone vaginal insert (n = 191): removed after 12 hoursOutcomesInduction to delivery time, (vaginal) delivery within 12 hours, (vaginal) delivery within 24 hours, tachysystole, clinical chorioamnionitis, endometritis, other postpartum complications, caesarean delivery, early neonatal outcomesNotesSetting: multicentre, USA\
period: July 2010 to February 2013\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskAllocated by an online randomisation system 1 to 1Allocation concealment (selection bias)Low riskAllocation web‐basedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT analyses reported, but women who did not deliver and went home were excluded (5 to 77. Patients with missing values for arterial cord pH level. properly described how this was dealt withSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[El Khouly 2017](#CD001233-bbs2-0027){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: singleton pregnancy, cephalic presentation, GA \> 28 weeks and the BS \< 6.\
Exclusion criteria: contraindication vaginal delivery, EFW \> 4500 g, a previous uterine scar, clinically significant cervical or vaginal infection, chorioamnionitis, unexplained vaginal bleeding, low‐lying placenta, abnormal cervical anatomy or cervical cerclage.InterventionsFoley catheter (n = 36): 18F, 30 mL, max of 12 hours\
Foley catheter + oxytocin (n = 36): 18F, 30 mL balloon, oxytocin, Foley max of 12 hours)\
Oxytocin alone (n = 36): increased by 2 mU/minute at 30‐minute intervals until adequate uterine activity was maintained, max dose 32 mU/minute, AROM at 3 cmOutcomesDuration and dose of required oxytocin, induction to delivery interval, mode of delivery and reason (in case of CS), maternal and neonatal complicationsNotesSetting: Menoufia University Hospital, Egypt\
Study period: between January 2015 and February 2016.\
Funding: no funding\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequenceAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskAlthough ITT is not mentioned, figure 1 and results are plausible for ITT, all cases analysed, no missing data describedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Filho 2002](#CD001233-bbs2-0028){ref-type="ref-list"}MethodsRCT.ParticipantsTerm or post‐term, live, singleton fetus in cephalic presentation, intact membranes, BS \< 6, not in labour, medically indicated for labour induction.\
Exclusion criteria: multiple gestations, non‐cephalic presentation, previous caesarean delivery or uterine scar, rupture of membranes, antepartum bleeding, genital herpes infection, fetal death, placenta previa or previous attempts to induce labour.InterventionsMisoprostol (n = 119): 25 mcg 6‐hourly, max 4 doses.\
Foley (n = 121): 30cc traction applied 24 hours followed by oxytocin.OutcomesInduction‐to‐vaginal delivery time, deliveries within 24 hours, mode of delivery, uterine contraction abnormalities, puerperal infection or neonatal outcomes.NotesSetting: Maternidade Monteiro de Morais, Recife, Brazil\
Dates of study: between September 2000 and December 2001\
Funding sources: financial support from CAPES\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence.Allocation concealment (selection bias)Low riskConsecutively numbered sealed opaque envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot describedIncomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow up, analysis ITT.Selective reporting (reporting bias)Low riskAll pre‐specified data reported.Other biasLow riskNo other bias detected[Garba 2016](#CD001233-bbs2-0029){ref-type="ref-list"}MethodsRCTParticipantsInclusion: multiparae, postdate (41+3), singleton, unfavourable cervix\
Exclusion: not mentionedInterventionsFoley catheter + oxytocin (n = 66) (no more info available)\
Vaginal misoprostol (n = 70), (no more information availableOutcomesMode of delivery, maternal and perinatal outcomes, induction to delivery interval, AS, maternal vital signs, estimated blood loss.NotesSetting: antenatal clinic at Aminu Kano Teaching Hospital, Nigeria\
Study period: February to May, 2015\
Funding: no funding\
Declaration of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequenceAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, in table 4 there are cases missing, not reported why. no missing data reportedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasUnclear riskAll eligible patients where randomised. Inclusion rate of 100% of all eligible patients is doubtful[Gelisen 2005](#CD001233-bbs2-0030){ref-type="ref-list"}MethodsRCT, randomisation by sealed opaque envelopes, no mentioning of sequence.ParticipantsSingleton live pregnancy, GA 41 completed weeks, BS \< 5, no contractions, AFI \> 5, estimated fetal body weight \< 4500 g.\
Exclusion: known hypersensitivity to PG, previous caesarean delivery or other uterine surgery, MBI \> 30, parity \> 4, low‐lying placenta.InterventionsFoley catheter 50 mL (n = 100).\
Vaginal misoprostol 50 mcg 6‐hourly, max 24 hours (n = 100). (group excluded because of high dose)\
Oxytocin low dose protocol (n = 100).\
Spontaneous follow‐up (n = 300). (not in analyses)OutcomesCS rate, neonatal outcomes: meconium, arterial pH, acidaemia, admissions to NICU\
secondary, tachysystole, hyperstimulation, fetal distress.NotesPrimary goals of study is to compare induction versus expectant management.\
Setting: tertiary training centre in Turkey\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk600 opaque envelopes, 1 was drawn every time.Allocation concealment (selection bias)Low riskOpaque envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesLow riskBlinded assessment of fetal monitor strips. (to assess hyperstimulation).Incomplete outcome data (attrition bias)   All outcomesUnclear riskNot addressed, seems like all data complete.Selective reporting (reporting bias)Low riskAll pre‐specified outcome measures are reported.Other biasLow riskNo other bias detected[Gilson 2017](#CD001233-bbs2-0031){ref-type="ref-list"}MethodsRCTParticipantsPatients eligible for medical inductionInterventionsFoley catheter + oxytocin (n = 526)\
Low dose titrated oral misoprostol (n = 575) dose not mentioned in abstractOutcomesEffectiveness, safetyNotesAbstract only\
Setting: Rwanda\
Study period: not reported\
Funding: not reported\
Declaration of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomisation not describedAllocation concealment (selection bias)Unclear riskNo informationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNo informationIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT mentioned, not clear why groups are different in size.Selective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear riskAbstract only, to little information to judge risk of bias[Glagoleva 1999](#CD001233-bbs2-0032){ref-type="ref-list"}MethodsRCT. No details were given on the method for concealment of the allocation.ParticipantsBS \< 5. Women with a past history of CS were excluded.InterventionsDilapan (4 tents) removed after 12 hours (27 women).  PGE2 intracervical gel 0.5 mg (1‐2 doses) (26 women).OutcomesCS.NotesAbstract only\
Setting: Russia\
Dates of study: not reported\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were randomly assigned.Allocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskInsufficient information to judgeSelective reporting (reporting bias)Unclear riskInsufficient information to judgeOther biasUnclear riskAbstract only, insufficient information to judge risk of bias[Goonewardene 2014](#CD001233-bbs2-0033){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singleton pregnancy, cephalic, cervix unfavourable (MBS \< 6), 40 weeks and 6 days\
Exclusion: multiple pregnancies, malpresentation, previous CS or any contraindication for normal delivery or misoprostol, prior intervention for ripening of the cervix, non‐reactive CTG after fetal acoustic stimulation test.InterventionsOral misoprostol (n = 74) 25 ug, every 4 hours, max of 2 gifts\
Foley catheter (n = 78) max 24 hoursOutcomesModified BS ≥ 6 day 2 after the intervention; Induction to delivery interval, mode of delivery, side effects of misoprostol (only reported in trial register)NotesSetting: Academic Obstetric Unit, Teaching Hospital, Mahamodara, Galle, India\
Study period: January 2011 to March 2012\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence, block randomisation, stratified for parityAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not mentioned, no FIgure 1, cases excluded for some selective outcomes because of spontaneous labour after intervention, no missing data reported.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in results, except secondary outcome \'side effects misoprostol\' not reported.Other biasLow riskNo other bias detected[Guinn 2000](#CD001233-bbs2-0034){ref-type="ref-list"}MethodsRCT. Computer‐generated sequence. Opaque, sealed, sequentially numbered envelopes.ParticipantsSingleton, vertex presentation, intact membranes. Unfavourable cervix (\< 2 cm dilated and effacement \< 75%). Exclusion: bleeding, labour, asthma. prior vertical uterine incision, acute fetal compromiseInterventionsLaminaria and IV oxytocin: as many laminaria as possible were kept for 12 hours, unless expelled or membranes ruptured. IV oxytocin was simultaneously given (165 women);  EASI + IV oxytocin: Foley catheter balloon filled with 30 mL of water followed by saline infusion 30 mL/hour. IV oxytocin was simultaneously given (169 women);  PGE2 intracervical gel 0.5 mg/6H, max 2 doses. IV oxytocin was started if not in labour after 2 doses of PGE2 (110 women).OutcomesCS, delay to delivery, delivery within 24 hours, infections, haemorrhage.NotesAfter interim analysis, the authors stopped recruiting in the PGE2 group. 68 protocol violations, but ITT analysis was conducted.\
Setting: University of Alabama and Cooper Green Hospitals Birmingham, Alabama\
Dates of study: January 1994 to August 1997\
Funding sources: UpJohn Pharmaceuticals provided funds to purchase study drugs\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random number tableAllocation concealment (selection bias)Low riskOpaque sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITTSelective reporting (reporting bias)Unclear riskAll pre‐specified outcomes reported for laminaria and EASIOther biasUnclear riskAfter interim analysis, the authors stopped recruiting in the PGE2 group.[Gunawardena 2012](#CD001233-bbs2-0035){ref-type="ref-list"}MethodsRCTParticipantsUncomplicated primipara with singleton pregnancies who underwent IOL at 40 weeks + 5 daysInterventionsPGE2 intracervical (72)\
Foley (73)OutcomesChange in mean MBS, uterine hyper‐stimulation, Broncho‐constriction, nausea and vomiting, postpartum haemorrhage and maternal fever, meconium at membrane rupture, AS at 5 minutes and PBU admissionNotesAbstract only\
Setting: Ward 5, Teaching Hospital, Kandy, India\
Study period: not reported\
Funding: not reported\
Declaration of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, no missing data or cases reportedSelective reporting (reporting bias)Unclear riskMaternal and neonatal adverse outcomes were not given in numbersOther biasLow riskNo other bias detected[Haugland 2012](#CD001233-bbs2-0036){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singleton pregnancy, \> 37 weeks, indication to induce birth, BS \< 2 cm, term date set by US before week 21\
Exclusion: IUFD, fetal malformations, low lying placenta, rupture of membranes, no understanding of Norwegian languageInterventionsFoley catheter (n = 90), 16‐19 hours\
Cook double balloon (n = 88), 16‐19 hoursOutcomesCervix dilatation ≥ 3 cm after removal or active labourNotesAbstract only\
Setting: Haukeland university hospital, Bergen, Norway\
Study period: March 2010 ‐ January 2011\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomisation not describedAllocation concealment (selection bias)Unclear riskNo informationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskDouble‐blind, says in the protocol that participants and outcome assessor will be blind to allocated treatment, but not cliniciansBlinding of outcome assessment (detection bias)   All outcomesLow riskDouble‐blind, in the study protocol says participant and outcome assessor will be blind to allocated treatmentIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not described mentioned, to little information to judgeSelective reporting (reporting bias)Unclear riskInsufficient informationOther biasUnclear riskAbstract only, too little information to judge risk of bias[Hay 1995](#CD001233-bbs2-0037){ref-type="ref-list"}MethodsRCT. No details were given on the method for concealment of the allocation.Participants28 women in the comparison between Dilapan and PGE2, with a total of 39 women recruited (15 Dilapan group, 13 PGE2 group, 11 amniotomy).InterventionsDilapan versus PGE2, no details on dosage provided.OutcomesCS, hyperstimulation, nausea.NotesAbstract only.\
Setting: UK\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskInsufficient information to judgeSelective reporting (reporting bias)Unclear riskInsufficient information to judgeOther biasUnclear riskAbstract only[Hemlin 1998](#CD001233-bbs2-0038){ref-type="ref-list"}MethodsRCTParticipantsSingleton vertex term pregnancies, BS \< 5InterventionsEASI 30 to 60 mL/hour infusion (43 women)  PGE2 0.5 mg intracervical (42 women)OutcomesCS, instrumental delivery, painful contractions, vaginal delivery achieved within 12 to 24 h0urs.NotesSetting: County hospital of Ekinstuna, Sweden\
Study period: November 1990 to November 1995\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were randomised using sealed envelopesAllocation concealment (selection bias)Low riskSealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, women delivered by CS and women with quote: " unsuccessful" treatment were excluded for some of the outcome measures. no missing cases of missing data for outcomes of interest.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Henry 2013](#CD001233-bbs2-0039){ref-type="ref-list"}MethodsRCTParticipantsInclusion: women ≥ 18 years gestational \> 37 weeks requiring IOL with a cervical preparation procedure\
Exclusion: unsuitable for outpatient management, unsuitable for randomisation to either PGE2 (e.g. previous CS) or catheter use (e.g. latex allergy), or prior attempted IOL in this pregnancy, ruptured membranes, regular uterine contractions, multiple pregnancy or non‐vertex presentation, unable to give informed consentInterventionsFoley catheter (n = 50): 30 mL, slight traction, spigot inserted to occlude the lumen, PCM 1 g/60 mg codeine, 20 mg temazepam., went home*. N*ext morning AROM or priming by choice of clinician (n = 50)\
PG gel (n = 51): (2 mg nulliparous -- 1 mg multi parous), fornix posterior, repeated if necessary after 6 hours (1 mg), PCM 1 g/60 codeine, temazepam 20 mg, next morning AROM or priming by choice of clinicianOutcomesDelivering vaginally within 12 hours of admission to Delivery Unit; total inpatient hours from induction to delivery, syntocinon for induction or augmentation of labour, mode of delivery, vaginal delivery within 24 hours of insertion of Foley catheter or first dose PGE2 gel, Induction to delivery interval, i.e. time from commencement of cervical ripening to delivery, delivery within 24 hours of insertion of Foley catheter or first dose PGE2 gel, requirement for second method of cervical ripening or (in Prostin group) 3rd dose of PG, patient satisfaction using questionnaire created for purposes of this study, return to hospital (Foleys group) prior to planned readmission and not in labour, maternal febrile morbidity, non‐reassuring FHR trace, CS or instrumental delivery for fetal distress, Admission to newborn care, AS 1 and 5 minutes, epidural.NotesSetting: Australian metropolitan tertiary teaching hospital, Australia\
Time period: June 2009 to December 2010\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table was performed prior to trial commencement.Allocation concealment (selection bias)Low riskSealed in sequentially‐numbered, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing data reported, no missing casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in results, except secondary outcome \'epidural\' (pre specified in trial registration)Other biasLow riskNo other bias detected[Hibbard 1998](#CD001233-bbs2-0040){ref-type="ref-list"}MethodsRCT. Computer‐generated sequence. Opaque, sequentially‐numbered envelopes.ParticipantsVertex, \> 34 weeks, intact membranes, BS \< 5. Exclusion of previous CS, cervicitis, macrosomia.InterventionsPGE2 (Prepidil) gel (17 women); PGE2 (Prepidil) and Dilapan (22 women).OutcomesCS, instrumental delivery, painful contractions, vaginal delivery not achieved in 24 hours, uterine hyperstimulation, infection.NotesSetting: University of Chicago, USA\
Study period: August 1994 ‐ May 1995\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomisation chartAllocation concealment (selection bias)Low riskSequential opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reportedOther biasHigh riskStudy ended prematurely (before power was reached) as Dilapan was removed of the USA market[Hoppe 2016](#CD001233-bbs2-0041){ref-type="ref-list"}MethodsRCTParticipantsInclusion: ≥ 18 years, singleton, vertex, BS of ≤ 5, \< 4 contractions in 10 minutes, category I fetal monitoring.\
Exclusion: contraindication for vaginal delivery, planned or received exogenous PG administration, unexplained vaginal bleeding, active herpes simplex, previous caesarean delivery, previous attempt at IOL, non‐English speakingInterventionsSingle balloon 18F Foley, 30 mL, traction applied, max 12 hours\
Double balloon, Cook 80 mL/80 mL, max 12 hoursOutcomesBS of \> 6 at time of catheter removal, change in BS, time from catheter insertion to spontaneous expulsion or removal, mean time from catheter insertion to vaginal\
delivery, vaginal delivery in 24 hours, the use of pharmacologic methods for further cervical ripening or augmentation of labour, AROM, epidural use, mode of delivery, indications\
for CS, chorioamnionitis, AS at 5 minutes \< 7, meconium, NICU admissionsNotesSetting: University of Washington Medical Center Labor and Delivery, USA\
Study period: January 2010 and November 2013\
Funding: no funding by Cook\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskBlock randomisation, stratified for parity, not clear how this was done.Allocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNo ITT reported, most likely per protocol, missing data in baseline characteristic, not in outcomes, no cases missingSelective reporting (reporting bias)Low riskAll pre‐specified outcome data reportedOther biasLow riskNo other bias detected[Hudon 1999](#CD001233-bbs2-0042){ref-type="ref-list"}MethodsRCT. No details on the method of randomisation or on concealment of the allocation.ParticipantsTerm, unfavourable cervix (BS \< 5).InterventionsFoley catheter placed above the internal os and inflated with 40 mL left in place for a max of 16 hours (56 women); intracervical PGE2 (0.5 mg), repeated if BS unfavourable (55 women). Oxytocin was given after achievement of cervical ripening.OutcomesCS.NotesSetting: USA\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were randomisedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskInsufficient information to judgeSelective reporting (reporting bias)Unclear riskInsufficient information to judgeOther biasUnclear riskAbstract only[Hughes 2002](#CD001233-bbs2-0043){ref-type="ref-list"}MethodsRandomised trial.ParticipantsSingleton gestation, cephalic presentation, intact membranes, GA 36‐42, indicated labour induction.InterventionsPGE 2 pessary (n = 34).\
Foley + EASI + oxytocin (n = 33).OutcomesChange in BS, induction‐delivery time.NotesOutcomes of interest not reported in this abstract.\
Setting: USA\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned, no further detailsAllocation concealment (selection bias)Unclear riskRandomly assigned, no further detailsBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear risk2 patients excluded after randomisation in Foley group, unclearSelective reporting (reporting bias)Unclear riskStudy protocol/predefined outcomes not availableOther biasUnclear riskOnly reported as abstract[Husain 2017](#CD001233-bbs2-0044){ref-type="ref-list"}MethodsRCTParticipantsInclusion: age 20 to 40 years, singleton pregnancy, cephalic presentation ≥ 37 weeks\
Exclusion: BS of \> 4, cephalopelvic disproportion on examination, history of placenta previa or unexplained vaginal bleeding, history of previous CS or other uterine surgery, active herpes simplex infection, chorioamnionitis, contraindication to use of PGs, acute pelvic inflammatory disease, contraindication to vaginal delivery, a non reassuring FHR pattern prior to induction.InterventionsOral misoprostol (n = 157): 50 mcg, every 4 hours, max 4 gifts\
Foley catheter + oral misoprostol (n = 161): 16 or 18F, filled with 30 mL + oral misoprostol (50 mcg) every 4 hours, max 4 gifts both groups: if labour was not established within 4 hours of the 4th dose of misoprostol, induction was considered to have failed and such cases were then delivered by CS.OutcomesFailure to achieve vaginal delivery after 24 hours, induction‐to‐delivery interval, mode of delivery, reason for CS maternal complications, NICU admissionsNotesSetting: Abbasi Shaheed Hospital in Karachi, Pakistan, tertiary care centre\
Study period: May 2016 to October 2016.\
Funding: no funding reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence, block randomisationAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT analysis not reported, cases excluded because of protocol violation. no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Jagani 1982](#CD001233-bbs2-0045){ref-type="ref-list"}MethodsRCT. Randomisation based on case number. No measure taken to conceal the allocation.ParticipantsIntact membranes.Interventions5 groups: no treatment (n = 10; exclude); laminaria n = 10 (as many as possible); Foley catheter n = 10 (inflated with 70 ‐ 80 mL water) under traction; amniotomy (n = 10); oxytocin (n = 10) increased by 5 mU/minute every 10 ‐15 minutes. In all groups, each of 10 women, an extraovular catheter with a 5 mL balloon was used to record uterine activity.OutcomesCS.NotesSetting: USA\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskMethod selected by last digit of the chart numberAllocation concealment (selection bias)High riskInadequate.No measure taken to conceal the allocation.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, not clear how many women were actually included.Selective reporting (reporting bias)Low riskAll outcome measures were reportedOther biasLow riskNo other bias detected[Jalilian 2011](#CD001233-bbs2-0046){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: singleton gestation, cephalic presentation, reactive FHR pattern, intact membranes and GA between 37‐41 weeks\
Exclusion criteria: BS at least 7 or cervical dilatation greater than 3 cm, EFW \> 4500 g or \< 2000 g, evidence of cephalopelvic disproportion, placenta previa or unexplained vaginal bleeding, previous section caesarean or uterine surgery and contraindications to PGInterventionsIntravaginal dinoprostone (n = 20), 3 mg every 6 hours, max 4 doses\
Foley catheter, 16F, 30 mL (n = 20), removed after 12 hoursOutcomesNot mentioned in method sectionNotesArticle is submitted as letter to the editor. no relevant outcomes reported\
Setting: Iran\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly described women were randomly allocated, no more info availableAllocation concealment (selection bias)Unclear riskOnly described women were randomly allocated, no more info availableBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, too little information to judgeSelective reporting (reporting bias)Unclear riskInsufficient information to judgeOther biasUnclear riskAbstract only (letter to editor), too little information to judge risk of bias[Jeeva 1982](#CD001233-bbs2-0047){ref-type="ref-list"}MethodsRCT. No details on the method of randomisation or on concealment of the allocation.ParticipantsNo description of inclusion/exclusion criteria. 10 primigravidas and 10 multigravidas.InterventionsLaminaria tents (2 ‐ 3 tents) (10 women); (PGE2) 4 mg tablets vaginally.OutcomesChange in BS after 16 hours, CS.NotesSetting: South Africa\
Dates of study: not reported\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were randomisedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not mentioned, but seems reasonable as numbers in tables are equal to randomised numbers, no cases missingSelective reporting (reporting bias)Unclear riskInsufficient information as no outcome measures were pre‐specified in reportOther biasLow riskNo other bias detected[Johnson 1985](#CD001233-bbs2-0048){ref-type="ref-list"}MethodsRCT. Sequence based on a random number table. No details were given on the method for concealment of the allocation.ParticipantsTerm, primiparas, BS \< 6.InterventionsLamicel (40 women);  PGE2 vaginal gel (4 mg) (40 women).OutcomesEpidural analgesia, CS, instrumental delivery, uterine hyperstimulation, fetal distress.NotesSetting: UK\
Dates of study: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number tableAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT unclear, no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Joshi 2016](#CD001233-bbs2-0049){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: 1 previous low transverse CS, singleton live pregnancy with cephalic presentation, reassuring fetal status, \> 37 weeks and BS \< 6\
Exclusion criteria: placenta praevia, CPD, various mal presentations, short interconceptional period of 18 months, previous 2 caesareans, in a case of previous myomectomy or hysterectomy, patient demands repeat elective CSInterventionsFoley catheter (n = 100), 16F, 30 mL, max 24 hours in situ\
Oxytocin (n = 100): starting from 1 mU/minute, increased to 2 mU/minute and max up to 32 mU/minuteOutcomesInduction delivery interval, indications for CS, mode of delivery, neonatal outcome and NICU admissions were studied in both groupsNotesSetting: Swami Dayanand Hospital Dilshad Garden New Delhi, India\
Study period: January 2015 ‐ June 2015\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly stated that women were randomly allocatedAllocation concealment (selection bias)Unclear riskOnly stated that women were randomly allocatedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, no figure 1 to check allocation, all cases analysed, no missing data describedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: pregnant women scheduled for IOL beyond 37 weeks of gestation with a vital singleton pregnancy in cephalic presentation, intact membranes, and an unfavourable cervix (BS \< 6). Exclusion criteria: women younger than 18 years, with a previous CS, placenta praevia, lethal fetal congenital anomaly, or known hypersensitivity for one of the products used for induction were ineligibleInterventionsFoley catheter (n = 411): 18F, 30 cc sterile saline.\
PG E2 gel (408): 1 mg, followed by 1 mg after 6 hours, with a max of 2 doses per 24 hours inserted into the posterior vaginal fornix. An initial dose of 2 mg was allowed in nulliparous women.\
2 days of induction, 1 day of \" rest\" followed by 2 more days of induction in case of BS \< 6OutcomesCS, maternal and neonatal morbidity and time from start induction to birth.NotesSetting: multicentre, the Netherlands\
Study period: Feb 2009 ‐ May 2010\
Funding: none\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomisationAllocation concealment (selection bias)Low riskWeb‐basedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, missing outcome data (pH and BMI) balanced in numbers across intervention groups, with similar reasons for missing data across groups. no missing casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}MethodsRCTParticipantsWomen \> 18 years with term pregnancy and unfavourable cervix, requiring IOL. Exclusion criteria were previous CS, non‐vertex presentation of the fetus, ruptured membranes, hypersensitivity for one of the products used for induction, or a lethal congenital anomaly of the fetusInterventionsFoley catheter (107),18F 30 cc sterile saline.\
10 mg slow release PG vaginal insert (n = 119). Removed after 12 hours, if BS \< 6, after 24 hours new PG vaginal insert was used\
2 days of induction, 1 day of \" rest\" followed by 2 more days of induction in case of BS \< 6OutcomesCS, maternal and neonatal morbidity and time from start induction to birth.NotesSetting: multicentre, the Netherlands\
Study period: February 2009 ‐ May 2010\
Funding: none\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomisationAllocation concealment (selection bias)Low riskWeb‐basedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias)   All outcomesLow riskITT analysis, missing outcome data (pH and BMI) balanced in numbers across intervention groups, with similar reasons for missing data across groups. no missing casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}MethodsPilot study within RCTParticipantsWomen \> 18 years, ≥ 37 weeks, BS \< 6, planned for IOL.\
Exclusion:previous CS, non vertex presentation, ruptured membranes, hypersensitivity for one of the products used for induction, lethal congenital anomalyInterventionsFoley catheter (n = 56), 16 or 18F, 30 mL\
Vaginal misoprostol (n = 64) 25 mcg tablets every 4 hours, max 3 doses in 24 hours.\
In both groups, if the cervix was still unfavourable for amniotomy after 48 hours of treatment, women were generally assigned a day of rest followed by another 48 hours of inductionOutcomesCS, instrumental vaginal delivery, reasons for operative delivery, time from induction to delivery, uterine hyperstimulation, uterine rupture, analgesics, antibiotics, maternal suspected intrapartum infection, maternal postpartum infection, postpartum haemorrhage (\> 1000 cc) postpartum blood transfusion, AS of \< 7 at 1 minute and 5 minutes, arterial cord blood pH \< 7·10, neonatal admissions neonatal ward/NICUNotesSetting:multicenter, the Netherlands\
Study period: February 2009 and May 2010\
Funding: no funding reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence, block randomisationAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT analysis, missing data reported, but even distributed over groups and likely for the same reasons. no missing casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in results, except secondary outcome maternal postpartum infectionOther biasLow riskNo other bias detected[Kandil 2012](#CD001233-bbs2-0053){ref-type="ref-list"}MethodsProspective quasi‐RCTParticipantsInclusion criteria: 41 weeks or more, primigravida, BS \< 4, singleton living fetus, vertex presentation, no evidence of active labour, a reassuring FHR pattern, no evidence of intrauterine infection.   Exclusion criteria: contra‐indication for vaginal delivery, previous uterine surgery, non‐reassuring FHR, IUFD, ruptured membranes, vaginal infection, malpresentation, macrosomic fetus, cephalopelvic disproportion, history of APH, contra‐indication to PGsInterventions1. 18F Foley catheter, 30 cc sterile saline. Taped to the inner thigh. Each patient received 1 g of ampicillin/6 hours. Removed after 12 hours. (N = 50)\
2. 25 ug misoprostol vaginally every 4 hours (N = 50)OutcomesInduction to delivery time, oxytocin use, route of delivery, occurrence of chorioamnionitis, AS, admission to NICU, tachysystole, hypertonus, hyperstimulationNotes9 patients were insertion of Foley was not possible were replaced by 9 other patients!\
Setting: Menofyia University Hospital, Egypt\
Study period: from January 2010 to October 2010\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskRandomisation by odd or even admission dateAllocation concealment (selection bias)High riskRandomisation by odd or even admission dateBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT was not mentioned. 9 patients in Foley group were replaced by 9 others because insertion of Foley was not possible. No flow chart, no description of lost to follow‐up.Selective reporting (reporting bias)Low riskAll pre‐described outcome measures were mentioned.Other biasLow riskNo other bias detected[Khamaiseh 2012](#CD001233-bbs2-0054){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: age 15 years or more, term, singleton, live fetus in vertex presentation, intact membranes and BS \< 6.\
Exclusion criteria: previous CS or history of other uterine surgery, history of ante partum haemorrhage, cephalopelvic disproportion, acute fetal distress revealed by a non stress test prior to induction, signs of infection, ruptured membranes, EFW \> 4300, or known allergy to PGInterventionsPG E2 (n = 204) tablets 3 mg, max 2 dose. AROM performed if labour did not commence after 2 doses\
Foley catheter (n = 210): 22/24F, 50‐60 mL in balloon.Removed after 24 hours and AROM if possibleOutcomesMode of delivery, time interval between the start of induction and delivery, oxytocin requirement, the indications for CS and adverse neonatal and maternal reactions to the cervical ripening agent. Hyperstimulation with and without FHR changes, failed induction.NotesSetting: King Hussein Medical Centre and Prince Ali Bin Al‐Hussein hospital, Jordan\
Study period: July 2009 ‐ July 2010\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom sequence generated by computerAllocation concealment (selection bias)Unclear riskNot described, only description: Randomisation was done by a computer‐generated list of random numbersBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT analysis not reported and not clear if used, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Krammer 1995a](#CD001233-bbs2-0055){ref-type="ref-list"}MethodsRCT. Computer‐generated sequence. No details were given on the method for concealment of the allocation.ParticipantsTerm women with a BS \< 9, absence of contraindication for labour and fetal distress. 441 women (224 in the Dilapan group and 217 in the PGE2 group).InterventionsDilapan, as many dilators as possible (224 randomised, 214 analysed);  intracervical PGE2 0.5 mg (217 women randomised, 202 analysed). In both groups, ripening was followed 6 hours later by oxytocin.OutcomesCS, uterine hyperstimulation, fetal and neonatal infection.Notes25 women excluded: 10 in the Dilapan group (8 protocol violations, 2 entered spontaneous labour before insertion) and 15 in the PG group (10 protocol violations, 3 entered labour before ripening and 2 delivered before the 6‐hour interval). Authors stated that including these excluded women do not alter the results. Numbers of CS derived from Williams 1997.\
Setting: Tampa general hospital, USA\
Dates of study: June 1991 ‐ December 1993\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequenceAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT was performed, but 25 women excluded: 10 in the Dilapan group (8 protocol violations, 2 entered spontaneous labour before insertion) and 15 in the PG group (10 protocol violations, 3 entered labour before ripening and 2 delivered before the 6‐hour interval)Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Kruit 2016](#CD001233-bbs2-0056){ref-type="ref-list"}MethodsRCTParticipantsInclusion: PROM \> 18 hours, ≥ 37 weeks, BS \< 6, vital singleton pregnancy, cephalic\
Exclusion: previous CS, placenta previa, vaginal bleeding, HIV, hepatitis B or C, maternal infection, fetal anomalyInterventionsFoley (n = 89): 22ch Rush balloon, traction, 40‐50 cc, max 8 hours. if unripe, further management by discretion of clinician\
oral misoprostol (n = 99): 50 mcg misoprostol every 4 hours, after 3 gifts dosis increased to 100 mcg or 25 to 50 mcg vaginal every 3‐4 hoursOutcomesCS rate, maternal and neonatal infections. Reason for CS (fetal distress, suspected infection, prolonged labour, failed induction, postpartum infection, postpartum haemorrhage, uterine hyperstimulation, fetal tachycardia, use of analgesics, AS, umbilical arterial pH, admission to neonatal care, induction to delivery interval.NotesTrial stopped prematurely due to insufficient patient enrolment\
Setting: multicentre, Finland\
Study period: March 2012 to September 2014\
Funding: grant from the Finnish medical society duodecim and Helsinky University Central Hospital research grant\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reported how this was done (only that they used sealed envelopes)Allocation concealment (selection bias)Low riskSealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskSeems to be per protocol analysis. Patients excluded after enrolment for cross‐over during analysing data, 3rd arm formedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasHigh riskTrial stopped prematurely due to insufficient patient enrolment[Kuppulakshmi 2016](#CD001233-bbs2-0057){ref-type="ref-list"}MethodsRCTParticipantsNot mentionedInterventionsintracervical dinoprostone (n = 100): 0.5 mg, 6‐hourly, max 2 doses\
Foley catheter (n = 100), 30 mL, max 12 hours in place.OutcomesVaginal delivery within 24 hours, improvement in BS, induction to onset of active labour and induction to delivery interval, mode of delivery, occurrence of maternal complications and fetal outcome, cost‐effectivenessNotesSetting: India\
Study period: June 2015 ‐ July 2016\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly described that patients were randomly allocatedAllocation concealment (selection bias)Unclear riskOnly described that patients were randomly allocatedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNo missing data described, difficult to judge how selection of patients was done, if there was ITT, if patients were excluded. no numbers of analysed patient in result sectionSelective reporting (reporting bias)Low riskPre specified outcomes reported in method section were all reportedOther biasLow riskNo other bias detected[Laddad 2013](#CD001233-bbs2-0058){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: primigravida, \> 37 weeks of gestation, singleton pregnancy, cephalic presentation, BS \< 4, Intact membranes\
Exclusion criteria: multiple pregnancy, mal‐presentation, absent membranes, APH, medical disease e.g. heart disease, renal disease, previous LSCSInterventionsFoley catheter (n = 200):\
PGE2 gel intracervical (n = 200), max 2 doses, failed induction declared if patient was not in active labour after 48 hoursOutcomesNot mentioned in method sectionNotesPGE2 dose not described\
Setting: KIMSDU; India,\
Study period: January 2011 ‐ December 2012\
Funding: none\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly stated that women were randomly assignedAllocation concealment (selection bias)Unclear riskOnly stated that women were randomly assignedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskUnclear if analysis was ITT, (no figure 1) all cases analysed, no missing data describedSelective reporting (reporting bias)Unclear riskNo pre ‐specified outcome measures reported, so cannot be determinedOther biasLow riskNo other bias detected[Lanka 2014](#CD001233-bbs2-0059){ref-type="ref-list"}MethodsRCTParticipantsInclusion: GA \> 28 weeks, singletons, intact membranes, absence of labour, cephalic presentation, BS \< 5.\
Exclusion: multifetal gestations, congenital malformations, Gravidity \> 4, non‐reassuring FHR trace, ruptured membranes, active genital infection, previous uterine surgery (including CS), low‐lying placenta, chorioamnionitis, EFW \> 4000 g, IUFD, known allergies to latex or PGsInterventionsFoley + misoprostol (n = 63): 16F Foley catheter, 30 cc, traction applied, max 12 hours ‐ 25 mcg vaginal misoprostol, every 4 hours up to a max of 8 doses.\
vaginal misoprostol (n = 63): 25 mcg vaginal misoprostol every 4 hours, with a max of 8 dosesOutcomesinduction to delivery interval, rate of vaginal deliveries, hyperstimulation, CS rate, neonatal outcome, chorioamnionitis, oxytocin useNotesSetting: tertiary care centre, India\
Study period: 2‐year period\
Funding: no funding\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence, block randomisationAllocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT analysis, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Lemyre 2006](#CD001233-bbs2-0060){ref-type="ref-list"}MethodsRCT.ParticipantsTerm pregnancy requiring cervical ripening.InterventionsFoley catheter for 12 hours (n = 31).\
Vaginal misoprostol 25 mcg 4‐hourly (n = 31).OutcomesInduction‐active labour, induction‐delivery, delivery within 12 and 20 hours, oxytocin, obstetric outcome, maternal and neonatal morbidityNotesReported as abstract, only outcome of interest reported is oxytocin infusion.\
Setting: Canada\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned, no details on sequence generation.Allocation concealment (selection bias)Unclear riskNo details on allocation concealment given.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNot reported in this abstract.Selective reporting (reporting bias)Unclear riskIn this abstract from the outcomes of interest only oxytocin infusion reported, other outcomes not reported.Other biasUnclear riskOnly abstract available.[Lewis 1983](#CD001233-bbs2-0061){ref-type="ref-list"}MethodsRCT. No details were given on the method for concealment of the allocation.ParticipantsSingleton vertex term pregnancy, unfavourable cervix.InterventionsVaginal pessary 3 mg PGE2 (22 women);  Foley catheter in the extra‐amniotic space 30 mL (22 women);  Control group with no treatment (22 women; exclude)OutcomesChange in BS, CS, uterine hyperstimulation, AS.NotesData on induction‐delivery intervals not interpretable to derive proportion of women with vaginal delivery not achieved in 24 hours.\
Setting: Manchester, UK\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandom allocation, no more details reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskUnclear if ITT was performed. no missing cases or data reportedSelective reporting (reporting bias)Unclear riskNo specific pre specified outcomes reported in method section.Other biasLow riskNo other bias detected[Lokkegaard 2015](#CD001233-bbs2-0062){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: intact membranes, cephalic position, BS ≤ 6, indication of IOL.\
Exclusion criteria: ruptured membranes, spontaneous labour, placenta praevia, acute fetal distress, asthma, glaucoma, latex allergy, infections (acute herpes, GBS, condylomata), previous CSInterventions1. Double balloon catheter (n = 412); 80 mL, max 12 hours, thereafter either AROM or start of oxytocin.\
2. PGE2 3 mg tablet (n = 413), 2 dose a day (4‐5 hourly), max 2 daysOutcomesFailed inductions, time interval from induction to delivery, mode of delivery, neonatal outcome as assessed by the AS after 5 minutes and referral to a neonatal care unit, subgroups by parity and indication for induction. Post hoc analyses included the percentage of women who gave birth within 24 hours and the need for additional oxytocin stimulationNotesSetting: multicentre, Denmark\
Study period: September 2002 to December 2005\
Funding: the randomisation procedure was funded by ' Snedkermester Sophus Jacobsen & Astrid Jacobsens fond and the Danish Toyota Foundation.\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated and was stratified for parity and department.Allocation concealment (selection bias)Low riskCentral allocation by telephoneBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, missing data reported, but evenly distributed.Selective reporting (reporting bias)Low riskAll pre‐specified outcome measures were reportedOther biasLow riskNo other bias detected[Lyndrup 1989](#CD001233-bbs2-0063){ref-type="ref-list"}MethodsRCT.ParticipantsWoman with unfavourable cervix.Interventions4 groups:\
oxytocin without Lamicel (according to a fixed schedule, with a max of 32 mU per minute) (24 women);oxytocin with Lamicel (1 unit) (22 women);PGs without Lamicel (2.5 mg PGE2) (19 women);PGs with Lamicel (1 unit) (20 women).OutcomesCS, forceps or vacuum extraction, endometritis.NotesSetting: Denmark\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported women were randomised by sealed envelope methodAllocation concealment (selection bias)Low riskSealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh risk6 women excluded for protocol violation.Selective reporting (reporting bias)Unclear riskNo outcomes were pre specified in method section.Other biasLow riskNo other bias detected[Lyndrup 1994](#CD001233-bbs2-0064){ref-type="ref-list"}MethodsRCTParticipantsSingleton vertex pregnancy, intact membranes with unfavourable cervix.InterventionsFoley extra‐amniotic 30 mL (59 women)  PGE2 2.5 mg pessaries (50 women)OutcomesVaginal delivery not achieved within 24 hours, CS, instrumental delivery, women not satisfied, caregiver not satisfied, pH, AS.NotesSetting: Denmark\
Study:period: June 1990 ‐ March 1993\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo details on the method of generation of the sequence.Allocation concealment (selection bias)Low riskConcealment of allocation by sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT reported, but 4 women were lost to follow‐up. Women were excluded if delivered after 48 hoursSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Mackeen 2018](#CD001233-bbs2-0065){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: women with a live, singleton gestation in cephalic presentation at 34 weeks of gestation or greater with PROM (at least 60 minutes prior to randomisation), an unfavourable cervical examination (less than 2 cm or 80% effaced), and no contraindication to labour. English speaking with a plan for vaginal delivery.\
Exclusion criteria: active labour and those with suspected intra‐amniotic infection, abruption or significant haemorrhage, latex allergy, greater than 1 prior caesarean delivery, any contraindication to vaginal delivery, or human immunodeficiency virus or acquired immunodeficiency syndrome, multifetal gestations, lethal fetal anomalies, intrauterine fetal demise, and category II or III FHR tracings.InterventionsOxytocin only (n = 108): start 2 mUh/minute, increase 2 mUh/minute every 30 minute, max 30 mUh/minute\
Foley catheter + oxytocin (n = 93): 16F, 30 mL, traction applied, max 12 hours, oxytocin concurrent (as above)\
If not in labour after 24 hours, management per discretion of clinicianOutcomesInterval from induction to delivery, interval from induction to vaginal delivery, induction to delivery excluding patients with PPROM before 34 weeks of GA, CS rate, rate of vaginal delivery within 12 or 24 hours, indication for CS, infection complications, maternal LOS, 5‐minute AS \< 5, neonatal infectious evaluation and diagnosis of sepsis, maternal and neonatal length of stay, NICU admission, chorioamnionitis, fetal tachycardia, endomyometritis,NotesSetting: multicentre, USA\
Study period: March 2014 to July 2016\
Funding: small internal grants to assist with the conduct and statistical analyses for the entire study.\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated schema in random‐sized blocks stratified by multiparity or primiparity, preterm or term gestation, and hospital site.Allocation concealment (selection bias)High riskNot concealed.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Matonhodze 2003](#CD001233-bbs2-0066){ref-type="ref-list"}MethodsRCT: Computer‐generated random sequence, sealed opaque envelopes.ParticipantsInclusion: completed 34 weeks GA, intact membranes\
Exclusion: uterine scar, uncontrolled medical complication, non‐vertex presentation, multiple pregnancy, fetal distress, APH.InterventionsFoley catheter + misoprostol (n = 174): 50 mL, traction, max 24 hours, followed by oral misoprostol solution 20 mcg every 2 hours, 40 mcg 2‐hourly after 3 doses, until active labour had started. If after established labour contractions became inadequate: augmentation with misoprostol solution 5‐20 mcg hourly. If ineffective: oxytocin.\
Titrated oral misoprostol (n = 176): as described above\
Dinoprostone vaginal (n = 176). 2 mg in posterior fornix, repeated after 6 hours. If no active labour after 12 hours: oxytocinOutcomesFailed vaginal delivery within 24 hours, augmentation, tachysystole, hypersystole, hyperstimulation syndrome, tocolysis, analgesia, meconium, CS, instrumental delivery, maternal side effects, AS \< 7, NICU admission, perinatal death, neonatal sepsis.NotesIt is not clear if all patients had an unfavourable cervix (not mentioned in baseline characteristics. Data reported for different numbers of subjects depending on outcome (selective reporting or missing outcome data?).\
Setting: Pakistan\
Study period: October 2000 ‐ December 2001\
Funding: not reported\
Declaration of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random sequence,Allocation concealment (selection bias)Low riskSequentially‐numbered opaque, sealed envelopes out of a dispenser. intact membranes/unfavourable cervix, intact membranes/favourable cervixBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT analysis, data reported for different numbers of subjects depending on outcome. not clear whySelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Mazhar 2003](#CD001233-bbs2-0067){ref-type="ref-list"}MethodsRCT randomisation: computer‐generated random numbers, concealed.ParticipantsInclusion: singleton pregnancy, cephalic presentation, reassuring fetal status, GA 37 completed weeks, BS 6 or lower.\
Exclusion: placenta praevia, chorioamnionitis, polyhydramnios, parity \> 5, SROM, previous CS, contraindication to labour induction.Interventions(PGE2) vaginal pessary max 2 x 6 hours (dose not mentioned) followed by ARM and oxytocin infusion (n = 100).\
Foley catheter 45 mL + EASI for 12 hours followed by ARM and oxytocin infusion (n = 100).OutcomesPrimary: time from insertion to delivery, mode of delivery.\
secondary: change is BS after 6 hours, neonatal AS.NotesNo sample size calculation.\
4 patients were excluded (1 left against medical advice, 1 had SROM, 2 failed inductions were induced at later stage).\
Setting: Pakistan\
Dates of study: October 2000 to December 2001\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence.Allocation concealment (selection bias)Unclear riskRandomised numbers concealed in the delivery suite?Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNo mention of incomplete data, however unlikely due to nature of outcome measures.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reported.Other biasLow riskNo other bias detected[Meetei 2015](#CD001233-bbs2-0068){ref-type="ref-list"}MethodsRCTParticipantsInclusion: 1 previous low transverse CS, singleton live pregnancy, cephalic presentation, \> 28 weeks and BS \< 5.\
Exclusion: previous classical or T‐shaped incision, unknown scar, transfundal uterine surgery, medical or obstetric complications that preclude vaginal delivery, placenta previa, low‐lying placenta undiagnosed vaginal bleeding, maternal heart disease, rupture of membranes, interval between previous CS and present pregnancy/conception \< 6 months, cervico‐vaginal infection, unclean vaginal examination, infection in previous CSInterventions1. Foley catheter (n = 30): 16F, 30 mL balloon, max 12 hours, thereafter start of oxytocin augmentation\
2. Oxytocin (n = 30): 1 mUh/minute, after 1 hour 2/mUh/minute, after 1 hour 4 mUh/minute (max 12 hours). oxytocin augmentation as aboveOutcomesChange in BS before and after 12 hours of ripening, percentage and time interval of spontaneous labour, insertion and expulsion interval of Foley catheter, route of delivery/outcome of delivery, time required from the beginning of cervical ripening to delivery, hyperstimulation, fetal distress, scar dehiscence, uterine ruptureNotesSetting: Department of Obstetrics and Gynecology, PGIMER, Chandigarh, India\
Study period: July 2004 and November 2005,\
Funding: no funding\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomisation by Tippet\'s tableAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskAnalysing method not reported and not clear, no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Moini 2003](#CD001233-bbs2-0069){ref-type="ref-list"}MethodsRCT: quote: \"randomly assigned\".ParticipantsSingleton gestation, cephalic presentation, GA between 37 and 42 weeks, BS \< 6.\
Exclusion: malpresentation, ruptured membranes, active genial herpes, antepartum bleeding, fetal death, cephalopelvic disproportion, indication for emergency termination of pregnancy, history of infertility or CS, women who had undergone induction before presenting.InterventionsDinoprostone intracervical 0.5 mg, oxytocin infusion after 6 hours (n = 35).\
Foley catheter 30 mL + EASI (n = 35).OutcomesChange in BS (after 6 hours), induction‐delivery interval, need for oxytocin, mode of delivery, fetal complications, maternal complications.NotesNo sample size calculation.\
Setting: Roointan‐Arash Maternity Hospital, Iran\
Dates of study: April 2000 ‐ April 2001\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskInsufficient information about sequence generation process quote: \"randomly assigned\".Allocation concealment (selection bias)Unclear riskInsufficient information.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNot mentioned.Selective reporting (reporting bias)Unclear riskAll pre‐specified outcomes are reported, it is however unclear what is meant by \'fetal complications\', and it is likely that there were more outcomes noted.Other biasLow riskNo other bias detected[Mullin 2002](#CD001233-bbs2-0070){ref-type="ref-list"}MethodsRCT: randomisation by computerised random number generator, consecutively‐numbered sealed envelopes.ParticipantsSingleton gestation, cephalic presentation intact membranes, BS 4 or less, \< 8 contractions per hour, reactive FHR tracing.\
EFW \> 4500 g or \< 1800 g, low‐lying placenta, placenta praevia, unexplained vaginal bleeding, active genital herpes, vasa praevia, chorioamnionitis, contraindication for PGs, previous uterine surgical procedure, parity \> 5.InterventionsFoley 30 mL+ EASI (max 12 hours) + IV oxytocin infusion (n = 100).\
Vaginal misoprostol 25 mcg every 4 hours max 24 hours (n = 100).OutcomesPrimary: mean time from start induction to delivery.\
Secondary: route of delivery, success of induction (vaginal delivery within 24 hours), uterine contraction abnormalities, chorioamnionitis, route of delivery, AS \< 7, NICU admission, neonatal resuscitation.NotesPower calculation states that 140 patients were necessary, yet 200 were included\
Setting: Los Angeles County--University of Southern California Medical Center, USA\
Dates of study: February 1999 to July 2001\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputerised random number generator.Allocation concealment (selection bias)Low riskSealed opaque envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskNo withdrawals from protocol, no mention of incomplete data.Selective reporting (reporting bias)Low riskAll predefined outcomes are reported.Other biasUnclear riskUnclear why 200 patients were included, while 140 were calculated in the power calculation.[Mundle 2017](#CD001233-bbs2-0071){ref-type="ref-list"}MethodsRCTParticipantsInclusion: age ≥ 18 years, ≥ 20 weeks' gestation or later with a live fetus, decision made to induce vaginal birth because of pre‐eclampsia or hypertension\
Exclusion: unable to give informed consent, previous CS, multiple pregnancy, ruptured membranes, chorioamnionitis, allergy to misoprostol.Interventions1. Foley catheter (n = 300): 18F, 30 mL balloon, traction applied, max 12 hours, afterward start oxytocin or AROM\
2. Oral misoprostol (n = 302) 25 mcg, 2‐hourly, max of 12 dose (24 hours). In primigravid women the dose could be increased to 50 mcg 2‐hourly after the first 2 doses\
oxytocin administered through gravity infusion setOutcomesVaginal birth within 24 hours, induction to birth interval (vaginal births, CSs, and all births), vaginal births within 12 hours, cervix unchanged at 12 hours and 24 hours, need for oxytocin augmentation, time from randomisation to start of induction and birth, total dose of misoprostol used and the number of participants given a 50 μg dose. Maternal complications, satisfaction, fetal/neonatal complicationsNotesFetal surveillance with doptone\
Setting: 2 public hospitals in Nagpur, India\
Study period: December 2013 to June 2015\
Funding: Department for International Development, Medical Research Council, and Wellcome Trust Joint Global Health Trials Scheme. The funder of the study had no role in data collection\
Declarations of interest: ADW is a scientific adviser to Azanta, a Danish pharmaceutical company, MAT has provided consultancy services to Chiesi, Bristol--Myers Squibb, Novartis, Shire, Janssen, and Grunenthal. both authors received no personal payment,***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated pseudo‐random numbers, block randomisation, stratified by centreAllocation concealment (selection bias)Low riskSequentially‐numbered, sealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, missing data reported, but small numbers and not in outcomes of interest for this review, no cases missingSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Niromanesh 2003](#CD001233-bbs2-0072){ref-type="ref-list"}MethodsQuote:\"randomly assigned\".ParticipantsBS \< 5, maternal age 20 to 30 years, gravidity 1 ‐ 3, parity 1 ‐ 2, \< 6 contractions per hour, singleton pregnancy.\
Exclusion: history of preterm labour, antepartum bleeding, low‐lying placenta, history of caesarean deliveries, active herpes infection, acute poly or oligohydramnios, high blood pressure, IUFD, GA \< 40 weeks, chronic condition or contraindication for use of PGs.InterventionsFoley catheter 30 mL max 8 hours (n = 45).\
(PGE2) tablet 6‐hourly, max 6 doses (n = 44).OutcomesPrimary: BS (after ripening).\
Secondary: ripening time, induction time, total time, delivery route, uterine hyperstimulation, adverse side effects, non‐reassuring FHR tracing, AS.NotesNo sample size calculation.\
1 patient withdrew due to \'complications\'.\
Time of ripening in Foley group 8 hours, PG group 12 hours\
Setting: Mirza Kochkhan Hospital, Tehran, Iran.\
Study period: March 2000 to May 2001\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Low riskSealed opaque envelope.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNo mention of incomplete data, insufficient information to permit judgment.Selective reporting (reporting bias)Unclear risk1 patient was withdrawn due to \'complications\', data for this patient not reported, other than this, data reported for all patients on the prespecified outcomes.Other biasLow riskNo other bias detected[Noor 2015](#CD001233-bbs2-0073){ref-type="ref-list"}MethodsRCTParticipantsSingleton pregnancies, cephalic presentation, \> 37 weeks, intact membranes, BS ≤ 4\
Exclusion: rupture of the membranes, chorioamnionitis, APH, cervical dilatation \> 2.5 cm, temperature \> 38 degrees Celsius, contracted pelvis, fetal distress, polyhydramnios, indication for immediate delivery previous CS or other uterine surgeries.Interventions1. Vaginal misoprostol (n = 60): 25 mcg, 4‐hourly, with a max of 6 doses. no effective uterine contractions after the 6th dose, then it was considered as failure of induction.\
2. Foley catheter (n = 44): 18F Foley 50 mL, traction applied, no max time period reportedOutcomesinduction to delivery interval, uterine tachysystole, uterine hypertonus, uterine hyperstimulation (tachysystole + FHR changes), meconium‐stained liquor, mode of delivery, maternal and neonatal outcome, AS.NotesSetting: Department of Obstetrics and Gynaecology in collaboration with the Department of Paediatrics, JNMCH,AMU, Aligarh (UP), India\
Study period: May 2013--August 2014.\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskOnly reported they were randomly assigned, unequal numbers in groups? (60 vs 44)Allocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not reported, although this is likely as numbers are equal to randomised numbers. no missing data or casesSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Ntsaluba 1997](#CD001233-bbs2-0074){ref-type="ref-list"}MethodsRCTParticipantsSingleton vertex presentation with intact membranes, BS \< 6, no previous CS.InterventionsIntracervical PGE2 (0.5 mg) (59 women)  Foley catheter with a 30 mL balloon extra‐amniotic (53 women)OutcomesChange in BS, CS, uterine hyperstimulation, fever, neonatal sepsis, fetal distress.NotesSetting: KIng Henry 8th hospital, Durban, South Africa\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo other details on the randomisation process.Allocation concealment (selection bias)Low riskSealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskNo ITT reported (although it\'s likely as numbers are equal as randomised numbers), no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reported.Other biasLow riskNo other bias detected[Oliveira 2010](#CD001233-bbs2-0075){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singletons in cephalic presentation, GA \> 37 weeks, live fetus, BS ≤ 4.\
Exclusion: ruptured membranes, uterine scar, placenta praevia, chorioamnionitis, EFW \> 4000 g, hypersensitivity for products used in interventionInterventions1. Foley catheter (n = 80): 14 or 16F, 30 cc, max 48 hours\
2. Misoprostol (n = 80) 25 mcg a 6 hours, with a max dose of 200 mcg max 48 hours of inductionOutcomesOxytocin use, tachysystole, hypertonus of the uterus, BS \> 6, total time until cervical modification, delivery route, FHR abnormalities, meconium stained liquor, ASNotesIn Portuguese, but translated\
Setting: Maternidade Escola de Vila Nova Cachoeirinha, public institution which is administrated by the Secretaria Municipal da Saúde de São Paulo, Brazil\
Study period:January 2006 to January 2008.\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random number sequence.Allocation concealment (selection bias)Low riskSequentially‐numbered, sealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing data or cases reportedSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasUnclear riskBased on translated article[Ophir 1992](#CD001233-bbs2-0076){ref-type="ref-list"}MethodsRCTParticipantsSingleton vertex presentation, BS 0‐4.InterventionsPGE2 (6 tablets 0.5 mg) intravaginally (27 women);  Foley catheter with a balloon filled with 40 mL water (27 women).OutcomesCSNotesSetting: Israel\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskAllocation sequence from a random numbers tableAllocation concealment (selection bias)High riskAllocation by odd and even numberBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not reported, 8 women missing in Foley group and 7 in PGE2 group. not clear why.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Orhue 1995](#CD001233-bbs2-0077){ref-type="ref-list"}MethodsRCTParticipantsSingleton, vertex, term fetus, adequate pelvis, maternal height \> 155 cm, BS \< 5. Exclusion if previous uterine scar, placenta praevia or abruptio, age \> 35 years.Interventions(PGE2) 3 mg every 6 hours, max 3 doses (34 women randomised, 30 women analysed)  oxytocin (2 mU/minute, doubled every 30 minutes, max 32 mU/minute) and ARM (30 women)  Foley 30 mL (30 women)OutcomesCS, instrumental delivery, uterine hyperstimulation, fetal distress, postpartum haemorrhage.Notes4 women excluded in PG group were re‐included for CS results only.\
Setting: University of Benin Teaching Hospital, Benin City, Nigeria\
Study period: April 1990 ‐ October 1991\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskAllocation sequence from a table of random numbersAllocation concealment (selection bias)Low riskConcealment of allocation by sequentially numbered, sealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not reported, 4 women excluded in PG group were because of unripe cervix after 12 hoursSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Peedicayil 1998](#CD001233-bbs2-0078){ref-type="ref-list"}MethodsRandomised equivalence trialParticipantsPrimigravid, requiring IOL, BS \< 5Interventionsn = 60 \'randomised into 2 groups\'\
Foley 12 hours\
PGE2 intracervicallyOutcomesChange in BS, ripening to delivery intervalNotesNone of our outcomes of interest were reported\
Setting: tertiary level teaching hospital, India\
Dates of study: not reported\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot described.Allocation concealment (selection bias)Low riskSequentially‐numbered opaque sealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskPerson assessing BS was blinded to what agent was used (after 12 hours and removal of agent I presume).Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNot reported how many women were randomised to which group, thus unclear.Selective reporting (reporting bias)Unclear riskThe methods section states that only BS and ripening to delivery interval were the outcomes of interest, which is questionable.Other biasHigh riskRetrospective power calculation, unclear how many women in which group.[Pennell 2009](#CD001233-bbs2-0079){ref-type="ref-list"}MethodsRCT: generation of sequence unclear, sealed opaque envelopes, patient chose from a selection of 12.ParticipantsInclusion: primipara, GA \> 36 weeks, intact membranes, BS \< 4.singleton fetus, cephalic presentation, intact membranes.\
Exclusion criteria were age \< 16 years, previous uterine surgery, low‐lying placenta, any active or purulent infection of the lower vaginal tract, or an abnormal pre‐induction FHR tracingInterventionsFoley catheter 30cc. (110).\
Atad catheter 80 cc. (107).\
PGE 2 gel 2 mg, 6‐hourly. (113).OutcomesVaginal delivery within 24 hours, uterine hyperstimulation with/without FHR changes, CS, epidural analgesia, instrumental vaginal delivery, antibiotics during labour, postpartum haemorrhage, maternal fever during labour, pH \< 7.10, placental abruption, endometritis, wound infection.NotesData for Foley catheter and double balloon catheter were entered in 1 comparison (any mechanical method versus PG).\
Setting: King Edward Memorial Hospital (KEMH) in Perth, Western Australia\
Dates of study: July 2001 to December 2003\
Funding sources: supported by a grant from the Women and Infants Research Foundation, King Edward Memorial Hospital, Perth, Australia. Adeza Biomedical Corporation contributed support for the fetal fibronectin test kits.\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskInsufficient information about sequence generation process in the paper.Allocation concealment (selection bias)Low riskSealed opaque envelopes (but why selection of 12??).Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of intervention.Blinding of outcome assessment (detection bias)   All outcomesLow riskResearch midwives were blinded to treatment allocation, especially important for satisfaction questionnaires.Incomplete outcome data (attrition bias)   All outcomesLow riskITT, loss to follow‐up is described, incomplete data not mentioned.Selective reporting (reporting bias)Low riskAll outcomes prespecified in methods were reported, report includes all expected outcomes.Other biasLow riskNo other bias detected.[Perry 1998](#CD001233-bbs2-0080){ref-type="ref-list"}MethodsRCT.ParticipantsInclusion: singleton gestation, cephalic presentation, BS of ≤ 4.\
Exclusion: spontaneous uterine contractions, rupture of membranes, placenta previa, unexplained vaginal bleeding, a non‐reactive nonstress test, an EFW \> 4500 g, a prior vertical uterine incision, parity of \> 5, active genital herpes infection, or a contraindication to receiving PGsInterventionsVaginal misoprostol 25 mcg every 4 hours (65 women)  intracervical Foley of 50cc and PGE2 (4 mg) every 4 hours (62 women)OutcomesCS, instrumental delivery, uterine hyperstimulation, AS, NICU admission, chorioamnionitis, perinatal death.NotesSetting: University of Mississippi Medical Center Labor and Delivery Unit, Jackson, USA\
Study period: August 1996 ‐ April 1997\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random schedule.Allocation concealment (selection bias)Low riskThe allocation of assignment was concealed by placement in a numbered, opaque, sealed envelopeBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not reported, although this is likely as numbers are equal to randomised numbers. No missing cases or data in outcomes of interestSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reportedOther biasLow riskNo other bias detected[Pineda Rivas 2016](#CD001233-bbs2-0081){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: obese (BMI \> 30 before 20 weeks\' GA). Singleton pregnancy. Vertex presentation, BS \< 6, Intact membranes,GA 37 + 0 to 42 + 0. Normal fetal heart tracing on admission for ripening\
Exclusion: IOL for intrauterine fetal demise, Intrauterine growth restriction, Suspected abruption at the start of induction, contraindication for a vaginal deliveryInterventionsFoley catheter (n = 20):\
PGE2 (n = 21): dinoprostone 10 mg slow release for 24 hoursOutcomesTime from initiation of IOL to vaginal delivery, number of vaginal deliveries within 24 hours in each group, CS operative vaginal deliveries chorioamnionitis oxytocin administration, epidural, ICU (NICU) admission, arterial pH \< 7, AS \< 7 at 5 minutesNotesAbstract only\
Setting: Canada\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskinsufficient information to judgeSelective reporting (reporting bias)Unclear riskinsufficient information to judgeOther biasUnclear riskAbstract only[Prager 2008](#CD001233-bbs2-0082){ref-type="ref-list"}MethodsRCT, not blinded.ParticipantsTerm pregnancy, BS 6 or less, different indication for IOL, including PROM\
Exclusion criteria: previous CS, malpresentation, immediate delivery indicated, contraindication to vaginal delivery, contraindication to PGs.InterventionsFoley catheter 30 cc (199).\
Dinoproston 2 mg 6‐hourly (191).\
Misoprostol 25 mcg vaginally 4‐hourly (199).OutcomesUterine hyperstimulation, CS, epidural analgesia, instrumental delivery, meconium, AS, NICU admissions, fever during delivery.NotesHyperstimulation is not further specified (with of without FHR changes).\
Patients who did not meet inclusion criteria were not excluded retrospectively\
Setting: Karolinska university Hospital, Sweden\
Dates of study: December 2004 to March 2008\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence.Allocation concealment (selection bias)Low riskOpaque numbered envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskMissing data described: 3 dinoprostone and 1 catheter. these were excluded.Selective reporting (reporting bias)Low riskAll outcomes prespecified in methods were reported, report includes all expected outcomes.Other biasUnclear riskPatients who did not meet inclusion criteria were not excluded retrospectively (n = 32).[Qamar 2012](#CD001233-bbs2-0083){ref-type="ref-list"}MethodsQuasi‐experimentalParticipantsInclusion: singleton alive fetus, cephalic presentation, gestation at or beyond 37 weeks, para 4 or less, BS less than 5, obstetric and medical indication for induction\
Exclusion: congenital anomalies, multiple pregnancies, mal‐presentation, CPD, placenta praevia or APH, previous CS, and PROMInterventionsPGE2 pessary (80) dosage not known, failure of improvement of modified BS after 6 hours (\< 5), a second PG E2 gel/pessary was applied and patient reassessed again after 6 hours. If still there was no improvement in BS (\< 5) a 3rd PG E2 gel/pessary was applied.\
PGE2 intracervical (80): as above\
EASI with oxytocin IV (80) Foleys catheter of 24 or 26 Fr, inflated with 45 mL of distilled water. Traction applied and then saline infusion was started extra‐amniotically at 30 mL per hour for 12 hours. oxytocin infusion was started at 2 mU/minute and the dose was doubled at half‐hourly interval up to the max dose of 40 mU/minuteOutcomesinduction labour interval, induction delivery interval, mode of delivery, AS at 1 and 5 minutes, and neonatal morbidity and mortality including ICU admission.NotesNo relevant outcomes reported in article\
Setting: Pakistan\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskAllocation in order of admissionAllocation concealment (selection bias)High riskMethod of induction could be foreseen as a rotation was usedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskUnclear if ITT was used, missing cases or outcomes not reportedSelective reporting (reporting bias)High riskNeonatal mortality not reported in numbers, only reported they dit not differ. neonatal morbidity not reported in resultsOther biasLow riskNo other bias detected[Ridgway 1991](#CD001233-bbs2-0084){ref-type="ref-list"}MethodsRCT. No details were given on the method for generating the allocation sequence or for the concealment of the allocation.ParticipantsBS \< 5.InterventionsIntracervical PGE2 (0.5 mg) and Lamicel (52 women);\
intracervical PGE2 (0.5 mg) alone (49 women).OutcomesCS.NotesSetting: San Antonio, USA\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomisation not describedAllocation concealment (selection bias)Unclear riskNo informationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNo informationIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not mentioned, insufficient information to judgeSelective reporting (reporting bias)Unclear riskInsufficient information to judgeOther biasUnclear riskAbstract only, insufficient information to judge risk of bias[Roberts 1986](#CD001233-bbs2-0085){ref-type="ref-list"}MethodsRCTParticipantsUnfavourable cervix (BS \< 5). Women with previous history of uterine surgery, fetal malpresentation or multiple gestation were excluded.Interventions4 groups:\
PGE1 in Tylose gel 3 mg (27 women) (exclude);\
laminaria tents (28 women);\
oxytocin 1 mU/minute (25 women);\
no treatment (24 women exclude).\
Then oxytocin was given in all groups.OutcomesCS.NotesSuccessful IOL and fetal distress not defined.\
Setting: Jackson, USA\
Dates of study: not reported\
Funding: supported by the Vicksburg hospital medical foundation:\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly ordered envelopes, not clear howAllocation concealment (selection bias)Low riskDrawing a sealed envelope by a third partyBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNo informationIncomplete outcome data (attrition bias)   All outcomesLow riskITT not reported, although this is likely as numbers are equal to randomised numbers. no missing cases or dataSelective reporting (reporting bias)Unclear riskNo outcomes pre specified in method sectionOther biasLow riskNo other bias detected[Rouben 1993](#CD001233-bbs2-0086){ref-type="ref-list"}MethodsRCT. Allocation sequence from a table of random numbers. Blocks of 6 women. Concealment of allocation by sequentially‐numbered, sealed, opaque envelopes.ParticipantsSingleton vertex term pregnancies, intact membranes, BS \< 6. Excluded if non‐reassuring FHR, placenta praevia.InterventionsFoley catheter inflated with 30 mL water and extra‐amniotic infusion of 1 mL/minute saline during up to 8 hours (56 women);  PGE2 vaginal gel 2.85 mg (56 women).OutcomesBS change, CS, uterine hyperstimulation, NICU admission, chorioamnionitis, spontaneous labour, failure of induction, endometritis.NotesAlso reported as abstract (Arias 1993).\
Setting: St. Louis, USA\
Dates of study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number tableAllocation concealment (selection bias)Low riskConsecutively‐numbered, opaque, sealed envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNo informationIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not reported, women with failed induction excluded from further analysisSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Roudsari 2011](#CD001233-bbs2-0087){ref-type="ref-list"}MethodsRCTParticipantsIndication for IOL, GA \> 37 weeks, BS \< 7, singleton, gestational diabetes mellitus, reassuring FHR tracing, cephalic presentation, intact membranes, low‐located placenta (no definition), and mild pre‐eclampsia. Excluded hypersensitivity to PG, temp \> 38, previous CS delivery or other uterine surgery, placenta previa, chorioamnionitis, vaginal bleeding, fetal distress, macrosomia and polyhydramnios.InterventionsLow‐dose vaginal misoprostol: 25 mcg, repeated up to 6 doses every 4 hours. If no BS \> 7 after 24 hours, oxytocin was started\
Foley catheter (n = 59) 18 F, 50 mL. After 12 hours oxytocin was started.Outcomesinterval time from the first intervention to the time of delivery. Uterine tachysystole, uterine hyperstimulationNotesSetting: Department of Obstetrics, teaching hospitals, Mashhad University of Medical Sciences, Iran\
Study period: September 2007 to March 2008\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reported howAllocation concealment (selection bias)Unclear riskNot reported howBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskNo ITT mentioned, no missing data, 1 woman excluded because of bad participation?Selective reporting (reporting bias)Unclear riskTime to delivery: not clear from when till delivery, most likely from active phase. primary outcome was for first intervention to delivery. other pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Roztocil 1998](#CD001233-bbs2-0088){ref-type="ref-list"}MethodsAllocation according to the week of admission. No concealment of allocation.ParticipantsSingleton vertex term pregnancies, BS \< 5. Excluded if labour, fetal hypoxia, previous CS.InterventionsDilapan S 4 units, removed after 14 hours (82 women);  PGE2 intracervical gel 0.5 mg, 1 dose (83 women).  In both groups, PGE2 vaginal tablets were administered after 14 hours for labour induction.OutcomesCS, hyperstimulation with FHR changes, instrumental vaginal delivery, AS \< 7, GI side effects, haemorrhage.NotesInadequate method of random allocation and of concealment of allocation.\
Setting: obstetrics department Brno, Chech Republic\
Study period: January 1994 to December 1996\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskAllocation according to the week of admission.Allocation concealment (selection bias)High riskNo concealment of allocationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not reported, but seems reasonable as numbers are equal to randomised numbers. no missing cases or dataSelective reporting (reporting bias)Low riskPre‐specified outcomes reportedOther biasLow riskNo other bias detected[Rudra 2012](#CD001233-bbs2-0089){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: low BS, AROM not possible\
Exclusion criteria: grande multiparas, preterm inductionInterventions1. Foley catheter (n = 200), 40 mL, 24 hours\
2. PGE2 vaginal; 2 mgOutcomesDuration of labour, mode of delivery, postpartum infection and haemorrhage and perinatal, ASNotesAbstract only\
Setting: Batticaloa General Hospital, Sri Lanka\
Study period: 18 months from 2004\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesLow riskDouble‐blind? Not clear how this is possibleBlinding of outcome assessment (detection bias)   All outcomesLow riskDouble‐blind? Not clear how this is possibleIncomplete outcome data (attrition bias)   All outcomesUnclear riskToo little information to judgeSelective reporting (reporting bias)Unclear riskToo little information to judgeOther biasUnclear riskAbstract only[Saleem 2006](#CD001233-bbs2-0090){ref-type="ref-list"}MethodsPatients randomly selected, randomisation method not described.ParticipantsSingleton live pregnancy BS 5 or lower, requiring induction between 37 and 42 weeks of gestation.InterventionsFoley catheter 40‐45 mL, after 8‐10 hours oxytocin infusion was started (n = 78).\
Dinoprostone pessary 3 mg 6‐hourly max 2 doses, followed by oxytocin infusion (n = 75).\
Oral misoprostol 50 mcg 4‐hourly, max 4 doses, followed by oxytocin infusion (n = 73).OutcomesVaginal delivery rate, Induction to delivery interval \< 12 hours, postpartum haemorrhage, tachysystole.NotesMethods describe random selection of patients, not randomisation.\
No neonatal outcomes.\
Setting: Hamdard University Hospital and Patel Hospital, Pakistan\
Dates of study: July 2005 ‐ June 2005\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\'Random selection\' of patients, insufficient information for judgement.Allocation concealment (selection bias)Unclear risk\'Random selection\' of patients, insufficient information for judgement.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskIt is unclear how many patients were assessed for randomisation or randomised, therefore it is also unclear if incomplete data were reported. There is no mention of this in the paper.Selective reporting (reporting bias)Unclear riskAll outcomes mentioned in the methods section are reported, it is however interesting why they did not report any neonatal data.Other biasUnclear riskNo sample size calculated[Salim 2011](#CD001233-bbs2-0091){ref-type="ref-list"}MethodsRCTParticipantsInclusion: viable singleton pregnancy, cephalic presentation, intact membranes, BS of ≤ 6.\
Exclusion: contraindication for vaginal delivery, previous caesarean delivery, a low‐lying placenta, fetal malformations that were incompatible with postpartum life, intrauterine fetal death, clinical amnionitis, carriers of hepatitis B/C, HIV, allergy to latex.Interventions1. Foley: (n = 145) 24 F, 60 mL, max 12 hours\
2. Double balloon (n = 148), 80/80 mL, max 12 hoursOutcomesTime from insertion of the catheter to delivery, mode of delivery, vaginal deliveries within 24 hours, abnormal fetal presentation, cord prolapse, intrapartum fever more than 38°C, bleeding related to catheter insertion, AS.NotesSetting: Emek medical centre, Afula, Israel. (teaching medical centre)\
Study period: June 2008 and December 2010\
Funding: Department of obstetrics, Emek medical centre\
Declarations of interest: none reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numbers, block randomisationAllocation concealment (selection bias)Low riskSequentially‐numbered allocation, stored in a box.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported and not clear if done, no missing data or cases.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Sanchez‐Ramos 1992](#CD001233-bbs2-0092){ref-type="ref-list"}MethodsRCT. Computer‐generated allocation sequence. No details on concealment of allocation.ParticipantsSingleton vertex term pregnancies, intact membranes, BS \< 6. Excluded if non‐reassuring FHR, placenta praevia, previous uterine scar, cervicitis.InterventionsHygroscopic cervical dilators (as many as possible) (36 women); (PGE2) 4 mg gel applied to the cervical os (n = 38). After 8‐12 hours, repeat in both groups if cervix unfavourable. Followed by oxytocin and amniotomy.OutcomesCS, instrumental vaginal delivery, haemorrhage, admission to NICU, infection.NotesUnclear whether PG was intracervical or intravaginal.\
Setting: Univerity medical Center of Jacksonville, USA. largely high risk, low income obstetric population\
Study period: June 1988 to July 1989\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomisation listAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported and not clear if done, no missing data or cases reportedSelective reporting (reporting bias)Unclear riskNo outcomes pre specified in method sectionOther biasLow riskNo other bias detected[Sarreau 2016](#CD001233-bbs2-0093){ref-type="ref-list"}MethodsRCTParticipantsInclusion: indication for IOL, vertex, singleton, \> 37 weeks of GA, previous CS (transverse incision), BS \< 5, no premature rupture of membranes, singleton in vertex presentation.\
Exclusion: \< 18 years, placenta praevia, cervical infection, malpresentation, latex allergy, induction for CSInterventions1. Foley catheter (n = 101): 50 mL, max 12 hours (N = 101)\
2. oxytocin (N = 103), low‐dose perfusionOutcomesVaginal birth rate, maternal and neonatal complicationsNotesAbstract only (awaiting publication)\
Setting: France, multicentre\
Study period: December 2010 tot December 2013\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT, too little information to judge incomplete outcome dataSelective reporting (reporting bias)Unclear riskToo little information to judgeOther biasUnclear riskAbstract only[Sciscione 1999](#CD001233-bbs2-0094){ref-type="ref-list"}MethodsRCT. Computer‐generated allocation sequence. Concealment of allocation by opaque, sealed, consecutively‐numbered envelopes.ParticipantsSingleton vertex pregnancies with intact membranes, BS \< 6. Term \> 28 weeks. Inclusion of women with previous CS.InterventionsIntracervical PGE2 (0.5 mg) every 6 hours (72 women).  Intracervical Foley catheter inflated with 30 mL (77 women).OutcomesSpontaneous onset of labour, nausea, maternal discomfort measured with an analogue scale 0‐10, non‐reassuring FHR, hyperstimulation, use of epidural, use of oxytocin, shoulder dystocia, vaginal delivery.Notes12 women excluded (6 women in PGE2 group because of use of Foley catheter, 2 removed consent, 1 pre‐eclampsia, 1 BS of 7 and 2 breech).\
Setting: Medical centre of Delaware, USA. tertiary referral centre,\
Study period: July 1995 to July 1996\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random allocation.Allocation concealment (selection bias)Low riskSealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskNo ITT, women excluded because of protocol violation. no missing data.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Sharami 2005](#CD001233-bbs2-0095){ref-type="ref-list"}MethodsRandomised trial: computer‐generated random number table, blocks of 4, sequentially‐numbered opaque sealed envelopes.ParticipantsNulliparous women, admitted for induction, between 34 and 42 weeks GA, singleton in cephalic presentation, BS \< 4, intact membranes, reassuring FHR tracing, \< 6 contractions per hour\
Exclusion: significant vaginal bleeding, fetal chorioamnionitis, any contraindication to vaginal delivery, previous uterine scar, FHR abnormalities, severe pre‐eclampsia, contraindication to PG.InterventionsFoley 30 mL + EASI + concurrent IV oxytocin for 12 hours (n = 76).\
PGE2 gel 0.5 mg intracervical 6‐hourly, max 3 doses (n = 75).OutcomesInterval from start induction to active phase, abnormal FHR tracing, tachysystole, hyperstimulation, meconium passage, caesarean delivery, chorioamnionitis, endometritis, AS \< 7, admission NICU\
Secondary: start induction to delivery, change in dilation at 1, 6, 12 hours, CS for failed induction.NotesNo sample size calculation.\
Prophylactic antibiotics after 12 hours of start induction\
Setting: Prenatal Clinic in Al‐Zahra Maternity\
Hospital, Iran\
Dates of study: March 2002 ‐ September 2003\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated sequence.Allocation concealment (selection bias)Low riskSequentially‐numbered opaque sealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskGood description of excluded patients, quite evenly spread over the groups. There is no information about missing/incomplete outcome data.Selective reporting (reporting bias)Low riskIt seems that all outcomes prespecified in methods were reported, report includes all expected outcomes.Other biasLow riskNo other bias detected[Shechter‐Maor 2015](#CD001233-bbs2-0096){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: singleton, GA 37 weeks or more, cephalic presentation, intact membranes, unfavourable cervix (BS =/\< 6), oligohydramnios (AFI =/\< 5)\
Exclusion criteria: multifetal gestation, fetal malpresentation, spontaneous labour, contraindication to PGs or a vaginal delivery (e.g. placenta previa), non‐reassuring FHR tracing, a fetus with major anomalies or previous CSInterventions1. Propess (10 mg slow release PGE), n = 26\
2. Double balloon (Cook), n = 26OutcomesTime from induction to active labour (defined as cervical dilation of at least 5 cm), induction to delivery time, CS and operative delivery rates, oxytocin augmentation, uterine tachysystole (defined as greater than 5 uterine contractions in 5 minutes), meconium passage, FHR changes, AS and maternal satisfactionNotesSetting: Israël\
Study period: not reported\
Funding: none received\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskUsing computer‐generated, random sequencesAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, no missing data described. No figure 1, all women analysedSelective reporting (reporting bias)High riskAll pre‐specified outcomes reported but secondary outcome \'AS\'Other biasUnclear riskNot mentioned in method section how long balloon/dinoprostone was given and what happened after ripening process.[Sheikher 2009](#CD001233-bbs2-0097){ref-type="ref-list"}MethodsRCTParticipantsInclusion: 1st or 2nd gravida, single, live fetus, cephalic, indication for IOL, GA 37‐42 weeks, BS ≤ 5, absence of uterine contractions.\
Exclusion: previous uterine surgery, non reassuring FHR tracing, IUGR, oligohydramnios, placenta praevia, multifetal pregnancy, chorioamnionitis, active herpes, EFW \> 4 kg, renal or hepatic diseaseInterventions1. Oral misoprostol (n = 30):, 50 mcg, repeated every 4 hours to a max of 5 doses.\
2. Vaginal misoprostol (n = 30): 25 mcg, repeated every 4 hours to a max of 5 dosis. n = 30\
3. Foley catheter (n = 30): 16 or 18 F, 35 mL. max of 16 hours\
In all 3 groups after 16 hours oxytocin was started.Outcomesinterval from induction to birth, mode of delivery, maternal complication, neonatal outcome, failed inductionNotesSetting: SMGS hospital, Jammu, India\
Study period: over 1 year\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandom assigned, no more information reportedAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskNo ITT reported, cases missing in table 2, not clear whySelective reporting (reporting bias)High riskNo outcome measures were mentioned in the method section, induction to delivery interval is given but no SDs,Other biasLow riskNo other bias detected[Solt 2009](#CD001233-bbs2-0098){ref-type="ref-list"}MethodsRCTParticipants100 primiparae and 100 multiparae women with an unfavourable BSInterventionsFoley catheter:(nulliparae n = 50)\
Double balloon:(nulliparae n = 45)OutcomesPrimary outcomes were BS increment, time from catheter withdrawal to delivery, CS rate and post caesarean febrile morbidity.NotesAbstract only, numbers only given for nulliparae\
Setting: Israel\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numbersAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskReported it was a single‐blinded study, not how blinding was performed.Incomplete outcome data (attrition bias)   All outcomesUnclear risk20 women excluded from analyses, not clear whySelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasUnclear riskAbstract only[Somirathne 2017](#CD001233-bbs2-0099){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: not delivered by 40 weeks + 5 days gestation, having uncomplicated pregnancies with a singleton fetus, longitudinal lie and cephalic presentation.\
Exclusion criteria were pregnancy‐induced hypertension, gestational diabetes mellitus, multiple pregnancies, planned CS, fetal growth restriction and scarred uterusInterventions1. Foley catheter, (n = 89), 60 mL, max 24 hours\
2. Low dose oral misoprostol (n = 91), 50 mcg, 3 gifts, 4 hourly (N = 91)\
In both groups, if cervix is unfavourable after 24 hours Foley group PGE2, oral misoprostol group Foley catheter)OutcomesThe induction delivery interval following IOL, the mode of delivery, the reasons for operative delivery, maternal morbidity, hyperstimulation, uterine rupture, peripartum hysterectomy, postpartum blood transfusion or crystalloid transfusion, IV antibiotics, maternal pyrexia of \> 38°C, fetal and neonatal outcome and morbidity, suspicious or pathological CTG according NICE guidelines, meconium‐stained liquor, birthweight, 1 minute AS, NICU and reason for admissionNotesSetting: University Unit of the THMG, Sri Lanka\
Study period: September 2014 to April 2015.\
Funding: none\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numbers, block randomisation,stratified by parityAllocation concealment (selection bias)Low riskSequentially‐numbered, sealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, no missing data or cases. referred to Figure 1, but not availableSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[St Onge 1995](#CD001233-bbs2-0100){ref-type="ref-list"}MethodsRCT. Computer‐generated allocation sequence. Concealment of allocation by sealed envelopes.ParticipantsSingleton vertex term pregnancies with intact membranes, BS \< 5. Exclusion of women with previous CS, low‐lying placenta.InterventionsIntracervical PGE2 (0.5 mg) (30 women).  Intracervical Foley catheter inflated with 30 mL (36 women).OutcomesCS, instrumental delivery, maternal side effects, maternal pyrexia, fetal distress.Notes2 women excluded in each group. Also reported as abstract (Lange 1994).\
Setting: Foothills Hospital in Calgary, Alberta, Canada\
Study period: October 1991 to November 1993\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated allocation sequence.Allocation concealment (selection bias)Low riskConcealment of allocation by sealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear risk2 women in each group excluded (not meeting inclusion criteria or in labour directly after randomisation). no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Suffecool 2014](#CD001233-bbs2-0101){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: nulliparous, 18 years or older, GA 37 weeks or more, singleton, cephalic presentation, intact membranes, BS \< 6, admission for IOL.\
Exclusion criteria: contraindication for vaginal delivery (placenta praevia, non vertex presentation), ruptured membranes, severe pre‐eclampsia, suspected fetal growth restriction with abnormal dopplers, presence of a uterine scar, non reassuring FHR trace requiring medical intervention.Interventions1. 10 mg dinoprostone vaginal insert (n = 31), max 12 hours, if after 12 hours unfavourable cervix start with oxytocin\
2. Double balloon (Cook) (n = 31), 80 mL, oxytocin started 6 hours after placement. Balloon removed after max 12 hours.OutcomesTime from insertion of ripening method until delivery, delivery rate \< 24 hours, CS rate, time to active labour, rate of operative vaginal delivery, maternal or fetal adverse eventsNotesSetting: USA\
Study period: February 2011 ‐ September 2012\
Funding: not reported\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numbersAllocation concealment (selection bias)Low riskThe allocation assignment was sealed in sequentially‐numbered, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing data or cases.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Sullivan 1996](#CD001233-bbs2-0102){ref-type="ref-list"}MethodsRCT. Concealment of allocation by opaque, sealed envelopes.ParticipantsBS \< 6 and indication/no contraindication for IOL.InterventionsIntracervical PGE2 (0.5 mg) and Foley catheter inflated with 50 mL of water (41 women); intracervical PGE2 (0.5 mg) repeated after 4 to 6 hours if needed (37 women).OutcomesCS, uterine hyperstimulation with and without FHR changes, infection.NotesSetting: Jackson, USA\
Study period: October 1993 ‐ May 1994\
Funding: supported by the Vicksburg hospital medical foundation\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot reportedAllocation concealment (selection bias)Low riskConcealment of allocation by opaque, sealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not reported, but is reasonable as numbers are equal to randomised numbers, no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcome reported.Other biasLow riskNo other bias detected[Tabowei 2003](#CD001233-bbs2-0103){ref-type="ref-list"}MethodsRandom number table, opaque sealed envelopes.ParticipantsTerm pregnancy, singleton fetus in cephalic presentation, BS \< 4.\
Exclusion: ruptured membranes, placenta praevia, non‐reactive non‐stress test, EFW \> 4000 g, prior uterine incision, parity \> 4, contraindication to PGs.InterventionsFoley 50 mL max 12 hours (n = 61).\
Vaginal misoprostol 25 mcg every 4 hours, max 6 doses (n = 60).OutcomesFailure to achieve ripening within 12 hours, vaginal delivery within 24 hours, need for oxytocin augmentation, CS rate, tachysystole, hypertonus, meconium, maternal and neonatal complications, AS \< 7, NICU admissions, febrile morbidity.NotesPrior uterine incision is exclusion criterion, but 18 women with previous CS included.\
Setting: Zonal general hospital, Nigeria\
Study period: June 1998 to May 2001\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Low riskOpaque sealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesUnclear riskIncomplete outcome data were not mentioned in the report.Selective reporting (reporting bias)Low riskAll outcomes prespecified in methods were reported, report includes all expected outcomes.Other biasUnclear riskPrior uterine incision is exclusion criterion, but 18 women with previous CS included, they were evenly divided between the groups.[Tan 2015](#CD001233-bbs2-0104){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: pregnant women aged 21 to 40 years old with a singleton pregnancy with no major fetal anomaly who were suitable for vaginal delivery and scheduled for a planned IOL at 37‐41 + 6 weeks of gestation.\
Exclusion criteria: spontaneous labour, had a cervical dilatation of 3 cm or more, confirmed rupture of membrane, had abnormal cardiotocogram, a scarred uterus such as previous CS, malpresentation in labour, or if CS delivery was indicatedInterventions1. Double balloon (80 mL, balloon started with 40 mL, every following hour 20 mL inserted until 80 mL total), max 12 hours (N = 31)\
2. PG 3 mg tablet, repeat once after 6 hours (N = 54)\
If not in labour or AROM possible after 12 hours, further management by local physician.OutcomesNot clearly mentioned in method sectionNotesSetting: tertiary referral maternity unit in Singapore.\
Study period: not reported\
Funding: double balloons provided by Cook Medica\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskShuffling of 150 envelopes with equal numbers of chance for intervention or control, labelled sequentiallyAllocation concealment (selection bias)Low riskSealed envelope, next allocated number of envelopeBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskITT not described, seems per protocol as woman in pain and breech during labour were excluded; no missing data describedSelective reporting (reporting bias)Unclear riskNo pre specified outcomes reported, so cannot be judgedOther biasLow riskNo other bias detected[ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}MethodsRCTParticipantsInclusion: singleton, scheduled for labour induction, GA ≥ 37 wk; BS \< 6, vertex presentation, intact membranes.\
Exclusion: placenta previa, previous uterine scar. contraindication to receive or known allergy to latex or PG.Interventions1. Foley catheter (n = 921): 30 mL, no traction, replaced after 48 hours, max 4 days\
2. Low dose oral misoprostol (n = 924): 50 mg every 4 hours, max 3 times a day, max 4 daysOutcomesPrimary outcome for safety was composite of fluxus postpartum and asphyxia, and for effectiveness CS rate. Secondary outcomes included maternal and neonatal outcomes, total induction time, interval between randomisation and active phaseNotesSetting: multicentre, 6 tertiary‐care and 23 secondary‐care hospitals, the Netherlands\
Study period: July 2012 to October 2013,\
Funding: FondsNutsOhra, no role in study design, data collection, data analysis, data interpretation, writing of the report or publication\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numbers, block randomisation, stratified by parity and centreAllocation concealment (selection bias)Low riskWeb‐based allocationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT, no missing cases. missing data in primary outcome (pH in umbilical artery). similar reasons for missing data across groups, pre‐specified in protocol, anticipated on as followed: data missing for umbilical artery pH and a 5‐minute AS of less than 7, the outcome was classified as abnormal; for patients with missing data for umbilical artery pH and a 5‐minute AS of 7 or more, the neonatal outcome was classified as normal.Selective reporting (reporting bias)Low riskAll pre‐specified outcomes were reported in resultsOther biasLow riskNo other bias detected[Thiery 1981](#CD001233-bbs2-0106){ref-type="ref-list"}MethodsRCT. Concealment of allocation by envelopes.ParticipantsSingleton vertex term pregnancies. Favourable cervix (BS \> 5).InterventionsFoley catheter with a balloon inflated with 30 mL saline and PGE2 0.5 mg extra‐amniotic (48 women);  PGE2 0.5 mg extra‐amniotic (43 women);  amniotomy and oxytocin if needed (52 women).OutcomesNo outcomes reported.NotesNo relevant outcomes reported.\
Setting: Belgium\
Study period: not reported\
Funding: received free PGE2. not clear if this gift is related to a pharmaceutical company\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskPrepared envelopes with numbersAllocation concealment (selection bias)Low riskConcealment of allocation by envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskUnclear if ITT was performed, but is reasonable as numbers are equal to randomised numbers), no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasLow riskNo other bias detected[Tita 2006](#CD001233-bbs2-0107){ref-type="ref-list"}MethodsRCTParticipantsInclusion: preterm rupture of membranes, cervix ≤ 2 cm\
GA ≥ 34 weeks, singleton gestation, cephalic,\
Exclusion: regular uterine contractions (contractions more frequent than every 5 minutes), 2 prior transverse uterine incisions/vertical uterine incision/transmural myomectomy or any obstetric contraindication to labour, evidence of chorioamnionitis, lethal fetal anomalies, intrauterine fetal demise, placenta previa, suspected abruption/significant haemorrhage, non‐reassuring FHR patternInterventionsFoley + oxytocin (n = 87)\
oxytocin only (n = 82)OutcomesReported outcomes: hours from placement of Foley or initiation of oxytocin to delivery, rate of delivery (vaginal or caesarean) within 24 hours caesarean rate, induction to vaginal delivery interval.NotesGrey literature: study terminated, primary outcomes reported in trial registration.\
Setting; USA\
Study period: December 2005 ‐ May 2008\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomisation process unclearAllocation concealment (selection bias)Unclear riskUnclearBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskUnclear if ITT analyses was used. for CS there are missing casesSelective reporting (reporting bias)High riskOnly primary outcomes were reported in trial registrationOther biasUnclear riskStudy was terminated (not clear why)[Turnquest 1997](#CD001233-bbs2-0108){ref-type="ref-list"}MethodsRCTParticipantsTerm women with unfavourable cervix (BS \< 5), intact membranes.InterventionsLaminaria (as many as possible) and (PGE2) vaginal gel (4 mg) (21 women);  (PGE2) vaginal gel (4 mg) alone (27 women).OutcomesNeed for oxytocin, CS, uterine hyperstimulation, admission to NICU, chorioamnionitis.NotesSetting: memorial hospital Indianapolis, USA\
Study period: October 1994 to May 1995\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated allocation sequence.Allocation concealment (selection bias)Low riskConcealment of allocation by consecutively‐numbered, opaque, sealed envelopes.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh risk4 women excludes because of protocol violation, no missing cases or dataSelective reporting (reporting bias)Low riskAll outcomes reportedOther biasLow riskNo other bias detected[Wang 2012](#CD001233-bbs2-0109){ref-type="ref-list"}MethodsRCTParticipantsInclusion criteria: primiparae, full‐term, singleton with cephalic presentation; indication for labour induction; intact membranes; BS \< 6; no contra indication for vaginal deliveryInterventionsFoley catheter (n = 138); 16F Foley, 80cc fluid, max 24 hours\
Propess: (n = 124), 10 mg slow release dinoprostone, fornix posterior, max 24 hours\
afterwards started with oxytocin. if after 3 days labour did not started, IOL was declared failedOutcomesThe duration of placement (of Propess or catheter, mode of delivery and time from IOL to delivery; usage of oxytocin, postpartum haemorrhage; meconium‐stained amnion fluid, AS, post‐delivery temperature monitoring (for a total of 10 days); 42 days after delivery follow‐up interview to check for lochia appearance or signs of infection.NotesArticle in Chinese =\> translated by native speaker\
Setting: China\
Study period; not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number tableAllocation concealment (selection bias)Unclear riskNot reportedBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskNo ITT, women were excluded for different reasons during the trial (n = 8)Selective reporting (reporting bias)Low riskAll pre‐specified outcomes reportedOther biasUnclear riskJudged from a translated article[Wang 2014](#CD001233-bbs2-0110){ref-type="ref-list"}MethodsRCTParticipantsInclusion: oligohydramnios (AFI \< 5 cm). GA beyond 37 0/7 weeks', singleton pregnancy, vertex presentation, BS ≤ 6, intact membranes, the absence of documented uterine contractions, the absence of prior CS delivery, reassuring antenatal fetal testing (non‐stress test) active, and oxytocin challenge test negative upon study entry.\
Exclusion: antepartum bleeding, chorioamnionitis, placenta previa, or any other contraindication to vaginal delivery, women with documented PG allergy, maternal asthma history, vaginitis or cervicitis at presentation, and/or glaucoma history were not eligible for the pharmacological treatment armInterventionsDouble balloon (n = 67): 80/80cc, no traction, max 12 hours. After 24 hours unsuccessful ripening start oxytocin\
10 mg dinoprostone insert (n = 59), fornix posterior, max 24 hours, After 24 hours unsuccessful ripening start oxytocinOutcomesPregnancy outcomes and success of inductionNotesSetting: The People's Liberation Army 174th Hospital, Xiamen, China,\
Study period: April 2010 ‐ February 2011\
Funding: financial support of The People's Liberation Army Nanjing Military Area Command Medicine Health Department in China.\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot described how random sequence was generated.Allocation concealment (selection bias)Low riskSealed envelope randomisation, opaque?Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh riskNo ITT =\> 5 woman reassigned after randomisation (non re‐assuring FHR, failed placement) no missing data or casesSelective reporting (reporting bias)Unclear riskNo pre specified outcomes reported, so can\'t be judgedOther biasLow riskNo other bias detected[Wu 2017](#CD001233-bbs2-0111){ref-type="ref-list"}MethodsRCTParticipantsInclusion: 18--40 years old; 37 + 0‐41 + 6 gestational weeks; BS ≤ 6; single alive fetus with cephalic presentation; in cephalopelvic proportion; without premature rupture of membrane; NST reaction type before labour induction. The indications of labour induction included delayed pregnancy, oligohydramnios (AFI = 3.0--8.0 cm), gestational diabetes mellitus, intrahepatic cholestasis of pregnancy, good control of gestational hypertension, with vaginal trial production condition and required pregnancy termination.\
Exclusion: placenta previa, vasa previa and APH; invasive cervical carcinoma; untreated HIV infection; allergic to induction drugs.InterventionsDouble‐balloon combined with IV drip of oxytocin (n = 60) AROM after 12 hours.\
IV drip of oxytocin at a concentration of 0.5% (n = 60); AROM after 12 hours\
If the patients did not enter the stage of active labour within 48 hours, the labour induction was regarded as failing, and other methods for pregnancy termination were usedOutcomesPostpartum haemorrhage, cervical laceration, uterine rupture, puerperal infection, neonatal asphyxia, neonatal infection and meconium aspiration syndromeNotesSetting: China\
Study period: January 2014 ‐ June 2015\
Funding: grants received from the Nature Science Foundation of China, the Science and Technology Project of Special Funds of Guangzhou, Guangdong Science and Technology Project, the Natural Science Foundation of Guangdong Province and Guangzhou Science and Technology Project\
Declarations of interest: none declared***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskWomen randomly divided, no information givenAllocation concealment (selection bias)Unclear riskNo information reported on allocation concealmentBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesLow riskITT not mentioned, but is reasonable as numbers are equal to randomised numbers. no missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcomes were reportedOther biasLow riskNo other bias detected[Yuen 1996](#CD001233-bbs2-0112){ref-type="ref-list"}MethodsRCTParticipantsSingleton vertex presentation, intact membranes, BS \< 5, no previous CS.InterventionsAtad device (100 mL) (36 women);  intracervical PGE2 (0.5 mg) (39 women);  vaginal pessary 0.5 mg PGE2 (39 women).OutcomesChange in BS, vaginal delivery achieved within 12 and 24 hours, CS, instrumental delivery, vaginal bleeding, uterine hyperstimulation, AS.Notes5 women were excluded (2, 2 and 1, respectively).\
Setting: Prince of Wales Hospital, Honkong teaching hospital, China\
Dates of study: period of 18 months\
Funding sources: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated numberAllocation concealment (selection bias)Low riskSealed, opaque envelopesBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNot reportedIncomplete outcome data (attrition bias)   All outcomesHigh risk5 women excluded because of protocol violation, no other missing cases or dataSelective reporting (reporting bias)Low riskAll pre‐specified outcome reportedOther biasLow riskNo other bias detected[Zahoor 2014](#CD001233-bbs2-0113){ref-type="ref-list"}MethodsRCTParticipantsWomen requiring IOL for common indications, no previous CSInterventionsPGE2 tablets (n = 100) dosage of 2 mg, every 6 hours, max of 4 doses\
transcervical balloon catheter(n = 100) filled with 60 mL of saline.OutcomesInduction to delivery interval, mode of delivery, meconium staining, CTG abnormalities, admission in NICU, low ASNotesNo relevant outcomes were reported in the abstract\
Setting: Pakistan\
Study period: not reported\
Funding: not reported\
Declarations of interest: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomisation not describedAllocation concealment (selection bias)Unclear riskNo informationBlinding of participants and personnel (performance bias)   All outcomesUnclear riskNot feasible due to nature of interventionBlinding of outcome assessment (detection bias)   All outcomesUnclear riskNo informationIncomplete outcome data (attrition bias)   All outcomesUnclear riskITT not reported, insufficient information.Selective reporting (reporting bias)Unclear riskInsufficient information.Other biasUnclear riskAbstract only, too little information to judge risk of bias[^1]

Characteristics of excluded studies \[ordered by study ID\] {#CD001233-sec2-0020}
===========================================================

StudyReason for exclusion[Abramovici 1999](#CD001233-bbs2-0114){ref-type="ref-list"}It is unclear whether all women had Foley catheter (included as \'intention to ripe the cervix\' with Foley catheter). Women only received a Foley catheter when they had no dilation at the start of induction (for this study this was the control group), and concurrent oxytocin was started. It is unclear how many women received a Foley catheter.[Adeniji 2005a](#CD001233-bbs2-0115){ref-type="ref-list"}Primary outcome fibronectin, other outcomes not mentioned.[Adeniji 2005b](#CD001233-bbs2-0116){ref-type="ref-list"}High‐dose misoprostol[Adeniji 2006](#CD001233-bbs2-0117){ref-type="ref-list"}Outcome cervical scores, other outcomes not mentioned.[Afolabi 2005](#CD001233-bbs2-0118){ref-type="ref-list"}Only reports outcomes for the successfully induced, thus not useful.[Ahmad 2015](#CD001233-bbs2-0119){ref-type="ref-list"}laminaria vs Foley =\> not within scope of review[Anabosy 2014](#CD001233-bbs2-0120){ref-type="ref-list"}Trial stopped before start patient inclusion because of technical issues[Arsenijevic 2012](#CD001233-bbs2-0121){ref-type="ref-list"}No dilatator vs hegar vs continues, controlled, balloon dilator =\> not within scope of review[Arshad 2016](#CD001233-bbs2-0122){ref-type="ref-list"}Laminaria prior to PGE2 vs nothing prior to PGE2 =\> not within scope of review[Atad 1991](#CD001233-bbs2-0123){ref-type="ref-list"}No randomised comparison of mechanical methods. A subgroup of women were randomised to receive PGE2 or placebo.[Atad 1999](#CD001233-bbs2-0124){ref-type="ref-list"}Compares 2 mechanical regimens.[Baacke 2006](#CD001233-bbs2-0125){ref-type="ref-list"}Trial registration, expected end date expired \> 2 years. no information could be obtained (authors were contacted)[Barrilleaux 2002a](#CD001233-bbs2-0126){ref-type="ref-list"}High‐dose misoprostol[Behrashi 2013](#CD001233-bbs2-0127){ref-type="ref-list"}Trial registration with no publication. anticipated end date 2013 =\> no information could be obtained (authors were contacted)[Ben‐Aroya 2001](#CD001233-bbs2-0128){ref-type="ref-list"}There is no mention of randomisation in the abstract. Retrospective cohort study.[Buccellato 2000](#CD001233-bbs2-0129){ref-type="ref-list"}High‐dose misoprostol[Cahill 1988](#CD001233-bbs2-0130){ref-type="ref-list"}Alternate randomisation.[Caughey 2007](#CD001233-bbs2-0131){ref-type="ref-list"}Balloon high vs low volume =\> not within scope of review[Chipato 1997](#CD001233-bbs2-0132){ref-type="ref-list"}2 regimens of extra‐amniotic infusion compared.[Chung 2003](#CD001233-bbs2-0133){ref-type="ref-list"}High‐dose misoprostol[Connolly 2016](#CD001233-bbs2-0134){ref-type="ref-list"}Foley+ oxytocin vs Foley =\> not within scope of review[Connolly 2017](#CD001233-bbs2-0135){ref-type="ref-list"}Foley + oxytocin vs Foley (multiparae) =\> not within scope of review[Cross 1978](#CD001233-bbs2-0136){ref-type="ref-list"}Randomisation based on the last digit of the hospital chart number. 6 women were excluded in the laminaria group, and 1 in the control group. No clinical outcomes were reported.[Cullimore 2009](#CD001233-bbs2-0137){ref-type="ref-list"}Trial registration. study terminated after n = 5).no information could be obtained (authors were contacted)[De Oliveira 2003](#CD001233-bbs2-0140){ref-type="ref-list"}Foley vs no ripening =\> not in scope[Delaney 2010](#CD001233-bbs2-0138){ref-type="ref-list"}Comparison of 2 mechanical methods.[Demirel 2015](#CD001233-bbs2-0139){ref-type="ref-list"}Nipple stimulation, no mechanical method included[Dias 2008](#CD001233-bbs2-0141){ref-type="ref-list"}Trial registration, expected end date expired \> 2 years. no information could be obtained (authors were contacted)[Du 2015](#CD001233-bbs2-0142){ref-type="ref-list"}Not randomised. women could choose induction method[Edwards 2017](#CD001233-bbs2-0143){ref-type="ref-list"}Foley + PGE2 vs Foley =\> not within scope of review[El Sharkwy 2017](#CD001233-bbs2-0145){ref-type="ref-list"}Foley + miso vs Foley (and miso after 12 hours) =\> not within scope of review[El‐Khayat 2016](#CD001233-bbs2-0144){ref-type="ref-list"}Foley + isorbide mononitrate vs misoprostol =\> not within scope of review[El‐Torkey 1995](#CD001233-bbs2-0146){ref-type="ref-list"}Foley + EASI vs Foley =\> not in scope[Emery 1988](#CD001233-bbs2-0147){ref-type="ref-list"}No information.[EUCTR 2012](#CD001233-bbs2-0148){ref-type="ref-list"}Trial registration, expected end date expired \> 2 years. no information obtained (authors were contacted)[Filshie 1992](#CD001233-bbs2-0149){ref-type="ref-list"}Insufficient information.[Forgie 2016](#CD001233-bbs2-0150){ref-type="ref-list"}Placement stylette vs no stylette =\> not within scope of review[Forooshani 2011](#CD001233-bbs2-0151){ref-type="ref-list"}Foley vs laminaria =\> not within scope of review[Fruhman 2017](#CD001233-bbs2-0152){ref-type="ref-list"}Tension vs no tension =\> not within scope of review[Gadel 2015](#CD001233-bbs2-0153){ref-type="ref-list"}Cervical ripening in case of stillbirth[Garebedian 2016](#CD001233-bbs2-0154){ref-type="ref-list"}Foley vs expectative management[Ghanaei 2009](#CD001233-bbs2-0155){ref-type="ref-list"}Foley + oxytocin vs EASI + oxytocin[Ghanaie 2013](#CD001233-bbs2-0156){ref-type="ref-list"}Foley +oxytocin vs EASI + oxytocin vs PGE2 + oxytocin =\> not within scope of review[Gibson 2013](#CD001233-bbs2-0157){ref-type="ref-list"}different kind of traction applied =\> not within scope of review[Gilson 1996](#CD001233-bbs2-0158){ref-type="ref-list"}Dilapan vs no treatment =\> not in scope[Gonsoulin 1989](#CD001233-bbs2-0159){ref-type="ref-list"}No clinical outcome reported.[Gower 1982](#CD001233-bbs2-0160){ref-type="ref-list"}Laminaria vs placebo =\> not in scope[Greybush 2001](#CD001233-bbs2-0161){ref-type="ref-list"}High‐dose misoprostol[Gu 2015](#CD001233-bbs2-0162){ref-type="ref-list"}Low‐ vs high‐volume balloon =\> not within scope of review[Guinn 2004](#CD001233-bbs2-0163){ref-type="ref-list"}Compares 2 mechanical regimens.[Haghighi 2015](#CD001233-bbs2-0164){ref-type="ref-list"}EASI vs isoniazide =\> not within scope of review[Hallak 2008](#CD001233-bbs2-0165){ref-type="ref-list"}Foley vs Foley + EASI vs ATAD + EASI =\> not in scope[He 2000](#CD001233-bbs2-0166){ref-type="ref-list"}Air vesicle odinopoeia =\> not within scope of review[Hill 2009](#CD001233-bbs2-0167){ref-type="ref-list"}High‐dose misoprostol[Hill 2013](#CD001233-bbs2-0168){ref-type="ref-list"}Balloon + miso vs balloon + placebo =\> not within scope of review[Hussein 2012](#CD001233-bbs2-0169){ref-type="ref-list"}Induction for fetal demise or early PE (begin third trimester), so no viable fetus[Ifnan 2006](#CD001233-bbs2-0170){ref-type="ref-list"}Hydrostatic membrane sweeping vs Foley =\> not within scope of review[Jagani 1984](#CD001233-bbs2-0171){ref-type="ref-list"}An extra‐amniotic catheter is used in all groups to record the uterine activity. This catheter uses a 5 mL balloon, which is much lower than the volume used by the other authors (30 mL to 40 mL). Thus, this study is a comparison between oxytocin and PG, with a control group without intervention.[Jasper 2000](#CD001233-bbs2-0172){ref-type="ref-list"}No clinical outcome reported (reported as abstract).[Jindal 2007](#CD001233-bbs2-0173){ref-type="ref-list"}Methods are interchanged after 24 hours, outcomes are given for the totals.[Jonsson 2011](#CD001233-bbs2-0174){ref-type="ref-list"}Digital vs manual placement Foley =\> not within scope of review[Kamilya 2011](#CD001233-bbs2-0175){ref-type="ref-list"}Trial registration, expected end date expired \> 2 years. no information could be obtained (authors were contacted)[Karjane 2006](#CD001233-bbs2-0176){ref-type="ref-list"}Compares 2 mechanical regimens.[Kasdaglis 2007](#CD001233-bbs2-0177){ref-type="ref-list"}The randomisation scheme is unclear and the numbers in both groups are very different (32 and 24).[Kashanian 2006](#CD001233-bbs2-0178){ref-type="ref-list"}High‐dose misoprostol[Kashanian 2009a](#CD001233-bbs2-0179){ref-type="ref-list"}Comparison of 2 mechanical regimens.[Kehl 2012](#CD001233-bbs2-0180){ref-type="ref-list"}2 hours cook balloon before vaginal miso vs no balloon before vaginal miso =\> not within scope of review[Kehl 2015](#CD001233-bbs2-0181){ref-type="ref-list"}Balloon before oral misoprostol vs no balloon before oral misoprostol =\> not within scope of review[Keirse 1983](#CD001233-bbs2-0182){ref-type="ref-list"}No clinical outcome reported.[Lackritz 1979](#CD001233-bbs2-0183){ref-type="ref-list"}Laminaria vs no treatment =\> not in scope[Lam 2006](#CD001233-bbs2-0184){ref-type="ref-list"}Foley +oxytocin vs EASI + oxytocin =\> not within scope of review[Leiberman 1977](#CD001233-bbs2-0185){ref-type="ref-list"}Alternate inclusion in each group. Imbalance between groups in numbers and prognostic factors.[Leong 2017](#CD001233-bbs2-0186){ref-type="ref-list"}Menbrane sweeping vs Foley =\> not within scope of review[Levine 2016](#CD001233-bbs2-0187){ref-type="ref-list"}High‐dose misoprostol[Levy 2000](#CD001233-bbs2-0188){ref-type="ref-list"}Comparison between early and late amniotomy.[Levy 2004](#CD001233-bbs2-0189){ref-type="ref-list"}Comparison between 2 mechanical regimens.[Lin 1995](#CD001233-bbs2-0190){ref-type="ref-list"}Laminaria vs EASI =\> not in scope[Lin 2006](#CD001233-bbs2-0191){ref-type="ref-list"}Trial registration only, study terminated.[Lin 2007](#CD001233-bbs2-0192){ref-type="ref-list"}Compares 2 mechanical regimens.[Lutgendorf 2012](#CD001233-bbs2-0193){ref-type="ref-list"}Traction vs no traction =\> not within scope of review[Macpherson 1983](#CD001233-bbs2-0194){ref-type="ref-list"}No clinical outcomes mentioned.[Mahomed 1988](#CD001233-bbs2-0195){ref-type="ref-list"}Foley catheter under traction compared with Foley catheter with extra‐amniotic PGE2.[Manabe 1985](#CD001233-bbs2-0196){ref-type="ref-list"}No clinical outcomes.[Manish 2016](#CD001233-bbs2-0197){ref-type="ref-list"}High‐ vs low‐volume balloon[Manyonda 2007](#CD001233-bbs2-0198){ref-type="ref-list"}Balloon vs expectant management =\> not in scope[Martin 1989](#CD001233-bbs2-0199){ref-type="ref-list"}Comparison of induction of labour vs surveillance in post‐term pregnancy.[Mattingly 2015](#CD001233-bbs2-0200){ref-type="ref-list"}Double balloon 12 hours vs double balloon 24 hours[Mawire 1999](#CD001233-bbs2-0201){ref-type="ref-list"}EASI vs PGE f2 alpha =\> not in scope[McGee 2016](#CD001233-bbs2-0202){ref-type="ref-list"}Foley silicone vs Foley latex[Mei‐Dan 2009](#CD001233-bbs2-0203){ref-type="ref-list"}Comparison of 2 mechanical regimens.[Mei‐Dan 2012](#CD001233-bbs2-0204){ref-type="ref-list"}Trial terminated before start.[Mei‐Dan 2012a](#CD001233-bbs2-0205){ref-type="ref-list"}Foley +EASI vs Cook balloon[Mei‐Dan 2014](#CD001233-bbs2-0206){ref-type="ref-list"}Single balloon + EASI vs double balloon + EASI[Miller 2015](#CD001233-bbs2-0207){ref-type="ref-list"}Induction vs expectant management. (choice of induction method was up to clinician.)[Moise 1991](#CD001233-bbs2-0208){ref-type="ref-list"}Duplicate information, already included.[Morrison 1993](#CD001233-bbs2-0209){ref-type="ref-list"}Insufficient information.[Movahed 2016](#CD001233-bbs2-0210){ref-type="ref-list"}Foley vs laminaria vs isorbide mononitrate[Mullin 2014](#CD001233-bbs2-0211){ref-type="ref-list"}Direct removal of Foley or not[Naseem 2007](#CD001233-bbs2-0212){ref-type="ref-list"}Quasi‐experimental, every second patient gets Foley[Nasir 2012](#CD001233-bbs2-0213){ref-type="ref-list"}Quasi‐experimental[Neethurani 2013](#CD001233-bbs2-0214){ref-type="ref-list"}Foley + EASI followed by miso vs miso[Owolabi 2005](#CD001233-bbs2-0215){ref-type="ref-list"}High‐dose misoprostol[Park 2011](#CD001233-bbs2-0216){ref-type="ref-list"}Trial registration, expected end date expired \> 2 years. No information could be obtained (authors were contacted)[Pathiraja 2014](#CD001233-bbs2-0217){ref-type="ref-list"}Trial registration, anticipated end date (2014) has expired \> 2 years. No information could be obtained (authors were contacted)[Pedersen 1981](#CD001233-bbs2-0218){ref-type="ref-list"}Comparison of the addition or not of estradiol to Foley catheter.[Pettker 2008](#CD001233-bbs2-0219){ref-type="ref-list"}Comparison of 2 mechanical regimens.[Rameez 2007](#CD001233-bbs2-0220){ref-type="ref-list"}Nitric oxide vs vitamin C[Reif 2012](#CD001233-bbs2-0221){ref-type="ref-list"}Trial registration, anticipated end date (2015) has expired \> 2 years. No information could be obtained (authors were contacted)[Rezk 2014](#CD001233-bbs2-0222){ref-type="ref-list"}Foley vs isorbide mononitrate[Rust 2001](#CD001233-bbs2-0223){ref-type="ref-list"}High‐dose misoprostol[Saad 2016](#CD001233-bbs2-0224){ref-type="ref-list"}Foley vs laminaria[Saito 1999](#CD001233-bbs2-0225){ref-type="ref-list"}Comparison of 2 mechanical regimens.[Salmeen 2012](#CD001233-bbs2-0226){ref-type="ref-list"}Outpatient, pre‐induction Foley before pharmacological hospital induction[Sanchez‐Ramos 1990](#CD001233-bbs2-0227){ref-type="ref-list"}Insufficient information.[Sandberg 2017](#CD001233-bbs2-0228){ref-type="ref-list"}High vs low volume[Schoen 2017](#CD001233-bbs2-0229){ref-type="ref-list"}Foley + oxytocin vs Foley[Schreyer 1989](#CD001233-bbs2-0230){ref-type="ref-list"}Allocation of women was performed according to alternate weeks.[Sciscione 2001](#CD001233-bbs2-0231){ref-type="ref-list"}High‐dose misoprostol[Sharma 2015a](#CD001233-bbs2-0232){ref-type="ref-list"}Foley: direct removal or not.[Sharma 2017](#CD001233-bbs2-0233){ref-type="ref-list"}Foley vs mifepristone =\> not in scope[Sherman 2001](#CD001233-bbs2-0234){ref-type="ref-list"}Comparison of PGE2 infusion vs saline infusion extra‐amniotically. This comparison is not included in this review.[Siddiqui 2013](#CD001233-bbs2-0235){ref-type="ref-list"}Placement Foley: stylette vs no stylette[Suri 2000](#CD001233-bbs2-0236){ref-type="ref-list"}No clinical outcome reported (reported only as abstract).[Thigpen 2004](#CD001233-bbs2-0237){ref-type="ref-list"}Compares a mechanical method with very high dose misoprostol (250 mcg).[Thomas 1986](#CD001233-bbs2-0238){ref-type="ref-list"}Randomisation by odd and even numbers of hospital charts[Torbenson 2015](#CD001233-bbs2-0239){ref-type="ref-list"}Outpatient Foley vs inpatient miso or Foley. Choice of inpatient method by clinician, so no RCT[Ugwu 2013](#CD001233-bbs2-0240){ref-type="ref-list"}Balloon vs misoprostol, crossover after 24 hours[Vengalil 1998](#CD001233-bbs2-0241){ref-type="ref-list"}High‐dose misoprostol[Walfisch 2014](#CD001233-bbs2-0242){ref-type="ref-list"}Foley vs expectative management[Walfisch 2015](#CD001233-bbs2-0243){ref-type="ref-list"}Balloon + EASI vs balloon[Welt 1987](#CD001233-bbs2-0244){ref-type="ref-list"}Insufficient information.[Wickramasinghe 2014](#CD001233-bbs2-0245){ref-type="ref-list"}Foley 24 hours vs Foley 48 hours[Wilkinson 2015](#CD001233-bbs2-0246){ref-type="ref-list"}Inpatient vs outpatient double balloon[Yaddehige 2015](#CD001233-bbs2-0247){ref-type="ref-list"}Membrane sweeping vs massage =\> not in scope[Yazdani 2011](#CD001233-bbs2-0248){ref-type="ref-list"}Trial registration of which anticipated end date (2008) has expired \> 2 years. Trial was registered in retrospect. not clear why there is no publication. no information could be obtained (author contacted)[Zakaria 2017](#CD001233-bbs2-0249){ref-type="ref-list"}Different charriere Foley catheter[Zhang 2014](#CD001233-bbs2-0250){ref-type="ref-list"}Trial registration, anticipated end date (2015) has expired \> 2 years. No information could be obtained (authors contacted)[Zimmer 1996](#CD001233-bbs2-0251){ref-type="ref-list"}No outcomes reported. The authors focused on breathing movements of the fetus.[^2]

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD001233-sec2-0021}
======================================================================

[ACTRN12618000510246 2018](#CD001233-bbs2-0252){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Agboghoroma 2015](#CD001233-bbs2-0253){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesPublication could not be obtained. To try again in next update[Amorosa 2017a](#CD001233-bbs2-0254){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Bauer 2018](#CD001233-bbs2-0255){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Chai 2018](#CD001233-bbs2-0256){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Cherian 2018](#CD001233-bbs2-0257){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[CTRI/2018/01/011574](#CD001233-bbs2-0258){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[de Vaan 2019](#CD001233-bbs2-0260){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[DeCesare 2018](#CD001233-bbs2-0259){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Diguisto 2017](#CD001233-bbs2-0261){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[EUCTR2017‐001914‐27‐GB 2018](#CD001233-bbs2-0262){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[IRCT20170326033142N2 2018](#CD001233-bbs2-0263){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[IRCT20170513033941N39 2018](#CD001233-bbs2-0264){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[IRCT20181123041731N1 2019](#CD001233-bbs2-0265){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Khatib 2019](#CD001233-bbs2-0266){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Leigh 2018](#CD001233-bbs2-0267){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Lim 2018](#CD001233-bbs2-0268){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Mallah 2011](#CD001233-bbs2-0269){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesAuthors contacted. outcomes reported in Iranian magazine, asked authors for reference[McGee 2018](#CD001233-bbs2-0270){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Mohamad 2018](#CD001233-bbs2-0271){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03172858 2017](#CD001233-bbs2-0272){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03399266 2018](#CD001233-bbs2-0273){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03435458 2018](#CD001233-bbs2-0274){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03588585 2018](#CD001233-bbs2-0275){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03629548](#CD001233-bbs2-0276){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03629548 2018](#CD001233-bbs2-0277){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03670836 2018](#CD001233-bbs2-0278){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03682718 2018](#CD001233-bbs2-0279){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03744078 2018](#CD001233-bbs2-0280){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03752073 2018](#CD001233-bbs2-0281){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[NCT03866772 2019](#CD001233-bbs2-0282){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Oskei 2018](#CD001233-bbs2-0283){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Osoti 2018](#CD001233-bbs2-0284){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Saad 2019](#CD001233-bbs2-0285){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Sanmugam 2018](#CD001233-bbs2-0286){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Souizi 2018](#CD001233-bbs2-0287){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[ten Eikelder 2017](#CD001233-bbs2-0288){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Tulek 2018](#CD001233-bbs2-0289){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update[Viteri 2019](#CD001233-bbs2-0290){ref-type="ref-list"}Methods Participants Interventions Outcomes NotesFound in search update of March 2019 =\> classification will be done in next update

Characteristics of ongoing studies \[ordered by study ID\] {#CD001233-sec2-0022}
==========================================================

[Argilagos 2016](#CD001233-bbs2-0291){ref-type="ref-list"}Trial name or titleComparison of vaginal misoprostol plus supracervical balloon versus vaginal misoprostol alone for induction of laborMethodsRCTParticipants InterventionsFoley + vaginal misoprostol\
Vaginal misoprostolOutcomes Starting dateUnknownContact information NotesAuthor contacted: still recruiting[Beckmann 2013](#CD001233-bbs2-0292){ref-type="ref-list"}Trial name or titleProstaglandin Inpatient iNduction of labour Compared with BALLOon Outpatient iNduction of labour: a randomised controlled trial ‐ The PINC BALLOON StudyMethodsRCTParticipants InterventionsFoley\
Vaginal PGE2Outcomes Starting dateUnknownContact information NotesAuthor contacted: recruiting[Bekele 2017](#CD001233-bbs2-0293){ref-type="ref-list"}Trial name or titleA randomised controlled trial of sequential versus simultaneous use of Foley balloon and oxytocin for induction of labour in nulliparous pregnant womenMethods ParticipantsFoley + oxytocin\
FoleyInterventions Outcomes Starting date9 August 2017Contact information NotesStatus unknown. author contacted[Berndl 2016](#CD001233-bbs2-0294){ref-type="ref-list"}Trial name or titleHigh volume Foleys increasing vaginal birth (high 5 birth) pilot trialMethods Participants InterventionsBalloon\
ProstaglandinOutcomes Starting dateDecember 2016Contact information NotesRecruiting (estimated end date: September 2019)[Bhide 2017](#CD001233-bbs2-0295){ref-type="ref-list"}Trial name or titleProstaglandin insert (propess) versus trans‐cervical balloon catheter for out‐patient labour induction: a randomised controlled trial of feasibilityMethods Participants InterventionsFoley\
Vaginal PGE2Outcomes Starting dateSeptember 2017Contact information NotesRecruiting (anticipated end date: August 2018)[Eser 2016](#CD001233-bbs2-0296){ref-type="ref-list"}Trial name or titleCompare prostaglandin e2 against to combined transcervical Foley catheter balloon and vaginal prostaglandin e2 for induction of labour at term: a randomised studyMethods Participants InterventionsFoley + vaginal PGE2\
Vaginal PGE2OutcomesJanuary 2016Starting date Contact information NotesRecruitment completed in January 2018[Goli 2017](#CD001233-bbs2-0297){ref-type="ref-list"}Trial name or titleComparison the results of induction of vaginal misoprostol with Foley catheter in prolonged pregnancy with unripe cervixMethods Participants InterventionsFoley\
Vaginal misoprostolOutcomes Starting dateMarch 2017Contact information NotesEstimated end date: June 2017 =\> author contacted. status unknown[Goonewardene 2016](#CD001233-bbs2-0298){ref-type="ref-list"}Trial name or titleOral misoprostol for 48 hours versus an intracervical Foley catheter for 48 hours for induction of labour in post dated pregnancies: a randomised control trialMethods Participants InterventionsFoley catheter\
Oral misoprostolOutcomes Starting dateOctober 2016Contact information NotesRecruitment completed[Gupta 2016](#CD001233-bbs2-0299){ref-type="ref-list"}Trial name or titleA randomised controlled trial of a synthetic osmotic cervical dilator for induction of labour in comparison to dinoprostone vaginal insErt: the SOLVE TrialMethods Participants InterventionsLaminaria\
Vagina PGE2Outcomes Starting date Contact information NotesNot yet recruiting[Hassanzadeh 2017](#CD001233-bbs2-0300){ref-type="ref-list"}Trial name or titleMisoprostol versus Foley catheter for cervical ripening in women with pre‐eclampsia or gestational hypertensionMethods Participants InterventionsFoley\
MisoprostolOutcomes Starting dateFebruary 2017Contact information NotesAuthors contacted. Still recruiting?[Igwe 2017](#CD001233-bbs2-0301){ref-type="ref-list"}Trial name or titleComparison between intravaginal misoprostol tablet and intracervical Foley\'s catheter in a low resource settingMethods Participants InterventionsFoley\
Vaginal misoprostol (dosage unclear)Outcomes Starting date Contact information NotesRecruitment completed in April 2018[Lacarin 2017](#CD001233-bbs2-0302){ref-type="ref-list"}Trial name or titleComparison between two strategies of induction in case of unfavourable cervix after 12 hours of premature rupture of membranes (prom) at term: cook cervical ripening + oxytocine from 6 hours versus dinoprostone vaginal insertMethods Participants InterventionsFoley\
Vaginal PGE2Outcomes Starting dateOctober 2017Contact information NotesExpected end date: July 2020[Lauterbach 2017](#CD001233-bbs2-0303){ref-type="ref-list"}Trial name or titleA comparison between labour induction with dinoprostone and a cervical ripening balloon in women with a BMI \> 30 as oppose with a BMI \< 30Methods Participants InterventionsBalloon\
PGE2Outcomes Starting dateJanuary 2017Contact information NotesExpected end date: January 2019[Levy 2016](#CD001233-bbs2-0304){ref-type="ref-list"}Trial name or titleA randomised controlled study comparing cervical Foley catheter, vaginal dinoprostone and a combination of the two methods for induction of laborMethods Participants InterventionsFoley + PGE2\
PGE2Outcomes Starting dateFebruary 2016Contact information NotesNot yet recruiting[Osoti 2016](#CD001233-bbs2-0305){ref-type="ref-list"}Trial name or titleA combination of Foley balloon and misoprostol versus misoprostol alone for induction of labour at Kenyatta national hospital, a randomised controlled trialMethods Participants InterventionsFoley + misoprostol\
MisoprostolOutcomes Starting dateMarch 2016Contact information NotesRecruitment completed[Park 2012](#CD001233-bbs2-0306){ref-type="ref-list"}Trial name or titleFoley catheter versus dinoprostone vaginal insert for induction of labour in parous women at term: a randomised trialMethods Participants Interventions Outcomes Starting dateMay 2012Contact information NotesTrial status unclear. expected end date 2017 =\> authors contacted[Perrotin 2016](#CD001233-bbs2-0307){ref-type="ref-list"}Trial name or titlePropess® versus double balloon for cervical ripening of prolonged pregnancies: a randomised controlled trialMethods Participants InterventionsDouble balloon\
Vaginal PGE2Outcomes Starting dateSeptember 2016Contact information NotesExpected end date: January 2020[Tagore 2015](#CD001233-bbs2-0308){ref-type="ref-list"}Trial name or titleCervical ripening balloon in induction of labour at term (crbii) ‐ a prospective randomised controlled trialMethods Participants InterventionsPGE2\
BalloonOutcomes Starting dateDecember 2015Contact information NotesExpected end date: March 2018 =\> recruiting[Viteri 2015](#CD001233-bbs2-0309){ref-type="ref-list"}Trial name or titleThe efficacy of transcervical Foley balloon plus vaginal misoprostol versus vaginal misoprostol alone for cervical ripening in nulliparous obese women: a randomised, comparative effectiveness trialMethods Participants InterventionsFoley + misoprostol\
MisoprostolOutcomes Starting dateDecember 2015Contact information NotesRecruiting[Wise 2016](#CD001233-bbs2-0310){ref-type="ref-list"}Trial name or titleComparison of low‐risk pregnant women undergoing induction of labour at term by outpatient balloon or inpatient prostaglandin in order to assess vaginal birth rate; a randomised controlled trialMethods Participants InterventionsBalloon\
PGE2Outcomes Starting dateMarch 2016Contact information NotesNot yet recruiting[Yildirim 2017](#CD001233-bbs2-0311){ref-type="ref-list"}Trial name or titleDinoprostone vaginal insert versus double balloon catheter for preinduction cervical ripeningMethods Participants InterventionsDouble balloon\
PGE2Outcomes Starting dateJanuary 2017Contact information NotesRecruitment completed[^3]

Comparisons of a balloon catheter with concurrent oxytocin or prostaglandins versus prostaglandins or oxytocin alone were added. Also, comparisons of a single versus a double balloon and different forms of laminaria tents were added. The comparisons with placebo/no treatment were excluded. Regarding studies where a comparison was made with misoprostol, we chose only to include studies in which low‐dose misoprostol was used. A number of non pre‐specified outcomes relevant to the comparisons made in this review were added (maternal fever, antibiotics during labour, endometritis, chorioamnionitis. fetal distress, umbilical artery pH \< 7.10).

For this update, we have also searched [ClinicalTrials.gov](ClinicalTrials.gov), the WHO International Clinical Trials Registry Platform ([ICTRP](ICTRP)).

For this update, M de Vaan, M ten Eikelder, KR Palmer and BW Mol performed data extraction. Risk of bias was assessed by M de Vaan, M ten Eikelder, KR Palmer and M Jozwiak. Marieke de Vaan and Marta Jozwiak entered the data and the review was drafted M de Vaan, which was finalised after feedback from M. ten Eikelder, M Jozwiak, KR Palmer, M Davies, K Bloemenkamp, BW Mol and M Boulvain. M. ten Eikelder, M. Jozwiak and BW Mol were not involved in data extraction nor in the \'Risk of bias\' assessment of [Jozwiak 2012](#CD001233-bbs2-0050){ref-type="ref-list"}; [Jozwiak 2013](#CD001233-bbs2-0051){ref-type="ref-list"}; [Jozwiak 2014](#CD001233-bbs2-0052){ref-type="ref-list"}; [ten Eikelder 2016](#CD001233-bbs2-0105){ref-type="ref-list"}, due to their authorship.
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[^1]: AFI: amniotic fluid index  APH: antepartum haemorrhage  ARM/AROM: artificial rupture of membranes  AS: Apgar score  BMI: body mass index  BS: Bishop score  CPD: cephalopelvic disproportion  CS: caesarean section  CTG: Cardiotocography  EASI: extra‐amniotic saline infusion  EFW: estimated fetal weight  FHR: fetal heart rate  GA: gestational age  GBS: group B Streptococcus  GI: gastrointestinal  ICU: intensive care unit  IOL: induction of labour  IFD/IUFD intrauterine fetal death  ITT: intention‐to‐treat  IV: intravenous  LSCS: lower segment caesarian section  max: maximum  Mbs: modified Bishop Score  mcg: microgram  mL: millilitre  mg: milligram  mU: milliunits  NICU: neonatal intensive care unit  NST: non‐stress test  PBU: premature baby unit  PCM:   PG: prostaglandin  PGE2: prostaglandin E2  PROM: pre labour rupture of membranes  RCT: randomised controlled trial  SROM: spontaneous rupture of membranes  US: ultrasound

[^2]: EASI: extra‐amniotic space infusion  PG: prostaglandin  PGE2: prostaglandin E2   RCT: randomised controlled trial  vs: versus

[^3]: BMI: body, mass index  PGE2: prostaglandin E2   RCT: randomised controlled trial
